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Abstract
Background
Hand eczema is an inflammation of the skin of the hands that tends to run a chronic, relapsing course. This common
condition is often associated with itch, social stigma, and impairment in employment. Many different interventions of unknown
effectiveness are used to treat hand eczema.
Objectives
To assess the effects of topical and systemic interventions for hand eczema in adults and children.
Search methods
We searched the following up to April 2018: Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase,
AMED, LILACS, GREAT, and four trials registries. We checked the reference lists of included studies for further references
to relevant trials.
Selection criteria
We included randomised controlled trials (RCTs) that compared interventions for hand eczema, regardless of hand eczema
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type and other affected sites, versus no treatment, placebo, vehicle, or active treatments.
Data collection and analysis
We used standard methodological procedures as expected by Cochrane. Primary outcomes were participant- and
investigator-rated good/excellent control of symptoms, and adverse events.
Main results
We included 60 RCTs conducted in secondary care (5469 participants with mild to severe chronic hand eczema). Most
participants were over 18 years old. The duration of treatment was short - generally up to four months. Only 24 studies
included a follow-up period. Clinical heterogeneity in treatments and outcome measures was evident. Few studies performed
head-to-head comparisons of different interventions. Risk of bias varied considerably, with only five studies at low risk in all
domains. Twenty-two studies were industry-funded.
Eighteen trials studied topical corticosteroids or calcineurin inhibitors, 10 studies phototherapy, three studies systemic
immunosuppressives, and five studies oral retinoids. Most studies compared an active intervention against no treatment,
variants of the same medication, or placebo (or vehicle). Below, we present results from the main comparisons.
Corticosteroid creams/ointments: when assessed 15 days after the start of treatment, clobetasol propionate 0.05% foam
probably improves participant-rated control of symptoms compared to vehicle (risk ratio (RR) 2.32, 95% confidence interval
(CI) 1.38 to 3.91; number needed to treat for an additional beneficial outcome (NNTB) 3, 95% CI 2 to 8; 1 study, 125
participants); the effect of clobetasol compared to vehicle for investigator-rated improvement is less clear (RR 1.43, 95% CI
0.86 to 2.40). More participants had at least one adverse event with clobetasol (11/62 vs 5/63; RR 2.24, 95% CI 0.82 to
6.06), including application site burning/pruritus. This evidence was rated as moderate certainty.
When assessed 36 weeks after the start of treatment, mometasone furoate cream used thrice weekly may slightly improve
investigator-rated symptom control compared to twice weekly (RR 1.23, 95% CI 0.94 to 1.61; 1 study, 72 participants) after
remission is reached. Participant-rated symptoms were not measured. Some mild atrophy was reported in both groups (RR
1.76, 95% CI 0.45 to 6.83; 5/35 vs 3/37). This evidence was rated as low certainty.
Irradiation with ultraviolet (UV) light: local combination ultraviolet light therapy (PUVA) may lead to improvement in
investigator-rated symptom control when compared to local narrow-band UVB after 12 weeks of treatment (RR 0.50, 95% CI
0.22 to 1.16; 1 study, 60 participants). However, the 95% CI indicates that PUVA might make little or no difference.
Participant-rated symptoms were not measured. Adverse events (mainly erythema) were reported by 9/30 participants in the
narrow-band UVB group versus none in the PUVA group. This evidence was rated as moderate certainty.
Topical calcineurin inhibitors: tacrolimus 0.1% over two weeks probably improves investigator-rated symptom control
measured after three weeks compared to vehicle (14/14 tacrolimus vs 0/14 vehicle; 1 study). Participant-rated symptoms
were not measured. Four of 14 people in the tacrolimus group versus zero in the vehicle group had well-tolerated application
site burning/itching.
A within-participant study in 16 participants compared 0.1% tacrolimus to 0.1% mometasone furoate but did not measure
investigator- or participant-rated symptoms. Both treatments were well tolerated when assessed at two weeks during four
weeks of treatment.
Evidence from these studies was rated as moderate certainty.
Oral interventions: oral cyclosporin 3 mg/kg/d probably slightly improves investigator-rated (RR 1.88, 95% CI 0.88 to 3.99; 1
study, 34 participants) or participant-rated (RR 1.25, 95% CI 0.69 to 2.27) control of symptoms compared to topical
betamethasone dipropionate 0.05% after six weeks' treatment. The risk of adverse events such as dizziness was similar
between groups (up to 36 weeks; RR 1.22, 95% CI 0.80 to 1.86, n = 55; 15/27 betamethasone vs 19/28 cyclosporin). The
evidence was rated as moderate certainty.
Alitretinoin 10mg improves investigator-rated symptom control compared with placebo (RR 1.58, 95% CI 1.20 to 2.07; NNTB
11, 95% CI 6.3 to 26.5; 2 studies, n = 781) and alitretinoin 30 mg also improves this outcome compared with placebo (RR
2.75, 95% CI 2.20 to 3.43; NNTB 4, 95% CI 3 to 5; 2 studies, n = 1210). Similar results were found for participant-rated
symptom control: alitretinoin 10mg RR 1.73 (95% CI 1.25 to 2.40) and 30mg RR 2.75 (95% CI 2.18 to 3.48). Evidence was
rated as high certainty. The number of adverse events (including headache) probably did not differ between alitretinoin 10
mg and placebo (RR 1.01, 95% CI 0.66 to 1.55; 1 study, n = 158; moderate-certainty evidence), but the risk of headache
increased with alitretinoin 30 mg (RR 3.43, 95% CI 2.45 to 4.81; 2 studies, n = 1210; high-certainty evidence). Outcomes
were assessed between 48 and 72 weeks.
Authors' conclusions
Most findings were from single studies with low precision, so they should be interpreted with caution. Topical corticosteroids
and UV phototherapy were two of the major standard treatments, but evidence is insufficient to support one specific
treatment over another. The effect of topical calcineurin inhibitors is not certain. Alitretinoin is more effective than placebo in
controlling symptoms, but advantages over other treatments need evaluating.
Well-designed and well-reported, long-term (more than three months), head-to-head studies comparing different treatments
are needed. Consensus is required regarding the definition of hand eczema and its subtypes, and a standard severity scale
should be established.
The main limitation was heterogeneity between studies Small sample size impacted our ability to detect differences between
treatments.
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Plain language summary
Treatments for hand eczema
Review question
We reviewed evidence on the effects of topical and systemic (oral or injected medicines that work throughout the entire body)
treatments for hand eczema when compared against placebo (an identical but inactive treatment), no treatment, vehicle
(inactive ingredients that help deliver an active treatment), or another treatment. We included 60 randomised trials (5469
participants) published up to April 2018.
Background
Hand eczema is an inflammation of the skin of the hands that can be caused by contact allergens (i.e. substances that cause
an allergic reaction) such as rubber chemicals, but other external factors (e.g. irritants such as water or detergents) and
atopic predisposition are often important triggers. Hand eczema can cause a reduction in quality of life leading to many work-
related problems. Various types of hand eczema exist, and different topical (creams, ointments, or lotions) and systemic
treatments with unknown effectiveness can be used.
Study characteristics
Most participants were hospital outpatients over 18 years of age with mild to severe chronic hand eczema. Treatment was
usually given for up to four months, and outcomes were mainly assessed after treatment. A large variety of treatments were
studied and compared to no treatment, variants of the same medication, placebo, or vehicle. Twenty-two studies were
funded by pharmaceutical companies.
Key results
Limited data are available to support the best way of managing hand eczema due to varying study quality and inability to pool
data from studies with similar interventions. Corticosteroid creams/ointments and phototherapy (irradiation with UV light) are
the major treatment options, although comparisons between these options are lacking. Below, we present results for the
main comparisons of interest.
Corticosteroid creams/ointments: clobetasol propionate foam probably increases participant-rated good/excellent control
of hand eczema when compared to vehicle (516 vs 222 per 1000), but the difference between groups was less clear for
investigator-rated control, and more adverse events were reported with clobetasol propionate (178 vs 79 per 1000) (all based
on moderate-certainty evidence).
Mometasone furoate cream used thrice weekly may slightly improve investigator-rated good/excellent control compared to
twice weekly treatment, and participant-rated control was not measured. Mild skin thinning occurred in both groups, but
cases were few (all based on low-certainty evidence).
Irradiation with UV light: various types of irradiation (i.e. exposure to radiation) were compared. Local PUVA may improve
investigator-rated good/excellent control compared to narrow-band UVB (400 vs 200 per 1000); however, we are uncertain of
this finding because results also show that local PUVA may make little or no difference. Participant-rated symptoms were not
measured. Nine out of 30 participants in the narrow-band UVB group reported adverse events (mainly redness) compared to
none in the PUVA group (all based on moderate-certainty evidence).
Topical calcineurin inhibitors: people receiving tacrolimus are probably more likely to achieve improved investigator-rated
good/excellent symptom control compared to those given vehicle (14/14 participants with tacrolimus compared to none with
vehicle), but participant-rated control of symptoms was not measured. Four of 14 people in the tacrolimus group versus zero
in the vehicle group had well-tolerated application site burning/itching. One small study compared tacrolimus and
mometasone furoate, which were well tolerated, but did not measure investigator- or participant-rated control (all based on
moderate-certainty evidence).
Oral interventions: oral immunosuppressant (a drug that hinders the immune response) cyclosporin probably slightly
improves investigator- or participant-rated control of good/excellent symptoms compared to topical betamethasone cream (a
corticosteroid). The risk of adverse events such as dizziness was similar between groups (all based on moderate-certainty
evidence).
The oral vitamin A derivative (retinoid) alitretinoin (10 mg) achieved investigator-rated good/excellent symptom control in 307
compared to 194 participants per 1000 with placebo, and alitretinoin 30 mg achieved investigator-rated control in 432
compared to 157 participants per 1000 with placebo. Similar results were shown for participant-rated control (high-certainty
evidence). When the dosage of alitretinoin was increased to 30 mg, risk of headache was higher compared to placebo (74 vs
251 per 1000; high-certainty evidence), but this probably does not differ between alitretinoin 10 mg and placebo (based on
moderate-certainty evidence).
Quality of the evidence
The quality of evidence was mainly moderate, with most analyses based on single studies of small sample size; therefore
some results should be interpreted with care.
Background 
Please note that unfamiliar terms may be listed in Appendix 1 ('Glossary of medical terms').
Future research would involve comparing different treatment groups. Focus on subgroups would provide reliable evidence for
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informed decisions about which treatment is effective in managing hand eczema.
The overall quality of evidence was very low. Many trials included in this review, particularly older ones, were of low quality
with methodological weaknesses in design (small studies, short duration) or were biased (not blinded, sponsored by
pharmaceuticals). Most included participants with chronic hand eczema in secondary care settings; some included only
specific subtypes of hand eczema, thereby limiting direct application of study findings. Most analyses were based on single
studies of small sample size and imprecise results.
Description of the condition
Definition and epidemiology
Hand eczema is an inflammation of the skin (dermatitis) that is confined to the hands. Hand eczema is a common
condition with a point prevalence varying between 1% and 5% in the general population. When mild cases are
included, one-year prevalence can reach 10% (Meding 2004; Thyssen 2010; Yngveson 2000). Thyssen et al
conducted a review of seven epidemiological studies on hand eczema and concluded the median incidence rate of
hand eczema was 5.5 cases/1000 person-years. For women, the incidence rate of hand eczema was 9.6
cases/1000 person-years, and for men, 4.0 cases/1000 person-years (Thyssen 2010). A possible explanation for
this sex difference is greater exposure of women to wet work, such as cleaning, nursing, and hair dressing, for
example (Mollerup 2014; Nilsson 1985). The incidence of notified (i.e. usually more severe) occupation-related
cases is estimated to be above 0.7 per 1000 people per year, with much higher incidences (up to 1 in 100) in high-
risk populations such as hairdressers (Diepgen 2003). Decreased prevalence has been observed in Swedish adults
and was attributed to a decline in occupational exposure to irritants (Meding 2002).
Over the years, several authors have proposed a workable definition of hand eczema, whereby different subtypes
have been recognised (Menné 2000). Hand eczema can be classified according to aetiological (causative)
factors, clinical-morphological typology, or a combination of both (Coenraads 2012; Diepgen 2009a). However, due to
multi-causality, it is difficult to assess the influence of each causative factor; therefore only one aetiological diagnosis
might be insufficient. The Danish Contact Dermatitis Group developed a classification system based on morphology
with clear definitions for each classification and one or more aetiological diagnoses (Menné 2011). This might
facilitate the classification of hand eczema and was demonstrated to be a useful tool in general practice (Johansen 2011).
However, there is an obvious need for international consensus regarding the classification of subgroups of hand eczema.
In the current literature, different names can be used for the same subgroups, or the same name can be used for
different subgroups. An example of this is vesicular hand eczema (Veien 2009): this might be called pompholyx, dyshidrotic
eczema, dyshidrosis, or vesicular eczema; no consensus has been reached regarding the definition. The original definition of
'pompholyx' states "an eruption of vesicles and bullae on the palms, which is accompanied by pain and severe itching". Fox
1873 hypothesised that pompholyx was caused by sweating of the palms and introduced the term 'dyshidrosis' (hydrosis
from sweating); both terms were used for the same clinical vesicular type. Later, Kutzner 1986 demonstrated that sweat
glands are not altered in vesicular hand eczema and discussed the histological features of eczema. However, despite this
evidence, the term 'dyshidrosis' is still used in current literature.
Hand eczema may be accompanied by similar skin changes on the feet.
Causes
In many people, hand eczema has more than one cause and both predisposing and external factors play a part.
Being atopic (a tendency to develop asthma, hay fever, or eczema) is a major predisposing factor responsible for
hand eczema; one-third to one-half of people with hand eczema can be considered atopic (Coenraads 1998; Meding 1990; 
Svensson 1988). The role of genetic factors, especially the association between filaggrin (FLG) mutations and hand
eczema, is still under investigation (Heede 2016; Kaae 2012; Molin 2015).
The most common external causes of hand eczema include contact with mild toxic agents or irritants (for instance,
water and soaps). The resulting irritant contact dermatitis can be distinguished from allergic contact dermatitis, which
is caused by skin contact with allergens. Allergic contact dermatitis is less common than irritant contact dermatitis,
and it occurs only in persons who have developed a contact allergy to a specific substance such as rubber, nickel, or
perfumes. Ingested allergens (e.g. nickel) may occasionally provoke hand eczema (Jensen 2006). Little evidence
suggests that inhalation of house dust mites may increase the severity of vesicular hand eczema (Schuttelaar 2013).
The relevance of psychosomatic factors remains speculative (Menné 2000). In many people with chronic hand eczema, a
combination of the above-mentioned factors plays a role. In addition, for several types of hand eczema, the cause is still
unknown.
Impact
Itch is common among those with hand eczema. The itch caused by hand eczema can be intense, leading to sleep loss in
the sufferer and in other family members. A vicious cycle of symptoms causing skin damage can develop, the so-called
itch/scratch/itch cycle. Cracks and blisters can be painful. Cracking, hyperkeratosis (callus-like thickening), and inflexibility of
the hands are also problematic and may limit mobility of the hands.
A visible skin disease can be a great burden and can lead to a social stigma. The hands are important organs of
communication and expression; therefore any visible skin disease on the hands may result in major psychosocial problems
(e.g. anxiety, low self-esteem, social phobia).
Painful cracks and blisters, besides their negative effects on daily life outside work, can impede an individual's ability
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to carry out manual work, leading to significant disability and huge economic losses for both individuals and society. A
systematic review estimated the mean annual total cost per hand eczema patient at between €1712 and €9792 (Politiek
2016). Hand eczema accounts for an estimated 90% of occupational skin disease. Patients have substantial use
of sick leave due to their hand eczema. Studies in patients with chronic severe hand eczema have reported job
loss up to 20% (Cvetkovski 2005). Quality of life assessments have shown an impact on daily life and on employment (
Agner 2008; Moberg 2009). A comparison between the generic quality of life instrument Short Form Health
Survey (SF-36) and the skin-related Dermatology Life Quality Index (DLQI) revealed slightly higher impact of
hand eczema on women compared to men for specific sub-items (Wallenhammar 2004). A comparison of physician-
rated versus participant-rated assessments of severity showed a poor correlation, indicating that patients may evaluate
several aspects of their hand eczema (including degree of erythema, vesicles, and fissures) differently from physicians (van
Coevorden 2006).
Prognosis
Previous studies have suggested that hand eczema tends to run a chronic relapsing course, with the vast majority of
people experiencing negative psychosocial consequences (Hald 2009; Meding 2005; Petersen 2014; Veien 2008).
Description of the intervention
Many diverse therapies are used to control the disease, such as:
skin protection measures, including gloves;
topical treatments (bland emollients, corticosteroid creams/ointments, calcineurin inhibitors, coal tar and derivatives,
irradiation with ultraviolet (UV) light or X-rays); and
systemic treatments (oral corticosteroids, oral retinoids, or other immunosuppressants such as cyclosporin).
The main groups of interventions covered by this review are topical corticosteroids, topical calcineurin inhibitors
(immunomodulators), irradiation with UV light, and oral retinoids or systemic immunosuppressants.
Overall, after proper education and counselling, including the recommendation of emollients, application
of topical corticosteroids remains the mainstream treatment for hand eczema (nationaleczema.org).
How the intervention might work
Theoretically, identifying and eliminating an allergic contact factor (e.g. nickel or rubber allergy) could result in cure of hand
eczema, provided this is the sole cause. In clinical practice, however, such cases are rare, as hand eczema is often due to a
combination of irritant and allergic contact exposure, as well as to endogenous factors.
This review deals with a great variety of interventions. Major types of interventions are topical corticosteroids, topical
immunomodulators, irradiation with UV light, and oral retinoids.
Topical corticosteroids are the most frequently prescribed treatments for hand eczema (Soost 2012). They have
overlapping mechanisms of action: like oral immunosuppressants (e.g. corticosteroids), they inhibit inflammation
(anti-inflammatory) and production of inflammatory substances (immunosuppressive) (Ahluwalia 1998; Sakuma 2001; 
Schleimer 1993).
Topical immunomodulators, such as tacrolimus and pimecrolimus, are non-steroidal immunosuppressants that are more
selective in their mode of action than corticosteroids. They inhibit the production of inflammatory substances in the body
(such as synthesis and release of inflammatory cytokines from T-lymphocytes, and release of inflammatory mediators
from mast cells). Calcineurin is present during activation of T-lymphocytes, and since tacrolimus and pimecrolimus block
this step, they are called 'calcineurin inhibitors' (de Paulis 1992; Sakuma 2001).
Topical moisturisers or emollients can relieve dryness of the skin, can improve the skin barrier function, and can
influence transepidermal water loss (depending on the composition of the emollient) (Lodén 2012b; Rawlings 2004).
Moisturisers are available in various compositions such as oil-in-water, water-in-oil, lotions, gels, and emulsions, among
others, and various adjuvants such as urea or salicylic acid can be added to reduce thickness and scaling of the skin.
Coal tar has been used to treat eczema since ancient times. It is claimed to increase epidermal differentiation and to
up-regulate various key barrier proteins such as filaggrin, thus improving the skin barrier function (McLean 2013; van den
Bogaard 2013). Moreover coal tar suppresses the Th2 cytokine response (McLean 2013; van den Bogaard 2013).
Irradiation with UV light can be performed with different types of UVA and UVB, depending on the wavelength.
UVA treatment overall is combined with a topical or oral agent (psoralen) to make the skin more sensitive to
UVA. Examples of different types of phototherapy include broad-spectrum UVB (280 to 315 nm), small-spectrum
UVB (311 to 313 nm, also known as TL-01 or narrow-band UVB), UVA-1 (340 to 400 nm), and topical and oral
psoralen combined with UVA (PUVA; 315 to 400 nm). UVA-1 phototherapy can be used at high (HD; 130 J/cm²),
medium (MD; 50 J/cm²), and low doses (LD; 10 J/cm²) (Hönigsmann 2003). The mechanism of photo(chemo)therapy
is multi-factorial. In general, UV light locally decreases the activity of the immune system and inhibits the quantity of
inflammatory cells. It suppresses the antigen-presenting function of the Langerhans cells and induction of apoptosis of
T-cells (Majoie 2009). In addition, photo(chemo)therapy results in an increase in the amount of stratum corneum; in
other words, the skin gets thicker (Jekler 1990). Finally, UVB reduces the number of microbes on the skin, including
Staphylococcus aureus (Faergemann 1987).
Oral retinoids are vitamin A derivatives. Retinoids are thought to interfere at different steps in the inflammatory process.
They have immunomodulatory properties and interfere with the epidermal differentiation process in various ways (Blair 2016; 
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Kislat 2014; Schmitt-Hoffmann 2012). Both alitretinoin and acitretin are retinoids, although their mechanism of action is
slightly different. Alitretinoin is thought to have anti-inflammatory and immunomodulatory effects on the skin. Alitretinoin
binds with high affinity to both retinoic acid receptor (RAR) and retinoid X receptor (RXR) and presents anti-inflammatory
and immunomodulatory activity, and acitretin binds only selectively to RAR, although both retinoids are thought to
reduce inflammation (Blair 2016; Kislat 2014; Schmitt-Hoffmann 2012).
Hand eczema is a chronic condition that might be accompanied by flares and might improve as a result of the natural course;
therefore, we believe a minimum treatment duration of three months is required to document important data such as duration
and frequency of disease relapse.
Why it is important to do this review
The high prevalence of hand eczema, along with its poor prognosis and associated disability with economic losses
and impairment of quality of life, makes hand eczema an important disease to study from an individual and a societal
perspective. This, coupled with the long list of diverse treatments of unknown effectiveness and several conflicting
studies (Diepgen 2007; van Coevorden 2004b), suggests that a systematic review is needed. Even if methodological
constraints do not permit sufficient clarification of existing conflicts to provide clear guidance in clinical practice, this review
will be an important step in identifying research gaps and consequently providing directions for future research.
The plans for this review were published as a protocol "Interventions for hand eczema" (van Coevorden 2009). Differences
between the review and the protocol are stated in the section Differences between protocol and review.
Objectives 
To assess the effects of topical and systemic interventions for hand eczema in adults and children.
Methods 
Criteria for considering studies for this review 
Types of studies 
We included randomised controlled trials (RCTs) of interventions for hand eczema regardless of hand eczema type and other
affected localisations.
Types of participants 
People (adults and children, occupational and non-occupational) with the diagnosis of hand eczema, regardless of the
underlying assumed cause, were eligible. We also included participants with other parts of the body affected in addition to
the hand. The terms 'eczema' and 'dermatitis' were acceptable whenever they referred to the hands. Other terms such as
'pompholyx', 'dyshidrosis', and 'pulpitis' were also deemed acceptable. We included participants with different types of hand
eczema, for example, chronic hand eczema, hyperkeratotic palmar (also know as tylotic) hand eczema, and vesicular
eczema (also known as dyshidrotic hand eczema or pompholyx).
We included in this review studies that included participants with other diagnoses besides hand eczema only when we were
able to obtain separate data for hand eczema participants.
Types of interventions 
We included only studies comparing the intervention versus no treatment, placebo, vehicle, or other active treatments. We
considered all types of interventions, except interventions to prevent hand eczema (primary prevention). We excluded
studies that focused on prevention of hand eczema and studies that investigated integrated care programmes or educational
programmes (non-pharmacological interventions).
We considered studies comparing different interventions, for example, topical corticosteroids versus topical calcineurin
inhibitors or oral cyclosporin versus topical corticosteroids, as most clinically relevant. For 'Summary of findings' tables, we
included the following comparisons.
Mometasone furoate cream on different treatment schedules.
Local narrow-band UVB versus local PUVA.
Tacrolimus 0.1% ointment versus vehicle.
Tacrolimus 0.1% ointment versus mometasone furoate ointment.
Oral cyclosporin versus topical betamethasone dipropionate.
Oral alitretinoin at 10 mg and 30 mg a day versus placebo.
When a study reported on treatment during a remission- or clearance-induction phase for participants before they were
randomised to a follow-up or maintenance phase, we considered only the latter (randomised) phase for this review.
Types of outcome measures 
We extracted the following primary and secondary outcomes from the included studies.
Primary outcomes
Percentage of participants with self-rated good/excellent control of symptoms.
Percentage of participants with investigator-rated good/excellent control of symptoms.
Adverse events: adverse effects (long- and short-term) of the intervention. Long-term adverse events are defined as
adverse events occurring after completion of the treatment phase; short-term adverse events occur during the treatment
#29 Interventions for hand eczema
6 / 280
phase.
Secondary outcomes
Reduction in severity (participant-rated).
Reduction in severity (investigator-rated).
Time until relapse, defined as the number of days/weeks until the participant reported worsening of symptoms after initial
response.
Dose reduction: reduction in treatment dose per time unit or cumulative prescribed treatment dose. For example, a
decrease in daily topical medication, or a decrease in weekly photo irradiation.
We did not exclude studies from the review that did not include these outcomes.
We believe that three months is the minimum study duration required to document important data such as duration and
frequency of disease relapse.
Search methods for identification of studies 
We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press, or in
progress).
Electronic searches 
The Cochrane Skin Information Specialist searched the following databases up to 19 April 2018, using strategies based
on the draft strategy for MEDLINE presented in our published protocol (van Coevorden 2009).
Cochrane Skin Group Specialised Register (search strategy in Appendix 2).
Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 3), in the Cochrane Library (search strategy in
Appendix 3).
MEDLINE via Ovid (from 1946) (search strategy in Appendix 4).
Embase via Ovid (from 1974) (search strategy in Appendix 5).
Allied and Complementary Medicine (AMED) via Ovid (from 1985) (search strategy in Appendix 6).
Latin American and Caribbean Health Science Information database (LILACS) (from 1982) (search strategy in Appendix
7).
Global Resource of Eczema Trials. Centre of Evidence Based Dermatology (accessed at http://www.greatdatabase.org.uk
on 19 April 2018), using the following terms in the title of the records: hand* or finger* or palm or palms.
Trials registries
We (WAC and PJC) searched the following trials registries up to 21 April 2018, using the following search terms: hand and
(eczema or dermatitis).
International Standard Randomized Controlled Trials Number (ISRCTN) registry (www.isrctn.com).
ClinicalTrials.gov (www.clinicaltrials.gov).
Australian New Zealand Clinical Trials Registry (www.anzctr.org.au).
World Health Organization International Clinical Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/).
Searching other resources 
Correspondence with authors
If we needed clarification regarding studies, we contacted study authors using the correspondence options stated in their
papers (for studies published since 1999). If email addresses did not work, we tried to find recent publications by the same
corresponding author with more recent contact data, or we searched Facebook, LinkedIn, and the Internet to connect with
these authors. In addition, we tried to contact all authors of studies that included other dermatoses among hand eczema, to
obtain separate data for hand eczema participants. We listed in the 'notes' section of the Characteristics of included studies
tables whether we contacted study authors, and if they responded. We have not included in the review complete
correspondence with all studies, but we have shown the relevant citations in the Characteristics of included studies tables.
The full correspondence with study authors is available upon request.
References from published studies
We checked the bibliographies of included studies for further references to relevant trials.
Adverse events
We did not perform a separate search for adverse events. However, we did examine data on adverse events from the
included studies.
Unpublished literature
We contacted authors and pharmaceutical companies in relation to ongoing trials that were recently completed according to
the trial registries mentioned under Electronic searches. When results were published on the trial register websites, we
included these in the results, and we tried to contact study authors for additional information if necessary.
Conference proceedings
We searched the conference proceedings of annual conferences of the European Academy of Dermatology and
Venereology (EADV) from 2000 to 2011 for further relevant RCTs. Some were available from the JEADV; however, some
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others had to be obtained from the organisation itself, from which we requested the material on CD-ROM.
Handsearching
We handsearched using the terms 'eczema', 'dermatitis', 'hand(s)', 'palmoplantar', and 'inflammatory' in 16 English, two
German, one Italian, one French, and one Dutch dermatology journal (all journals 1977 through 2003). We searched the
journals listed in Appendix 8.
Data collection and analysis 
Selection of studies 
Three review authors (PJC, JLB, and WAC) independently checked titles and abstracts identified from the searches. Three
review authors (PJC, TD, and ÅS) conducted an additional handsearch. If it was clear that the study did not refer to a
randomised controlled trial on hand eczema, we excluded it. We retrieved all potential trials as full-text articles for further
independent examination by two review authors (TD and ÅS). These two review authors decided which trials conformed to
the inclusion criteria and resolved discrepancies by discussion in consensus meetings. We obtained missing data from the
trial authors when possible. Whenever we found duplicate publications of the same trial, we used the paper with the most
relevant data (usually we had a conference abstract and a full article) as the primary reference and listed the other
publication in the additional references following the reference section.
Data extraction and management 
Three review authors (PJC, TD, and ÅS) extracted data independently, using a standardised data extraction form. These
review authors and future reviewers piloted the data extraction form during a meeting of the European Dermato-
Epidemiology Network, in July 2000. This form was based on a preceding systematic review of psoriasis interventions and
was later updated according to Cochrane recommendations. We resolved discrepancies and uncertainties in a series of
consensus meetings, which were led by one review author (PJC).
Two other review authors (JLB and WAC) entered into Review Manager 5.3 and checked the outcome data
extracted from the included studies (RevMan).
Assessment of risk of bias in included studies
Two review authors (ÅS and TD) independently assessed the risk of bias in included studies following the domain-based
evaluation described in Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions and, using the
Cochrane risk of bias tool, assessed all included studies from the following aspects for potential risk of bias (Higgins 2011b).
Random sequence generation, which refers to selection bias due to inadequate generation of a randomised sequence.
Allocation concealment, which also refers to selection bias but due to inadequate concealment of the allocation sequence
before assignment.
Blinding of participants and personnel, which refers to performance bias due to knowledge of intervention allocation by
participants or personnel.
Blinding of outcome assessment, which refers to detection bias due to knowledge of intervention allocation by the
outcome assessor.
Incomplete outcome data, which refers to the quantity, nature, or manner in which incomplete outcome data were
handled.
Selective reporting, which refers to reporting bias due to selective reporting.
Other source of bias, which refers to any other types of bias not covered above, including inclusion of baseline
comparisons, certainty of the diagnosis, and premature ending.
Whenever we encountered disagreement regarding assessment of risk of bias, we resolved this in a consensus meeting with
a third review author (PJC or HW). Two review authors (JLB and WAC) assessed completed 'Risk of bias' forms and entered
the data into RevMan.
Measures of treatment effect
We employed risk ratios (RR) with 95% confidence intervals (CIs) to measure the effect of a treatment for
dichotomous outcomes. We expressed results as number needed to treat for an additional beneficial outcome
(NNTB) when appropriate, along with different rates of baseline risk. We expressed results from analyses of
continuous data as mean differences (MDs), along with CIs and respective P values. Whenever a small study (fewer
than 30 participants) included zero events in one arm, we used Fisher's exact test to calculate the P value, and we
provided numerical data for the numerator/denominator for each treatment (Grainge 2013). We calculated
Fisher's exact test using GraphPad software (GraphPad).
We interpreted numerical data in charts and tables when possible. We tried to extract numerical data from graphical
presentations by using a ruler, or we contacted study authors for recent trials if the data were unclear. For data that had been
extracted from a graph, we added remarks.
For studies that exclusively presented median values for a particular outcome, we substituted the median for the mean,
provided that data were not too skewed. When standard deviations were not available from a paper, we tried to calculate
these from other available data. When confidence intervals were provided, we used the formula given in Chapter 7.7.3.2 of
the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a).
For multi-arm studies, we analysed each arm in comparison with placebo when possible.
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Unit of analysis issues 
Cluster randomised trials
We checked cluster randomised trials (groups of individuals instead of individuals randomised to intervention or control) for
unit of analysis errors based on advice provided in Section 16.3.4 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011d).
Cross-over studies
In cross-over studies (with each participant allocated to a sequence of interventions, instead of to only one intervention), unit
of analysis issues can arise when participants have been randomised to multiple treatments over multiple periods, or when
there has been an inadequate washout period. We dealt with cross-over studies by analysing only the first treatment period
as a simple parallel-group study.
Within-participant studies (self-controlled, left-right designs)
Given that analysis of paired data was not possible with RevMan, we summarised the data from within-participant studies in
the text. The unit of analysis in within-participant studies was one hand per participant, whereas in parallel-group studies, the
unit of analysis was per participant. Relevant data were presented in the analysis as "other data", in table format.
Studies with multiple arms
For studies including multiple arms (more than two) in the analyses, we plotted the different comparisons in different forest
plots when possible.
Dealing with missing data
For trials published from 1999 onwards and with uncertainty, we tried to contact trial authors if we felt that this may yield
essential additional information. In these cases, we contacted the first author or, when stated, the corresponding author of
the article. For the current review, we did not make any assumption or imputation to missing data. We extracted all outcome
data as they were reported in the original studies. We stated when authors were contacted and whether additional
information was provided under Characteristics of included studies.
Assessment of heterogeneity 
We had planned to explore reasons for heterogeneity amongst studies and, if necessary, to carry out sensitivity analyses to
examine the effects of excluding study subgroups (e.g. children vs adults, atopic vs allergic contact hand eczema) or studies
with high risk of bias.
Clinical heterogeneity (or clinical diversity) is considered as variability among participants, interventions, and outcomes. In
future updates of this review, we plan to assess clinical heterogeneity by examining characteristics of the studies and
similarity between types of participants, interventions, and outcomes. If studies were sufficiently similar, we achieved
statistical pooling by using a weighted treatment effect.
We used random-effects model meta-analysis because of anticipated differences across studies in, amongst other things,
the participant base included. Statistical heterogeneity was investigated with the I² test. If the I² statistic had been greater
than 50%, reasons for heterogeneity in studies would have been explored.
Assessment of reporting biases
We planned on including statistical methods for detecting publication bias (e.g. Begg's funnel plots). However, funnel plots
are recommended by the Cochrane Handbook for Systematic Reviews of Interventions, Section 10.4 (Higgins 2011c), when
at least a substantial number of studies (10 or more) are included in the meta-analysis. This was not feasible due to the
heterogeneity of included studies. For reporting bias, we studied the study authors and institutions involved (pharmaceutical
companies or not), funding, sponsorship of commercially available supplements, and, finally, conflicts of interest.
Data synthesis
When data permitted, we had planned to conduct statistical pooling, using a random-effects model whenever studies
appeared sufficiently similar.
Subgroup analysis and investigation of heterogeneity 
We conducted no pre-planned subgroup analyses in the current review, but in future updates, we will carry out analyses, if
data permit, to examine the effects of including specific study subgroups (e.g. children vs adults, recurrent vesicular vs
hyperkeratotic hand eczema).
Sensitivity analysis
We conducted no pre-planned sensitivity analyses in this review, but for future updates, we will consider performing
sensitivity analyses for pooled analysis involving only studies at low risk of bias.
'Summary of findings' tables
We included in the 'Summary of findings' tables all primary outcomes and the secondary outcome 'investigator-rated
reduction in severity' for the clinically most relevant studies (Ryan 2016). We assessed clinical relevance based
on the clinical experiences of study authors. We tried to include studies from every group of interventions (topical
corticosteroids, topical calcineurin inhibitors, UV therapy, and systemic treatments), and to keep the total number
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of included studies to a minimum. We therefore aimed to include studies that compared different groups of
comparisons or studies that answered the questions that authors ask themselves on a regular basis in everyday
practice. The 'Summary of findings' tables are based on the GRADE principles (GRADEPro, version 3.6.1). The GRADE
approach is a sequential process that evaluates the quality of a body of evidence by considering the following domains.
Study limitations, which refers to risk of bias in either study design or conduct that could lead to biased estimation of
treatment effect.
Inconsistency of results, which refers to unexplained heterogeneity of results.
Indirectness of evidence, which refers to directness of comparisons of target populations, interventions, comparators, and
outcomes of the included studies compared to those of the planned PICO of the systematic review.
Imprecision, because results are generally imprecise when the study includes few participants, few events, or a wide
confidence interval of the effect estimate.
Publication bias.
Randomised controlled trials (RCTs) began as high-quality/certainty evidence, but If concerns were identified in the above
domains, certainty was rated down by one or two levels depending on the severity of the concern. The GRADE approach
completes assessments of the body of evidence by grading it in the high, moderate, low, or very low certainty category.
A duration of longer than three months was preferred for evaluating a clinically relevant effect. We considered interventions
comparing different groups of interventions and studies providing different treatment regimens with regards to dosages or
frequency as clinically most relevant. Therefore we included the following comparisons in the 'Summary of findings' tables.
Clobetasol foam compared to vehicle (Summary of findings table 1).
Mometasone furoate cream in different treatment schedules (Summary of findings table 2).
Local narrow-band UVB compared to local PUVA (Summary of findings table 3).
Tacrolimus 0.1% ointment compared to mometasone furoate ointment (Summary of findings table 4).
Tacrolimus 0.1% ointment compared to vehicle (Summary of findings table 5).
Oral cyclosporin compared to topical betamethasone dipropionate (Summary of findings table 6).
Oral alitretinoin compared to placebo at 10 mg and 30 mg a day (Summary of findings table 7; Summary of findings table
8).
Results 
Description of studies 
We included 60 RCTs on different interventions for hand eczema.
Results of the search
Our searches of the databases yielded 588 records (Electronic searches). Our searches of the trials registries identified six
further studies. We therefore had a total of 594 records.
No duplicate records were identified, hence we screened 594 references. We excluded 493 records based on
titles and abstracts. We obtained the full text of the remaining 101 records. We excluded 11 studies (Characteristics of
excluded studies). We added 20 records to Characteristics of studies awaiting classification because we were
unable to extract separate data on hand eczema patients. We identified eight ongoing studies (Characteristics of ongoing
studies).
We included 60 studies reported in 62 references. For a further description of our screening process, see the study
flow diagram (Figure 1).
Included studies
Details of the 60 included studies with a total of 5469 participants are summarised in the Characteristics of included studies
table. We included studies published from May 1967 to April 2018, as well as unpublished data from studies registered in trial
registries up to April 2018.
Design
Of the 60 RCTs, 18 were within-participant studies (i.e. having a left-right design, comparing one hand with the other)
(Adams 2007; Baskan 2005; Cartwright 1987; Chu 2009; Faghihi 2008; Fairris 1984; Fairris 1985; Fredriksson 1975; Grattan
1991; Kemper 1998; King 1984; Lindelöf 1987; Möller 1983; Odia 1996; Schnopp 2002; Sezer 2007; Sheehan-Dare 1989; 
Uggeldahl 1986). In total, 41 studies used a parallel-group design. Fowler 2005 used a parallel-group design but
within each group chose a within-participant design as well. Two of these parallel-group studies used a cross-over
design (Burrows 1986; Granlund 1996), but they were parallel before cross-over.
Participants
The original protocol stipulated diagnosis by a physician. Although only one of the identified studies stated this
explicitly, all studies were based on participants being outpatients at hospitals. Therefore, we assumed that the
diagnosis was established by a physician for all participants. Some studies included a specific subgroup of hand
eczema, while others excluded these subgroups, for example, vesicular (or dyshidrotic) hand eczema was included
by 11 studies (Adams 2007; Grattan 1991; Odia 1996; Pigatto 1990; Polderman 2003; Said 2010; Schnopp 2002; Sezer
2007; Sharma 2006; Sheehan-Dare 1989; Tzaneva 2009), and vesicular hand eczema was excluded by three
studies (Bleeker 1989; Chu 2009; Hordinsky 2010). The same was true for atopic dermatitis and atopic dermatitis on
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the hands: six studies targeted atopic eczema specifically (Bauer 2012; Fowler 2005; Lauriola 2011; NCT01231854; Veien
1995; Yousefi 2012), while six other studies excluded participants with characteristics of atopic eczema (Bleeker 1989; 
Burrows 1986; Chu 2009; Hordinsky 2010; Katsarou 2012; Lodén 2012a).
All studies were performed in a secondary setting and included participants who had hand eczema for at least several weeks
to months; therefore the review did not include acute hand eczema.
The studies included participants with different grades of severity, and not all studies included a severity grade as an
inclusion criterion. Moderate to severe hand eczema was included in the following studies: Baskan 2005; Kircik 2013; Krejci-
Manwaring 2008; Pacor 2006; Ruzicka 2004; Schnopp 2002; Tzaneva 2009; van Coevorden 2004a. Chu 2009 included only
mild hand eczema. Mild to moderate hand eczema was included in Belsito 2004, Hordinsky 2010, Kucharekova 2003,
Lauriola 2011, and Odia 1996. Cherill 2000, Fowler 2005, Hanifin 2004, and Uggeldahl 1986 included moderate hand
eczema. Fowler 2014, NCT01231854, and Ruzicka 2008 included only severe hand eczema, and Bauer 2012 included
moderate to very severe hand eczema. In two studies, the included severity was not completely clear (Veien 1995; Veien
1999).
Another inclusion criterion was poor response or resistance to conventional therapies such as topical corticosteroids (Adams
2007; Brass 2015; Cartwright 1987; Fairris 1984; Fairris 1985; Fowler 2014; Granlund 1996; King 1984; Lindelöf 1987; 
NCT01231854; Odia 1996; Pacor 2006; Ruzicka 2004; Ruzicka 2008; Sezer 2007; Sheehan-Dare 1989; Sjövall 1987; 
Tzaneva 2009). Only one study included a minimally affected area of hand eczema (Bayerl 1999). Disabling hand
eczema was an inclusion criterion in two studies (Granlund 1996; Grattan 1991).
Overall, children were not included as a study population. One study included participants between 1.5 and 70
years of age (Uggeldahl 1986), another study included participants at least 10 years of age (Boroujeni 2017), four
studies included participants 12 years of age and older (Faghihi 2008; Jowkar 2011; Jowkar 2014; Kircik 2013), and
one study had a minimum inclusion age of 16 years (Grattan 1991). The remaining studies included only adults. A few
studies excluded older participants. Two studies used an upper age limit of 60 years (Jowkar 2011; Yousefi 2012),
three studies 65 years (Agarwal 2013; Bleeker 1989; Fowler 2005), three studies 70 years (Granlund 1996; Ruzicka 2004; 
Uggeldahl 1986), and three studies 75 years (Fowler 2014; NCT01231854; Ruzicka 2008).
One study included female participants exclusively (Kaaber 1983). The remaining studies included both female and male
participants. Pregnant or lactating women, or both, were excluded from about half of the studies (32 studies).
Overall, participants were in general good health, and studies often excluded systemic diseases such as diabetes and renal
or hepatic disease.
Sample size calculation
A total of 5469 participants were enrolled. Most studies were relatively small (12 to 158 participants), and sample size
calculations often were not stated. A large proportion of the 5469 participants were included in five trials (Belsito 2004; 
Fowler 2014; Hordinsky 2010; Ruzicka 2004; Ruzicka 2008). Twelve studies included fewer than 25 participants (Burrows
1986; Fairris 1984; Grattan 1991; Kemper 1998; King 1984; Lindelöf 1987; Odia 1996; Pigatto 1990; Schnopp 2002; Sezer
2007; Sharma 2006; Sjövall 1987). In 27 studies, between 25 and 50 participants were included (Baskan 2005; Bauer 2012; 
Bayerl 1999; Cartwright 1987; Cherill 2000; Faghihi 2008; Fairris 1985; Fredriksson 1975; Granlund 1996; Gupta 1993; 
Hanifin 2004; Jowkar 2011; Kaaber 1983; Katsarou 2012; Krejci-Manwaring 2008; Kucharekova 2003; Lauriola 2011; Lodén
2012a; Odia 1996; Pacor 2006; Polderman 2003; Said 2010; Sheehan-Dare 1989; Thestrup-Pedersen 2001; Tzaneva 2009; 
Veien 1995; Whitaker 1996). Between 50 and 100 participants were included in eight studies (Bleeker 1989; Boroujeni 2017; 
Brass 2015; Fowler 2005; Jowkar 2014; Möller 1983; Uggeldahl 1986; Yousefi 2012). Between 100 and 500
participants were included in eight studies (Agarwal 2013; Belsito 2004; Bissonnette 2010; Hill 1998; Kircik 2013; Ruzicka
2004; van Coevorden 2004a; Veien 1999). Three studies included more than 500 participants (Fowler 2014; Hordinsky 2010;
Ruzicka 2008).
NCT01231854 aimed to include 78 participants based on a sample size calculation; however the study was ended
prematurely and included only 15 participants.
Setting
None of the studies were conducted in a primary care setting. As far as we know, all studies were conducted in a
secondary care setting and included outpatients from hospitals. About half of the studies were conducted as multi-
centre studies, usually within the same country. Six studies were international multi-centre studies (Belsito 2004; 
Bissonnette 2010; Cherill 2000; Hordinsky 2010; Ruzicka 2004; Ruzicka 2008).
Although most studies did not declare the country in which the study was conducted, we assumed that they were
conducted in the hospitals of the investigators. Based on this assumption, most studies were conducted in North
America and Europe. A substantial number of studies were conducted in the United Kingdom (Brass 2015; Burrows 1986; 
Cartwright 1987; Fairris 1984; Fairris 1985; Grattan 1991; Hill 1998; King 1984; Sheehan-Dare 1989), Sweden (Bleeker
1989; Fredriksson 1975; Lindelöf 1987; Möller 1983; Sjövall 1987), Germany (Adams 2007; Bauer 2012; Bayerl 1999; 
Bissonnette 2010; NCT01231854; Odia 1996; Schnopp 2002), Denmark (Kaaber 1983; Thestrup-Pedersen 2001; Veien
1995; Veien 1999), and the Netherlands (Kemper 1998; Kucharekova 2003; Polderman 2003; van Coevorden 2004a).
A few studies were conducted in other parts of the world, including Iran (Boroujeni 2017; Faghihi 2008; Jowkar 2011; Jowkar
2014; Yousefi 2012), India (Agarwal 2013; Sharma 2006), Turkey (Baskan 2005; Sezer 2007), Singapore (Said 2010
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), South Africa (Whitaker 1996), and Taiwan (Chu 2009).
Treatment duration
Overall the studies were of relatively short duration. One study had a duration of only one week (Gupta 1993). The
treatment episode was less than one month in 22 studies (Belsito 2004; Bleeker 1989; Boroujeni 2017; Chu 2009; Faghihi
2008; Fowler 2005; Fredriksson 1975; Hill 1998; Jowkar 2011; Jowkar 2014; Kemper 1998; King 1984; Kircik 2013; Lauriola
2011; Lodén 2012a; Odia 1996; Pacor 2006; Polderman 2003; Schnopp 2002; Sharma 2006; Uggeldahl 1986; Yousefi
2012), and it was less than two months (eight weeks) in 12 studies (Adams 2007; Baskan 2005; Bauer 2012; Bayerl 1999; 
Cherill 2000; Grattan 1991; Kucharekova 2003; Lindelöf 1987; Said 2010; Sheehan-Dare 1989; Sjövall 1987; Thestrup-
Pedersen 2001); nine studies had a treatment duration between two and four months (Brass 2015; Cartwright 1987; Fairris
1984; Fairris 1985; Katsarou 2012; Krejci-Manwaring 2008; Pigatto 1990; Sezer 2007; van Coevorden 2004a).
Only 11 studies had a duration of active treatment longer than four months (Agarwal 2013; Bissonnette 2010; Fowler 2014; 
Hanifin 2004; NCT01231854; Ruzicka 2004; Ruzicka 2008; Tzaneva 2009; Veien 1995; Veien 1999; Whitaker 1996).
Studies with a cross-over design had an active treatment phase of six weeks for both drugs (Burrows 1986; Granlund 1996),
and Hordinsky 2010 had an active treatment phase of six weeks, followed by an open-label phase.
The total duration of active treatment was unclear in two studies (Kaaber 1983; Möller 1983).
Follow-up
Most studies did not include a follow-up period. Only 24 studies included a follow-up period (Baskan 2005; Cartwright 1987; 
Fairris 1984; Fairris 1985; Fowler 2014; Granlund 1996; Grattan 1991; Jowkar 2011; Krejci-Manwaring 2008; Lindelöf 1987; 
NCT01231854; Pacor 2006; Polderman 2003; Ruzicka 2004; Ruzicka 2008; Said 2010; Schnopp 2002; Sezer 2007; 
Sharma 2006; Sheehan-Dare 1989; Sjövall 1987; Tzaneva 2009; van Coevorden 2004a; Whitaker 1996). This period varied
from a week to several months and involved scheduled visits or just a single follow-up questionnaire. Veien 1999 clearly
states that the treatment episode was 30 weeks, although data in the survival analyses suggest follow-up to 250 days.
Two studies were ended prematurely (Burrows 1986; NCT01231854).
Interventions and comparisons
In most studies, an active intervention was compared to no treatment, variants of the same medication, or placebo
(or vehicle). Very few studies compared two different classes of interventions: one study compared coal tar paste
with a corticosteroid (Kemper 1998), one study phototherapy (PUVA) with X-rays (Sheehan-Dare 1989), one study
phototherapy (UVA-1) with a topical corticosteroid (Said 2010), two studies a calcineurin inhibitor with a
corticosteroid (Katsarou 2012; Schnopp 2002), one study cyclosporin with a topical corticosteroid (Granlund 1996),
and one study cromoglycate with a diet (Pigatto 1990). One study compared oral cyclosporin to oral
alitretinoin (NCT01231854). We organised the remaining trials into the categories described below and provide details of the
various dose regimens. Full details of interventions and comparisons for each included study are given in the Characteristics
of included studies.
I. Skin protection measures, including gloves
These were not included in this review.
II. Topical treatments
A. Bland emollients
One study (Table 1) compared effects of two different emollients - an emollient with ceramides (Locobase
Repair) in 17 participants versus a regular petrolatum-based emollient (Vaseline-lanette) in 15 participants - as
adjuvants in the treatment of hand eczema over two months (Kucharekova 2003).
One within-participant study compared an emollient with E-DO lotion once daily to vehicle lotion. E-DO claims to be a
potential agent for revitalising skin cells to regain their moisture retention capacity and might improve wound healing and
inhibition of Staphylococcus aureus and Propionibacterium acnes, according to the study authors (Chu 2009).
B. Corticosteroid creams or ointments
Nine studies evaluated topical corticosteroids as the main intervention (Bleeker 1989; Faghihi 2008; Fowler 2005; Gupta
1993; Kircik 2013; Lodén 2012a; Möller 1983; Uggeldahl 1986; Veien 1999).
Bleeker 1989 compared two topical corticosteroids to determine whether the less potent fluprednidene (Cortoderm) cream
was as effective as the more potent betamethasone-17-valerate (Betnovate) cream. Each product was applied once daily, in
the evenings, for a study period of three weeks. In both study groups, a specific emollient was used if required.
In a within-participant study (Fowler 2005), the effectiveness of hydrocortisone butyrate (HB) 0.1% cream was compared with
three other medium-potency corticosteroid creams (fluticasone propionate 0.05% cream (FP), prednicarbate emollient 0.1%
cream (PC), and mometasone furoate 0.1% cream (MF)) for treatment of chronic atopic and hand dermatitis. Participants
were randomised to one of three treatment groups: HB versus FP, HB versus PC, or HB versus MF. Subsequently,
participants applied twice-daily HB to one hand, and FP, PC, or MF to the other hand, for a duration of two weeks.
A double-blind within-participant study investigated whether the addition of zinc sulphate to clobetasol cream is
effective in the treatment of chronic hand eczema (Faghihi 2008). Forty-seven participants were randomised and
subsequently were treated twice daily with clobetasol + zinc sulphate cream on one hand and clobetasol 'only' cream on the
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other hand for two weeks.
In Gupta 1993, one group received betamethasone dipropionate polyacrylic film-forming lotion (Occlucort) twice a day for
seven days. The other group received a traditional betamethasone dipropionate (Diprosone) lotion, slightly thickened to
resemble the consistency of the other product.
In Kircik 2013, participants received clobetasol propionate 0.05% foam or vehicle foam twice daily for a period of 15 days.
In a double-blind randomised clinical trial (Lodén 2012a), twice-daily application of betamethasone-valerate 0.1% cream (BV
group) was compared to once-daily application of betamethasone-valerate 0.1% cream in combination with once-daily
application of a moisturiser cream containing 5% urea (BV + M group). The study duration was two weeks. Both groups were
allowed to use urea 5% cream for additional hand treatment.
A multi-centre study was designed to investigate whether twice-weekly application of a steroid was effective in keeping
hand eczema, which had been brought into remission, under control (Möller 1983). To induce remission, 61 participants with
symmetrical hand eczema of at least six months duration were treated with clobetasol propionate (Dermovate) cream twice
weekly. Then, the 55 (out of 61) participants who were healed were included in a maintenance study and were followed for a
mean period of 138 days (range 55 to 193 days); this occurred in the form of an RCT that compared one hand (receiving
clobetasol (Dermovate) cream) with the other hand (receiving fluprednidene (Cortoderm) cream). When relapse occurred
during the maintenance phase, the cream allocated to that hand could be applied more frequently; if this failed, the cream for
the other (best) hand could be used temporarily. Participants were allowed to use an emollient (Essex cream) as needed.
Two strengths of the same topical corticosteroid were compared in a within-participant design (Uggeldahl 1986). Forty-six
participants were treated twice daily with desonide (Tridesilon) cream 0.1% on one hand and desonide (Apolar) cream 0.05%
on the other for two weeks. Participants had not been treated for eczema for at least one week before the study began.
The aim of one study was to compare mometasone (Elocon) ointment ("fatty cream") applied three times per week
versus two times per week (Veien 1999). Initially, all participants were treated for three weeks with daily application of
mometasone furoate to bring their dermatitis under control. This RCT investigated 106 participants whose dermatitis was
brought under control. They were randomised to three parallel study groups for up to 36 weeks: treatment with mometasone
furoate ointment once daily three times a week, treatment with mometasone furoate ointment once daily two times a week,
and treatment with only emollients. In this study, in case of obvious bacterial infection, a course of oral antibiotics or
potassium permanganate soaks, or both, was permitted. All participants were given an emollient to be used freely. Clinical
evaluations were carried out after 3, 6, 12, 18, 24, and 30 weeks of maintenance treatment.
For an overview of the outcome 'Investigator-rated good/excellent control' in these studies, see the additional tables
section (Table 2).
C. Coal tar and derivatives
Kemper 1998 investigated the efficacy of coal tar paste (pix lithanthracis) compared to zinc oxide paste and betamethasone-
valerate. Nineteen participants with symmetrical hand eczema were included and were treated with coal tar paste on one
hand and betamethasone-valerate ointment 0.1% or zinc oxide paste on the other hand. Participants were instructed to wear
gloves on both hands for protection and bandage. Clinical evaluation of the hands was carried out once a week, and at that
same visit, the corresponding treatment was applied, again to the hands. Treatment duration was four weeks.
For an overview of the outcome 'Investigator-rated good/excellent control' in this study, see the additional tables section
(Table 3).
D. Irradiation with UV light
Variations in UV phototherapy (UVA, UVB, PUVA) were investigated in 10 studies (Adams 2007; Bayerl 1999; Brass 2015; 
Grattan 1991; Polderman 2003; Said 2010; Sezer 2007; Sjövall 1987; Tzaneva 2009; van Coevorden 2004a).
Said 2010 compared the efficacy of topical betamethasone-valerate 0,1% cream twice daily to UVA-1 phototherapy thrice
weekly for six weeks. Twenty-four participants with chronic vesicular hand eczema were treated with phototherapy, and 23
participants were treated with topical corticosteroids.
Treatment with a portable UVB phototherapy unit, to be used at home, was compared with treatment by non-specific
topical treatment in a study among 48 participants with occupational hand dermatitis (Bayerl 1999). It seems that the UVB-
treated group also applied this non-specific topical treatment. The UVB-treated group irradiated their hands at home five
days per week for eight weeks according to a predetermined dosage scheme.
Two studies compared oral PUVA with topical bath PUVA: van Coevorden 2004a and Tzaneva 2009.
Tzaneva 2009 compared oral PUVA versus bath PUVA. Immediately after immersion for 15 minutes, the hands and feet
were exposed to UVA irradiation. The irradiation doses in both groups were increased depending on the degree of
erythematous response. Treatment was given three to four times a week until complete clearance, or over a maximum period
of 20 weeks. After clearing, participants were maintained on PUVA twice weekly for two weeks and then once weekly for
another four weeks.
van Coevorden 2004a compared a randomised controlled parallel study of oral PUVA phototherapy whereby the hands were
irradiated by participants themselves at home with bath PUVA; the hands were soaked in a psoralen (trioxsalen) solution
followed by UVA in the clinic. The aim was to demonstrate equal clinical efficacy, assuming that costs for home treatment
would be substantially lower. Treatment was given for 10 weeks, and there was follow-up after the end of treatment for
another eight weeks. Emollients were allowed in both groups.
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Sezer 2007 compared UVA with UVB: 12 participants received local narrow-band UVB three times a week on one hand and
local PUVA on the other hand for nine weeks. The initial dose was 150 mJ/cm² for each participant. A 20% increasing dose
schedule was used until a final dose of 2000 mJ/cm² was reached versus local PUVA three times a week during nine weeks
on 12/15 contralateral hands. The initial dose of psoralen plus UVA irradiation was 1.0 J/cm² with an increase of 0.5 J/cm² in
every second session until a final dose of 7.5 J/cm² was achieved.
Brass 2015 compared the efficacy of narrow-band UVB with localised PUVA. Sixty participants received immersion PUVA or
narrow-band UVB twice a week for 12 weeks.
Studies that employed UVA treatment were Adams 2007 and Grattan 1991.
A within-participant study compared the effectiveness of middle-dose UVA-1 irradiation to topical cream PUVA
therapy (Adams 2007). UVA-1 is a newer form of UV therapy that contains only long-wavelength UVA-1 radiation (340 to 400
nm) and thus reduces the risk of burning. Participants with chronic relapsing dyshidrotic hand eczema received one
treatment modality on one hand and one treatment modality on the other hand. Treatment was given three times a week
during a period of five weeks (middle-dose UVA-1 irradiation three times a week during five weeks (cumulative dose of 600
J/cm²) vs local 8-MOP-cream-PUVA irradiation three times a week during five weeks (cumulative dose of 17.4 J/cm²)). 8-
MOP-crème was applied 30 minutes before the start of irradiation. Grattan 1991 used topical PUVA three times weekly for
eight weeks versus UVA (with placebo psoralen paint). The PUVA treatment was performed by applying a liquid ("paint")
containing methoxypsoralen to one hand. On the contralateral hand, an inactive paint was applied, whereupon both hands
were irradiated with UVA. Moisturisers were allowed on both hands, and both hands received a small fraction of UVB from
UVA lamps.
Polderman 2003 used UVA-1 (long-wavelength UV radiation) irradiation 40 J/cm² on the hands five times weekly for three
weeks versus placebo (simulated blue light). Emollients seem to have been allowed in both groups.
Sjövall 1987 used UVB irradiation only on the hands four times a week for eight weeks in six participants versus a placebo
for UVB (filtered light) on the hands four times a week for eight weeks in six participants versus hand UVB followed by whole-
body UVB + UVA four times a week during eight weeks in six participants. Their 'ordinary topical treatment' was permitted in
all groups. Emollients were allowed in both groups.
For an overview of studies with UV therapy, see Table 4.
E. Irradiation with X-rays (ionising radiation)
X-rays/radiotherapy/Grenz rays were studied in five publications (Cartwright 1987; Fairris 1984; Fairris 1985; King 1984; 
Lindelöf 1987). One study compared conventional superficial radiotherapy to UV phototherapy (Sheehan-Dare 1989). All
these studies used within-participant designs (i.e. comparing one hand with the contralateral hand).
Two of these studies used superficial X-rays 300 Rad as active treatment (Fairris 1984; King 1984).
King 1984 included 20 participants and treated one hand with three fractionated doses of 100 Rad (i.e. a total of 300 Rad) at
45 kV given at one-week intervals; Fairris 1984 treated participants with a combination of topical therapy and superficial X-
ray therapy, and assessed them at 6, 9, and 18 weeks after the start of X-ray therapy. One hand was treated with 100 Rad at
50 kV on three occasions at intervals of 21 days (i.e. total 300 Rad), and the other hand with placebo. Participants continued
treatment with tar paste or steroid ointments on both hands throughout the trial.
Lindelöf 1987 gave six fractionated doses of 3 Gy at one-week intervals for six weeks. Placebo therapy was achieved by
allowing the apparatus to hum without emitting radiation.
In Cartwright 1987, one hand was irradiated three times with 3 Gy of Grenz rays (total 900 Rad), and the contralateral hand
was treated in an exactly similar manner with sham radiation. Treatments were repeated at 21-day intervals for a total of
three visits. Evaluations were performed by the doctor and the participant at 3, 6, 9, 12, 15, and 18 weeks after initial
treatment.
One study compared superficial X-ray and Grenz ray irradiation (Fairris 1985). Both radiation therapies were given in three
divided doses at 21-day intervals. One hand received 1 Gy of conventional superficial X-ray 50 kV, the other 3 Gy of Grenz
ray 10 kV.
One study compared X-ray irradiation to UV phototherapy (Sheehan-Dare 1989). Superficial X-ray irradiation (0.9 Gy at 50
kV administered on three occasions at 21-day intervals) on one hand was compared with topical PUVA therapy (three times
a week for six weeks) on the contralateral hand in 25 participants. Assessments were performed before and at 6, 9, and 18
weeks after the start of treatment.
For an overview of studies including irradiation with X-rays, see Table 5.
F. Topical calcineurin inhibitors
Tacrolimus was studied in four papers (Katsarou 2012; Krejci-Manwaring 2008; Pacor 2006; Schnopp 2002).
Pimecrolimus was evaluated in three papers (Bauer 2012; Belsito 2004; Hordinsky 2010), as well as in two
conference abstracts (Baskan 2005; Cherill 2000).
Topical tacrolimus 0.1% ointment (FK506) twice daily was compared with the topical corticosteroid mometasone
furoate 0.1% ointment in a within-participant design (Schnopp 2002). Participants were encouraged to use emollients in
addition. Treatment duration was four weeks, and treatment was followed by a washout period of two weeks. Tacrolimus
ointment 0.1% twice daily during four weeks versus mometasone furoate 0.1% ointment twice daily was also used in
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Katsarou 2012 (with tapering mometasone furoate dose in the mometasone arm of the trial).
Katsarou 2012 compared topical tacrolimus 0.1% twice daily for 30 days and once daily for 31 to 90 days in 15 participants to
mometasone furoate ointment twice daily for one week, once daily during week two and week three, once daily three times a
week for weeks four and five, and once daily two times a week during the rest of the study (for 90 days) in 15 participants.
Two studies addressed tacrolimus ointment versus vehicle (Krejci-Manwaring 2008; Pacor 2006).
Twice-daily application of tacrolimus ointment was compared to its vehicle to study its effectiveness in keeping hand
eczema in remission (Krejci-Manwaring 2008). Remission was induced after a three-week taper of prednisone. Simultaneous
to the prednisone taper, participants started with tacrolimus or its vehicle for a total treatment duration of 12 weeks.
The aim of another trial was to evaluate the efficacy of 0.1% tacrolimus ointment for nickel sulphate-induced allergic
contact dermatitis of the hands (Pacor 2006). Participants were randomised to twice-daily treatment with either 0.1%
tacrolimus ointment or its vehicle during 14 days.
Five of our included studies addressed the use of pimecrolimus cream: Baskan 2005; Bauer 2012; Belsito 2004; Cherill
2000; Hordinsky 2010.
A large multi-centre study with 294 participants compared twice-daily application of pimecrolimus 1% cream to twice-
daily application of vehicle in a three-week study (Belsito 2004). In both groups, the evening application was followed
by six-hour occlusion. Time to relapse was compared between pimecrolimus 1% cream and vehicle in a randomised
controlled parallel study (Bauer 2012). Before commencement, participants with atopic hand eczema used
mometasone furoate for one to three weeks until symptoms had cleared. This was followed by an eight-week
maintenance period with pimecrolimus versus vehicle cream. Another published abstract reporting a placebo-
controlled randomised trial comparing pimecrolimus 1% cream with vehicle over eight weeks found pimecrolimus to
be effective in suppressing all clinical signs of hand eczema apart from vesiculation (Baskan 2005). Only limited data
could be extracted from one study comparing pimecrolimus 1% cream (with or without occlusion) to vehicle because
this study was published as a conference abstract (Cherill 2000). In a large multi-centre study (Hordinsky 2010), 652 adults
were randomised to pimecrolimus 1% or vehicle cream twice daily with overnight occlusion for six weeks.
For an overview of studies including topical calcineurin inhibitors, see Table 6.
G. Other topical interventions
Two antibacterial agents - clioquinol cream and fusidic acid cream - each combined with a corticosteroid (betamethasone-
valerate) were compared in a multi-centre study on 120 hand eczema participants with confirmed or suspected secondary
infection of their eczema (Hill 1998). The unblinded study had a duration of four weeks.
One study investigated urea cream (Fredriksson 1975), that is, Aquacare HP cream, a moisturising emulsion containing
multi-sterols, phospholipids, and fatty diols (pH 6), twice a day (morning and evening) for four weeks, versus control of
Calmurid cream containing betaine and lactic acid (pH 3), twice a day for four weeks.
Bexarotene, a novel type of retinoid, was evaluated in 55 participants by a three-arm unblinded (phase I to II open
label) study lasting 22 weeks (Hanifin 2004). The intervention was bexarotene 1% gel applied in a stepwise accumulation
every two weeks from once every other day to three times daily (bexarotene only group). Comparators were bexarotene
application in combination with mometasone furoate (B + MF group) and in combination with hydrocortisone (B + HC group).
All three groups used emollients.
One study compared topical furpalmate-containing cream (0.3%) with a topical corticosteroid (hydrocortisone acetate
0.5%) twice a day (Lauriola 2011).
Jowkar 2014 studied the efficacy of topical fumaric acid 5% cream twice daily compared to triamcinolone 0.1% cream twice
daily in 92 participants.
Three studies investigated herbal topical treatments: one study compared a 2% oil extract of Nigella sativa L. to
betamethasone ointment 0.1% and Eucerin (Yousefi 2012). Nigella sativa L. (family Ranunculaceae) is an annual
flowering plant that grows in south and southwest Asia, of which the seeds can be used as spice. Another study
compared a cream with 4% Fumaria parviflora Lam. twice daily to vehicle cream (Jowkar 2011). Fumaria parviflora Lam.
extract (family Papaveraceae) is a Persian herbal medicine that is called 'Shahtareh' in Iran. The plants were dried, and from
them an abstract was made for the cream. Finally, twice-daily application with an oil-in-water emulsion-based herbal cream
containing fenugreek seeds 5%, marshmallow 5%, chamomile 5%, and walnut leaves 5% was compared with twice-daily
application of the topical steroid fluocinolone acetonide cream 2%, in the study of Boroujeni 2017.
In a within-participant study, pulsed direct iontophoresis on one hand was compared with no iontophoresis on the
contralateral hand (Odia 1996), in which one of the participants' hands received pulsed direct current iontophoresis, 20 times
15 minutes each during three weeks in 20 hands, or as a control, no iontophoresis on contralateral hands for three weeks.
Both hands received steroid-free tar solution and zinc paste.
For an overview of other topical interventions, see Table 7.
III. Systemic treatments
A. Oral corticosteroids
We identified no RCTs addressing oral corticosteroids.
B. Immunosuppressants
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We found two publications on cyclosporin (Granlund 1996), but these studies were based on the same trial, which had three
phases. Oral cyclosporin 3 mg/kg/d and placebo cream for six weeks was compared with topical betamethasone
dipropionate 0.05% cream and placebo capsules identical to cyclosporin. This was a cross-over trial, in which participants
who failed to respond to their intervention in phase I were crossed over to the alternative intervention. The use of own
emollients was allowed in both groups.
Agarwal 2013 investigated a low dose of azathioprine combined with topical clobetasol 0.05% cream compared to topical
clobetasol 0.05% cream alone during 24 weeks.
NCT01231854 compared the effects of oral cyclosporin 2.7 to 4.0 mg/kg to those of alitretinoin 30 mg/d during 24 weeks.
Please see Table 8.
C. Oral retinoids
We identified six studies evaluating oral retinoids (Bissonnette 2010; Fowler 2014; NCT01231854; Ruzicka 2004; Ruzicka
2008; Thestrup-Pedersen 2001). Ruzicka 2004 had previously been presented in part as a conference abstract (Larsen
2003, listed under Ruzicka 2004).
Three studies investigated the effect of 10 mg oral alitretinoin (Bissonnette 2010; Ruzicka 2004; Ruzicka 2008)
Two large multi-centre studies compared a total of four different oral doses of a novel retinoid (alitretinoin) with
placebo capsules (Ruzicka 2004; Ruzicka 2008). In Ruzicka 2004, three groups, each receiving respectively, 10, 20,
or 40 mg per day, were compared with a placebo group. The trial lasted 12 weeks. The other study (Ruzicka 2008; also
known as Benefit of Alitretinoin in Chronic Hand Eczema or BACH study) compared two groups receiving, respectively, oral
alitretinoin 10 or 30 mg once daily versus placebo up to 24 weeks. In both studies, participants were allowed to use a
standard emollient.
The large multicenter study of Fowler 2014 compared alitretinoin 30 mg/d to placebo in 596 participants with severe chronic
hand eczema. The treatment duration was 24 weeks, and afterwards participants were followed up for a substantial period of
time.
NCT01231854 aimed to compare the effectiveness and safety of 30 mg alitretinoin to cyclosporin during 24 weeks in 78
participants.
In Bissonnette 2010, 117 participants suffering from chronic hand eczema were included who had been successfully
treated with alitretinoin in an earlier study (Ruzicka 2008), and who had relapsed within the 24-week observation
period after treatment. These 117 relapsed participants were randomised to receive their previous treatment or
placebo in a 2:1 ratio. A total of 73 participants were included who had been treated with 30 mg alitretinoin in the
previous BACH study (Ruzicka 2008). No other topical or systemic medication for hand eczema was allowed during the
treatment period. Dose reductions of study medication were not allowed.
Thestrup-Pedersen 2001 compared acitretin given orally at 30 mg daily for eight weeks to placebo capsules given for eight
weeks. Both groups were allowed to use topical emollients.
For an overview of studies on oral retinoids, see Table 9.
D. Other oral interventions
This group included six studies (Table 10) - one on triethylenetetramine (Burrows 1986), two on disulphiram (Kaaber 1983; 
Sharma 2006), one comparison of a low-nickel diet versus oral treatment with disodium cromoglycate (Pigatto 1990),
one on oral ranitidine (Veien 1995), and one on evening primrose oil (Whitaker 1996).
Three studies aimed specifically to intervened on the imputed role of nickel allergy in hand eczema, and included
exclusively nickel-sensitive participants (Burrows 1986; Kaaber 1983; Sharma 2006).
Burrows 1986 compared oral triethylenetetramine (Trientine) 300 mg daily for six weeks to placebo and was designed as a
cross-over study, but this trial was terminated prematurely (23 participants had been included) because of literature reports
on teratogenicity in rats.
Kaaber 1983 compared oral tetraethylthiuram disulphide 50 mg/d first week, increasing to 200 mg/d for at least six weeks, to
placebo, and was performed in 30 nickel-sensitive (patch test-positive) women with pompholyx-type hand eczema. Half of
the participants (n = 15) received tetraethylthiuram disulphide (Antabuse) with gradually increasing dosage (up to 20 mg/d)
for "at least six weeks"; probably this maximum dose was given for six weeks. The other 15 women received placebo tablets.
Both groups were allowed to use a topical corticosteroid (desoximethasone) and emollients.
Twenty-one nickel-sensitive participants (proven by means of patch testing) with vesicular hand eczema were
included in a single-blinded trial and were randomised into two treatment groups (Sharma 2006); a low-nickel diet in
combination with disulphiram was compared with a normal diet in combination with placebo.
Pigatto 1990 compared a low-nickel diet in eight participants to oral disodium cromoglycate (DSCG) 1500 to 2000 mg three
times a day in nine participants to no treatment in seven participants for a period of three months; however this last group
was not randomised and therefore was not included in the analyses.
Veien 1995 compared oral ranitidine 300 mg twice daily to placebo tablets in a trial of probably 16 weeks. Both groups were
allowed to use betamethasone cream/ointment and emollients.
Evening primrose oil (GLA - gamma linolenic acid) 50 mg in 20 participants was compared to placebo capsules in
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19 participants for 16 weeks (Whitaker 1996). Both groups were allowed to use unlimited qualities of emollients and a limited
amount of group III corticosteroids. Participants were followed up for eight weeks after the end of treatment, resulting in a
total study duration of 24 weeks.
For an overview, see Table 10.
Outcomes
The 60 included RCTs reported diverse outcomes. About half of these studies (n = 33) included our primary outcome
good/excellent control either participant- or investigator-rated, although not all included reproducible data. Almost all studies
reported our primary outcome 'adverse events' (n = 55). There was substantial heterogeneity between the studies in terms of
outcome measures, duration, and timing of outcome assessments.
Most studies used a scale to score the (change in) severity of hand eczema or the rate of clearance. However, many
different scoring systems were composed to score different items on different scales, and some did, while others did not,
include the affected area. Most scoring systems were unnamed, non-validated, and self-created, and combined objective and
subjective scores; in these cases, we provided a narrative account of study results and did not attempt quantitative analyses.
The Hand Eczema Severity Index (HECSI) is an assessment of the clinical severity of hand eczema that includes the
extent and severity of hand eczema. The hands are divided into five areas (fingertips, fingers, palms, backs of hands
and wrists). For each of these areas, the intensity of the six following clinical signs is scored on a grade from 0 (no skin
changes) to 3 (severe changes): erythema, induration/papulation, vesicles, fissures, scaling, and oedema were graded
on this scale. Moreover, the affected area for each is scored from 0 to 4 (0 = 0%; 1 = 1% to 25%; 2 = 26% to 50%; 3 =
51% to 75%; 4 = 76% to 100%) for the extent of clinical symptoms. Finally, the scores given for each extent location are
multiplied by the total sum of the intensity of each clinical feature, resulting in a score of 0 (no hand eczema symptoms)
to a maximum severity score of 360 points (very severe hand eczema). Scores above 28 represent severe hand
eczema. This is a validated scoring system with excellent agreement for both interobserver and intraobserver reliability (
Held 2005). Four studies used the HECSI (Agarwal 2013; Bauer 2012; NCT01231854; Yousefi 2012
); three studies awaiting classification (EUCTR2005-005793-75-DE; IRCT201112018263N1; NCT01950494
), as well as six ongoing studies, included this outcome parameter (IRCT2014012916412N1; ISRCTN80206075; 
NCT02664805; NCT03026907; NCT03026946; PACTR201704002194318).
The Dyshydrotic Eczema Area and Severity Index (DASI) is an assessment of severity combining objective (vesicles,
erythema, and desquamation) and subjective (itch) evaluations. Each item has to be assessed on a scale ranging from
0 to 3 (0 = absent, 1 = mild, 2 = moderate, 3 = severe), and the grading must be representative for all affected areas.
The severity grading is multiplied by a number representative of the total affected area. DASI score = (Vesicles +
Erythema + Desquamation + Itch) × Area score points. This results in a DASI ranging from 0 to 60. A DASI score
between 0 and 15 represents mild dyshidrotic eczema, 16 to 30 is moderate, and between 31 and 60 represents severe
dyshidrotic eczema. The DASI was first described by Odia (Odia 1996). It was used as primary outcome in five
studies (Adams 2007; Odia 1996; Polderman 2003; Said 2010; Schnopp 2002); however, this regularly used instrument is
not validated.
The Hand Eczema Area and Severity Score (HEAS) is used to assess clinical severity, corrected for the percentage
of affected skin area (Simons 1997). The score ranges from 0 (no hand eczema) to 96 (very severe hand eczema)
points. Two studies used the HEAS score, although this score is not validated for hand eczema (Chu 2009; Kucharekova
2003).
The Hand Eczema Extent Score (HEES) is a simple clinical score that is not validated (Meding 1989). The HEES
scores only the extent of the presence of eczema signs on different locations of the hands, without including intensity
of the lesions, with a range of 0 (no hand eczema) to 74 (very severe hand eczema) points. One study included the
HEES (Lodén 2012a).
The Total Lesion Symptom Score (TLSS) is the sum of seven items (erythema, oedema, vesicles, desquamation,
hyperkeratosis, fissures, and pruritus/pain) scored on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe). The
TLSS was used in Ruzicka 2004, and afterwards a slightly modified version (modified Total Lesion Symptom Score -
mTLSS) was used in Ruzicka 2008, Bissonnette 2010, Fowler 2014, and Brass 2015; the seven items were erythema,
oedema, vesiculation, scaling, lichenification/hyperkeratosis, fissures, and pruritus/pain. A high mTLSS represents severe
hand eczema. The mTLSS relates to the Physician Global Assessment, and a photographic guide has been developed to
train observers.
Some studies used scoring systems derived and validated for atopic dermatitis. For example, the validated Eczema
Area and Severity Index (EASI) was used (Jowkar 2011; Jowkar 2014), and this scoring system was adjusted to a
Hand Eczema Area and Severity Index (HEASI) score (Hanifin 2004). NCT01231854 included the validated SCORing Atopic
Dermatitis (SCORAD) next to the HECSI for participants with atopic hand eczema.
The Hand Eczema Area and Severity score is adapted from the well known EASI. The HEASI is calculated by (sum of
severity scores for signs) × (involved hand area integer), whereby for the area, 1 = < 10% involvement, 2 = 10% to 29%, 3 =
30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, and 6 = 90% to 100%. Severity score is 0 = none, 1 = mild, 2 = moderate, 3
= moderately severe, and 4 = severe for the following signs: erythema, scaling, oedema, lichenification, vesiculation, and
fissuring.
Investigator and Physician Global assessments (PGA and IGA) or variants of this scoring system (such as the
Investigator's Static Global Assessment (ISGA)) were used in different studies, on a 4- or 5-point scale for both hands
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overall (Bauer 2012; Belsito 2004; Bissonnette 2010; Bleeker 1989; Brass 2015; Cartwright 1987; Chu 2009; Fairris 1984; 
Fairris 1985; Fowler 2014; Grattan 1991; Gupta 1993; Hill 1998; Hordinsky 2010; King 1984; Kircik 2013; Krejci-Manwaring
2008; Kucharekova 2003; Lauriola 2011; NCT01231854; Pacor 2006; Ruzicka 2004; Ruzicka 2008; Sheehan-Dare 1989; 
Sjövall 1987). In general, a low IGA or PGA score represents well-controlled hand eczema, whereas a high score
represents severe hand eczema. PGA scores have been extensively studied and compared to, for example,
HECSI and HEAS (Coenraads 2005; Van Der Valk 2013).
Itch was scored as subjective parameter in most studies (Agarwal 2013; Bayerl 1999; Bleeker 1989; Boroujeni 2017; Brass
2015; Cherill 2000; Chu 2009; Faghihi 2008; Fowler 2005; Fowler 2014; Granlund 1996; Gupta 1993; Hanifin 2004; Hill
1998; Hordinsky 2010; Jowkar 2014; Katsarou 2012; Kemper 1998; Kircik 2013; Krejci-Manwaring 2008; Kucharekova 2003;
Lauriola 2011; Lindelöf 1987; Odia 1996; Pacor 2006; Pigatto 1990; Polderman 2003; Ruzicka 2004; Ruzicka 2008; 
Schnopp 2002; Sezer 2007; Sharma 2006; Thestrup-Pedersen 2001; Uggeldahl 1986; van Coevorden 2004a; Veien 1995).
Ten studies included quality of life as an outcome parameter; especially more recent studies and studies in trial registries
included quality of life. The extensively studied and validated Dermatology Life Quality Index (DLQI from Finlay 1994)
was used in seven studies (Bauer 2012; Brass 2015; Chu 2009; Kircik 2013; Lodén 2012a; Ruzicka 2004; Yousefi 2012
). The DLQI contains 10 questions regarding the impact of skin conditions and their treatment on participants' lives,
which are answered on a scale ranging from 0 (not at all) to 3 (very much). A total DLQI score between 0 and 1
represents no or minimal effect at all on a participant's life. A DLQI score of 10 or greater represents significant impact
on life quality, whereas a score over 21 represents an extremely large effect on quality of life. A change in DLQI score
of at least 4 points is considered clinically relevant in inflammatory skin conditions (Basra 2008; Basra 2015).
Another quality of life questionnaire that was used is the Eczema Disability Index (EDI) (Granlund 1996). The EDI
includes 15 questions representing different dimensions of quality of life on a scale from 0 (not at all) to 6 (very much).
The Skindex-29 was used by one study (Fowler 2014). Finally the Skindex-17 was used in another study (NCT01231854).
The Skindex-17 is a dermatological health-related quality of life instrument that is derived from the Skindex-29 and includes
only 17 items instead of 29, and a 3-point scale for answers instead of a 5-point scale. A high score on the Skindex
represents the huge impact of a skin condition on quality of life.
Economic losses such as sick days or out-of-pocket expenses were rarely registered as outcome parameters and were not
included as outcome parameters before 2004. NCT01231854 and Brass 2015 contained an extensive cost-effectiveness
analysis based on the EQ-5D. In addition, out-of-pocket expenses were registered in NCT01231854. van Coevorden 2004a
registered travel expenses and time off work for participants. Two studies included the influence of hand eczema on
work impairment with the Work Productivity and Activity Impairment Questionnaire (WPAI) (Kircik 2013; NCT01231854).
Cosmetic acceptability was considered as another outcome parameter in four studies (Fowler 2005; Fredriksson 1975; 
Kucharekova 2003; Lauriola 2011).
One of our secondary outcomes was 'dose reduction' - reduction in treatment dose per time unit or cumulative prescribed
treatment dose. None of the included studies provided reproducible data regarding this outcome.
Funding
For many older studies, it is unclear who funded the study. More recent studies often declared funding for the study or
clearly stated relationships with pharmaceutical companies. In total, 22 studies were funded by pharmaceutical
industries or were (co-)authored by employees of pharmaceutical companies (Bauer 2012; Belsito 2004; Bissonnette 2010; 
Bleeker 1989; Cherill 2000; Chu 2009; Fowler 2005; Fowler 2014; Granlund 1996; Gupta 1993; Hill 1998; Hordinsky 2010; 
Kircik 2013; Krejci-Manwaring 2008; Lodén 2012a; Möller 1983; Ruzicka 2004; Ruzicka 2008; Uggeldahl 1986; Veien 1995; 
Veien 1999; Whitaker 1996). Thirteen studies were sponsored by governmental organisations, universities, or
hospitals (Baskan 2005; Brass 2015; Faghihi 2008; Jowkar 2011; Jowkar 2014; Katsarou 2012; NCT01231854; Pacor 2006; 
Schnopp 2002; Sharma 2006; Tzaneva 2009; van Coevorden 2004a; Yousefi 2012).
Excluded studies
The excluded studies are summarised under Characteristics of excluded studies. The 11 excluded studies comprised studies
that were excluded for different reasons such as:
study on 'slightly irritated hands' in employees, which we did not accept as being hand eczema (Berndt 2001);
quasi-randomised study, or unclear whether the study was randomised (Aertgeerts 1985; Güler Özden 2004; HogenEsch
1998; Petering 2004; Rosén 1987; Zimmerman 1967);
study that did not examine hand eczema but rather colonisation with a bacterium - Staphylococcus aureus (Grivcheva-
Panovska 2013);
study without a comparator (Zeichner 2018);
study on prevention of hand eczema after initial treatment of hand eczema (Gergovska 2017); and
study from which we were unable to extract separate data on hand eczema because the study combined data on
hand and foot eczema (Chen 2015).
Ongoing studies
The search yielded eight ongoing studies whose content we have summarised under Characteristics of ongoing studies:
Three studies are focused on topical treatments.
NCT02664805: comparing the efficacy of twice daily applications of LEO 124249 ointment with LEO 124249 ointment
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vehicle for up to eight weeks for treatment of chronic hand eczema.
IRCT2014012916412N1: comparing the efficacy of pumpkin ointment twice daily with betamethasone ointment twice
daily, and almond ointment twice daily and Eucerin ointment twice daily.
IRCT2017070922965N10: evaluating the effect of topical atorvastatin as adjuvant therapy for treatment of hand eczema.
One study is examining palmar botulinum toxin injections.
PACTR201704002194318: evaluating the efficacy and tolerability of botulinum toxin type A for treatment of hand eczema.
Four are exploring systemic treatments.
JPRN-UMIN000003326: determining the effect of olopatadine on itching in hand eczema.
ISRCTN80206075: comparing alitretinoin 30 mg with PUVA twice weekly as first-line treatment for severe chronic hand
eczema.
NCT03026946: comparing the efficacy of alitretinoin 30 mg and cyclosporine for treatment for severe recurrent vesicular
hand eczema.
NCT03026907: comparing alitretinoin 30 mg with azathioprine in severe non-hyperkeratotic hand eczema.
Data from ongoing trials that have been completed at the time of the next update will be included in the review, if those
results are available.
Studies awaiting classification
We added 20 records to Characteristics of studies awaiting classification. These include a lot of studies on different topical
treatments such as hand creams and sanitisers for the treatment of hand eczema that were listed in different trial registries
and, although they seem completed, results have never been posted and we were unable to obtain these results.
This section also contains studies that included different dermatoses among hand eczema, but for which we were unable to
obtain separate data for hand eczema despite contacting the study investigator.
Risk of bias in included studies 
Many studies were at high or unclear risk of bias in one or more components of trial design. We assessed only six
studies as having low risk of bias in all components of trial design (Baskan 2005; Bauer 2012; Fowler 2005; Lindelöf 1987; 
Pacor 2006; Ruzicka 2004). Eight studies had only one unclear risk of bias with remaining domains rated as low
risk (Bissonnette 2010; Fairris 1984; Fairris 1985; Fowler 2014; Kircik 2013; Ruzicka 2008; Sheehan-Dare 1989; Yousefi
2012). We rated 29 studies as having high risk of bias in at least one domain (Adams 2007; Agarwal 2013; Bayerl 1999; 
Brass 2015; Burrows 1986; Cartwright 1987; Fredriksson 1975; Hanifin 2004; Hill 1998; Jowkar 2014; Katsarou 2012; 
Kemper 1998; King 1984; Krejci-Manwaring 2008; Kucharekova 2003; Lauriola 2011; Möller 1983; NCT01231854; Odia
1996; Pigatto 1990; Said 2010; Schnopp 2002; Sharma 2006; Sjövall 1987; Thestrup-Pedersen 2001; Tzaneva 2009; van
Coevorden 2004a; Veien 1995; Veien 1999).
Further information can be found in the risk of bias tables for each included study and in Figure 2 and Figure 3.
Allocation (selection bias)
Randomisation procedure
We judged the procedure as adequate (low risk of bias) when the allocation sequence was able to protect against biased
allocation of comparison groups. If no details were given about the methods of sequence generation (i.e. if there was doubt
about the adequacy of sequence generation), we judged studies as having unclear risk. We considered systematic methods
that allow biased allocations, such as alternation or assignment based on day of admission, as inadequate (high risk of bias).
References to a lottery system, throwing dice, or using a computer programme were considered as adequate (low risk of
bias).
The randomisation procedure was unclear in 22 studies. For 25 studies, we judged the randomisation procedure as
adequate based on the article (Adams 2007; Bauer 2012; Bayerl 1999; Cartwright 1987; Fairris 1984; Fairris 1985; Fowler
2014; Hanifin 2004; Hordinsky 2010; Kaaber 1983; Katsarou 2012; Kemper 1998; Kircik 2013; Krejci-Manwaring 2008; 
Lindelöf 1987; Lodén 2012a; NCT01231854; Polderman 2003; Ruzicka 2004; Ruzicka 2008; Sezer 2007; Sheehan-Dare
1989; Tzaneva 2009; van Coevorden 2004a; Yousefi 2012). For 13 studies, we were unable to base judgement on
the article, but personal communication with study authors clarified that the randomisation procedure was adequate (
Agarwal 2013; Baskan 2005; Bissonnette 2010; Brass 2015; Fowler 2005; Jowkar 2014; Kucharekova 2003; Pacor 2006; 
Schnopp 2002; Sharma 2006; Thestrup-Pedersen 2001; Veien 1995; Veien 1999). In total, we judged the randomisation
procedure as adequate in 38 studies.
Concealment of allocation
We judged this as adequate (low risk of bias) when clinicians and participants were unaware of future allocations before
participants gave consent to the study. Examples of these include randomisation by a third party or use of sequentially
numbered, opaque, sealed envelopes. We judged this as unclear risk of bias if insufficient details are given about methods of
allocation concealment. We judged the allocation inadequate (high risk of bias) when there was a possibility of knowledge of
the next assignment, so when investigators could have successfully guessed the allocation before the participant gave
consent.
Of the above-mentioned 38 studies with an appropriate randomisation procedure, concealment of allocation was
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adequate in 25 (Adams 2007; Agarwal 2013; Baskan 2005; Bauer 2012; Bayerl 1999; Fowler 2005; Fowler 2014; Jowkar
2014; Kircik 2013; Krejci-Manwaring 2008; Kucharekova 2003; Lindelöf 1987; Lodén 2012a; NCT01231854; Pacor 2006; 
Polderman 2003; Ruzicka 2004; Ruzicka 2008; Schnopp 2002; Sharma 2006; Thestrup-Pedersen 2001; van Coevorden
2004a; Veien 1995; Veien 1999; Yousefi 2012).
For eight studies, concealment of allocation was clear, but the randomisation procedure was unclear (Fredriksson 1975; 
Granlund 1996; Grattan 1991; Gupta 1993; Jowkar 2011; King 1984; Möller 1983; Uggeldahl 1986).
In total, in 33 studies the method used to conceal allocation was judged as adequate. In the remaining 27 studies, it is
unclear if allocation was concealed.
Blinding (performance bias and detection bias)
Performance bias
Performance bias refers to systematic differences between groups in the care provided, or in exposure to factors
other than the interventions of interest (Higgins 2011a). After enrolment into the study, blinding of participants and site staff
can reduce the risk that knowledge of which intervention was received, rather than the intervention itself, affects outcomes.
Effective blinding can also ensure that the compared groups receive similar amounts of attention, ancillary treatment, and
diagnostic investigation. With regards to performance bias, blinding of participants and of study personnel was judged
separately. Use of identical looking study and control drugs (vehicle or placebo) was considered an adequate method of
blinding, if the study was double-blind.
If study authors made every attempt to blind the study to the best of their abilities, we judged the study as low risk. When, for
example, the radiographer was the only person aware of treatment allocation but the study could not have been done in
another way, we judged this as low risk of bias because we considered this the best possible way to minimise the risk of
performance bias.
For 27 studies, both participants and staff were blinded in an adequate manner (Baskan 2005; Bauer 2012; Bissonnette
2010; Cartwright 1987; Chu 2009; Faghihi 2008; Fowler 2014; Fredriksson 1975; Granlund 1996; Grattan 1991; Gupta 1993;
Jowkar 2011; Jowkar 2014; King 1984; Kircik 2013; Krejci-Manwaring 2008; Lindelöf 1987; Lodén 2012a; NCT01231854; 
Pacor 2006; Ruzicka 2004; Ruzicka 2008; Sheehan-Dare 1989; Thestrup-Pedersen 2001; Veien 1995; Whitaker 1996; 
Yousefi 2012). Seven studies were only participant-blinded (Fairris 1984; Fairris 1985; Fowler 2005; Kaaber 1983; Möller
1983; Polderman 2003; Uggeldahl 1986). Nine studies had unclear risk of blinding (Belsito 2004; Bleeker 1989; Boroujeni
2017; Brass 2015; Burrows 1986; Cherill 2000; Hordinsky 2010; Lauriola 2011; Sezer 2007).
For 17 studies, no blinding of participants was attempted, so the risk of performance bias was considered high (Adams 2007;
Agarwal 2013; Bayerl 1999; Hanifin 2004; Hill 1998; Katsarou 2012; Kemper 1998; Kucharekova 2003; Odia 1996; Pigatto
1990; Said 2010; Schnopp 2002; Sharma 2006; Sjövall 1987; Tzaneva 2009; van Coevorden 2004a; Veien 1999). Some
studies claimed a double-blind design but this was not feasible because participants had to follow lifestyle interventions such
as a low-nickel diet (e.g. Pigatto 1990; Sharma 2006), or because treatment groups received completely different treatment
such as whole-body irradiation versus local radiation (e.g. Sjövall 1987).
Detection bias
'Detection bias' refers to systematic differences between groups in how outcomes are determined. Blinding of
outcome assessors reduces the risk that knowledge of which intervention was received, rather than the intervention
itself, affects outcome measurement (Higgins 2011a). We judged the procedure as having low risk of bias for detection when
the outcome assessor was unaware of the allocation. When an article states only that the study was investigator-blinded or
double-blinded, we considered this as too little information by which to judge the risk of bias and concluded that risk was
unclear. We judged low risk of detection bias for studies that used independent observers, that received study drugs packed
and dispensed by a third party, or that described another adequate method used to blind the observer.
The observer was blinded in an adequate manner in 30 studies (Agarwal 2013; Baskan 2005; Bauer 2012; Bissonnette
2010; Brass 2015; Fairris 1984; Fairris 1985; Fowler 2005; Granlund 1996; Grattan 1991; Gupta 1993; Jowkar 2011; Jowkar
2014; Katsarou 2012; King 1984; Kircik 2013; Krejci-Manwaring 2008; Kucharekova 2003; Lindelöf 1987; Lodén 2012a; 
NCT01231854; Odia 1996; Pacor 2006; Polderman 2003; Ruzicka 2004; Ruzicka 2008; Schnopp 2002; Sheehan-Dare
1989; Tzaneva 2009; Veien 1995).
Ten studies made no attempt to blind the observer (Adams 2007; Bayerl 1999; Hanifin 2004; Hill 1998; Kemper 1998; Said
2010; Sharma 2006; Thestrup-Pedersen 2001; van Coevorden 2004a; Veien 1999). For the remaining 20 studies, it is
unclear whether the observer was truly blinded.
Incomplete outcome data (attrition bias)
We tried to minimise the quantity of missing data by contacting all study authors from 1999 forward. We contacted them
through personal communication by email, letters, or social media features such as LinkedIn. We asked questions with
regard to uncertainty in the assessment of risks of bias or trial design. We also tried to search other sources such as trial
registries, which may provide additional information with regards to study design, or we compared the study to similar studies
done by the same authors.
We judged attrition bias as low risk in 50 studies (Baskan 2005; Bauer 2012; Belsito 2004; Bissonnette 2010; Bleeker 1989; 
Boroujeni 2017; Burrows 1986; Cherill 2000; Chu 2009; Faghihi 2008; Fairris 1984; Fairris 1985; Fowler 2005; Fowler 2014; 
Fredriksson 1975; Granlund 1996; Grattan 1991; Gupta 1993; Hill 1998; Hordinsky 2010; Jowkar 2011; Kaaber 1983; 
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Katsarou 2012; Kircik 2013; Kucharekova 2003; Lauriola 2011; Lindelöf 1987; Lodén 2012a; Möller 1983; NCT01231854; 
Odia 1996; Pacor 2006; Pigatto 1990; Polderman 2003; Ruzicka 2004; Ruzicka 2008; Said 2010; Schnopp 2002; Sezer
2007; Sharma 2006; Sheehan-Dare 1989; Sjövall 1987; Thestrup-Pedersen 2001; Tzaneva 2009; Uggeldahl 1986; van
Coevorden 2004a; Veien 1995; Veien 1999; Whitaker 1996; Yousefi 2012). We judged attrition bias as unclear in
two studies (Agarwal 2013; Hanifin 2004), and as high in eight studies (Adams 2007; Bayerl 1999; Brass 2015; Cartwright
1987; Jowkar 2014, Kemper 1998; King 1984; Krejci-Manwaring 2008).
Loss to follow-up and intention-to-treat (ITT) analysis
We judged the risk of attrition bias (incomplete outcome bias) as adequate (low risk of bias) when more than 80% of
participants were followed up and analysed in the groups to which they were originally randomised. In addition, we
considered an intention-to-treat (ITT) analysis as having low risk of bias for the attrition bias. When more than 20% of
participants dropped out and no ITT analysis was carried out, we considered the study element to have high risk of bias.
A total of 13 studies reported no dropouts (Cherill 2000; Faghihi 2008; Fredriksson 1975; Katsarou 2012; Lauriola 2011; 
Lodén 2012a; Odia 1996; Pacor 2006; Pigatto 1990; Schnopp 2002; Sharma 2006; Thestrup-Pedersen 2001; Veien 1999).
Despite loss of participants during follow-up, data were analysed according to the ITT analysis principle in 14 studies (Bauer
2012; Belsito 2004; Bissonnette 2010; Chu 2009; Fowler 2014; Granlund 1996; Hill 1998; Hordinsky 2010; Kircik 2013; 
Polderman 2003; Ruzicka 2004; Ruzicka 2008; van Coevorden 2004a; Veien 1995). NCT01231854 included an ITT analysis
but included only 14 of the 78 planned participants due to early termination.
For 23 studies, at least 80% of participants were followed up and were included in the analyses (Agarwal 2013; Baskan
2005; Bleeker 1989; Boroujeni 2017; Burrows 1986; Fairris 1984; Fairris 1985; Fowler 2005; Grattan 1991; Gupta 1993; 
Jowkar 2011; Kaaber 1983; Kucharekova 2003; Lindelöf 1987; Möller 1983; Said 2010; Sezer 2007; Sheehan-Dare 1989; 
Sjövall 1987; Tzaneva 2009; Uggeldahl 1986; Whitaker 1996; Yousefi 2012).
The highest dropout rates were, respectively, 40%, 39%, 37%, and 37% (Cartwright 1987 ; Krejci-Manwaring 2008; Kemper
1998; Jowkar 2014). Eight studies analysed less than 80% (Adams 2007; Bayerl 1999; Brass 2015; Cartwright 1987; 
Jowkar 2014, Kemper 1998; King 1984; Krejci-Manwaring 2008).
For one study, it is unclear how many participants were analysed because the text states that less than 80% finished
the protocol; however all participants seem to have been analysed without mention of ITT analyses (Hanifin 2004).
Selective reporting (reporting bias)
We found a total 38 studies that we judged as having low risk of bias (Adams 2007; Agarwal 2013; Baskan 2005; Bauer
2012; Bayerl 1999; Belsito 2004; Bissonnette 2010; Bleeker 1989; Brass 2015; Fairris 1984; Fairris 1985; Fowler 2005; 
Fowler 2014; Granlund 1996; Hanifin 2004; Jowkar 2011; Jowkar 2014; Katsarou 2012; King 1984; Krejci-Manwaring 2008; 
Kucharekova 2003; Lindelöf 1987; NCT01231854; Odia 1996; Pacor 2006; Pigatto 1990; Ruzicka 2004; Schnopp 2002; 
Sezer 2007; Sheehan-Dare 1989; Sjövall 1987; Thestrup-Pedersen 2001; Tzaneva 2009; Uggeldahl 1986; van Coevorden
2004a; Veien 1999; Whitaker 1996; Yousefi 2012). We judged 17 studies as having unclear risk of reporting bias (Boroujeni
2017; Burrows 1986; Cartwright 1987; Cherill 2000; Chu 2009; Faghihi 2008; Grattan 1991; Gupta 1993; Hill 1998; 
Hordinsky 2010; Kaaber 1983; Kircik 2013; Lodén 2012a; Polderman 2003; Ruzicka 2008; Said 2010; Sharma 2006
), and five as having high risk of reporting bias (Fredriksson 1975; Kemper 1998; Lauriola 2011; Möller 1983; Veien 1995
). High risk of bias was assigned whenever we found severe discrepancies between the Materials and Methods
section and the study protocol and Results section, when the stated primary outcome was neglected (Fredriksson 1975
), and when significance levels were reached on subscores or on other scores, or were not stated at all (Kemper 1998; 
Lauriola 2011; Möller 1983). For example, Fredriksson 1975 used an unclear severity scale ranging from 0 to 5 and did not
state the results of this outcome at all.
Many, especially older studies, did not register before commencement of the trial, so that the correspondence
between actually reported outcomes and outcomes intended to be reported could not be assessed for most included
studies. We found trial registration for 13 studies (Adams 2007; Bauer 2012; Bissonnette 2010; Brass 2015; Chu 2009; 
Fowler 2014; Hordinsky 2010; Jowkar 2011; Kircik 2013; Lodén 2012a; Ruzicka 2008; NCT01231854; Yousefi 2012), and
we found discrepancies in Chu 2009, Hordinsky 2010, Kircik 2013, Lodén 2012a, and Ruzicka 2008 with regards to
additional or missing outcome parameters. We found no major discrepancies between protocol and report in eight
studies (Adams 2007; Bauer 2012; Bissonnette 2010; Brass 2015; Fowler 2014; Jowkar 2011; NCT01231854; Yousefi
2012), although one study was registered two years after the recruitment start date (Yousefi 2012).
For the other studies, we examined discrepancies between the Materials and Methods section and the Results
section and noted no major discrepancies in most (Agarwal 2013; Baskan 2005; Bayerl 1999; Belsito 2004; Bleeker 1989; 
Fairris 1984; Fairris 1985; Fowler 2005; Granlund 1996; Hanifin 2004; Jowkar 2014; Katsarou 2012; King 1984; Krejci-
Manwaring 2008; Kucharekova 2003; Lindelöf 1987; Odia 1996; Pacor 2006; Pigatto 1990; Schnopp 2002; Sezer 2007; 
Sheehan-Dare 1989; Sjövall 1987; Thestrup-Pedersen 2001; Tzaneva 2009; Uggeldahl 1986; van Coevorden 2004a; Veien
1999; Whitaker 1996), although in some studies we did find severe discrepancies, mainly involving missing
information (Fredriksson 1975; Kemper 1998; Lauriola 2011; Möller 1983; Veien 1995).
Other potential sources of bias
Baseline comparison for severity of disease and diagnostic certainty
When assessing other potential sources of bias, we considered several aspects, namely, baseline balance for severity of
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disease and/or participants, diagnostic certainty, and whether the study was completed or ended prematurely.
Diagnostic certainty, meaning that the diagnosis was confirmed by a physician, was applicable to almost all studies. We
judged this as low risk in all but one study (Said 2010).
For within-participant studies, we considered a baseline comparison dispensable. This was true for 18 within-
participant studies (i.e. having a left-right design, comparing one hand with the other) (Adams 2007; Baskan 2005; 
Cartwright 1987; Chu 2009; Faghihi 2008; Fairris 1984; Fairris 1985; Fredriksson 1975; Grattan 1991; Kemper 1998; King
1984; Lindelöf 1987; Möller 1983; Odia 1996; Schnopp 2002; Sezer 2007; Sheehan-Dare 1989; Uggeldahl 1986).
For three studies, we found significant differences at baseline and therefore declared them as having unclear risk of
bias (Granlund 1996; Hill 1998; Krejci-Manwaring 2008). Sixteen studies did not state baseline comparisons (Agarwal 2013; 
Bayerl 1999; Boroujeni 2017; Burrows 1986; Cherill 2000; Kaaber 1983; Kucharekova 2003; Lauriola 2011; Lodén 2012a; 
Pigatto 1990; Polderman 2003; Said 2010; Sharma 2006; Sjövall 1987; Thestrup-Pedersen 2001; Tzaneva 2009),
and these were unclear in three studies (Bleeker 1989; Jowkar 2011; Whitaker 1996). For the remaining studies,
baseline comparisons were clearly stated (Adams 2007; Bauer 2012; Belsito 2004; Bissonnette 2010; Brass 2015; Fowler
2005; Fowler 2014; Gupta 1993; Hanifin 2004; Hordinsky 2010; Jowkar 2014; Katsarou 2012; Kircik 2013; NCT01231854; 
Pacor 2006; Ruzicka 2004; Ruzicka 2008; van Coevorden 2004a; Veien 1995; Veien 1999; Yousefi 2012).
Studies ending prematurely
Two studies were ended prematurely (Burrows 1986; NCT01231854). Burrows 1986 ended because teratogenicity in rats
was reported during the study, and NCT01231854 ended because the investigator-initiated study was unable to include the
planned number of participants. For this, we judged high risk of bias.
In total, we judged the risk of other potential sources of bias as high in two studies, unclear in 21 studies, and low in the
remaining 37 studies.
Effects of interventions 
In the text below, where it has been possible to calculate an effect size, we have reported these with 95% confidence
intervals. If no data were available for these analyses, we removed the result from this section and mentioned this in Table 1,
Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, Table 8, Table 9, and Table 10 for the primary outcome investigator-
rated good/excellent control.
We considered statistical pooling, but the studies were too heterogeneous in terms of design, types of particular
treatment compared, assessment of outcomes, duration of the trial, and presentation of data. The exceptions were
two studies that compared 10 mg alitretinoin as active treatment versus placebo (Ruzicka 2004; Ruzicka 2008), along
with studies regarding topical calcineurin inhibitors with regard to adverse events (Bauer 2012; Belsito 2004; Hordinsky
2010). Beside results of the pooled analysis, these studies also reported heterogeneity statistics. We considered, for
example, pooling Brass 2015 and Sezer 2007, although treatment intensity (twice weekly vs thrice weekly) and study
duration were too different. Moreover, only limited information was available on Brass 2015. Finally, Sezer 2007 was a
within-participant study, and Brass 2015 was a parallel-group study.
In the additional tables section, we have tabulated the primary outcome investigator-rated good/excellent control for the
different categories of interventions, that is, corticosteroids, irradiation with UV light, and irradiation with X-rays (respectively,
Table 2, Table 4, and Table 5).
I. Skin protection measures, including gloves
We identified no randomised controlled trials.
II. Topical treatments
Comparison 1. Bland emollients: ceramide-containing emollients
A comparison was made between an emollient with ceramides (Locobase Repair) in 17 participants versus a
regular petrolatum-based emollient (Vaseline-lanette) in 15 participants (Kucharekova 2003). Results were mainly depicted in
graphic presentation (bar diagrams), and exact numbers cannot be extracted.
Primary outcome: adverse events
One participant in the ceramide group experienced an exacerbation of hand dermatitis, as did two participants in the
comparison group (risk ratio (RR) 0.44, 95% confidence interval (CI) 0.04 to 4.39; P = 0.49; Analysis 1.1). This showed no
clear difference between groups.
Comparison 2. Bland emollients: emollient E-DO versus vehicle
Primary outcome: percentage of participants with self-rated good/excellent control at week 4
Chu 2009 conducted a within-participant study. After four weeks, the percentage of hands with a self-rated reduction of at
least 50% on the participants' global assessment (PaGA) was 34.92% (22 hands) in the E-DO group, and 36.51% (23 hands)
in the vehicle group (reported as 'other data'; see Analysis 2.1).
Primary outcome: percentage of participants with investigator-rated good/excellent control at week 4
We identified one within-participant study on E-DO (Chu 2009). After four weeks, 12 (19.0%) hands responded to E-DO only,
11 (17.5%) responded to vehicle only, and 25 (39.7%) responded to both. The overall response rate was 37 (58.73%) E-DO
hands and 36 (57.14%) vehicle hands (reported as 'other data'; see Analysis 2.2). Also see Table 1.
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Primary outcome: adverse events
At least one adverse event was reported by 19.4% of participants; 12 occurred on the E-DO hand (17.9%), and eight (11.9%)
on the vehicle hand. Prurirtus was recorded for six E-DO hands and for two vehicle hands (reported as 'other data'; see
Analysis 2.3). No serious adverse events were reported.
Comparison 3. Corticosteroid creams or ointments: fluprednidene acetate cream versus betamethasone-
valerate
For an overview of studies on topical corticosteroids for the outcome investigator-rated good/excellent control, see the
additional tables section (Table 2). That overview presents only the primary outcomes as defined according to our protocol
(i.e. participant- or investigator-rated good or excellent control); consequently, this does not necessarily reflect the primary
outcome that may be stated in the study report.
The point estimates (RRs) and confidence intervals (CIs), if available, are based on the per-protocol evaluation of
participants, and are not based on an ITT analysis, unless stated otherwise. We considered statistical pooling, but the
studies were too heterogeneous in terms of design, types of corticosteroid, assessment of outcomes, and presentation of
data.
Primary outcome: percentage of participants with investigator-rated good/excellent control (healed) after three weeks of
treatment
In a parallel study (Bleeker 1989), 14 out of 38 participants in the betamethasone group healed, as did 8 of 37 in the
fluprednidene group. There was no clear difference between groups (RR 0.59, 95% CI 0.28 to 1.23; Analysis 3.1; Table 2).
Primary outcome: adverse events
Eight participants in the betamethasone group and seven in the fluprednidene group reported adverse events such as
redness, smarting, swelling, irritation, or dryness (RR 0.90, 95% CI 0.36 to 2.23; Analysis 3.2), showing no clear differences
between groups.
Secondary outcome: reduction in severity, investigator-rated scoring improvement > 50% after three weeks
After three weeks of treatment, 23 of 38 participants in the betamethasone group and 27 of 37 participants in the
fluprednidene group showed improvement greater than 50% (Bleeker 1989). There were no clear differences between
groups (RR 1.21, 95% CI 0.87 to 1.67; Analysis 3.3).
Comparison 4. Corticosteroid creams/ointments: betamethasone-dipropionate film-forming lotion versus
betamethasone-dipropionate thick lotion
For this comparison, we found only one relevant trial (Gupta 1993).
Primary outcome: percentage of participants with investigator-rated good/excellent control of symptoms at day 7
Five of the 28 people in the betamethasone-dipropionate film-forming lotion group achieved good/excellent symptom
control compared to zero of 26 in the control group. Fisher's exact test results in a P value of 0.051 (Analysis 4.1; Table 2).
Primary outcome: adverse events
No clear difference was found in relation to the occurrence of at least one adverse event (RR 1.33, 95% CI 0.33 to 5.44;
Analysis 4.2).
In the betamethasone-dipropionate film-forming lotion group, two participants had stinging at the application site, one stinging
in the eyes when opening the bottle close to the face, and one a "melting" feeling during the sauna visit compared to no
application site reactions in the control group (Fisher's exact test P = 0.11). In the thickened lotion group, one participant
experienced headache (probably not related to the study drug), and two had an exacerbation of hand eczema, compared to
none in the control group (Fisher's exact test P = 1.00 and 0.49; also see Analysis 4.2). Zero events were reported in one of
the arms for all of these three subgroups, and the confidence interval around the point of estimate was wide.
Secondary outcome: reduction in severity, investigator-rated scoring (not specified), and in overall severity at day 7
At day 7, 23 out of 28 participants in the film-forming group improved compared to 10 out of 26 participants in the thickened
lotion group. There may be a difference between corticosteroid creams/ointments in favour of the betamethasone-
dipropionate film-forming lotion at day 7 (RR 2.30, 95% CI 1.35 to 3.93; number needed to treat for an additional beneficial
outcome (NNTB) 2, 95% CI 1 to 5; Analysis 4.3).
Secondary outcome: reduction in severity, investigator-rated global improvement, of eczema
The global comparison between treatments at day 7 showed improved eczema in 23 of 28 participants treated with
polyacrylic film-forming lotion versus 18 of 26 participants treated with thickened lotion (RR 1.19, 95% CI 0.87 to 1.62;
Analysis 4.4), indicating no clear difference in improvement between the two treatments.
Comparison 5. Corticosteroid creams/ointments: clobetasol propionate cream versus intermittent fluprednidene
acetate cream
Primary outcome: percentage of participants with investigator-rated good/excellent control
No relapses were observed in 32 of 46 (70%) hands treated with clobetasol propionate cream and in 14 of 46 (30%)
hands treated with fluprednidene acetate cream (Möller 1983). This is reported as 'other data'; see Analysis 5.1 and Table 2.
Primary outcome: adverse events
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Adverse events occurred in four participants treated with clobetasol and in three participants treated with fluprednidene
(reported as 'other data' in Analysis 5.2). One participant reported an adverse event from both glucocorticoids.
Comparison 6. Corticosteroid creams/ointments: clobetasol propionate foam 0.05% versus vehicle foam
This comparison included one study of 125 participants (Kircik 2013).
Primary outcome: percentage of participants with investigator-rated good/excellent control at day 15
In the clobetasol group, 38.7% (24/62 participants) had an Investigator Static Global Assessment (ISGA) score of 0 or 1
versus 27% (17/63 participants) in the vehicle group. There was no clear difference between groups (RR 1.43, 95% CI 0.86
to 2.40; Analysis 6.1; Summary of findings table 1; Table 2).
Primary outcome: percentage of participants with self-rated good/excellent control at day 15
At the end of the study on day 15, 51.6% (32/62 participants) in the clobetasol group graded their hand eczema as clear or
almost clear versus 22.2% (14/63 participants) in the vehicle group using the subject's global assessment (SGA). The
relative risk of 2.32 favours clobetasol propionate foam over vehicle (RR 2.32, 95% CI 1.38 to 3.91; NNTB 3, 95% CI 2 to 8;
Analysis 6.2; Summary of findings table 1).
Primary outcome: adverse events
Adverse events were reported in 18% (11/62) of participants in the clobetasol propionate foam group and in 8% (5/63) of
those in the vehicle foam group (RR 2.24, 95% CI 0.82 to 6.06; Analysis 6.3; Summary of findings table 1). One participant
reported application site burning/pruritus after clobetasol foam application. Three participants in the clobetasol group
reported nasopharyngitis compared to one participant in the control group (RR 3.05, 95% CI 0.33 to 28.52; Analysis 6.3). No
serious adverse events were reported in the clobetasol propionate foam group, and one participant in the vehicle group
discontinued due to severe fissures (RR 0.34, 95% CI 0.01 to 8.16; Analysis 6.3). The wide confidence interval in this case
could in part be the result of zero events in the clobetasol propionate foam group.
Secondary outcome: reduction in severity, participant-rated scoring, at day 15
At the end of treatment, 51 out of 62 participants (82.3%) had at least one grade improvement in SGA score, compared to 33
out of 63 participants (52.4%) in the vehicle group (RR 1.57, 95% CI 1.21 to 2.04; NNTB 3, 95% CI 2.2 to 7; Analysis 6.4; 
Summary of findings table 1). This difference is statistically significant, but we have reduced confidence in it is clinical
significance due to small sample size and limitation in study design.
Secondary outcome: reduction in severity, investigator-rated scoring, at day 15
In Kircik 2013, 26 out of 62 participants (41.9%) in the clobetasol group versus 18 out of 63 (28.6%) in the control group
improved by two grades or more in ISGA score. There was no clear difference between groups (RR 1.47, 95% CI 0.90 to
2.39; Analysis 6.5).
In total, 45 participants (72.6%) in the clobetasol group versus 38 (60.3%) in the control group improved by at least one
grade in ISGA score after 15 days of treatment. Again, there was no clear difference between groups (RR 1.20, 95% CI 0.94
to 1.55; Analysis 6.5).
Comparison 7. Corticosteroid creams/ointments: desonide cream 0.1% versus desonide cream 0.05%
Two strengths of the same topical corticosteroid were compared in a study using a within-participant (left/right)
design (Uggeldahl 1986). Forty-six participants were treated twice daily with desonide (Tridesilone) cream 0.1% on one hand
and desonide (Apolar) cream 0.05% on the other hand. These participants had not been treated for eczema for at least one
week before the study. The duration of the study was only 14 days.
Primary outcome: adverse events
Two participants reported stinging upon application of desonide 0.05% cream (reported as 'other data'; Analysis 7.1).
Comparison 8. Corticosteroid creams/ointments: intermittent treatment with topical mometasone furoate at
different frequencies (long term)
Veien 1999 included participants with chronic hand eczema that had cleared upon daily treatment for a maximum of 9 weeks
with mometasone furoate cream.
Primary outcome: percentage of participants with investigator-rated good/excellent control
Mometasone furoate 3 times/week versus mometasone furoate 2 times/week
For this subgroup, we found only one relevant trial (n = 72) (Veien 1999). Among participants treated with mometasone three
times a week, 29 out of 35 (83%) had no recurrences, compared to 25 out of 37 (68%) of those treated with mometasone two
times a week. Mometasone furoate cream used thrice weekly may slightly improve investigator-rated good/excellent control
of symptoms when compared to twice weekly application; however, the 95% confidence interval does include 1 (RR 1.23,
95% CI 0.94 to 1.61; Analysis 8.1; Summary of findings table 2; Table 2).
Mometasone furoate 3 times/week versus emollients only
For this subgroup, we found only one relevant trial (n = 69) (Veien 1999). We noted a clear difference between corticosteroid
creams/ointments: mometasone furoate cream 3 times weekly versus no steroids (RR 3.13, 95% CI 1.75 to 5.59; NNTB 2,
95% CI 1 to 3; Analysis 8.2; Table 2), but the difference may not be clinically significant due to imprecision of results caused
by small sample size and limitations in study design/conduct.
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Mometasone furoate 2 times/week versus emollients only
For this subgroup, we found only one relevant trial (n = 71) (Veien 1999). There was a statistically significant difference
between corticosteroid creams/ointments: mometasone furoate cream 2 times weekly versus no steroids (RR 2.55, 95% CI
1.40 to 4.67; NNTB 2, 95% CI 2 to 5; Analysis 8.2), i.e. mometasone furoate twice a week was better than emollient only, but
again, the difference may not be clinically significant due to imprecision of results caused by small sample size and
limitations in study design/conduct.
Primary outcome: adverse events
Mometasone furoate 3 times/week versus mometasone furoate 2 times/week
In 10 participants, mild skin atrophy was noted at some point during the study. In five participants, atrophy disappeared
during the study, and five participants had mild atrophy at the end of the study. The difference between groups was not clear
(RR 1.76, 95% CI 0.45 to 6.83; Analysis 8.3; Summary of findings table 2).
Comparison 9. Corticosteroid creams/ointments: 0.05% clobetasol and 2.5% zinc sulphate cream versus
0.05% clobetasol cream
Faghihi 2008 investigated whether zinc sulphate added to clobetasol cream is effective in the treatment of chronic hand
eczema (n = 47 hands).
Primary outcome: percentage of participants with investigator-rated good/excellent control
After eight weeks, 25 out of 47 hands (53%) treated with clobetasol + zinc sulphate cream were clear from scaling compared
to three hands (6%) treated with clobetasol cream alone (presented as 'other data' in Analysis 9.1; Table 2). Regarding
erythema, 41 hands (87%) treated with clobetasol + zinc sulphate cream were clear after eight weeks compared to one hand
(2%) treated with clobetasol cream alone (reported as 'other data' in Analysis 9.1). Last, 24 hands (51%) treated with
clobetasol + zinc sulphate cream and seven hands (15%) treated with clobetasol cream alone were clear of lichenification
(reported as 'other data' in Analysis 9.1). Absence of scaling, redness, and/or lichenification was seen as investigator-rated
good/excellent control. An overall assessment of good/excellent control was not possible.
Primary outcome: adverse events
Treatments were well tolerated and no significant adverse events were reported or observed by participants in both groups.
Trial authors concluded that treatments were generally well tolerated (no exact data given).
Comparison 10. Corticosteroid creams/ointments: betamethasone-valerate 0.1% cream twice daily versus
betamethasone-valerate 0.1% cream and urea 5% cream
Lodén 2012a compared the application of betamethasone-valerate 0.1% cream twice daily versus the application of
betamethasone-valerate 0.1% cream in the morning and a moisturiser containing urea 5% cream in the evening.
Primary outcome: percentage of participants with investigator-rated good/excellent control (cleared)
For this outcome, we found only one relevant trial (Lodén 2012a; n = 44). Clearance was defined as a score ≤ 3 on the
HEES. There was no clear difference between betamethasone-valerate 0.1% cream (15 out of 22) and urea 5% cream (20
out of 22) (RR 0.75, 95% CI 0.55 to 1.03; Analysis 10.1; Table 2).
Secondary outcome: reduction in severity, participant-rated
For this outcome, we found only one relevant trial (Lodén 2012a; n = 44). The average reduction in VAS (mm) was 36.3 in
the betamethasone-valerate 0.1% cream (BV) twice daily treatment group compared with 54.0 in the betamethasone-
valerate and urea (BV + M) group. The mean difference with regards to the VAS score was -17.70, although the relatively
wide confidence interval did borderline include zero; therefore the results should be interpreted with caution (mean difference
(MD) -17.70, 95% CI -35.42 to 0.02; Analysis 10.2).
Secondary outcome: reduction in severity, investigator-rated
For this outcome, we found only one relevant trial (Lodén 2012a; n = 44). After two weeks, the average reduction in HEES
was 12.5 (standard deviation (SD) 13.9) in the BV group compared to 10.5 (SD 9.0) in the BV + M group. There was no clear
difference between groups (MD 2.00, 95% CI -4.92 to 8.92; Analysis 10.3).
Comparison 11. Topical others: coal tar paste versus betamethasone-valerate ointment 0.1% versus zinc oxide
paste
In an unblinded randomised within-participant study (Kemper 1998), the efficacy of pix lithanthracis (coal tar paste) compared
to zinc oxide paste and betamethasone-valerate was investigated (n = 19). Also see Table 3.
Primary outcome: adverse events
Six participants dropped out because they experienced problems with wearing gloves (the specific type of problem is not
identified). One participant dropped out due to pompholyx as a result of allergy to 5% pix lithanthracis (reported as 'other
data' in Analysis 11.1).
Comparison 12. Irradiation with UV light: UVB versus no UVB
For the phototherapy studies (UVA, UVB, PUVA), pooling was considered for two studies with data comparing UVB
with no UVB or placebo (Bayerl 1999; Sjövall 1987); however, we found these studies too heterogeneous in terms of design,
outcome assessment, and presentation of data to do so.
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Treatment with a portable UVB phototherapy unit, to be used at home, was compared to no UVB treatment in a study
among 48 participants with occupational hand dermatitis (Bayerl 1999).
Primary outcome: adverse events
In both groups, two participants showed an exacerbation. Other adverse events were stinging and burning sensations in
some participants, which limited the increase in UVB therapy (RR 1.00, 95% CI 0.15 to 6.53; Analysis 12.1).
Comparison 13. Irradiation with UV light: whole body UVB versus placebo or local UVB hands
Primary outcome: percentage of participants with investigator-rated good/excellent control (cleared)
Local UVB hands alone versus placebo
For this subgroup, we found only one relevant trial. Three groups were compared in a trial of 18 participants with
chronic hand eczema, and data for 10 participants were available (Sjövall 1987). Among participants receiving local UVB,
two cleared, while in the group receiving filtered light (placebo UVB), one participant cleared (RR 2.00, 95% CI 0.26 to 15.62;
Analysis 13.1; Table 4), but the confidence interval for the RR did not indicate clear differences between groups.
Whole-body UVB + local UVB hands versus placebo
For this subgroup, we found only one relevant trial (Sjövall 1987; n = 10). Five out of five participants in the whole-body UVB
group showed good symptom control compared to one in the control group (RR 3.67, 95% CI, 0.90 to 14.97; Analysis 13.1;
Table 4). However, the confidence interval around the effect estimate was wide and imprecise.
Whole-body UVB + local UVB hands versus local UVB hands alone
Five participants in the whole-body UVB irradiation group had good symptom control compared to two in the control group,
but due to the small sample size, the intervention group did not demonstrate clear advantage over the group given local UVB
of the hands alone (RR 2.20, 95% CI 0.83 to 5.84; Analysis 13.1; Table 4).
Primary outcome: adverse events
Adverse events were not seen in either group.
Secondary outcome: time until relapse (low score = better outcome)
A postal follow-up questionnaire three months after completion of treatment asked participants about the course of
their hand dermatitis: the number of weeks in remission was presented in a descriptive way. In the local UVB group,
two participants were still in remission after 15 weeks. The other three participants relapsed after 1 to 12 weeks
(median 5 weeks). In the UVB local + whole-body group, all participants relapsed within 3 to 10 weeks (median 6
weeks). The participant in the placebo group who had reached remission relapsed after three weeks. This difference
was not statistically significant for local UVB hands alone versus placebo (MD 4.10, 95% CI -3.25 to 11.45); for
whole-body UVB + local UVB hands versus placebo (MD 0.50, 95% CI -4.98 to 5.98); nor for whole body UVB +
local UVB hands versus local UVB hands alone (MD -3.60, 95% CI -9.68 to 2.48) (Analysis 13.2).
Comparisons 14 and 15. Irradiation with UV light: local narrow-band UVB versus local PUVA
For this outcome, we found two relevant trials (Sezer 2007, n = 24; and Brass 2015, n = 60). Brass 2015 was a parallel-
group study that investigated local narrow-band UVB twice weekly compared to local PUVA twice weekly over a period of 12
weeks. Sezer 2007 studied local narrow-band UVB thrice weekly for nine weeks compared to local PUVA thrice weekly in a
left-right study.
Primary outcome: percentage of participants with investigator-rated good/excellent control (clearance) in UVB versus PUVA
In Brass 2015, six out of 30 participants treated with narrow-band UVB improved compared to 12 out of 30 participants on
local PUVA after 12 weeks (RR 0.50, 95% CI 0.22 to 1.16; Analysis 14.1; Summary of findings table 3; Table 4).
In Sezer 2007, two out of 12 hands treated with UVB cleared (17%). On the PUVA-treated side, one hand cleared (8%), as
presented in Analysis 15.1 and in Table 4.
Primary outcome: adverse events
Brass 2015 reported no serious treatment-related adverse events. An adverse event (mainly erythema) was reported in nine
participants treated with local narrow-band UVB and in none of the participants treated with local PUVA (Fisher's exact test P
= 0.0019; RR 19.00, 95% CI 01.16 to 312.42; Analysis 14.2; Summary of findings table 3).
In Sezer 2007, one participant dropped out because of an exacerbation of eczema in both hands (unclear from which group).
Palmar hyperpigmentation due to PUVA was observed in three participants (see Analysis 15.2).
Secondary outcome: reduction in severity, investigator-rated, by local narrow-band UVB versus local PUVA
The data for Brass 2015 were not reproducible; however in the PUVA group, the mTLSS was reduced from a
median of 8.5 (range 0 to 16) and 8 (range 3 to 15) for the left and right hand, to a median of 3 (range 0 to 13) and
3 (range 0 to 14) (n = 23). In the local narrow-band UVB group, the median mTLSS was reduced from 7 (range 0 to
16) and 8.5 (range 1 to 15) to 5 (range 0 to 11) and 4.5 (range 0 to 11) after 12 weeks of treatment (n = 20) (Summary of
findings table 3).
We identified Sezer 2007 as the only relevant trial for this comparison (Sezer 2007, n = 24). For both treatments,
researchers observed a marked clinical improvement in nine out of 12 hands (75%). The difference in total clinical scores
between irradiation with UV light, local narrow-band UVB, and local PUVA was not clear (see Analysis 15.3).
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Comparison 16. Irradiation with UV light: oral PUVA versus topical bath PUVA
Two studies investigated oral PUVA and bath PUVA (Tzaneva 2009; van Coevorden 2004a); however because the designs
of these studies were substantially different, and because van Coevorden 2004a mainly focused on the at-home versus
hospital-based version, we did not pool these studies. Also see Table 4.
Primary outcome: adverse events
van Coevorden 2004a included only adverse events that constituted a reason to discontinue. From the oral/home PUVA
group, three participants dropped out because of adverse events (nausea). From the hospital/bath PUVA group, one
dropped out because of adverse events (burn). There were no clear differences between groups (nausea Fisher's exact test
P = 0.1180; RR 7.18, 95% CI 0.38 to 136.71; burn Fisher's exact test P = 1.00; RR 0.34, 95% CI 0.01 to 8.26; Analysis 16.1).
In Tzaneva 2009, investigators gave oral PUVA (8-methoxypsoralen capsules) to 14 participants and topical bath PUVA
therapy with 8-methoxypsoralen to 13 participants. Erythema occurred in 10 participants (71%) in the oral PUVA group, and
in eight participants (62%) in the bath PUVA group (Fisher's exact test P = 0.49; RR 1.16, 95% CI 0.67 to 2.00; Analysis
16.1). In the oral PUVA group, 10 participants reported nausea (Fisher's exact test P = 0.0002; RR 19.60, 95% CI 1.26 to
304.14; number needed to treat for an additional harmful outcome (NNTH) 1, 95% CI 1 to 2), five reported dizziness (Fisher's
exact test P = 0.04; RR 10.27, 95% CI 0.62 to 169.16), and three reported headache (Fisher's exact test P = 0.22; RR 6.53,
95% CI 0.37 to 115.49). Adverse events were observed most often at the beginning of therapy and improved during
subsequent treatments. None of these adverse events led to dropouts.
With the exception of 'erythema', all other subgroups in this outcome had zero events in one of the arms, which could have
been responsible in part for the wide confidence interval around the point of estimate, and for which FIsher's exact test was
used.
Secondary outcome: reduction in severity, investigator-rated improvement, in mean eczema scores at week 10
For this outcome, we found only one relevant trial (van Coevorden 2004a, n = 158). At the end of the treatment phase (10
weeks) in the home PUVA group, 56/78 participants (72%) showed improvement (mean 3.3, SD 3.8) versus 49/80
participants (61%) in the hospital/bath PUVA group (mean 2.5, SD 3.4) (MD 0.80, 95% CI -0.33 to 1.93; Analysis 16.2).
Secondary outcome: reduction in severity, investigator-rated improvement, in mean scores at week 18 (low score = better
outcome)
For this outcome, we found only one relevant trial (van Coevorden 2004a, n = 158). At eight weeks after the treatment phase,
the reduction in mean score from baseline was 3.1 (SD 4.05) versus 2.7 (SD 3.4), respectively; there was no clear difference
between irradiation with UV light: oral PUVA and topical bath PUVA (MD 0.40, 95% CI -0.77 to 1.57; Analysis 16.3).
Comparison 17. Irradiation with UV light: topical PUVA versus UVA
In a 16-week within-participant (left-right) study, topical PUVA was compared with UVA (Grattan 1991) in 15 participants (n =
30 hands).
Primary outcome: adverse events
Only one participant who completed the study experienced a burning sensation on the back of his PUVA-treated hand (see
Analysis 17.1). Probably two participants had to be withdrawn due to exacerbation of eczema - one from each group (see
Analysis 17.1).
Comparison 18. Irradiation with UV light: UVA-1 versus betamethasone-valerate 0.1% cream
Irradation with UVA-1 three times a week was compared to topical betamethasone-valerate 0.1% twice a day over a six-
week period in 47 participants (Said 2010).
Primary outcome: adverse events
Tolerance of both treatments was good. The only adverse event noted was post-phototherapy pigmentation, which occurred
in 18 of the 24 participants treated with UVA-1 compared to none of the participants in the control group (Fisher's exact test
P = 0.0001; RR 35.52, 95% CI 2.26 to 557.08; NNTH 1, 95% CI 1 to 2; Analysis 18.1). Zero events in the control group is
likely to explain the wide confidence interval.
Comparison 19. Irradiation with UV light: UVA-1 versus placebo
UVA-1 irradiation for three weeks in 15 participants with dyshidrotic hand eczema was compared with placebo
(simulated blue light) in 13 participants (Polderman 2003).
Primary outcome: adverse events
Apart from some minor erythemal reactions, no adverse events occurred. Three of 13 participants in the placebo group
dropped out after two weeks because of exacerbation, but no clear differences was identified between groups (Fisher's exact
test P = 0.2258; RR 0.13, 95% CI 0.01 to 2.22; Analysis 19.1). Zero events in the intervention group is likely to explain the
wide confidence interval.
Secondary outcome: reduction in severity of itch, participant-rated decrease in VAS, at week 3 (higher score = greater
reduction)
For this outcome, we found only one relevant trial (Polderman 2003, n = 28). Although there was a notable difference
between irradiation with UV light: UVA-1 (mean 2.31, SD 2.01) and placebo (mean -1.37, SD 4.05) with regards to VAS
scores for itch (MD 3.68, 95% CI 1.25 to 6.11; Analysis 19.2), we have low confidence about the strength of the finding due
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to limited sample size (i.e. imprecision).
Secondary outcome: reduction in severity, investigator-rated improvement in DASI, at week 3 (higher score = greater
reduction)
In the same group of participants (Polderman 2003), the severity score on the Dyshydrotic eczema Area and Severity Index
(DASI) decreased in the UVA-1 group (mean 8.67, SD 6.72) compared to the placebo group (mean -0.38, SD 8.87) in week
3 (MD 9.05, 95% CI 3.15 to 14.95; Analysis 19.3).
Comparison 20. Irradiation with UV light: PUVA versus UVA-1
In a within-participant study, the effectiveness of middle-dose UVA-1 irradiation was compared with topical cream
PUVA therapy in 15 participants with chronic relapsing dyshidrotic hand eczema (Adams 2007).
Primary outcome: adverse events
Burning occurred in three participants in the topical cream PUVA group and in one participant in the UVA-1 group,
and increased pruritus occurred in five participants in the topical PUVA group versus three in the UVA-1 group (Analysis
20.1).
Comparison 21. Irradiation with X-rays (ionising radiation)
Among trials evaluating the effects of ionising radiation (X-rays), we considered pooling the results of four studies
comparing X-rays with placebo irradiation (Cartwright 1987; Fairris 1984; King 1984; Lindelöf 1987), but dosages,
presentation of results, and follow-up times were considered too heterogeneous in most cases. Moreover, all these
studies used a within-participant design (i.e. comparing one hand vs the contralateral hand). Superficial X-ray
irradiation on one hand was compared with topical PUVA on the contralateral hand in 25 participants (Sheehan-Dare 1989).
Also see Table 5.
Comparison 21A. Irradiation with X-rays: X-rays versus placebo
Primary outcomes: percentage of participants with investigator-rated good/excellent control
After one month in seven out of 15 participants, hands treated with X-rays were categorised as showing good response
(defined as 'clear' or 'nearly clear'), whereas all 15 placebo-treated hands were categorised as showing poor response
(defined as 'partly clear', 'no change', or 'relapse') (King 1984; see Analysis 21.1 and Table 5). After three months, ten
irradiated hands and six placebo-treated hands were categorised as showing good response (see Analysis 21.1), and after
six months there was a good response in 11 irradiated and eight placebo-treated hands (see Analysis 21.1). There were no
clear differences between groups.
Primary outcome: adverse events
No systemic or local adverse events were noted.
Comparison 21B. Irradiation with X-rays: Grenz ray
The effect of 3 Gy Grenz ray therapy six times in weekly intervals was investigated in within-participant studies (Lindelöf
1987; 24 participants, 48 hands in a within-participant design; Cartwright 1987; 30 participants, 60 hands in a within-
participant design).
Primary outcome: adverse events
Six participants had hyperpigmentation in treated hands, and no participants in the placebo group experienced adverse
events (see Analysis 21.2); however, there is no clear difference between groups.
Comparison 21C. Irradiation with X-rays: X-rays versus Grenz rays
A within-participant study on 25 participants compared superficial X-ray and Grenz ray irradiation (Fairris 1985).
Primary outcome: adverse events
Fairris 1985 reported no adverse events from either therapy.
Comparison 22. Topical calcineurin inhibitors: tacrolimus ointment versus mometasone furoate
An overview of all of the studies on topical calcineurin inhibitors can be found in Table 6.
The current comparison included two studies (Schnopp 2002, n = 16; Katsarou 2012, n = 30).
Primary outcome: adverse events
Both treatments were well tolerated. None of the participants in Schnopp 2002 dropped out because of adverse events.
Katsarou 2012 investigated adverse events but did not report any.
Secondary outcome: reduction in severity, investigator-rated
Although the reduction in mean DASI equalled improvement in scores for both treatments after two weeks, no clear
difference was found between groups. The mean DASI score was reduced from 18 (SD 12.68) to 6.6 (SD 6.18) in
the tacrolimus group, and from 18.5 (SD 14.09) to 6.9 (SD 7.7) in the mometasone furoate group, respectively (Schnopp
2002; see Analysis 22.1 and Summary of findings table 4).
Comparison 23. Topical calcineurin inhibitors: tacrolimus 0.1% ointment versus vehicle cream
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Two studies addressed this comparison (Krejci-Manwaring 2008, n = 32; Pacor 2006, n = 28).
Primary outcome: percentage of participants with investigator-rated good/excellent control (remarkable
improvement/complete remission)
Pacor 2006: In the tacrolimus group, complete remission at the end of treatment was observed in six participants (6/14), and
remarkable improvement in eight participants (8/14). Treatment with vehicle cream did not lead to remarkable improvement
(0/14) and led to only mild improvement in 4 of 14 participants (Fisher's exact test P = 0.0001; RR 29.00, 95% CI 1.90 to
443.25; NNTB 1, 95% CI 1 to 1; Analysis 23.1; Summary of findings table 5; Table 6). Zero events in the control group is
likely to explain the wide confidence interval.
Primary outcome: adverse events
In Krejci-Manwaring 2008, researchers observed one case of each of the following adverse events: acute contact dermatitis
at the site of the necklace, flare of atopic dermatitis on the foot, acne-like rash on the face, leg cramps, and worsening of
hand dermatitis. Stinging was not reported.
In Pacor 2006, four participants (4/14) in the tacrolimus group experienced transient burning and itching at the application
site, which was well tolerated (Fisher's exact test P = 0.1129; RR 9.00, 95% CI 0.53 to 152.93; Analysis 23.2; Summary of
findings table 5).
RR given above is based on zero events in one arm, which is likely to explain the wide confidence interval.
Comparison 24. Topical calcineurin inhibitors: pimecrolimus 1% cream versus vehicle
Five of the included studies addressed this comparison: Belsito 2004 (n = 294), Hordinsky 2010 (n = 652), Bauer 2012 (n =
36), Cherill 2000 (n = 48), and Baskan 2005 (n = 25).
Primary outcome: percentage of participants with investigator-rated good/excellent control (clear or almost clear) with
pimecrolimus cream versus vehicle at three weeks
For this subgroup, we found only one relevant trial (Belsito 2004, n = 294). In all, 42 of 151 versus 26 of 143 participants had
good investigator-rated symptom control in intervention and control groups, respectively. The favourable outcome for
pimecrolimus was borderline because the confidence interval includes 1 and therefore should be interpreted with care (RR
1.53, 95% CI 0.99 to 2.36; NNTB 10, 95% CI 5 to 1111; Analysis 24.1). When the subgroups were analysed based
on aetiology, we did not find significant differences for irritant, allergic, or endogenous hand eczema (Analysis 24.1; Table 6).
Primary outcome: percentage of participants with investigator-rated good/excellent control (clear or almost clear) with
pimecrolimus cream versus vehicle at six weeks
For this subgroup, we found only one relevant trial (Hordinsky 2010, n = 652). Treatment success (IGA score 0 = clear and 1
= almost clear) was achieved in 97 of 325 participants (29.8%) in the pimecrolimus cream 1% group and in 76 of 327
participants in the vehicle group. Favourable outcomes for pimecrolimus were borderline significant because the confidence
interval included 1 and should be interpreted with care (RR 1.28, 95% CI 0.99 to 1.66; Analysis 24.1).
Primary outcome: adverse events
Bauer 2012, Belsito 2004, and Hordinsky 2010 reported adverse events (Analysis 24.2). Hordinsky 2010 found no clear
differences between groups in terms of treatment-related erythema or irritation (RR 0.56, 95% CI 0.30 to 1.06; n = 652);
itching (RR 0.89, 95% CI 0.52 to 1.53; n = 652); warmth, stinging, and burning (RR 0.82, 95% CI 0.52 to 1.29; n = 652); or
herpes simplex infection (RR 0.60, 95% CI 0.15 to 2.51; n = 652). No adverse events were stated in Cherill 2000 and
Baskan 2005.
Secondary outcome: reduction in severity, participant-rated
For pruritus relief between pimecrolimus 1% and vehicle, we found only one relevant trial (Hordinsky 2010, n = 652). There
appears to be greater pruritus relief in the intervention group (pimecrolimus 1% cream) than in the vehicle group (RR 1.15,
95% CI 1.06 to 1.25; NNTB 9, 95% CI 6 to 22; Analysis 24.3); however, benefit relative to the control group appears to be
marginal.
Secondary outcome: time until relapse
Time to relapse was compared between pimecrolimus 1% cream and vehicle in Bauer 2012 (n = 36). Time to relapse did not
differ significantly between groups according to the trial authors (pimecrolimus: 39.35 days; vehicle: 33.19 days); this was
represented in a survival graph. We were unable to reproduce these analyses.
Comparison 25. Topical antibacterial agents: betamethasone-valerate/clioquinol cream versus betamethasone-
valerate/fusidic acid
Primary outcomes: percentage of participants with investigator-rated good/excellent control (intention-to-treat) after four
weeks
For this outcome, we found one relevant trial (Hill 1998, n = 120). In the ITT analysis, 34 of 62 participants (54.8%) in the
betamethasone-valerate/clioquinol group and 31 of 58 (53,4%) in the betamethasone-valerate/fusidic acid group had a good
response (RR 1.03, 95% CI 0.74 to 1.43; Analysis 25.1; Table 7).
Primary outcome: adverse events
In the clioquinol group, 11 of 62 participants experienced adverse events versus nine of 58 participants in the fusidic acid
group (RR 1.14, 95% CI 0.51 to 2.56; Analysis 25.2). Several other adverse events were observed, including chest
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infection (1/62 vs 0/58), application-related irritation (5/62 vs 5/58), deterioration of eczema (4/62 vs 4/58), eye
watering (1/62 vs 0/58), hands coloured yellow (1/62 vs 0/58), hands feeling thick (0/62 vs 1/58), and vesicle on the
hands (0/62 vs 1/58), but none of these showed between-group differences (Analysis 25.2).
As shown above, quite a few subgroups under this outcome had zero events in one of the arms; this is likely to explain the
wide 95% confidence interval.
Comparison 26. Topical retinoids: bexarotene 1% gel versus bexarotene with corticosteroids
Primary outcomes: percentage of participants with investigator-rated good/excellent control (> 90% clearance on physician
response rates)
Treatment success (> 90% clearance) was achieved by 39% in the bexarotene only group, by 46% in the B + MF group, and
by 21% in the B + HC group.
Bexarotene only versus bexarotene + mometasone
For this subgroup, we found only one relevant trial (Hanifin 2004, n = 41). There was no clear difference between topical
retinoids: bexarotene 1% gel and bexarotene with mometasone (RR 0.85, 95% CI 0.40 to 1.8; Analysis 26.1; Table 7).
Bexarotene only versus bexarotene + hydrocortisone
For this subgroup, we found only one relevant trial (Hanifin 2004, n = 42). There was no clear difference between topical
retinoids: bexarotene 1% gel and bexarotene with hydrocortisone (RR 1.83, 95% CI 0.61 to 5.53; Analysis 26.1; Table 7).
Bexarotene + mometasone versus bexarotene + hydrocortisone
For this subgroup, we found only one relevant trial (Hanifin 2004, n = 27). There was no clear difference between topical
retinoids: bexarotene 1% gel and mometasone versus bexarotene with hydrocortisone (RR 2.15, 95% CI 0.67 to 6.89;
Analysis 26.1; Table 7).
Primary outcome: adverse events
Forty-one participants (75%) had one or more adverse events during the study, of whom 27 (49%) had one or more
events possibly related to the study drugs. The bexarotene group had irritation/rash in eight participants;
stinging/burning in two; and dermatitis flare in five. The B + MF group had irritation/rash in four participants and
stinging/burning in four participants. The B + HC group had irritation/rash in four participants; stinging/burning in four
participants, and dermatitis flare in zero participants (which is likely to explain the wide 95% confidence interval).
None of the adverse events occurred significantly more often in a study or control group (Analysis 26.2; Analysis 26.3).
Secondary outcome: reduction in severity, investigator-rated: > 90% and > 50% reduction in hand eczema area and severity
index (HEASI)
The percentage with > 90% reduction in Hand Eczema Area and Severity Index (HEASI) score in the bexarotene only group
was 36%, in the B + MF group 38%, and in the B + HC group 14%. But there was no clear difference between groups
according to the study authors. For > 50% reduction in HEASI, the percentages were, respectively, 79%, 85%, and 64%.
Bexarotene only versus bexarotene + mometasone
For this subgroup, we found only one relevant trial (Hanifin 2004, n = 41). There was no clear difference between topical
retinoids: bexarotene 1% gel and bexarotene with mometasone (RR 0.93, 95% CI 0.69 to 1.26; Analysis 26.4).
Bexarotene only versus bexarotene + hydrocortisone
For this subgroup, we found only one relevant trial (Hanifin 2004, n = 42). There was no clear difference between topical
retinoids: bexarotene 1% gel and bexarotene with hydrocortisone (RR 1.22, 95% CI 0.79 to 1.89; Analysis 26.4).
Bexarotene + mometasone versus bexarotene + hydrocortisone
For this subgroup, we found only one relevant trial (Hanifin 2004, n = 27). There was no clear difference between topical
retinoids: bexarotene 1% gel and mometasone versus bexarotene with hydrocortisone (RR 1.32, 95% CI 0.84 to 2.07;
Analysis 26.4).
Comparison 27. Other topical agents: calmurid versus Aquacare
A within-participant study compared topical Aquacare HP cream to a calmurid cream (Fredriksson 1975).
Primary outcome: adverse events
In the calmurid group, 13 participants experienced a burning sensation upon application compared to no adverse events in
the Aqua HP group (see Analysis 27.1).
Comparison 28. Fumaric acid 5% cream versus triamcinolone 0.1% cream
This study compared topical fumaric acid twice daily to triamcinolone cream twice daily for four weeks in 58
participants (Jowkar 2014).
Primary outcome: adverse events
Erythema and pruritus were noted in two participants in each treatment group (RR 0.93, 95% CI 0.14 to 6.18; Analysis 28.1).
Comparison 29. Furpalmate 0.3% cream versus hydrocortisone acetate 0.5% cream
Primary outcome: percentage of participants with investigator-rated and/or self-rated good/excellent control (complete
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remission)
For this outcome, we found only one relevant trial (Lauriola 2011, n = 40). In the study report, treatments were shown to be
equally effective in "curing" or "improving" hand dermatitis after 14 days. In the furpalmate group, 18 of 20 participants (90%)
were cured or improved after 14 days, and this occurred in 20 of 20 participants in the hydrocortisone group (100%) (RR
0.90, 95% CI 0.76 to 1.07; Analysis 29.1; Table 7).
Comparison 30. Fumaria parviflora versus vehicle cream
Studies using a parallel-group design compared use of 2% Nigella sativa L. (family Ranunculaceae) ointment (a
traditional medicine) twice daily with 0.1% betamethasone ointment twice daily and with Eucerin cream twice daily in
60 participants over four weeks (Yousefi 2012, n = 60).
A parallel-group study (Jowkar 2011, n = 44) compared the effect of an extract of 4% Fumaria parviflora Lam. cream twice a
day versus vehicle cream (placebo) twice daily in 44 participants for four weeks.
Primary outcome: adverse events
Yousefi 2012 reported no adverse events for treatment with Nigella sativa L. and Eucerin cream.
In Jowkar 2011, one participant dropped out due to development of redness and papules in the Fumaria parviflora Lam.
cream group (RR 3.00, 95% CI 0.13 to 69.87; Analysis 30.1). Zero events in the vehicle group is likely to explain the wide
confidence interval and Fisher's exact test results with a P value of 1.00.
III. Systemic treatments
We identified no randomised controlled trials on oral corticosteroids.
Comparison 31. Oral immunosuppressants: oral azathioprine and topical clobetasol propionate versus topical
clobetasol propionate only
Agarwal 2013 compared oral azathioprine with topical clobetasol propionate 0.05% cream to topical clobetasol propionate
0.05% cream alone in 108 participants; 91 participants completed the trial.
Primary outcome: percentage of participants with investigator-rated good/excellent control
After eight weeks, 36.95% in the clobetasol only group had a good response (defined as 75% improvement in signs and
symptoms) versus 73.3% in the clobetasol with additional azathioprine 50 mg group (RR 1.98, 95% CI 1.31 to 3.01; NNTB 3,
95% CI 2 to 6; Analysis 31.1). After 24 weeks, 39.13% in the clobetasol only group improved, as did 91.1% in the clobetasol
and azathioprine group (RR 2.33, 95% CI 1.61 to 3.38; NNTB 2, 95% CI 1 to 3; Analysis 31.1; Table 8).
Primary outcome: adverse events
No adverse events that would require reduction of dosage or discontinuation of treatment were reported.
Secondary outcomes: reduction in severity, investigator-rated (higher score = greater reduction)
This was measured by the hand eczema severity index (HECSI): after 24 weeks, 64.66% in the control group showed
improvement, as did 91.29% in the intervention group (MD 10.79, 95% CI 4.77 to 16.81; Analysis 31.2).
Secondary outcome: reduction in severity of itch, participant-rated (higher score = greater reduction)
After 24 weeks, the itch score difference was 6.04 (SD 2.35) in the intervention group, and 4.56 (SD 2.26) in the control
group (MD 1.48, 95% CI 0.53 to 2.43; Analysis 31.3). This is a participant-rated outcome, measured on a numerical scale
from 0 to 10.
Comparison 32. Oral immunosuppressants: oral cyclosporin versus topical betamethasone dipropionate
Primary outcome: percentage of participants with investigator-rated good/excellent control
Overall assessment of good/very good efficacy was 60% in the cyclosporin group and 31% in the betamethasone
group (Granlund 1996). There was no apparent difference between groups (RR 1.88, 95% CI 0.88 to 3.99; n = 34; Analysis
32.1; Summary of findings table 6; Table 8).
Primary outcome: percentage of participants with self-rated good/excellent control
One study addressed this (Granlund 1996, n = 34; the original randomised number was n = 41, but seven people left the
study early; hence data were available for only 34 people). Overall assessment of good/very good efficacy was 60% in the
cyclosporin group and 48% in the betamethasone group; the difference between groups was unclear (RR 1.25, 95% CI 0.69
to 2.27; Analysis 32.2; Summary of findings table 6).
Primary outcome: adverse events
"Some kind of adverse event" occurred in 19 of 28 participants on cyclosporin and in 15 of 27 participants in the
betamethasone group (RR 1.22, 95% CI 0.80 to 1.86; Analysis 32.3; Summary of findings table 6). In the cyclosporin group,
one participant experienced dizziness, vomiting, and facial oedema versus zero events in the control group (Fisher's exact
test P = 1.00; RR 2.90, 95% CI 0.12 to 68.15; Analysis 32.3). In the betamethasone group, one participant had insomnia
versus zero events in the cyclosporin group (Fisher's exact test P = 0.49; RR 0.32, 95% CI 0.01 to 7.57; Analysis 32.3
) (Granlund 1996). Two people in the cyclosporin group had an increase in serum creatinine of greater than 30% versus zero
events in the betamethasone group (Fisher's exact test P = 0.49; RR 4.83, 95% CI 0.24 to 96.16; Analysis 32.3). Zero events
in some of the above analyses is likely to explain the wide 95% confidence interval.
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The number of participants in this section is different from that in the other sections because in the publication, adverse
events in the run-in and cross-over phases are combined.
Secondary outcome: reduction in severity, investigator-rated total disease activity score (six weeks; higher score = greater
reduction)
For this outcome, we found only one relevant trial (n = 34) (Granlund 1996).
The mean total decrease in total disease activity score was 6.0 (SD 4.3) in the cyclosporin group and 5.7 (SD 4.0) in the
betamethasone group (MD 0.30, 95% CI -2.50 to 3.10; Analysis 32.4; Summary of findings table 6).
Comparison 33. Oral immunosuppressants: oral cyclosporin versus alitretinoin
NCT01231854 compared cyclosporin to alitretinoin but was ended prematurely due to inability to include the total number of
participants. According to the sample size calculation, 78 participants should have been included; however, only 15
participants were included and 14 were analysed.
Primary outcome: percentage of participants with investigator-rated good/excellent control (IGA) after 24 weeks
In the cyclosporin group, three out of seven participants (42.9%) reached complete or nearly complete clearance of hand
eczema according to the Investigator Global Assessment (IGA), as did two out of seven participants (28.6%) in the
alitretinoin group, after 24 weeks. There was no apparent difference between groups (Fisher's exact test P = 1.00; RR 1.50,
95% CI 0.35 to 6.40; Analysis 33.1; Table 8).
Primary outcomes: percentage of participants with participant-rated good/excellent control (PGA) after 24 weeks
In the cyclosporin group, four out of seven participants (57.1%) reached complete or nearly complete clearance of hand
eczema according to the Patient Global Assessment (PGA), as did two out of seven participants (28.6%) in the alitretinoin
group. There was no apparent difference between groups (Fisher's exact test P = 0.59; RR 2.00, 95% CI 0.53 to 7.60;
Analysis 33.2).
Primary outcome: adverse events
Six adverse events were documented, of which two were possibly related to the use of cyclosporin (fatigue, bone ache, dry
lips in one participant, and exacerbation of atopic eczema in another participant). No serious adverse events were recorded
throughout the trial. At least one adverse event occurred in 3 of 7 cyclosporin participants and in 2 of 7 alitretinoin
participants (Fisher's exact test P = 1.00; RR 1.50, 95% CI 0.35 to 6.40; Analysis 33.3).
Secondary outcome: time until relapse
None of the participants relapsed during the 24 weeks of follow-up (0 of 7 vs 0 of 7).
Comparison 34. Oral retinoids: acitretin versus placebo
Oral acitretin was compared with placebo capsules in a study that enrolled 29 participants with hyperkeratotic
dermatitis of the palms (Thestrup-Pedersen 2001). Fourteen participants were allocated to 30 mg acitretin once daily for
eight weeks, and 15 participants received identical looking placebo capsules. This study did not provide useable data for
analysis, as only subscale mean score was available, without SD.
Primary outcome: adverse events
No adverse events were reported and all biochemical parameters were within normal limits in both groups.
Secondary outcome: reduction in severity, investigator rated, after four and eight weeks
Trial authors used a score system composed of subscales with hyperkeratosis, fissures, scaling, itch, and redness.
After four weeks of treatment, a 51% reduction in all symptoms was seen in the acitretin group compared to a 9%
reduction in the placebo group. No further improvement was seen after eight weeks of treatment (Thestrup-Pedersen 2001).
No reproducible data were given.
Secondary outcome: reduction in severity, participant-rated number of participants with improvement in itch
After eight weeks of treatment, itch was reduced by 41% in the acitretin group compared to 19% in the placebo
group (Thestrup-Pedersen 2001). No reproducible data were given.
Comparison 34A. Oral retinoids: alitretinoin versus placebo
Four studies investigated the effect of oral alitretinoin: Bissonnette 2010, Fowler 2014, Ruzicka 2004, and Ruzicka 2008.
Primary outcome: percentage of participants with investigator-rated good/excellent control (clear or almost clear) at week 12,
at week 24, or at end of treatment
In Ruzicka 2004 and Ruzicka 2008, clearance or almost clearance of eczema occurred more often in all groups treated with
alitretinoin compared to placebo after 12 weeks. Fowler 2014 studied this after 24 weeks.
Alitretinoin 40 mg versus placebo
For this subgroup, we found only one relevant trial (Ruzicka 2004, n = 159). There might be a difference between groups, as
43 out of 81 participants in the 40 mg group had clear or almost clear status for PaGA compared to 21 of 78 in the placebo
group (RR 1.97, 95% CI 1.30 to 3.00; NNTB 4, 95% CI 2 to 9; Analysis 34.1; Table 9).
Alitretinoin 30 mg versus placebo
For this subgroup, we found two relevant trials (Ruzicka 2008, n = 614; Fowler 2014, n = 596). There was a clear difference
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between alitretinoin 30 mg and placebo, and the alitretinoin group was 2.75 times more likely to achieve symptom-clear
status compared to the placebo group (RR 2.75, 95% CI 2.20 to 3.43; NNTB 4, 95% CI 3 to 5; Analysis 34.1; Summary of
findings table 7; Table 9).
Alitretinoin 20 mg versus placebo
For this subgroup, we found only one relevant trial (Ruzicka 2004, n = 158). There was no clear difference between groups,
as 32 out of 80 participants in the 20 mg group had clear or almost clear status for PaGA, compared to 21 of 78 in the
placebo group (RR 1.49, 95% CI 0.94 to 2.34; Analysis 34.1; Table 9).
Alitretinoin 10 mg versus placebo
For this subgroup, we found two relevant trials (n = 781). According to both studies (Ruzicka 2004; Ruzicka 2008), alitretinoin
10 mg was more effective for this outcome (respectively, 39% and 28%) compared to placebo (RR 1.58, 95% CI 1.20 to
2.07; NNTB 11, 95% CI 6.3 to 26.5; Analysis 34.1; Summary of findings table 8; Table 9). There might be a difference
between groups, but we are uncertain of the strength of the evidence due to imprecision of the estimates.
Primary outcome: percentage of participants with self-rated good/excellent control (clear or almost clear) with PaGA at week
12, at week 24, or at end of treatment
Ruzicka 2004 shows that for all doses of alitretinoin, statistically significantly more participants rated their eczema as clear or
almost clear compared to those given placebo.
Alitretinoin 40 mg versus placebo
For this subgroup, we found only one relevant trial (Ruzicka 2004, n = 147). Of 74 participants in the 40 mg group, we judged
that 32 had clear or almost clear status for PaGA compared to nine of 73 in the placebo group (RR 3.51, 95% CI 1.80 to
6.82; NNTB 3, 95% CI 2 to 6; Analysis 34.5). There might be a difference between groups, but we are uncertain of the
strength of the evidence due to imprecision of the estimates.
Alitretinoin 30 mg versus placebo
For this subgroup, we found two relevant trials (Ruzicka 2008, n = 614; Fowler 2014, n = 596). There might be a difference in
the study of Ruzicka 2008: 163 out of 409 participants in the 30 mg group were judged as having clear or almost clear status
for PaGA after 200 days or at the end of treatment, compared to 31 of 205 in the placebo group (RR 2.64, 95% CI 1.87 to
3.72; Analysis 34.5), but we are uncertain of the strength of the evidence due to imprecision of the estimates.
Pooling the data for alitretinoin 30 mg (heterogeneity statistics: Chi² test = 0.11, P = 0.74; I² = 0) gives an effect estimate that
clearly favours the intervention group and demonstrates that the alitretinoin group was 2.75 times more likely to achieve
improvement relative to the placebo group (RR 2.75, 95% CI 2.18 to 3.48; NNTB 4, 95% CI 3 to 5; Analysis 34.5; Summary
of findings table 7).
Alitretinoin 20 mg versus placebo
For this subgroup, we found only one relevant trial (Ruzicka 2004, n = 147). Of 74 participants in the 20 mg group, 25 were
judged to have clear or almost clear status for PaGA compared to 9 of 73 in the placebo group (RR 2.74, 95% CI 1.37 to
5.46; NNTB 5, 95% CI 3 to 13; Analysis 34.5). There might be a difference between groups, but we are uncertain of the
strength of the evidence due to imprecision of the estimates.
Alitretinoin 10 mg versus placebo
For this subgroup, we found two relevant trials (n = 765). Both studies found that 10 mg alitretinoin was more
effective (respectively, 29% and 24% clear or almost clear) than placebo (Ruzicka 2004; Ruzicka 2008). Pooling these data
for 10 mg alitretinoin (heterogeneity statistics: Chi² test = 0.89, P = 0.35; I² = 0) shows there might be a difference between
groups, but we are uncertain of the strength of the evidence due to imprecision of the estimate (RR 1.73, 95% CI 1.25 to
2.40; NNTB 9, 95% CI 6 to 20; Analysis 34.5; Summary of findings table 8).
Primary outcome: adverse events
Studies listed in detail the adverse events observed; headache was one of the most frequent events (22 in 40 mg group,
eight in 20 mg group, four in 10 mg group, and seven in the placebo group in Ruzicka 2004; and 87 of 296 and 81 of 409
participants using alitretinoin 30 mg in Fowler 2014 and Ruzicka 2008, respectively). There was no clear difference
between groups for 10 mg (Analysis 34.6), 20 mg (Analysis 34.7), or 40 mg (Analysis 34.9) versus placebo.
However, the 30 mg versus placebo subgroup comparison produced a few notable between-group differences (Analysis
34.8), specifically for the following adverse events: headache (RR 3.43, 95% CI 2.45 to 4.81; NNTH 6, 95% CI 4 to 11),
flushing (RR 7.28, 95% CI 2.05 to 25.86; NNTH 25, 95% CI 17 to 50), erythema (RR 5.79, 95% CI 2.09 to 16.06; NNTH 25,
95% CI 14 to 100), nausea (RR 3.82, 95% CI 1.67 to 8.76; NNTH 27, 95% CI 18 to 56), elevated blood triglycerides (RR
7.05, 95% CI 1.89 to 26.28; NNTH 33, 95% CI 20 to 50), vomiting (RR 8.00, 95% CI 1.01 to 63.57; NNTH 50, 95% CI 23 to
250), and tinnitus (RR 4.33, 95% CI 1.25 to 15.05; NNTH 33, 95% CI 17 to 100). With the exception of headache, we have
limited confidence in the clinical significance of the differences mentioned above because in most of these analyses, the
number of events was too small; hence, this reduced the precision of the effect estimates. Limitations in the quality of the trial
further compromised our confidence in this finding.
Some of the outcomes above had zero events in one arm, which is likely to explain the wide 95% confidence interval. These
outcomes are dry lips, fatigue, rigours, tonsillitis, and elevated blood triglycerides.
Secondary outcome: reduction in severity, investigator-rated, in total lesion symptom score
Ruzicka 2004 observed a higher median % reduction in total lesion symptom score for all doses of alitretinoin compared to
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placebo: 25% in the placebo group (stated 95% CI -42 to -14) versus 52% in the 20 mg group (stated 95% CI -73 to -42) and
71% in the 40 mg group (stated 95% CI -80 to -44; Analysis 34.10). The difference between alitretinoin and placebo
was apparent for both doses according to study authors (Analysis 34.10). There was also reporting of a decrease in
extent of disease in all groups, but no details were given. We have plotted these data (Analysis 34.11) based on the
medians. Because the original data were not available to us, we were unable to assess whether the data were skewed;
therefore, it is uncertain whether the medians are close to the means.
Alitretinoin 40 mg versus placebo
For this subgroup, we found only one relevant trial (Ruzicka 2004, n = 159). Only median data were available;
hence, we reported these as 'other data' in a table (Analysis 34.11). The median of the alitretinoin group is evidently higher
than that of the placebo group; however, we are unsure of the clinical importance of the observed difference.
Alitretinoin 20 mg versus placebo
For this subgroup, we found only one relevant trial (Ruzicka 2004, n = 158). Only median data were available;
hence, we reported these as 'other data' in a table (Analysis 34.11). Similar to the previous analysis, the median of the
alitretinoin group is evidently higher than that of the placebo group; however, we are unsure of the clinical importance of the
observed difference.
Alitretinoin 10 mg versus placebo
For this subgroup, we found only one relevant trial (Ruzicka 2004, n = 158). Only median data were available;
hence, we reported these as 'other data' in a table (Analysis 34.11). The median of the alitretinoin group is evidently higher
than that of the placebo group, as in the previous analysis, and we are unsure of the clinical importance of the observed
difference.
Secondary outcome: reduction in severity, investigator-rated, in modified total lesion symptom score
Fowler 2014: the modified total lesion symptom score showed a change of -53.99% in the alitretinoin 30 mg group after 24
weeks and a change of -29.86% in the placebo group. For the mean difference in reduction, these numbers were inverted, so
the mean difference in reduction of severity was 24.13 (MD 24.13, 95% CI 17.87 to 30.39; Analysis 34.12).
Ruzicka 2008: the median reduction in the modified total lesion symptom score was 75% in the 30 mg group and
56% in the 10 mg group, compared to 39% in the placebo group (Analysis 34.10).
Secondary outcome: time to relapse
Fowler 2014 included a follow-up phase up to 48 weeks after end of treatment. The median time to relapse after end of
treatment was 83.0 weeks, with a 95% CI of 48.3 to 83.0, according to trial authors.
For Ruzicka 2008, the median time to relapse was 5.5 months for alitretinoin 30 mg, 6.2 months for alitretinoin 10 mg, and
5.4 months for placebo.
Comparison 35. Oral retinoids: re-treatment with alitretinoin versus placebo
In Bissonnette 2010, 117 participants with chronic hand eczema were successfully treated with alitretinoin in an
earlier study (Ruzicka 2008); 24 withdrew.
Primary outcome: percentage of participants with investigator-rated good/excellent control (clear or almost clear)
Alitretinoin 30 mg versus placebo
For this subgroup, we found only one relevant trial (Bissonnette 2010, n = 73). A total of 39 out of 49 participants (80%) who
were re-treated with 30 mg alitretinoin were rated as 'clear' or 'almost clear' according to the PGA, compared to 2 of 24
participants (8%) who were re-treated with placebo. There appears to be a large effect favouring the intervention group (RR
9.55, 95% CI 2.51 to 36.27; NNTB 1, 95% CI 1 to 2; Analysis 35.1; Table 9); however, we have limited confidence in this
finding due to the small sample size and risk of bias in the study itself.
Alitretinoin 10 mg versus placebo
For this subgroup, we found only one relevant trial (Bissonnette 2010, n = 31). Ten out of 21 participants were cleared or
almost cleared again under re-treatment with 10 mg alitretinoin in comparison to 1 out of 10 participants who were re-treated
with placebo (10%) (RR 4.76, 95% CI 0.70 to 32.25; Analysis 35.1; Table 9). In the group that was re-treated with placebo, 9
out of 13 participants (69%) responded again.
Primary outcome: adverse events
Headache was the most frequently reported adverse event in the 30 mg group; 7 of 50 participants reported headache in the
intervention group compared with zero events in the placebo group (Fisher's exact test P = 0.0129; RR 13.82, 95% CI 0.81 to
235.45; Analysis 35.3). None of the participants in the alitretinoin 10 mg group or in the placebo group reported
headache. Adverse events occurred similarly in both groups (Analysis 35.2; Analysis 35.3). Three serious adverse events
were reported: one case of acute cardiac failure with fatal outcome in the 10 mg group, which was not related to the study
drug; one case of aortic aneurysm and one case of coronary artery disease (both in the 30 mg group) were assessed as
having a remote relationship to the study drug.
Comparison 36. Other oral interventions: oral triethylenetetramine versus placebo
Burrows 1986 (n = 23) studied oral triethylenetetramine versus placebo and included exclusively nickel-sensitive participants.
Primary outcome: percentage of participants with investigator- and participant-rated good/excellent control
#29 Interventions for hand eczema
34 / 280
We found one study for this outcome (Burrows 1986), including 23 participants in a cross-over design, of which 20
were analysed. Because the data before cross-over are not available, rather than analysing the post-cross-over
data, we have presented them in a table for the readers' review (Analysis 36.1; Table 10). This outcome was based on a
global assessment (improved/no change/deterioration) by participant and doctor, probably by consensus, and included both
phases of the cross-over study.
Primary outcome: adverse events
None of the participants in Burrows 1986 reported adverse events; however, this trial was ended prematurely due to
increased teratogenicity among rats who received trientine.
Comparison 37. Other oral interventions: tetraethylthiuram disulfide (TETDS) versus placebo
Kaaber 1983 studied oral tetraethylthiuram disulfide (TETDS) versus placebo in 24 nickel-sensitive participants.
Primary outcome: percentage of participants with investigator-rated good/excellent control during treatment period
For this outcome, we found only one relevant trial (Kaaber 1983, n = 24). Among participants receiving the active compound,
5 out of 11 'healed' versus 2 out of 13 in the placebo group. Analysis 37.1 shows no clear difference between the two groups
in that the 95% CI includes 1 and is wide (Fisher's exact test P = 0.1819; RR 2.95, 95% CI 0.71 to 12.34). Also see Table 10.
Primary outcome: adverse events
In the group receiving tetraethylthiuram disulphide, hepatic toxicity was experienced in two participants (Fisher's exact test P
= 0.48; RR 5.00, 95% CI 0.26 to 96.13; Analysis 37.2) and headache in one (Fisher's exact test P = 1.00; RR 3.00, 95% CI
0.13 to 68.26; Analysis 37.2). Two participants had mild acne, but it is not clear to which group they were assigned. In the
intervention group, there was one case of discontinuation due to depression and one case of discontinuation due to
dyspepsia, whereas neither event occurred in the control group (Fisher's exact test P = 1.00; Analysis 37.2). There were zero
events in placebo group for all of the above subgroups; this is likely to explain the wide 95% confidence intervals.
Comparison 38. Other oral interventions: low-nickel diet (LND) and disulphiram versus normal diet and placebo
Sharma 2006 (n = 21) compared a low-nickel diet combined with disulphiram versus a normal diet and placebo and included
exclusively nickel-sensitive participants.
Primary outcomes: percentage of participants with self-rated good/excellent control (clearance of eczema) after four weeks
For this outcome, we found only one relevant trial (Sharma 2006, n = 21). Ten of the 11 participants in the LND group
reached good/excellent control compared to 1 of 10 in the control group (Fisher's exact test P = 0.0003; RR 9.09, 95% CI
1.40 to 58.91; NNTB 1, 95% CI 1 to 2; Analysis 38.1).
Primary outcome: adverse events
Three out of 11 participants treated with disulphiram experienced a metallic taste (Fisher's exact test P = 0.2143; RR 6.42,
95% CI 0.37 to 110.71; Analysis 38.2), and two had mild drowsiness (Fisher's exact test P = 0.4762; RR 4.58, 95% CI 0.25
to 85.33; Analysis 38.2 ). Three participants treated with disulphiram showed mild elevation of liver enzymes (Fisher's exact
test P = 0.2143; RR 6.42, 95% CI 0.37 to 110.71; Analysis 38.2).
Comparison 39. Other oral interventions: oral evening primrose oil versus placebo
Secondary outcome: reduction in severity, investigator-rated score at week 24
For this outcome we only found one relevant trial (Whitaker 1996, n = 34) on oral gamma-linoleic acid (GLA, evening
primrose oil, Epogam). Mean and SD of the evening primrose oil group is 18 ± 12.37, and for the placebo group is 30.4 ±
23.36. There was no clear difference between the oral interventions (MD -12.40, 95% CI -25.46 to 0.66, Analysis 39.1).
Comparison 40. Other oral interventions: ranitidine versus placebo
Primary outcome: percentages of participants with self- and/or investigator-rated good/excellent control (clearance / marked
alleviation)
For this outcome, we found only one relevant trial (Veien 1995, n = 47). Although it is not clear whether this was participant-
or investigator-rated, 17 out of 23 with ranitidine cleared or were markedly improved versus 8 out of 24 receiving placebo
(RR 2.22, 95% CI 1.20 to 4.10; NNTB 2, 95% CI 2 to 7; Analysis 40.1; Table 10).
Primary outcome: adverse events
No adverse events were reported in the ranitidine or placebo group.
Comparison 41. Other oral interventions: disodium cromoglycate diet (DSCG) versus low-nickel diet
For this comparison, we found one study (Pigatto 1990), which included 16 participants in three different treatment groups
(disodium cromoglycate diet (DSCG) vs low-nickel diet vs a non-randomised control for eight participants who did not give
consent for the study and were only followed up). Because participants were not randomised, this subgroup is deleted from
the review.
Primary outcomes: number of participants with self-rated good/excellent control of itch after three months
For this outcome, we found only one relevant trial (n = 16) (Pigatto 1990). The numbers of events in the disodium
cromoglycate and low-nickel groups were 5 of 8 and 1 of 8, respectively (Fisher's exact test P = 0.1189; RR 5.00, 95% CI
0.74 to 33.78; Analysis 41.1).
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Discussion 
Summary of main results
Hand eczema is a common condition. In light of the high prevalence of hand eczema, it is striking that the results of all
60 identified randomised controlled trials (RCTs) are based on approximately 5469 participants, whereby about half of
them (n = 2893) were enrolled in five RCTs: three on the oral retinoid alitretinoin (Fowler 2014; Ruzicka 2004; Ruzicka 2008
), and two on the topical calcineurin inhibitor pimecrolimus (Belsito 2004; Hordinsky 2010).
Although many systematic reviews focus on a single treatment modality or its closely related variants, we have tried to
include all interventions in this review in an attempt to determine which therapy would reflect current standard treatment and
the extent to which there is evidence for its effectiveness. The wide range of available treatments underlines the fact that
there does not seem to be a single candidate for standard therapy. Topical corticosteroids and ultraviolet (UV) phototherapy
are the major treatment options for chronic hand eczema, although in this review, we found little strong or consistent
evidence that one intervention for hand eczema should be recommended over the other.
About half of the studies (n = 33) included our primary outcome of good/excellent control of symptoms rated by participants
or by investigators. The definition of good/excellent control varied across studies because a wide variety of outcome
measures were used. Most studies included the primary outcome adverse events (n = 55). None of the adverse events were
life-threatening, and most were mild (local irritation with stinging, erythema, and burning).
Of the nine trials on topical corticosteroids, each dealt with a different type of steroid. The duration of six studies was
rather short, namely, one week (Gupta 1993), two weeks (Faghihi 2008; Fowler 2005; Kircik 2013; Lodén 2012a; Uggeldahl
1986), and three weeks (Bleeker 1989). Treatment in Veien 1999 lasted up to 36 weeks, and treatment duration in Möller
1983 is unknown. Three trials compared two different corticosteroids. The comparators used in the remaining trials were the
same corticosteroids as those used for the intervention, the same treatment but in a different vehicle, or a different dosage,
or they were applied at a different frequency or were combined with zinc sulphate or urea, or consisted of vehicle alone.
Based on one study (125 participants), which compared clobetasol propionate foam with vehicle, clobetasol probably
improves participant-rated good/excellent symptom control more than vehicle; however, the difference between groups
on observer-rated scales is less clear (moderate-certainty evidence) (Kircik 2013). Another study (72 participants)
compared mometasone furoate cream used thrice weekly compared to twice weekly, and mometasone furoate cream
used thrice weekly may slightly improve investigator-rated good/excellent control of symptoms (low-certainty evidence);
participant-rated symptoms were not measured (Veien 1999). See Summary of findings table 1 and Summary of findings
table 2.
The 10 trials on UV phototherapy were too heterogeneous for pooling. Three studies provided UVB as the main
intervention, three gave UVA-1, and six used oral psoralen combined with UVA (PUVA) as the main intervention
or comparator. Other comparators included no treatment, placebo, UVB, the same treatment as the intervention
but at different sites, UVA, and topical betamethasone-valerate cream. One study had a treatment duration of less
than one month (Polderman 2003), five had a treatment duration of less than two months (Adams 2007; Bayerl 1999; 
Grattan 1991; Said 2010; Sjövall 1987), three had a treatment duration of two to four months (Brass 2015; Sezer 2007; van
Coevorden 2004a), and one had a treatment duration greater than four months (Tzaneva 2009).
In one of the studies comparing local narrow-band UVB to local PUVA, results showed that PUVA may lead to an
improvement in investigator-rated good/excellent symptom control (60 participants), but the 95% confidence interval
indicates that local PUVA might make little or no difference (moderate-certainty evidence). Participant-rated symptoms
were not measured (Brass 2015). See Summary of findings table 3.
The topical calcineurin inhibitors were studied in nine RCTs, and almost all studies compared tacrolimus or
pimecrolimus to vehicle. Based on one small study comparing tacrolimus over two weeks to vehicle, investigator-rated
good/excellent symptom control is probably more likely to be achieved in those treated with tacrolimus (14/14
participants in the tacrolimus group vs zero people in the vehicle group), but participant-rated good/excellent control of
symptoms was not measured (28 participants) (moderate-certainty evidence) (Pacor 2006). Tacrolimus was
compared to mometasone in a within-participant trial but did not measure investigator- or participant-rated
good/excellent symptoms (Schnopp 2002). See Summary of findings table 4 and Summary of findings table 5.
Three studies assessed immunosuppressants, which were compared against a steroid or a retinoid. In one cross-
over RCT comparing oral cyclosporin to topical betamethasone dipropionate, cyclosporin probably slightly improves
participant- or investigator-rated good/excellent control of symptoms (34 participants) (moderate-certainty evidence)
(Granlund 1996). See Summary of findings table 6.
A relatively new treatment option is oral alitretinoin, which has been compared with placebo in three large trials, with a
total enrolment of 1947 participants (Fowler 2014; Ruzicka 2004; Ruzicka 2008). These trials investigated, in addition to
other dosages, a daily dosage of 10 mg. Ruzicka 2004 and Ruzicka 2008 were considered sufficiently equivalent to
pool the data for 10 mg daily, which showed that alitretinoin was more effective than placebo in both investigator- and
participant-rated good/excellent control of symptoms (high-certainty evidence). Even larger risk ratios were observed
when a higher dosage of alitretinoin (30 mg) was compared to placebo for both outcomes (Fowler 2014; Ruzicka 2008)
(high-certainty evidence). See Summary of findings table 7 and Summary of findings table 8.
Oral alitretinoin has not yet been compared to other treatment modalities such as corticosteroids or UV
phototherapy. Unfortunately, the study that was expected to further clarify the position of systemic treatments
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with retinoids or systemic immunosuppressants (alitretinoin vs cyclosporin) in the treatment of hand eczema
was ended prematurely (NCT01231854). Although this study shows low risk of bias in all other domains, it included only 15
of the required 78 participants.
Adverse events were reported by 55 of the 60 studies; they were generally mild and similar between groups. Mild atrophy
was reported with mometasone furoate thrice weekly or twice weekly (low-certainty evidence), but more adverse events (e.g.
application site burning/pruritus after intervention application, nasopharyngitis, one incident of severe fissures) were noted
when clobetasol propionate foam was compared to vehicle placebo (moderate-certainty evidence). In the study comparing
local narrow-band UVB to local PUVA, only the narrow-band UVB group reported adverse events (mainly erythema)
(moderate-certainty evidence). When tacrolimus was compared to vehicle, well-tolerated burning/itching was reported only in
the tacrolimus group (moderate-certainty evidence). With systemic treatment, the risk of adverse events with oral cyclosporin
compared to topical betamethasone was similar, and dizziness was reported (moderate-certainty evidence). The occurrence
of headaches and flushing was similar when alitretinoin 10 mg was compared to placebo (moderate-certainty evidence), but
risk of headache was greater with alitretinoin 30 mg than with placebo (high-certainty evidence).
Overall completeness and applicability of evidence
We included 60 RCTs with a total of 5469 participants. Overall, studies included adults of both genders in general good
health, which in our opinion is applicable to an important part of the hand eczema population, since hand eczema can be
related to occupation.
The applicability of evidence is limited by several methodological weaknesses of the included studies; one of the most
prominent of these is the varied definition of hand eczema. Furthermore, the definition of hand eczema was different in
almost all trials. Studies defined 'chronic hand eczema' as duration longer than six months or longer than three months, or
did not include a minimal duration of disease at all. We intended to conduct subgroup analyses, but a minority of the trials
defined subgroups (e.g. Ruzicka 2004 and Ruzicka 2008 did include subgroups). In general, it is not clear which participants
had hyperkeratotic hand eczema or vesicular hand eczema, and clinical experience suggests that the clinical subtype might
influence treatment success. Without logical and comprehensive definitions of hand eczema with clear diagnostic criteria for
hand eczema and its subgroups, RCTs are seriously flawed, which is one of the main pitfalls of this review.
Furthermore, in this review, we found a wide range of severity scoring systems for hand eczema, which prevented
meaningful data pooling.
Finally, some studies, especially older studies, did collect useable data with regard to the effectiveness of
treatment but did not report these data (Fredriksson 1975). Since these were all single-study results, which could not have
been pooled anyway, we do not believe that this influenced the overall completeness of the evidence.
Of all treatment categories, the largest number of studies focus on topical steroids (nine RCTs) and UV therapy (10 RCTs).
Nevertheless, most trials do not include one of these treatments as a comparator. In fact, most trials provide placebo,
vehicle, or a variant of the intervention as a comparator, making it difficult to draw conclusions on the comparative
advantages of different treatments. We did identify some ongoing studies, for example, ISRCTN80206075, NCT03026907,
and NCT03026946; results of these trials might eventually help to fill some of the gaps. With regard to phototherapy, it is
difficult to compare different studies because different treatment regimens were used. Although in daily practice the treatment
regimens are highly dependent on patient skin type and on the occurrence of adverse events, it might be challenging to align
treatment protocols. Topical steroids were assessed in nine studies, although different treatment regimens were not
investigated intensively, nor was the strength of different corticosteroids. Topical calcineurin inhibitors were investigated in
nine studies. Topical calcineurin inhibitors were compared with placebo and with active treatment (topical corticosteroids),
although this last comparator might have been used more often. Alitretinoin was examined in well-designed studies with a
substantial number of participants. Other oral treatments such as cyclosporin, methotrexate, or acitretin were barely/not
investigated, which is a severe shortcoming in the overall completeness of evidence.
With regard to outcomes, our primary outcomes percentage of participants with investigator-rated and/or self-rated
good/excellent control of symptoms and/or adverse events were reported in most of the included studies. However, the
secondary outcome dose reduction was not stated in any of the included studies. Moreover, various studies did not report on
time until relapse.
The enrolled participants had typical long-standing eczema. Studies included overall chronic hand eczema with long-lasting
disease and included patients in secondary care settings; therefore acute eczema is not included in these studies.
Consequently, the results are less applicable for the primary care setting. This review included participants of all ages;
however, most of the included studies did not include children. Only four studies included participants under the age of 16
years and did not provide separate results for this subgroup; therefore, the results of this review may not be applicable to
children. With regard to external validity, these studies were conducted all over the world, supporting the generalisability of
the results.
The objective of this Cochrane Review was to assess the effects of topical and systemic interventions for hand eczema in
adults and children. Because of the above-mentioned implications, it is difficult to answer our review question with a single
answer. As stated before, we cannot comment on children based on the included studies, which mainly include adults.
However, this review does provide a clear overview of different studies on potential topical and systemic interventions for
adult patients with chronic hand eczema. A pitfall is the lack of head-to-head studies, which makes it impossible to know
whether one treatment is favoured over another.
Quality of the evidence
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We found some serious limitations in the quality of reporting and aimed to discuss these according to the GRADE
considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias).
Limitations in study design and implementation
We included only RCTs in this review. Overall, the older studies had more shortcomings with regard to risk of bias, and we
judged them as having 'high' or 'unclear' risk of bias with regard to allocation concealment, blinding, and/or loss to follow-up.
Frequent shortcomings included missing information on randomisation and blinding, no justification of the number of
participants, and no analysis of dropouts. Studies that were conducted more recently had an overall low or unclear risk of
bias for most of the risks (allocation concealment, blinding, intention-to-treat analysis, and selective reporting of outcomes),
although they sometimes were sponsored by pharmaceutical industries. Over a third of the studies used a within-participant
design (left-right studies). Although these studies show strengths in terms of power to obtain statistically significant results
with small numbers of participants, this is done at the expense of problems in interpreting studies finding no difference in
effect. This might be a consequence of cross-contamination of topical interventions, possible systemic effects of topical
preparations, or both. In general, we consider the body of evidence in this review as having 'unclear risk of bias'.
As a consequence, we downgraded evidence only for one of our main comparisons (mometasone furoate cream three times
per week vs two times per week; Summary of findings table 2), as we considered the included study to be at high risk
of detection and performance bias (Veien 1999).
Indirectness of evidence
Overall the included studies were of relatively small sample size and short duration. Although hand eczema usually has a
chronically relapsing course, less than half of the studies had a duration longer than three months, which in our opinion is the
minimum duration required to document important data such as duration and frequency of disease relapse. Therefore, this is
considered as a form of indirectness. This review analysed the efficacy of many different interventions, of which various
included a placebo. Moreover, because the number of studies comparing different groups of interventions (e.g.
corticosteroids, oral retinoids, phototherapy) is limited and the number of participants for each intervention is limited (with the
exception of alitretinoin), the evidence is mostly indirect. Overall, participants in a secondary care setting with chronic
eczema were included. As mentioned above, the definition of 'chronic hand eczema' was not always clear; this could be
defined as having a minimal duration of six weeks to six months. Some studies included participants with specific subtypes of
hand eczema such as recurrent vesicular hand eczema, whereas others excluded this subgroup. We were unable to pool the
data for different subgroups of hand eczema, for example, to focus on hyperkeratotic palmar hand eczema, since the data for
specific subgroups often were not stated. A wide range of outcome parameters was presented, most of which were not
validated. Some studies used a validated outcome measure such as the Hand Eczema Severity Index (HECSI), whereas
most created their own non-validated, un-named scoring system. Another limitation arose from the comparators used: most
interventions were compared to an inactive placebo, which is less effective than standard treatment in most settings. We
decided not to downgrade the evidence in our main comparisons for indirectness, as we judged this to be a less serious
concern than imprecision (see below).
Consistency of results
It is difficult to judge the consistency of the results because we were unable to pool the study results for most of the
outcomes assessed because only a single study was available, or because of clinical heterogeneity in interventions (and co-
interventions), treatment duration, comparison groups, and outcomes measured or reported. As a direct consequence of the
overwhelming diversity in study characteristics (i.e. clinical heterogeneity), most of the comparisons are based on single
studies, hence making it difficult for the review authors to draw any firm conclusions with confidence. We can interpret this
review only as a scoping review. Hence, we could not downgrade any evidence for inconsistency.
Imprecision of results
Most of the analyses are based on a single study of small sample size, and often with low event rates (in some cases, zero
events), and the 95% confidence interval of effect estimates was often very wide, resulting in a low-precision assessment.
Hence, we downgraded most of the outcomes included in the summary of findings tables for imprecision because we believe
the small sample size means there was not enough power to detect any differences between groups. The effectiveness
outcomes in two of our main comparisons comparing alitretinoin 10 mg or 30 mg versus placebo were not downgraded for
imprecision because the analyses included two studies equalling a larger sample size, and the results had fairly narrow 95%
confidence intervals, which did not include one showing high-certainty evidence supporting the effectiveness of alitretinoin
(see Summary of findings table 7 and Summary of findings table 8).
Probability of publication bias
We did not produce funnel plots due to insufficient numbers of included trials for all given outcomes. Publication bias may
especially be present in the wide range of studies on different moisturisers to treat hand eczema: we did find various
registered trials in trial registries that were not (yet) published. Contact with study authors in some cases revealed that the
results were minimal and would not be published, or study authors did not respond to our writings at all. In other cases, study
authors were not at liberty to disclose results but referred us to pharmaceutical sponsors, who often remained unresponsive.
Potential biases in the review process
We acknowledge that there was potential for bias at all stages of the review process, but we made various attempts to
restrict the level of bias.
We comprehensively searched for randomised controlled trials from a wide range of databases to avoid the risk of
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publication bias, and we used clinically relevant outcome measures. We tried to compare respective trial registrations with
published trials to ascertain whether there was lack of correspondence between what was intended to be an outcome and
actually reported outcomes. We attempted to be as inclusive as possible in our search strategy and included studies reported
in languages other than English. The different language backgrounds of review authors enabled us to include Dutch -
Kemper 1998 - and German articles - Adams 2007; Bayerl 1999. We translated a Turkish article to minimise
language bias (Baskan 2005). Nevertheless, the studies included in this review were predominantly conducted in European
or North American countries and were published in European or American journals.
The authors of this review independently assessed the eligibility of studies for inclusion in this review; two other
review authors extracted data and assessed risk of bias to minimise the potential for additional bias beyond that
detailed in the 'Risk of bias in included studies’ tables. Discrepancies between review authors were resolved by
discussion to reach consensus. However, we acknowledge that our assessments may occasionally have been
subjective, for example, in the case of the not-blinded radiographers (Cartwright 1987; Fairris 1984; Fairris 1985; King 1984).
Therefore, readers may not agree with all of our decisions.
Review authors who were involved as trialists for certain studies were not involved in selection, assessment, and data
extraction for those studies. Pieter-Jan Coenraads was involved in the studies of Ruzicka 2004, Ruzicka 2008, and van
Coevorden 2004a. Thomas L Diepgen was involved in the studies of Bauer 2012 and Ruzicka 2008 (Declarations of
interest).
The authors of this review are aware that some differences between protocol and review (see Differences between protocol
and review) may have been a source of bias. The protocol was published in 2009, and Cochrane guidance has since
developed. Such differences include changing adverse events to a primary outcome, adding a time point of a minimum of
three months for measuring outcomes such as relapse, changing the way measures of treatment effect are expressed, and
making changes to the literature search. We tried to not make these decisions based on the data we had extracted, but
rather on the new Cochrane guidance.
We judged a lot of studies to have unclear risk of bias, especially with regard to selection bias, since a substantial number of
studies did not describe the way allocation concealment and sequence generation were performed. To obtain more clarity on
this matter, we contacted all authors from studies published after 1999 by email or through other forms of social media such
as LinkedIn. Study authors with a personal or professional relation to one of the authors of this review may have been
reached more easily and might have been more prone to respond to our requests. Therefore, these studies may have been
judged more often as having low risk of bias. For studies pre-1999 and for reports for which study authors were
unresponsive, we had less information and had to deal with more ambiguity, which we were unable to resolve; this may have
contributed to some bias in assessments of these studies, and these studies were more often judged as having unclear risk
of bias.
The time frame for the studies included in this review inevitably shows that there is a time trend in treatments that are
evaluated: earlier studies tend to focus on corticosteroids, UV phototherapy, or X-rays, and more recent trials evaluate the
effects of novel medicaments such as oral retinoids and topical calcineurin inhibitors.
The fact that 20 studies have not yet been incorporated into this review may be a source of potential bias.
Agreements and disagreements with other studies or reviews
This Cochrane Review studies a wide range of treatments that have been evaluated by RCTs since 1967. Within the same
time frame, many uncontrolled and non-randomised controlled studies have been published. van Coevorden 2004b
conducted a review to describe study design and the quality of studies on hand eczema, covering the time period from 1977
up to 2003. These review authors included 90 studies, of which 44 were case series, 15 non-randomised controlled trials,
and 31 RCTs. In total, 11 different categories of treatment were found, and most trials studied ultraviolet irradiation (n = 32)
or corticosteroids (n = 13). This review concluded that the overall quality of reporting on hand eczema was poor, and most
hand eczema trials were not considered adequate to guide clinical practice. Since the current Cochrane Review was
conducted in part by the same review authors and incorporated the same RCTs, it is not surprising that the results and
conclusions of both reviews overlap. However, since we tried to obtain more information by contacting authors in this
Cochrane Review, and since we sought additional published and unpublished data, we had fewer uncertainties with regard to
the quality of evidence. We also included RCTs that were conducted after 2003, and in general these studies are of better
quality than the older studies. We maintain that the overall quality of reporting in hand eczema is low, and that there is a
need for well-designed head-to-head studies of adequate duration, reported according to the CONSORT guidelines.
Over the years, various groups have composed guidelines for the management of (chronic) hand eczema (Veien 2003; 
Diepgen 2007; Diepgen 2009b; English 2009; Lynde 2010; Menné 2011). These guidelines have in common that they all
acknowledge the lack of RCTs. All guidelines recommend topical corticosteroids as one of the first steps in pharmacological
treatment for all types of hand eczema. Thereafter, the guidelines recommend different steps, in which the subtype of hand
eczema can be a leading factor, usually starting with topical treatments (e.g. more potent or prolonged use of corticosteroids
or calcineurin inhibitors).
For severe hand eczema that is unresponsive to topical treatment, basically all guidelines recommend a treatment
regimen with tar, phototherapy, and systemic (oral) treatment (acitretin, alitretinoin, cyclosporin, corticosteroids, or
others). Since alitretinoin was recently licensed for the treatment of hand eczema in Europe and Canada (not yet in
the United States), the more recent guidelines include this treatment option for severe chronic hand eczema (Diepgen 2009b;
English 2009; Lynde 2010; Menné 2011).
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English 2009 published a consensus statement on the management of chronic hand eczema in the view of general
practitioners and dermatologists. The authors did not conduct a systematic review but based their statement on a mix of
clinical experience and a variety of RCTs and non-RCTs on hand eczema and atopic dermatitis. In general, they advise a
skin protection programme and topical treatment with corticosteroids or calcineurin inhibitors in a primary care setting
whenever possible. For referrals to secondary care (dermatologist), PUVA, cyclosporin, azathioprine, and alitretinoin are
preferred treatment options for hyperkeratotic and vesicular hand eczema, with emphasis on the importance of patient
preference and local availability. Furthermore, PUVA (also in our review a well-studied intervention) is recommended for
hyperkeratotic hand eczema. Methotrexate and mycophenolate are recommended after failure of other systemic
interventions; however, this recommendation is not supported because of lack of RCTs examining these interventions.
The German Dermatologic Society stresses the importance of education and prevention (Diepgen 2009b). Topical
corticosteroids, topical calcineurin inhibitors, and iontophoresis are the first treatment steps. For moderate to severe hand
eczema, highly potent corticosteroids, UV therapy, and alitretinoin are recommended, while other systemic treatment options
such as cyclosporin are the final resort. This recommendation is based largely on the fact that alitretinoin is registered for the
treatment of hand eczema, while cyclosporin is an off-label therapy.
The Canadian guideline states that treatment of hand eczema can be difficult and unsatisfactory (Lynde 2010). Researchers
distinguish three important clinical types: irritant contact dermatitis, allergic contact dermatitis, and atopic hand eczema. This
guideline provides a clear flow diagram for acute hand eczema and chronic hand eczema, which is divided into mild,
moderate, and severe. Topical corticosteroids are the mainstream of treatment, and phototherapy is recommended for
moderate chronic hand eczema unresponsive to topical corticosteroids. For severe cases that are unresponsive to potent
topical corticosteroids, phototherapy and alitretinoin are recommended. When this is insufficient as well, cyclosporin can be
considered. Because the comparative study NCT01231854 was ended prematurely, we do not know whether alitretinoin
should be preferred over cyclosporin.
Danish guidelines state that treatment for hand eczema should be tailored to the individual and that skin care
education is very important (Menné 2011). They classify hand eczema into six different clinical types: chronic fissured hand
eczema, recurrent vesicular hand eczema, hyperkeratotic palmar hand eczema, pulpitis, interdigital eczema, and nummular
hand eczema. Furthermore, they distinguish between mild/moderate hand eczema and severe hand eczema. Mild/moderate
hand eczema should be treated with topical corticosteroids, potentially in rotation with calcineurin inhibitors. For severe hand
eczema, a step-up with topical corticosteroids and "possibly potassium permanganate baths" for vesicular hand eczema and
"silver nitrate solutions" for hyperkeratotic eczema is recommended. However, our review did not find evidence for these
treatment options. If topical treatment is insufficient, a further step-up regimen is recommended with tar, phototherapy, and
systemic treatment (acitretin, alitretinoin, cyclosporin, corticosteroids, or others), although the guideline does not given an
order of priority and does not make further recommendations regarding the different subtypes of hand eczema.
The American Academy of Dermatology has published guidelines on the use of topical glucocorticoids - the mainstay
of treatment for hand eczema (Drake 1996). The British Photodermatology Group developed a guideline on
phototherapy and included a comment on the use of phototherapy in hand eczema (Halpern 2000). Although the evidence
for topical PUVA over oral PUVA is scarce, this group suggests a commonsense approach, which is not contradictory to the
findings of this review.
The studies included in this review regarding alitretinoin did find an increase in the number of participants
reporting headache while taking alitretinoin compared to placebo with a high level of evidence (Bissonnette 2010; Ruzicka
2004; Ruzicka 2008), which is in line with multiple daily life studies that have reported headache as a well known
side effect of alitretinoin (Diepgen 2012; Augustin 2016).
Overall, we can conclude that most guidelines do not give a single recommendation based on the current literature, which is
consistent with the main finding of this review.
Authors' conclusions 
Implications for practice 
The results of this review cannot be used to inform clinical practice with regard to the best way of managing hand eczema,
especially in the long term. Until such data are forthcoming, physicians will be tempted to use an array of treatments.
For the comparison of clobetasol propionate versus vehicle foam, the percentage of participants with self-rated
good/excellent control of symptoms probably improves with clobetasol propionate, but the effect is less clear for investigator-
rated symptoms (moderate-quality evidence). Mometasone furoate cream thrice-weekly may slightly improve investigator-
rated symptoms compared to twice-weekly application (low-quality evidence); participant-rated control was not measured.
Tacrolimus ointment probably improves investigator-rated good/excellent control of symptoms compared to vehicle foam
(moderate-quality evidence); participant-rated control was not measured.
A relatively new systemic treatment (an oral retinoid called alitretinoin) for patients with severe chronic hand eczema,
showed clearance or almost clearance of about half the participants in three large RCTs (Fowler 2014; Ruzicka 2004, 
Ruzicka 2008). We found high-quality evidence that relative to placebo, people who are given alitretinoin were more likely to
achieve good symptom control (investigator or participant rated). The benefit became more apparent with increased dosage
(10 mg vs 30 mg).
Local PUVA may lead to improvement compared to local narrow-band UVB; however, the 95% confidence interval indicates
that local PUVA might make little or no difference (moderate-quality evidence). Participant-rated control was not measured.
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Oral cyclosporin probably slightly improves investigator/participant-rated control of symptoms compared with topical
betamethasone dipropionate (moderate-quality evidence).
For the comparison tacrolimus 0.1% ointment vs mometasone furoate ointment, investigator-rated symptoms and participant-
rated control was not measured.
Adverse events: adverse (long- and short-term) effects of the interventions
Clobetasol propionate led to more adverse events (including application site burning/pruritus after intervention application,
nasopharyngitis, and one incident of severe fissures) compared to vehicle foam (moderate-quality evidence)
With regard to mometasone furoate cream used thrice weekly compared to twice weekly, mild atrophy was reported in
both groups (low-quality evidence)
When compared to local PUVA, adverse events (mainly erythema) were reported in the local narrow-band UVB group
only (moderate-quality evidence)
With regard to tacrolimus ointment compared to mometasone furoate ointment, both treatments were well tolerated; none
of the participants dropped out due to adverse events (moderate-quality evidence)
When compared to vehicle foam, adverse events (well-tolerated burning/itching at the application site) were reported in
the group taking tacrolimus ointment only (moderate-quality evidence)
The risk of adverse events such as dizziness was fairly similar between those taking oral cyclosporin and those taking
topical betamethasone dipropionate (moderate-quality evidence)
The 20 studies listed under Studies awaiting classification may alter the conclusions of the review once assessed.
Implications for research 
The most important implication of this review is the need to conduct high-quality RCTs of people with hand eczema to
compare commonly used interventions by using simple outcome measures that can be understood by participants and
clinicians.
E (Evidence): current evidence for managing hand eczema is mainly of low to moderate certainty and especially head-to-
head trials are missing. Recently, head-to-head trials for different (systemic) treatments have been
registered in trial registries (ISRCTN80206075; NCT03026907; NCT03026946), which might alter the outcomes of this
review in the near future.
P (Population): people with chronic (longer than six months) moderate to severe hand eczema should be included in
future trials. Subgroup analyses on participants with different variants of hand eczema are recommended, although lack of
consensus regarding the classification of hand eczema is a major limitation. We need international consensus regarding
the definition of (chronic) hand eczema and subgroups of hand eczema, based on morphology or aetiology. Subgroups of
especial interest include participants with hyperkeratotic hand eczema and participants with recurrent vesicular hand
eczema. Studies on acute hand eczema were not included in this review but may be of interest, especially in primary care
settings. Not many children were included in these studies, and this is a potential subgroup of interest for future studies.
I (Intervention): all sources of treatment can be included, although we would recommend including the main interventions
(topical corticosteroids, UV therapy, topical calcineurin inhibitors, acitretin, alitretinoin, and cyclosporin).
C (Comparison): head-to-head trials, in which different groups of commonly used interventions are compared, are highly
desirable, for example, cyclosporin versus alitretinoin or UVA therapy versus topical corticosteroids. If an RCT includes
placebo (or vehicle or inactive treatment) as the only comparator instead of an established treatment modality, this should
be clearly and convincingly justified.
O (Outcome): at the moment, international consensus on a standard severity scale for hand eczema is lacking. Many of
the scales used were not validated, and validation of commonly used scoring systems is needed. Alternatively, a simple
global rating measure with, for example, photographic anchors is highly recommended (Charman 2005; Weistenhöfer
2010). We would like to recommend the same procedure as is currently ongoing in atopic dermatitis: Harmonising
Outcome Measures for Eczema (HOME) (Schmitt 2010). The HOME group is a worldwide initiative with the aim of
developing a consensus-based set of core outcome domains for trials and clinical record keeping in atopic dermatitis. This
is important, to allow comparison of data across trials - one of the difficulties that we encountered in this review on
interventions for hand eczema. Duration of remission, the way the disease is brought under control, adverse events, focus
on patient-reported outcomes, and simple outcome measures applicable to all participants are preferable. Hand eczema is
known to influence quality of life; therefore quality of life should be an important outcome. In addition, trials should focus
on economic consequences, since hand eczema is a common occupational disease. A major limitation of almost all
reviewed trials is that no measure of effect size including precision is given. This is necessary to enable judgement of
whether advantages of treatments are not only statistically significant but also meaningful.
T (Time stamp): our latest search was conducted in April 2018. Older studies focused mainly on topical corticosteroids,
UV therapy, and irradiation, and more recent (namely, industry-funded) studies focus on topical calcineurin inhibitors
(pimecrolimus and tacrolimus) and alitretinoin. The included studies were predominantly of short duration. Future studies
should have adequate treatment duration, preferably longer than three months, which in our opinion is the minimum
duration required to document important data such as duration and frequency of disease relapse. Furthermore, studies on
chronic hand eczema should include a follow-up period of at least equal duration. Acute hand eczema, especially the
allergic type, tends to respond quickly to treatment and needs only a short follow-up, in which case a few weeks of
treatment and follow-up should be sufficient.
It is obvious in many of the reviewed trials that the approach to statistical analyses was limited. Several parametric and non-
parametric statistical procedures that are able to model both within (person and/or time) and between subject (treatment)
factors simultaneously have been offered by most statistical packages for many years. A major limitation of many of the
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treatment comparisons is that they did not control for baseline variation. In addition, omnibus factorial designs (allowing
contrasts to be specified a priori) reduce the type 1 error rate because they test several hypotheses at the same time. Post-
hoc comparisons would be necessary only should the data reveal surprising results. These analyses, of course, would have
to be viewed in an explorative fashion. Future studies need to overcome said limitations.
Many deficiencies in trial reporting thus far can be avoided if all specialist dermatology journals adopt the CONSORT
guidelines (Moher 2001), especially since many of the 'unclear' risks, turned out to be based on missing information in the
report instead of flaws in the study design. All future studies should adhere to these guidelines. Future studies should ensure
they are adequately powered to detect any differences between treatment groups and to reduce imprecision.
Practical recommendations for upcoming studies include the above-mentioned recommendations on
chronic hand eczema. Studies that are highly recommended include the comparison of phototherapy
(e.g. bath-PUVA) versus alitretinoin 30 mg in a large cohort of participants with chronic hand eczema
with a duration of at least three months and follow-up of at least equal length. This study is already
registered (ISRCTN80206075), and results of this trial might influence the outcomes of this review in future updates.
Another recommendation would be to compare alitretinoin 30 mg to cyclosporin in participants with vesicular
hand eczema and with hyperkeratotic hand eczema, since participants with vesicular hand eczema seemed
to respond less to alitretinoin in the included trials on alitretinoin. This study design is already registered for
vesicular hand eczema as well, and we are awaiting the results (NCT03026946). Other potential research
options include comparison of a potent topical corticosteroid, since this is the mainstream of treatment, to
alitretinoin 30 mg or to phototherapy. The comparative advantage over other treatments needs further
evaluation, since the only study that did compare alitretinoin to another immunosuppressant (cyclosporin)
was ended prematurely (NCT01231854).
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Differences between protocol and review 
The protocol for this review was published in 2009. Since that time, methodological guidance has changed including
development of the MECIR standards. Hence, many sections have been edited and some new sections have been added,
including Background > Description of the Intervention and Background > How the intervention might work. 
Moreover, we were also required to retrospectively select the most important comparisons for our Summary of Findings
(SoF) tables, and we selected them based on clinical relevance and on our own experiences.
We have changed the review question slightly and made it more precise. The original protocol stated "To assess the effects
of interventions for hand eczema”, which was changed to “To assess the effects of topical and systemic interventions for
hand eczema in adults and children" to make the review question a bit more concise, since this is already a very
comprehensive review.
Methods > Types of outcome measures: in the original protocol, we stated primary (percentage of participants with self-rated
good/excellent control of symptoms and percentage of participants with investigator-rated good/excellent control of
symptoms), secondary (reduction in severity and time until relapse), and tertiary outcomes (adverse events and dose
reduction). We adjusted the review to the most recent Cochrane guidelines and used only primary outcome measures
(percentage of participants with self-rated good/excellent control of symptoms, percentage of participants with investigator-
rated good/excellent control of symptoms, and adverse events) and secondary outcome measures (reduction in severity,
time until relapse and dose reduction).The 'Side effects' were changed into the primary outcome 'Adverse events'. Adverse
effects were divided into short-term adverse events occurring during the treatment phase and long-term adverse events
occurring after completion of treatment. We also removed from the primary outcomes the conditional element 'with adequate
length of follow-up' because a substantial otherwise well-conducted number of studies did not include long-term follow-up,
and there is no consensus regarding 'adequate' in this context. The secondary outcome time until relapse was not defined in
the protocol. In the review, time until relapse was defined as the number of days/weeks until the participant reports
worsening of symptoms after initial response.
We added a recommended time point for outcome measures of a minimum of three months, which is considered the most
clinically important time point for decision-makers. Hand eczema is a chronic, relapsing condition that might improve due to
the natural course. However, because of the tremendous impact of hand eczema on quality of life, we considered analyses
after three months to be undesirable.
Methods > Measures of treatment effect: in the original protocol, we stated that results would be expressed as odds ratios
(ORs with 95% confidence intervals (CIs)) and risk differences (RDs with 95% CIs) for dichotomous outcomes and weighted
mean differences (WMDs and 95% CI) for continuous outcomes. However, during the review process, we decided that risk
ratios should be used instead (RRs with 95% CIs), since these would give a more accurate estimation of relative differences
between comparison groups, as in some studies the proportion of outcome events was close to one in one or both groups. In
addition, risk difference is not a relative measure and is not recommended as the first choice for reporting pooled results; we
decided to abandon the risk difference and include risk ratios instead. We also expressed results from analyses of
continuous data as mean differences (MDs), including CIs and respective P values. If insufficient data were available for any
of the two analyses, we summed up available data from the respective study including the stated P value. Subsequent to
publication of the protocol, in studies where exclusively median values were presented for a particular outcome, we
substituted the median for the mean, provided that data were not too skewed. Whenever standard deviations were not
available from a paper, we tried to calculate them from other available data. When confidence intervals were provided, the
formula given in Chapter 7.7.3.2 of the Cochrane Handbook for Systematic Reviews of Interventions was used (Higgins
2011a). The results were also expressed as number needed to treat (NNT) where appropriate with different rates of baseline
risk.
Methods > Types of interventions: we encountered different studies that reported on treatment during a remission- or
clearance-induction phase for participants before they were randomised to a follow-up or maintenance phase. This problem
was not addressed in the protocol. In the review, we considered only the latter (randomised) phase for these studies.
Methods > Electronic searches: we tried to obtain additional data regarding unpublished and ongoing trials, or grey literature,
via correspondence with study authors and pharmaceutical companies. However, the results of contacting authors and
pharmaceuticals were often disappointing. We did not search Pascal and JICT-EPLUS as planned in our protocol, as we did
not have access to these databases by the time the review was written. In the review, we searched MEDLINE from 1946,
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rather than from 1957, as planned, and we did not use old MEDLINE, because a newer version was available and the old
data were incorporated in the new database. We additionally searched LILACS and the Global Resource of EczemA Trials
(GREAT) because these became available over the years. We also searched a number of trials registries, which were not
part of our original plan, because over the years, the search strategy was updated, and newer ways to conduct searches
became available.
Methods > Searching other resources: we contacted trial authors of articles published after 1999 for clarification of date
issues. Older contact data were often obsolete, and we considered it unlikely that researchers would have saved study data
longer than 15 years. We did not perform a separate search for adverse events. Although not planned in the protocol, we did
examine data on adverse events from the included studies. We handsearched the following additional journals: H+G
Zeitschrift für Hautkrankheiten, Annales de Dermatologie et Venerelogie, and Journal of Dermatologic Treatment, because
these were expected to provide additional studies; however these journals were digitised during the time this review was
compiled.
The original protocol stated that the review authors would also record methodological quality in the review. We performed a
thorough assessment of risk of bias (authors PJC and AS).
The original protocol stipulated diagnosis of hand eczema by a physician. Although only one of the studies that we identified
stated this explicitly, all studies were based on participants being outpatients at hospitals. Therefore, we assumed that the
diagnosis was established by a physician for all participants.
The original protocol expressed the plan to conduct subgroup analyses on different classifications of hand eczema, such as
recurrent vesicular hand eczema or hyperkeratotic hand eczema. However, in almost all studies, the different classifications
of hand eczema were combined and we were unable to extract sufficient information to conduct subgroup analyses, or the
subgroups were combined or were unclearly defined in general. This might be the topic of a future update.
Several studies reported scoring systems using un-named, non-validated, self-created, and combined objective and
subjective scores; in these cases we provided a narrative account of study results and summarised statistical tests reported
by study investigators; we did not attempt quantitative analyses.
Methods > Types of participants: in the review, we additionally included participants who had other parts of their body
affected, in addition to having hand eczema, because patients with hand eczema often have comorbidities such as atopic
dermatitis. In the protocol, we stated that we would consider other terms, such as 'pompholyx', 'dyshidrosis', and 'pulpitis', as
acceptable if diagnosed by a physician. However, in the review, we did not apply the need for diagnosis by a physician
because all participants were included from hospitals, and although it was almost never stated in the methods, we therefore
believed that the diagnosis was confirmed by a physician. Subsequent to publication of the protocol, we decided to include
participants with other diagnoses besides hand eczema in the review when we were able to obtain separate data for hand
eczema participants, because otherwise some studies had to be excluded although they contained potentially valuable data.
We also clarified in the methods that we included participants with all types of hand eczema.
Methods > Types of participants: in the protocol, we did not impose any age limits on the participants; however, we changed
this because treatment requirements and ethics for children are considerably different from adults.
Methods > Selection of studies: specified authors that we assigned in the protocol to independently check titles and abstracts
were different in the review because the composition of the review author team changed over the years. The specified
authors that we assigned in the protocol to independently examine the trials retrieved as full text were also different in the
review because of this. In the protocol, we planned to resolve discrepancies with a third review author (PE), but instead,
differences between review authors were resolved in consensus meetings because we considered these discrepancies to be
substantial for the review and therefore aimed for consensus between all review authors.
Methods > Data extraction and management: specified authors that we assigned in the protocol to independently extract data
were different in the review because of an organisational change in the author team. In the protocol, we planned to resolve
discrepancies with a third review author (ÅS), but instead, we resolved differences between review authors in consensus
meetings because consensus is preferred over partial consensus. We planned for one review author to check and enter data
into Review Manager; however, in the review, three review authors did this.
Methods > Assessment of risk of bias in included studies: we updated our process for assessing methodological quality in
the review, following more up-to-date guidance than was planned in the protocol. We used the Cochrane risk of bias tool,
described in Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011b).
Methods > Unit of analysis issues: we did not plan for cluster randomised trials or within-participant studies in the protocol, so
the text in the Unit of analysis issues section regarding these types of trials was not envisioned at the time of development of
the protocol.
Methods > Dealing with missing data: we did not state plans for dealing with missing data in the protocol, so the text in the
Dealing with missing data section was not envisaged at the time of development of the protocol.
Methods > Assessment of heterogeneity: in the protocol, we did not define clinical heterogeneity as we did in the review
because this was not an item at the time of writing the protocol. We did not specify in the protocol that we would investigate
statistical heterogeneity using the I² test. Neither did we plan to explore reasons for heterogeneity in studies if the I² statistic
was greater than 50%, because these were not issues at the time of writing the protocol.
Methods > Assessment of reporting biases: we did not state plans for assessing reporting biases in the protocol, so the text
in the Assessment of reporting biases section was not envisaged at the time of development of the protocol.
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Methods > Subgroup analysis and investigation of heterogeneity: had there been sufficient data, we would have examined
the effects of studying or excluding study subgroups, for example, children versus adults, or recurrent vesicular versus
hyperkeratotic hand eczema. This was different from the atopic versus allergic contact hand eczema analysis that we had
planned in the protocol, because these subgroups often were not defined and data were not available, which were defined a
priori, or those studies had high risk of bias. Future updates of this review will carry out these analyses if data permits.
Methods > Sensitivity analysis: in the protocol, we planned to undertake sensitivity analyses to examine the effects of
excluding study subgroups (e.g. children vs adults, atopic vs allergic contact hand eczema) or studies with high risk of bias.
But in the review, we stated, "had there been sufficient data, we had intended to perform sensitivity analyses for pooled data.
Data on these subgroups were not sufficient for sensitivity analyses and often not available".
Methods > Summary of findings: we included Summary of findings table 1 to Summary of findings table 8 for the clinically
most relevant outcomes. "Summary of findings tables" were not included in the protocol but were recommended during an
update of the review.
Published notes 
Characteristics of studies
Characteristics of included studies 
Adams 2007
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Methods Within-participant, randomised controlled study (left-right design).
This study was carried out in the secondary care setting; it was a single-centre study
conducted in Germany
 
Participants 15 participants at least 18 years old suffering from chronic relapsing dyshidrotic hand
eczema with a minimal duration of 1 month that was resistant to conventional
therapies
Dropouts: 4
Inclusion criteria of the trial
At least 18 years old
Chronic relapsing dyshidrotic hand eczema with a duration of at least 1 month
Resistant to conventional therapies
Exclusion criteria of the trial
Other dermatological diseases
Pregnancy
Light therapy during the last 4 weeks
Topical corticosteroids during the last week
> 200 PUVA treatments in the past
Medication or alcohol abuse
Immune suppressive therapy
Study population
Gender: 8 female, 3 male
Age: median 45.1 years, range 28 to 66 years
 
Interventions Intervention
• Middle-dose UVA-1 irradiation 3 times a week (cumulative dose of 600 J/cm²) in
11/15 hands during 5 weeks
• Local 8-MOP-cream-PUVA irradiation 3 times a week during 5 weeks (cumulative
dose of 17.4 J/cm²) in 11/15 contralateral hands. 8-MOP-crème was applied 30
minutes before the start of irradiation
Duration
5 weeks
 
Outcomes Primary outcomes of the trial
• Observer-rated assessment of improvement (DASI score)
Other outcomes
• Adverse events
 
Notes Therapeutic efficacy was shown with relatively low cumulative doses of UVA and
UVA-1
The secondary outcome - reduction in severity, investigator-rated - was included but
did not provide reproducible data
Study authors were contacted by mail on 6 March 2014 and responded 10 March 2014
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk The article states that randomisation was done by an independent third
person. No information regarding random sequence generation appeared
in the article; however personal communication clarified that this was done
appropriately: "cards with the characterisation "A" and "B" were enclosed
in envelopes by a third person, mixed like a card play by a third person,
then numbered consecutively by a third person and opened by the study
doctor consecutively after informed consent to the study"
 
Allocation concealment (selection
bias)
Low risk Quote: "randombriefe wurden nach Wűrfeln von einer von der Studie
unabhängigen Person erstellt" (free translation: the randomisation letter
was created by an independent person after throwing dices)
Comment: adequate allocation concealment as randomisation was
accomplished by a third party
 
Blinding of participants and
personnel (performance bias)
High risk Quote: "eine Verblindung der Studie erfolgte nicht" (free translation: the
study was not blinded)
Comment: no attempts were made to blind participants or personnel
 
Blinding of outcome assessment
(detection bias)
High risk Quote: "eine Verblindung der Studie erfolgte nicht" (free translation: the
study was not blinded)
Comment: observers were not blinded
 
Incomplete outcome data (attrition
bias)
High risk No intention-to-treat analysis but per protocol (11 of 15 = less than 80%)
 
Selective reporting (reporting bias) Low risk No trial registration found; however all outcomes listed in Materials and
Methods are given in the Results section
 
Other bias Low risk Baseline comparisons revealed no significant differences between groups,
as within-participant study was not applicable
Diagnostic certainty: yes
The study was completed
 
Agarwal 2013
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Methods Parallel-group, randomised controlled trial
This study was probably carried out in a secondary care setting as a single-centre
study at a Department of Dermatology in India
 
Participants 108 participants with clinically diagnosed hand eczema included; 91 completed the
study
Dropouts: 17
Inclusion criteria of the trial
Clinical diagnosis of hand eczema with duration longer than 6 months
Exclusion criteria of the trial
Pregnancy
Lactating mothers
Younger than 18 years or older than 65 years
Any associated systemic disease (diabetes, hypertension, thyroid disorders, any
renal or liver disease, malignancy, etc.)
Hypersensitivity to azathioprine
Study population
Gender: 29 female, 62 male
Age: group A mean 36.86 years, SD 11.55 years; group B mean 35.82 years, SD
10.67 years
 
Interventions Intervention
• Topical clobetasol propionate 0.05% cream twice daily with oral azathioprine 50 mg
daily in 46 participants for 24 weeks
Control intervention
• Topical clobetasol propionate 0.05% cream twice daily alone in 45 participants for 24
weeks
Participants were instructed to use the topical clobetasol intermittently and to stop
application whenever the signs and symptoms disappeared and restart when the
complaints returned
Duration
24 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
• Reduction in severity, investigator-rated scoring measured by the Hand Eczema
Scoring Index (HECSI) at 2, 4, 8, 12, and 24 weeks
• Reduction in severity of itch, participant-rated, measured on a numerical scale from 0
to 10
• Number of exacerbations
• Adverse events
 
Notes The total quantity of corticosteroids used was not registered
Study authors were contacted on 27 February 2014 by email and responded 1 March
2014
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
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#29 Interventions for hand eczema
48 / 280
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "patients were randomised into 2 groups using block
randomization"
Comment: unclear from the article how these blocks were generated;
however contact with study authors clarified that a valid computer-
generated table was used
 
Allocation concealment (selection
bias)
Low risk No information is provided in the article on how allocation was concealed
from participants and investigators, but personal communication revealed
that randomisation was done by a third person
 
Blinding of participants and
personnel (performance bias)
High risk Quote: "patients paid for the medicine themselves"
Comment: participants were not blinded because they had to buy their
own study drugs, and no placebo was used
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "an observer blinded randomized comparative trial"
Comment: study authors stated that the study was observer blinded but
gave no details as to how this was achieved. Contact with study authors
clarified that observers were independent and were not involved in
treatment nor in dispensation of study drugs
 
Incomplete outcome data (attrition
bias)
Unclear risk 91 of the 108 (84.3%) included participants were analysed. No intention-
to-treat analysis. Dropouts were not evenly distributed between the 2
groups
 
Selective reporting (reporting bias) Low risk No trial registration found. However, all mentioned outcomes are
described in the Results section
 
Other bias Unclear risk No baseline comparisons were conducted or reported
Diagnostic certainty: yes
The study was completed
 
Baskan 2005
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Methods Within-participant, placebo-controlled, randomised controlled trial
The study was conducted in the secondary setting at a single centre in Turkey
 
Participants 25 participants with moderate to severe bilateral hand dermatitis with a minimal
duration of 6 months
Dropouts: 1
Inclusion criteria of the trial
Bilateral hand dermatitis
Moderate to severe hand eczema with a minimal duration of 6 months
18 years of age or older
Exclusion criteria of the trial
Pregnancy
Lactation
Use of systemic immunosuppressants
Other diagnosis such as urticaria, psoriasis, bacterial or fungal infection
Illness in the previous 4 weeks
Study population
Gender: 15 female, 9 male
Age: mean 35.8 years, range 18 to 63 years
 
Interventions Intervention
• Pimecrolimus 1% cream twice daily in 24/25 hands presumably for 8 weeks
Control intervention
• Placebo cream twice daily presumably for 8 weeks in 24/25 hands
• Participants were followed up for the same period
Duration
16 weeks (8 weeks active treatment, 8 weeks follow-up)
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
• Clinical response to therapy; erythema, desquamation, lichenification, oedema,
vesiculation, and fissuring were scored between 0 and 4 and were controlled at 2nd,
4th, 6th, and 8th weeks of therapy
• Clinical response to therapy for pruritus
• At the end of therapy, participants were followed up for the same period to observe
recurrences
• Adverse events
 
Notes Conference abstract from which only limited information can be extracted
Study authors were contacted for additional information, which led to review of an
additional full-text article in Turkish. The secondary outcome - reduction in severity,
investigator-rated - was included but did not provide reproducible data
Declarations of interest: not stated
Funding: not stated in the paper, but personal communication clarified that study
authors did not receive any funding
Sample size rationale: not stated
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Study authors stated randomised but gave no clear description of how this
was attained. Personal communication with study authors clarified that
they used a card drawing system
Quote: "a simple randomisation method by card drawing was performed"
 
Allocation concealment (selection
bias)
Low risk No information on how allocation was concealed from participants and
investigators is provided in the abstract Personal communication clarified
that one investigator drew the cards after participants gave their consent.
The topical drugs were packed in yellow and red boxes, and staff gave
participants the corresponding boxes for treatment, without knowledge
about the content of those boxes
 
Blinding of participants and
personnel (performance bias)
Low risk Not clear from the abstract; however personal communication clarified that
dispensation of study drug was done by a third person in boxes labelled
for each hand. The vehicle and pimecrolimus were packed in similar
boxes and were indistinguishable for participants
 
Blinding of outcome assessment
(detection bias)
Low risk Not clear from the abstract; however personal communication clarified that
observation was done by another physician who was not involved in
randomisation or drug dispensation
 
Incomplete outcome data (attrition
bias)
Low risk Unclear whether an intention-to-treat analysis was conducted; however 24
of the 25 included participants completed the study, which is more than
80%
 
Selective reporting (reporting bias) Low risk No trial registration found. All relevant clinical signs were scored in the
symptom score, and all described outcomes were depicted in the Results
section
 
Other bias Low risk No baseline comparisons were conducted or reported, as within-
participant study was not applicable
Diagnostic certainty: yes
The study was completed
 
Bauer 2012
Methods Parallel-group, randomised controlled trial.
Multi-centre study at the outpatient clinics of the University Hospitals Heidelberg and
Dresden, Germany
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Participants 40 adult outpatients
Dropouts: 4.
Inclusion criteria of the trial
Patients with moderate to very severe chronic relapsing atopic hand dermatitis (IGA
≥ 3)
18 years of age or older
Responded to treatment with mometasone furoate 0.1% once daily over 1 to 3
weeks (IGA ≤ 2) once IGA ≤ 2; participants received pimecrolimus cream or vehicle
for up to 56 days
Exclusion criteria of the trial
Atopic dermatitis covering over 20% of the body surface area
Use of phototherapy
Systemic prednisone or systemic immunosuppressive agents 4 weeks before
screening visit
Use of topical tar, pimecrolimus, and tacrolimus 7 days before screening visit
Hypersensitivity to ingredients of the study medication and/or vehicle
Women without adequate contraception or pregnancy or lactation
Patients with malignant diseases within the last 5 years
Concomitant skin disease
Infections of the hands
Study population
Gender: 22 female, 14 male
Age: mean 33.06 years, SD 10.78 years, range 18 to 54 years
 
Interventions Participants were randomly allocated in a ratio of 1:1 to receive the following
Intervention
• Pimecrolimus 1% cream twice a day for 8 weeks after clinical response (IGA 2) to 1
to 3 weeks of treatment with mometasone furoate 0.1% in 20/20 participants
Control intervention
• Vehicle twice a day for 8 weeks after clinical response (IGA 2) to 1 to 3 weeks of
treatment with mometasone furoate 0.1% in 16/20 participants
To control for compliance, study medication was weighed at every visit
Duration
8 weeks after 1 to 3 weeks of start-up treatment
 
Outcomes Primary outcomes of the trial
Proportion of participants maintaining a stable remission (IGA 2) with twice-daily
application of pimecrolimus or vehicle. The study endpoint was defined as the time
interval from commencement of treatment to relapse (IGA 3) during the 8-week
active treatment period
Secondary outcomes of the trial
Mean change IGA, patient self-assessment, HECSI, and DLQI
Other outcomes
Mean change in IGA from baseline during study period
Mean change in patient self-assessment (PSA) from baseline during study period
Mean change in HECSI from baseline during study period
Mean change in DLQI from baseline during study period
Adverse events
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Notes Secondary outcomes - reduction in severity, participant- and observer-rated - were
included but did not provide reproducible data
Study authors were contacted on 27 February 2014 and provided additional
information on 27 February 2014
Funding: the study was funded by a grant from Novartis Pharma GmbH, Nurnberg,
Germany, the manufacturer of the study drug Study authors gave lectures for Novartis,
although they claim this is not directly related to the study. One study author was an
employee of Novartis Pharma, the manufacturer of the pimecrolimus cream
Sample size rationale: adequate
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "randomization was performed by allocation of the consecutive
patients to the lowest available number from the randomisation list. The
allocation sequence was generated by use of a permutated block
randomisation list in blocks of 4 with equal allocation to pimecrolimus and
vehicle"
Comment: this is considered as adequate random sequence generation
 
Allocation concealment (selection
bias)
Low risk This was unclear from the article. Personal communication with study
authors clarified that the investigators had no access to the randomisation
code and used sealed envelopes for the allocation procedure
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "verum and vehicle creams were prepared from the commercial
product and blinded labelled for this study by Novartis Pharma GmbH.
Patients and investigators were blinded to assignment of patients during
the entire study period until the closing of the data bank"
Comment: participants and personnel of the study at the study site
(except personnel for Novartis, which was located somewhere else) were
unaware of the allocation during the study
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "verum and vehicle creams were prepared from the commercial
product and blinded labelled for this study by Novartis Pharma GmbH.
Patients and investigators were blinded to assignment of the patients
during the entire study period until the closing of the data bank"
Comment: investigators were blinded during the entire study, and only the
investigators from Novartis were aware of allocation
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "ITT analysis was performed"
Comment: intention-to-treat analysis for primary outcome as well as per
protocol (35/36 ≥ 80%)
 
Selective reporting (reporting bias) Low risk The trial was registered under Eudra CT Nr 2005-0003644-59 before the
start of the study. We found no discrepancy between outcomes stated in
the protocol and reported in the publication
 
Other bias Low risk Baseline comparison: no statistically significant differences were found
between the pimecrolimus (n = 20) and vehicle (n = 16) groups with
regards to age, sex, body weight, height, and ethnicity, and in IGA at
baseline Diagnostic certainty: yes
The study was completed
 
Bayerl 1999
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Methods Parallel-group, randomised controlled trial
The study was conducted in the secondary setting at 2 different dermatology
departments in Germany
 
Participants 48 participants with chronic hand eczema (21 irritant, 18 allergic, 9 atopic) > 3 months'
duration, more than 30% of the hands involved. All had occupation-related hand
eczema: 41% were in a wet occupation
Dropouts: 12
Inclusion criteria of the trial
Occupational chronic hand eczema of > 3 months' duration
> 30% involvement of hands
Exclusion criteria of the trial
Non-compliance
Liver disease
Porphyria
Polymorphic light dermatitis
Use of light-sensitive medication
Malignancies
Use of chemotherapies or immunosuppressives
History of skin malignancies
Specific topical or systemic therapy (including corticosteroids and coal tar)
Study population
Gender: not stated
Age: not stated
 
Interventions Intervention
• UV-B phototherapy 5 days/week for 8 weeks in 19/24 participants
Control intervention
• No UVB for 8 weeks in 17/24 participants
Both groups were allowed to use non-specific creams/emollients
Duration
8 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Observer-rated extent of hand eczema, and scoring 1 to 4 (1 = absent, 2 = mild, 3 =
moderate, 4 = severe) on erythema, oedema, maceration, excoriation,
lichenification, fissuration, infection, scaling, itch
Participant-rated VAS (0 to 10) on itching and restrictions in daily life
TEWL and Nitrazinyellow-test
Adverse events
 
Notes Study authors rightly state that this is a pilot study. Only graphic presentation of a few
components of some outcome parameters. Not clear, but assumed, that 24
participants were randomised to each group. The secondary outcome - reduction in
severity, investigator-rated - was included but did not provide reproducible data
Study authors were contacted on 7 March 2014 and responded 10 March 2014
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk The article states only that the study is randomised, without details about
the method of randomisation. Personal communication clarified that the
same method was used as in Adams 2007: "cards with the
characterisation "A" and "B" were enclosed in envelopes by a third person,
mixed like a card play by a third person, then numbered consecutively by a
third person and opened by the study doctor consecutively after informed
consent to the study" This is an adequate method
 
Allocation concealment (selection
bias)
Low risk No details about whether the allocation was concealed from participants
and investigators in the article, but personal communication clarified that
this was done appropriately by a third person, and that the study doctor
and participants opened the consecutively numbered envelopes after
informed consent was retrieved
 
Blinding of participants and
personnel (performance bias)
High risk Participants and personnel were not blinded during the study
 
Blinding of outcome assessment
(detection bias)
High risk Observers were not blinded
 
Incomplete outcome data (attrition
bias)
High risk No intention-to-treat analysis but per protocol (36 of 48 = less than 80%)
 
Selective reporting (reporting bias) Low risk No trial registration found; however outcomes described in Materials and
Methods are depicted in the Results section and are adequate
 
Other bias Unclear
risk
Baseline comparisons: no baseline comparisons regarding group
differences (randomisation check)
Diagnostic certainty: yes
The study was completed
 
Belsito 2004
Methods Parallel-group, randomised controlled trial
The study was carried out in a secondary care setting
This was a multi-centre study that was conducted in Brazil, Canada, and the USA
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Participants 294 participants with mild to moderate chronic hand eczema (117 irritant, 94
endogenous, 32 irritant + endogenous, 32 irritant + allergic, 9 allergic, 4 allergic +
endogenous, 4 irritant + allergic + endogenous)
Dropouts: 22
Inclusion criteria of the trial
At least 18 years old
Mild to moderate chronic hand eczema for a minimum duration of 6 weeks
Exclusion criteria of the trial
Pregnancy
Treatments that possibly interfere with study evaluations
Hand-foot-and-mouth disease
Contact urticaria
Severe vesicobullous dermatitis of hands
Latex allergy
Mosaic warts
History of malignancies or current pre-malignant disease of hands
Concurrent flaring atopic dermatitis
Psoriasis or skin disease of hands requiring therapy
Use of systemic therapy in previous month and use of systemic antibiotics for hand
infection or topical therapy within the previous 7 days
Study population
Gender: 176 female, 118 male
Age: mean age 44.6 years, range 18 to 86 years
 
Interventions Intervention
• Pimecrolimus 1% cream twice daily with 6 hours of love occlusion in the evenings for
3 weeks in 140/151 participants
Control intervention
• Vehicle cream twice daily with 6 hours of glove occlusion in the evenings for 3 weeks
in 132/143 participants
Barrier creams or emollients were allowed in both groups if applied more than 1 hour
before study cream
Duration
3 weeks
 
Outcomes Primary outcomes of the trial
Investigator Global Assessment (IGA) on a 5-point scale: ranging from 0 = clear to
4 = severe
Efficacy measured was proportion of treatment successes at end of study (day 22)
in each group; treatment success was defined as an IGA score of 0 (clear) or 1
(almost clear)
Other outcomes
Adverse events
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Notes Overall efficacy (proportion of treatment successes) for both groups at end of study
presented as graph (bar chart); exact figures not given. In separate table, exact figures
for treatment successes, with strata of selected groups overlapping ("to identify groups
highly responsive")
Study authors contacted by email and LinkedIn 27 February 2014, but we were unable
to obtain additional information
Declarations of interest: some study authors were employees of pharmaceutical
companies
Funding: the study was supported by a grant from Novartis Pharmaceuticals
Corporation, East Hanover, New Jersey, which is the manufacturer of pimecrolimus
cream. Four study authors had an ongoing financial relationship with Novartis, and
four were employees of Novartis
Sample size rationale: not stated
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear
risk
Quote: "a multicenter, randomized, vehicle-controlled 3 week study..."
Comment: the article states only that subjects were randomised, without
further information. Insufficient information provided to judge the risk of
bias
 
Allocation concealment (selection
bias)
Unclear
risk
No details about how allocation was concealed from participants and
investigators
 
Blinding of participants and
personnel (performance bias)
Unclear
risk
Quote: "study design - the study was a double-blind, multicenter, vehicle-
controlled trial of ...."
Comment: unclear; participants and personnel probably blinded as this is
stated in the paper, but no further details are given. It is unclear whether
vehicle and placebo were identical in appearance
 
Blinding of outcome assessment
(detection bias)
Unclear
risk
Quote: "study design - the study was a double-blind, multicenter, vehicle-
controlled trial of ...."
Comment: no details regarding blinding of observers
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "the intention-to-treat (ITT) and safety populations consisted of all
randomized patients who received the study medication, and the per-
protocol population included all patients from the ITT population who did
not violate the protocol in ways that would affect efficacy evaluations"
Comment: intention-to-treat analysis
 
Selective reporting (reporting bias) Low risk No trial registration found; however all outcomes listed in the Methods
section are described in the Results section
 
Other bias Low risk Baseline comparisons: no significant differences in demographic or
disease characteristics between groups Diagnostic certainty: yes
The study was completed
 
Bissonnette 2010
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Methods Parallel-group, placebo-controlled, randomised study with participants who
initially responded in a previous BACH study (Ruzicka 2008), but who relapsed in the
observational period
This study was carried out in a secondary care setting
This was a multi-centre study conducted in Canada, France, and Germany
 
Participants 117 participants with chronic hand eczema who relapsed after they were successfully
treated with alitretinoin 30 mg, 10 mg, or placebo
Dropouts: 24
Inclusion criteria of the trial
Participants who relapsed after successful treatment with alitretinoin or
placebo in a previous trial (Ruzicka 2008)
Exclusion criteria of the trial
Well defined
Study population
Gender: placebo group 23 female, 24 male; alitretinoin 10 mg 5 female, 15 male;
alitretinoin 30 mg 24 female, 25 male
Age: mean placebo group 50.4 years; alitretinoin 10 mg 49.0 years; alitretinoin 30
mg 52.0 years
 
Interventions Intervention
• Alitretinoin 10 mg once daily for 12 to 24 weeks in 21 participants
• Alitretinoin 30 mg once daily for 12 to 24 weeks in 49 participants
Control intervention
• Placebo for 12 to 24 weeks in 47 participants
Participants were re-treated with the same dose that they had received in the previous
study, or they were treated with placebo Participants who were initially treated with
placebo in the first trial were treated with placebo again
No other topical or systemic therapy for hand eczema was allowed
Duration
12 to 24 weeks
 
Outcomes Primary outcome of the trial
Physician's Global Assessment (PGA): whereby physician global assessment is
categorised as clear, almost clear, mild, moderate, severe. Responders were
defined as clear or almost clear at week 12 or last evaluation
Other outcomes
Patient's Global Assessment (PaGA)
Modified Total Lesion Symptom Score (mTLSS)
Extent of disease
Time to response
Adverse events
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Notes Study included participants who relapsed after successful treatment in a
previous study (Ruzicka 2008). No other active treatment as comparator. Analysis of
efficacy based on intention-to-treat principle. Study included a safety assessment by
careful medical and laboratory monitoring. The primary outcome percentages of
participants with self-rated good/excellent and secondary outcome reduction in
severity, investigator-rated scoring were included in the study, but we were unable to
reproduce the data
Study authors were contacted and referred us for further information to GSK, which
provided additional information
Declarations of interest: various study authors were investigators or consultants for
Basilea Pharmaceutica International Ltd.
Funding: the study was supported and funded by Basilea Pharmaceutica International
Ltd, Basel, Switzerland, the manufacturer of alitretinoin. Study authors were
investigators in Basilea clinical trials, or were consultants or employees of Basilea
Pharmaceutica International Ltd.
Sample size rationale: not stated
Quote: "the sample size was not prespecified, and all relapsing patients from the
BACH trial were eligible for trial screening"
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "patients were randomised to the same dose they received in the
BACH study or to placebo"
Comment: no further details given. In personal communication, the study
authors clarified: "the study was a follow on from the BACH study
BAP00089, which was a randomised double blind placebo controlled study
of subjects in a 2:2:1 randomisation of treatment to alitretinoin 30 mg,
alitretinoin 10 mg, or placebo, respectively. Patients who responded in
study BAP00089 and relapsed during the posttreatment observation period
were assigned to the same dose they had received or to placebo in a 2:1
ratio. Responding patients who had received placebo in study BAP00089
were assigned to continue receiving placebo. Each was assigned a coded
allocation of study drug containing either placebo or a dosage of active
drug. The randomisation was computer generated"
 
Allocation concealment (selection
bias)
Unclear
risk
No details about how allocation was concealed from participants and
investigators. In personal communication, the study authors stated: "it is
unclear how this knowledge was imparted, but it is clear from the protocols
that those subjects who had received placebo in the original trial
BAP00089, and who had been successfully treated but had subsequently
relapsed, would upon entering this study be given placebo again, as it was
considered unethical to expose them unnecessarily to drug"
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Bias Authors'judgement Support for judgement
Blinding of participants and
personnel (performance bias)
Low risk Quote: "the investigator, sponsor and all participants remained blinded
throughout the course of the BACH and re-treatment studies"
Comment: Study authors stated that they conducted a double-blind study
but made no statements about how this was done
Quote: "the placebo and active drug were indistinguishable and packaged
in the same way"
Comment: use of identical packages is a sufficient form of blinding;
however it is unclear whether site staff were also blinded because the
study was a follow-up study in which most participants received the same
treatment as in the previous study
Personal communication clarified: "a list of treatment assignments was
sealed and kept in a central repository by the Biometrics Department and
by the Drug Safety Department. No open key to the code was available at
the Study Center, or to monitors or members of the project team"
 
Blinding of outcome assessment
(detection bias)
Low risk Investigators were blinded throughout the study; however no details
regarding blinding were given. The observers might have been the same
as in the study of Ruzicka 2008. Personal communication clarified: "the
investigator had access to coded, sealed envelopes for each participant to
be used in an emergency that would have required knowledge of the study
medication to manage the emergency. If the investigator wished to know
the identity of the treatment given to study subjects for any other purpose,
this request was first to be discussed with Basilea Pharmaceutica"
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "efficacy evaluations are based on the intention-to-treat population,
which included all randomized patients"
Comment: intention-to-treat analysis
 
Selective reporting (reporting bias) Low risk The trial was registered at clinicialtrials.gov (NCT00124436 and BAP00091
and EUCTR2004-000432-85-HU). No major changes in primary or
secondary outcomes. The only difference is that the trial registration states
enrolment of 300 participants, and the actual trial included only 117
participants; this was done so all participants from the BACH study who
relapsed could be included
 
Other bias Low risk Baseline comparison of disease severity in table, but no significance of
differences in tests provided. Personal communication clarified that there
were no statistically significant differences
Diagnostic certainty: yes
The study was completed
 
Bleeker 1989
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Methods Parallel-group, randomised controlled trial
This study was conducted as a multi-centre study at dermatology departments and
private clinics in Sweden
 
Participants 76 participants (22 male, 54 female; ages 18 to 65) with different subtypes of hand
eczema. Vesicular and infected dermatitis excluded
Dropouts: 1
Inclusion criteria of the trial
Allergic or trauma-induced contact dermatitis or atopic dermatitis for at least 3
months
Age limits: 18 to 65 years
Exclusion criteria of the trial
Infected or vesicular dermatitis
Use of steroid therapy in the last 2 weeks
Study population
Gender: not stated
Age: not stated
 
Interventions Intervention
• Fluprednidene cream once daily in the evening for 3 weeks in 37/38 participants
• Betamethasone cream once daily in the evening for 3 weeks in 38/38 participants
Emollient (Unguentum Merck) was allowed in both groups if required
Duration
3 weeks
 
Outcomes Primary outcomes of the trial
Not stated
Other outcomes
Observer- and participant-rated general assessment of therapeutic result (0 =
healed, 1 = improved, 2 = unchanged, 3 = worse)
Reduction in scoring based on symptoms (erythema, scaling, papules, vesicles,
lichenification, fissures, excoriation, pruritus) on a scale from 0 to 3 (0 = healed, 1 =
improved, 2 = unchanged, 3 = worse)
Adverse events
 
Notes Unclear whether severity score as stated in Methods was used in analysis. Aim was to
study equivalency of treatment effect
The secondary outcome - reduction in severity, participant-rated - was included but did
not provide reproducible data
Declarations of interest: not stated
Funding: E. Merck A.B. Sweden, which was the manufacturer of unguentum Merck,
supported the study
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "each patient was allocated a patient number and assigned at
random to one of the two treatment groups"
Comment: the article states only that each participant was allocated a
participant number and was assigned at random, without further details
 
Allocation concealment (selection
bias)
Unclear risk Quote: "each patient was allocated a patient number and assigned at
random to one of the two treatment groups"
Comment: no details about how allocation was concealed from
participants and investigators
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quote: "a double blind study design was used"
Comment: participants and personnel probably blinded, as this is stated in
the paper, but no details are given as to how this was achieved
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "a double blind study design was used"
Comment: the article states a double-blind design; however no details are
given regarding blinding of observers
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (75 of 76 = more than 80%)
 
Selective reporting (reporting bias) Low risk No trial registration found; however all important clinical outcomes
described in Materials and Methods are depicted in the Results. The only
drawback is that with regards to the participant-rated general assessment,
the Results section states only that this was "significantly improved (P <
0.001) after 1 week in both treatment groups"; however no details are
given
 
Other bias Unclear risk Baseline comparison: a baseline comparison of disease severity is
depicted in a table, but no significance of differences in tests is provided
Diagnostic certainty: yes
The study was completed
 
Boroujeni 2017
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Methods Parallel-group, randomised controlled study
The study was conducted at a single centre in Iran
 
Participants 64 participants with hand eczema
Dropouts: 4
Inclusion criteria of the trial
Patients over 10 years of age
Exclusion criteria of the trial
Pregnancy
History of oral and topical medication use before and during treatment
Having systemic disease or other skin condition such as fungus infection
Study population
Gender: herbal group 19 female, 13 male; fluocinolone acetonide group 21 female,
9 male
Age: the most frequent age was 30 to 40 years old; no further details were given
 
Interventions Intervention
• Twice-daily application with an oil-in-water emulsion-based herbal cream.
Concentrations of plant material were as follows: fenugreek seeds 5%, marshmallow
5%, chamomile 5%, and walnut leaves 5%
• Twice-daily application of fluocinolone acetonide cream 2%
Duration
Two weeks
 
Outcomes Primary outcomes of the trial
Reduction in severity of symptoms such as burning, itching, erythema level, papules
and vesicles bumps, and fissures of the skin (method and scale not stated)
Other outcomes
Questionnaires at baseline and follow-up at week 2
 
Notes Study authors were contacted for additional information in April 2018 but remained
unresponsive
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "64 patients with hand eczema were randomly divided into two
groups of 32 patients each"
Comment: no further details on randomisation procedure
 
Allocation concealment (selection
bias)
Unclear risk No details about how allocation was concealed from participants and
investigators
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quote: "this study is a double blind clinical trial"
Comment: no details regarding blinding
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "this study is a double blind clinical trial"
Comment: no details regarding observer blinding
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (60 of 64 = more than
80%)
 
Selective reporting (reporting bias) Unclear risk No trial registration found
We did not find major differences between what was stated in the
Methods and Result sections; however it is unclear how the outcomes
were scored
 
Other bias Unclear risk Baseline comparison: not stated
Diagnostic certainty: yes
The study was completed
 
Brass 2015
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Methods Parallel-group, randomised controlled pilot study
The study was conducted at a single centre in the United Kingdom
 
Participants 60 participants with hand eczema unresponsive to clobetasol propionate
Dropouts: 17
Inclusion criterion
Patient has provided written informed consent for participation in the study before
undergoing any study-specific procedures
Palmar eczema not responsive to topical treatments
Over 18 years of age
No topical treatments (except emollients for 48 hours)
No systemic treatments for eczema for 3 months
Absence of clinical evidence of bacterial, fungal, or viral infection
Not pregnant
Exclusion criteria of the trial
Inability to give informed consent
Significant eczema on the dorsal surface of the hands
Previous phototherapy within the last 3 months
Previous sun bed use within the last 3 months
Current involvement in other investigational studies or trials, or involvement within 3
months before study entry
Study population
Gender: not stated
Age: not stated
 
Interventions Intervention
• Immersion PUVA twice weekly for 12 weeks with 4-weekly assessments in 30
participants
• NB-UVB twice weekly for 12 weeks with 4-weekly assessments in 30 particiBpants
Duration
12 weeks
 
Outcomes Primary outcomes of the trial
Number of participants achieving a 'clear' or 'almost clear' treatment response at 12
weeks
Other outcomes
Percentage improvement based on the mTLSS (modified total lesion symptom
score) at weeks 0, 4, 8, and 12
Change in quality of life based on the Dermatology Life Quality index (DLQI) at
weeks 0, 4, 8, and 12
Change in health economic evaluation with the EuroQol health outcome score
(EQ-5D) at weeks 0, 4, 8, and 12
Adverse events
 
Notes Data are based on a conference abstract with limited data. Study authors were
contacted and provided some additional information
Additional information was extracted from the trial register (ISRCTN18213910)
Declarations of interest: not stated
Funding: the study was sponsored by Newcastle upon Tyne Hospitals NHS
Foundation Trust (UK)
Sample size rationale: not stated
 
Risk of bias table
#29 Interventions for hand eczema
65 / 280
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Personal communication with study authors clarified that a computerised
randomisation programme was used
 
Allocation concealment (selection
bias)
Unclear risk Personal communication with study authors stated that before
recruitment no one knew what the treatment allocation would be, as the
trial was randomised
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quote: "we performed a randomized, observer-blinded pilot study of
PUVA vs. NB-UVB for the treatment of hand eczema"
Comment: no data available
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "we performed a randomized, observer-blinded pilot study of
PUVA vs. NB-UVB for the treatment of hand eczema"
Comment: the abstract states that observers were blinded
Personal communication clarified that only the research co-ordinator was
aware of the treatment allocation. All observers carrying out assessments
were blind
 
Incomplete outcome data (attrition
bias)
High risk No intention-to-treat analysis but per protocol (43 of 60 = less than 80%)
 
Selective reporting (reporting bias) Low risk The trial was registered at http://www.isrctn.com/ISRCTN18213910
before the start. No significant differences between the trial register and
the abstract were found
 
Other bias Low risk Baseline comparison: a baseline comparison of disease severity was
provided
Diagnostic certainty: yes
The study was completed
 
Burrows 1986
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Methods Parallel-group, randomised controlled study; cross-over design
This multi-centre study was conducted in Ireland and in the UK in a secondary setting
at 3 different centres
 
Participants 23 participants with chronic eczema on palms or dorsa, with positive patch test to
nickel
Dropouts: 3
Inclusion criteria of the trial 
Chronic hand eczema and a positive patch test to 5% nickel sulphate
Exclusion criteria of the trial
Pregnancy
Atopic eczema
History of peptic ulcer, hepatic or renal disease
Aberrations in serum iron, CPK, bilirubin, alkaline phosphatase, LDH, AST, ALT,
creatinine, urea, urine analysis, and antinuclear factor
Study population
Gender: 21 female, 2 male
Age: mean age 29.3 years, SD 13.3 years, range 19 to 66 years
 
Interventions Intervention
• Triethylenetetramine (Trientene) 300 mg daily for 6 weeks in an unknown number of
participants
Control intervention
• Placebo for 6 weeks
Cross-over after 4-week washout. The total expected duration of the study was thus
16 weeks; however the trial was terminated prematurely
Duration
6 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Observer-rated: improvement/no change/deterioration
Participant-rated: improvement/no change/deterioration
Urinary nickel and copper excretion
Adverse events
 
Notes The trial was terminated due to a literature report on potential adverse events
(teratogenicity). Study results were based on participants entered before termination.
Results table is difficult to interpret in view of the cross-over; probably based on 20
participants
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear riskQuote: "patients were allocated randomly"
Comment: no further details on randomisation procedure
 
Allocation concealment (selection
bias)
Unclear riskNo details about how allocation was concealed from participants and
investigators
 
Blinding of participants and
personnel (performance bias)
Unclear riskQuote: "a multicentre, double-blind, crossover trial was initiated to test the
ability of...."
Comment: participants and staff were probably blinded, as this is stated in
the paper, and a placebo was used, but no details are given as to how this
was achieved. It is not clear whether placebo was identical in appearance
 
Blinding of outcome assessment
(detection bias)
Unclear riskQuote: "a multicentre, double-blind, crossover trial was initiated to test the
ability of...."
Comment: no details regarding observer blinding
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (20 of 23 = more than 80%)
 
Selective reporting (reporting bias) Unclear riskNo trial registration found. The outcome parameters used are very
concise. The Materials and Methods section describes that observer- and
participant-rated scores would be used with regard to improvement/no
change/deterioration; however, only one table shows improvement versus
no improvement and worse, and it is unclear whether this was participant-
or observer-rated
 
Other bias High risk No baseline comparisons
Diagnostic certainty: yes
The study was ended prematurely
 
Cartwright 1987
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Methods Within-participant, randomised controlled trial
This was a single-centre study, conducted in the UK
 
Participants 30 participants with bilateral symmetrical constitutional hand eczema, resistant to
previous treatment
Dropouts: 12
Inclusion criteria of the trial
Resistant bilateral hand eczema
Exclusion criteria of the trial
Not defined
Study population
Gender: not stated
Age: not stated
 
Interventions Intervention
• Superficial X-ray 300 Rad 10 kV 3 times with a 21-day interval in 18/30 hands
Control intervention
• Placebo-radiation in 18/30 contralateral hands 3 times with a 21-day interval
Participants were followed up for 18 weeks after initial treatment
Participants continued application of tar paste or steroid ointments throughout the trial
Duration
21 weeks (3 weeks active treatment, 18 weeks follow-up)
 
Outcomes Primary outcomes of the trial
Not defined.
Other outcomes
Participant-rated severity score on scale 0 to 10 with increasing severity
Observer-rated score 0 to 4 (0 = no eczema; 1 = eczema, mild scaling; 2 =
erythema, scaling, fissures; 3 = erythema, severe scaling, bleeding fissures; 4 =
active pompholyx)
Adverse events
 
Notes Secondary outcomes - reduction in severity, investigator- and participant-rated scoring
- were included but provided no reproducible data. Only graphic representation of
outcome scores. Graphs in Figures 1 and 2 seem to have been exchanged.
High dropout: 12 out of 30. Reasons given for the 12 dropouts: unwilling to attend,
mostly because eczema improved
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "according to a predetermined random code known by the
radiographer..."
Reference to a predetermined random code known only by the
radiographer
 
Allocation concealment (selection
bias)
Unclear risk No details about how allocation was concealed from participants and
investigators, although the article states that only the radiographer knew
the randomisation code
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "according to a predetermined random code known by the
radiographer and unknown to patient and observer, one hand was
irradiated with 300 rad (3 Gy) of Grenz rays (...) and the other hand
treated in an exactly similar manner, except that sham therapy was given"
Comment: participants were truly blinded and received placebo-radiation.
The radiographer was the only one aware of the randomisation code in
that he had to programme the radiation; however in our opinion, this study
could not have been done in another fashion; therefore we judged this trial
to have low risk, although not all staff were blinded
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "according to a predetermined random code known by the
radiographer and unknown to patient and observer..."
Comment: the observer was unaware of the allocation; however no further
details are provided
 
Incomplete outcome data (attrition
bias)
High risk No intention-to-treat analysis but per protocol (18 of 30 = less than 80%)
 
Selective reporting (reporting bias) Unclear risk No trial registration found. Outcomes mentioned in the Methods section
are depicted in graphs and tables in the Results section; however
participant- and observer-rated graphs probably are switched because
results in the participant section range from 0 to 3, and results for the
observer range from 0 to 7
 
Other bias Low risk Baseline comparisons: within-participant study was not applicable
Diagnostic certainty: yes
The study was completed
 
Cherill 2000
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Methods Parallel-group (4 groups), randomised controlled trial; proof of concept
Single-centre study, probably conducted in the USA, although not clear from abstract
 
Participants 48 adult participants with chronic irritant hand dermatitis of moderate severity
No dropouts
Inclusion criteria of the trial
Chronic irritant hand dermatitis of moderate severity
Exclusion criteria of the trial
Not defined
Study population
Gender: not stated
Age: not stated
 
Interventions Intervention
• Pimecrolimus 1% cream twice daily for 6 weeks in 12 participants
• Pimecrolimus 1% cream under occlusion twice daily for 6 weeks in 12 participants
Control intervention
• Vehicle twice daily for 6 weeks in 12 participants
• Vehicle under occlusion for 6 weeks in 12 participants
Duration
6 weeks
 
Outcomes Primary outcome of the trial
Observer-rated (?) total key sign/symptom score (0 to 3 for erythema, excoriation,
oedema/ papulation, pruritus) at days 8, 15, 22, 29, 36, and 43
Other outcomes
(Serious) adverse events
Key scores for erythema, excoriation, oedema/papulation, pruritus rated on a scale
from 0 to 3 at days 8, 15, 22, 29, 36, and 43
 
Notes Study was published as a conference abstract; therefore information on quality issues
is limited. Study authors were contacted by email and LinkedIn but were unresponsive.
Similar abstract published in JEADV 2000;14(S1):128
The secondary outcome - reduction in severity, investigator-rated - was included but
did not provide reproducible data
Declarations of interest: some study authors were employee of Novartis Pharma AG
Funding: study authors were employees of Novartis Pharmaceuticals Corp., East
Hanover, New Jersey, USA, and Novartis Pharma AG, Basel, Switzerland, the
manufacturer of the study drug
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "within each treatment group, patients were randomly assigned
(1:1) to occlusion or no occlusion"
Comment: not stated whether participants were randomly assigned to
pimecrolimus or vehicle - only that participants in both groups were
randomly assigned to occlusion or no occlusion. No further details are
given
 
Allocation concealment (selection
bias)
Unclear risk No details about how allocation was concealed from participants and
investigators
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quote: "a 6-week, randomized, double-blind, vehicle controlled, single
center study"
Comment: title suggests double-blinded; however, no details about how
this was accomplished. Participants used pimecrolimus or vehicle: it is
unclear whether these were similar in appearance
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "a 6-week, randomized, double-blind, vehicle controlled, single
center study"
Comment: no details regarding blinding of observers
 
Incomplete outcome data (attrition
bias)
Low risk All included participants were analysed
 
Selective reporting (reporting bias) Unclear risk No trial registration found, and only limited information could be extracted
from the abstract. In the abstract, only the overall scores were given - not
the key scores for each item
 
Other bias Unclear risk No baseline comparisons conducted or reported
Diagnostic certainty: yes
The study was completed
 
Chu 2009
Methods Within-participant, randomised controlled trial
This study was conducted at a single centre in Taiwan
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Participants 67 participants with chronic hand eczema
Inclusion criteria of the trial
Males or females 20 years of age or older
Participants must have chronic hand dermatitis based on clinical diagnosis and at
least mild dermatitis of both hands at baseline, as defined by an Investigator Global
Assessment score of 2 (mild) to 5 (very severe)
Participants must have been informed of study procedures and therapies and must
have given their written informed consent
Exclusion criteria of the trial
Women who are pregnant or who are breast-feeding
Participants who have received systemic corticosteroids (i.e. oral, intravenous,
intra-articular, rectal, intramuscular) within 1 month before first application of study
medication
Participants who have received phototherapy (e.g. UVB, PUVA) or systemic
therapy (e.g. immunosuppressants, cytostatics) known or suspected to have an
effect on hand dermatitis within 1 month before first application of study medication
Patients who were treated with topical therapy (e.g. tar, topical corticosteroids)
known or suspected to have an effect on hand dermatitis within 7 days before first
application of study medication
Patients who have a diagnosis on the hands of active atopic dermatitis, dyshidrotic
eczema, psoriasis, urticaria, active fungal or bacterial infection, or identified allergic
contact dermatitis (e.g. poison ivy dermatitis)
Patients with hypersensitivity to vitamin B, vitamin C, vitamin E, beta-carotene
Study population
Gender: 52 female, 15 male
Age: mean age 42.95 years, range 20.5 to 72.6 years
 
Interventions Intervention
• E-DO (HK-03) topical lotion, once daily (evening), for 4 weeks, applied to 1 hand in
67 participants
Control intervention
• Placebo applied once daily on the contralateral hand for 4 weeks, on 67 contralateral
hands
Duration
4 weeks
 
Outcomes Primary outcome of the trial
Observer-rated therapeutic response rate (clear or almost clear) based on
Investigator Global Assessment (IGA) at week 4 (or at time of early discontinuation)
Secondary outcomes of the trial
Participant-rated reduction in severity: the proportion of participants with at least
50% improvement (clinically significant response) base on the patient's global
assessment (PaGA) at week 4 (or at time of early discontinuation) 
Observer-rated reduction in severity: the percent change in HEAS (Hand Eczema
Area and Severity Score) from baseline to post treatment during 4 weeks 
Change in pruritus score and pain score from baseline to post treatment during 4
weeks
Change in the degree of moisture on the skin's surface, and water evaporation on
skin surfaces by transepidermal water loss (TEWL) after 4 weeks
Change in quality of life scores (DLQI) from baseline to end of study during 4
weeks 
Safety and tolerability of E-DO including adverse events/serious adverse events
reported during 4 weeks
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Notes This study is (not yet) published but was registered on clinicaltrials.gov, and Dr. Chu
released the results in personal communication after obtaining consent from HenKan
Pharmaceutical
The secondary outcomes - reduction in severity, investigator-rated and participant-
rated - were included but did not provide reproducible data
Declarations of interest: not stated, although the study was sponsored by HenKan
Pharmaceutical Co.
Funding: the study was sponsored by HenKan Pharmaceutical Co., Ltd., and results of
this negative study (E-DO was not statistically significant better than vehicle) were not
published, although HenKan Pharmaceuticals did give Dr. Chai-Yu consent to release
the results
Sample size rationale: not stated
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk The report and the trial register claim a randomised design; however it is
unclear how randomisation was done Personal communication did not
reveal further information
 
Allocation concealment (selection
bias)
Unclear risk Not described in the protocol; personal communication did not reveal
further details
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "randomized, double-blind, vehicle controlled..."
Comment: double-blind study in which a placebo vehicle was used
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "randomized, double-blind, vehicle controlled..."
Comment: double-blind study; unclear how this was done
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "sixty-three subjects received at least one dose of each
investigational product (..) and [having] at least one post-baseline
assessment on both hands were included in the ITT population"
Comment: intention-to-treat analysis was carried out on all participants
who received the study drug. Only 63 of the 67 randomised participants
received the study drug (94%)
 
Selective reporting (reporting bias) Unclear risk The trial was registered at clinicaltrials.gov (NCT00556855). We found no
major discrepancies between the trial registration and the final study
report; however for most of the secondary outcomes (quality of life, TEWL,
HEAS, pain score), the report states only that no statistically significant
differences were found and does not provide actual numbers
 
Other bias Low risk Baseline comparisons: a baseline comparison with regards to disease
severity is provided; however because this trial used a within-participant
design, this is not further applicable
Diagnostic certainty: yes
The study was completed
 
Faghihi 2008
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Methods Within-participant, randomised controlled trial
This study was conducted in a secondary setting at 2 different centres in Iran
 
Participants 47 participants with nearly symmetrical chronic hand eczema with a duration > 4
weeks
No dropouts
Inclusion criteria of the trial
Symmetrical chronic hand eczema with duration > 4 weeks
Older than 12 years of age
Exclusion criteria of the trial
Pregnancy
No topical treatment during the last 2 weeks nor systemic medication treatment in
the last month
Systemic illness
Study population
Gender: 35 female, 12 male
Age: range 17 to 74 years
 
Interventions Intervention
• 0.05% clobetasol + 2.5% zinc sulphate cream on 1 hand in 47 participants for 2
weeks
• 0.05% clobetasol cream alone on the other hand in 47 participants for 2 weeks
Duration
2 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Assessment and scoring of different characteristics of hand eczema, namely,
scaling, erythema, lichenification, and itch, on a 3-point scale
Severity of itching evaluated by means of the visual analogue scale (VAS)
Adverse events
 
Notes Overall severity of hand eczema was not an outcome. Use of the Mann-Whitney U-test
for statistical analysis appears incorrect, as the data were related (within-subject
design)
The secondary outcomes - reduction in severity, participant-rated, and time until
relapse - were included but did not provide reproducible data
Study authors were contacted by mail on 28 February 2014 but remained
unresponsive
Declarations of interest: not stated
Funding: the study was funded and supported by Isfahan University of Medical
Sciences
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "... right or left hand of them were randomised to be treated..."
Comment: no further details given
 
Allocation concealment (selection
bias)
Unclear risk No details about how allocation was concealed from participants and
investigators
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "the patients and investigators were blinded to type of treatment"
Comment: the drugs were made in "similar shape" by a third party; this is
considered an adequate way to blind participants
Quote: "drugs were made by the Isfahan Pharmacy School in the similar
shape, and the patients and investigators were blinded to the type of
treatment"
Comment: the code of drugs was revealed only at the end of the study
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "drugs were made by the Isfahan Pharmacy School in the similar
shape, and the patients and investigators were blinded to the type of
treatment. The code of drugs was revealed only at the end of the study"
Comment: no details regarding blinding of outcome assessors, although
study authors mention a double-blind design; this is insufficient
information to judge the risk of bias
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "overall, 47 patients (94 samples) were evaluated and all of them
completed the study"
Comment: all participants completed the study and were included in the
analyses
 
Selective reporting (reporting bias) Unclear risk No trial registration found. All outcomes described in Subjects and
Methods are described in the Results section, although for itch, only the
statistical significance level is stated, but the other outcomes are stated in
tables with exact numbers
 
Other bias Low risk Baseline comparisons revealed no significant differences between
groups in terms of erythema, scaling, lichenification, and pruritus; further
within-participant design
Diagnostic certainty: yes
The study was completed
 
Fairris 1984
#29 Interventions for hand eczema
76 / 280
Methods Within-participant, randomised controlled trial
The study was conducted at a single centre in the UK and was carried out in a
secondary care setting
 
Participants 24 participants with chronic constitutional therapy-resistant hand eczema
Dropouts: 1
Inclusion criteria of the trial
Chronic symmetrical constitutional hand eczema resistant to topical therapy
Exclusion criteria of the trial
Not defined
Study population
Gender: not stated
Age: not stated
 
Interventions Intervention
• Ionising radiation 100 rad 50 kV 3 times with 21-day interval in 23/24 hands
Control intervention
• Placebo radiation 3 times with a 21-day interval in 23/24 contralateral hands
Participants were followed up until 18 weeks after initial treatment
Duration
21 weeks (3 weeks active treatment, 18 weeks follow-up)
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Participant-rated comparisons between both hands based on best improvement at
weeks 6, 9, and 18: greater improvement in irradiated hand, placebo hand, or no
difference
Participant-rated severity score of hand eczema on a scale of 0 to 10 at weeks 6, 9,
and 18
Observer-rated severity score (0 = normal skin, 1 = mild scaling and erythema, 2 =
moderate scaling and erythema and shallow fissures, 3 = severe scaling erythema
and deep bleeding fissures, 4 = active pompholyx)
Adverse events
 
Notes The secondary outcomes - reduction in severity, participant-rated and investigator-
rated - were included but did not provide reproducible data. Only graphic presentation
of scores with statistical significance
Declarations of interest: not stated
Funding: not stated.
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "the radiographer (D.P.M.) treating the patient gave the active
radiation or placebo treatment according to a predetermined code"
Comment: reference to a predetermined code
 
Allocation concealment (selection
bias)
Unclear
risk
No details about how allocation was concealed from participants and
investigators; only that the code was broken after the end of the trial
 
Blinding of participants and
personnel (performance bias)
Low risk Double-blind study: participants were unaware of which hand received
treatment and which one placebo due to the placebo-irradiation. The
radiographer did know the code of randomisation and gave placebo-X-ray
therapy to participants that was indistinguishable from actual X-ray
therapy. Although the radiographer (staff) was aware of the treatment, this
study could not have been done in another fashion; therefore we judged
low risk of bias
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "the observer (G.M.F.) did not know which hand was receiving X-
ray therapy until the code was broken at the end of the trial"
Comment: the observer was unaware of the treatment group, and we
judged this as low risk
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (23 of 24 = more than 80%)
 
Selective reporting (reporting bias) Low risk No trial registration found. However all outcomes described in the Methods
section are clearly described in the Results section
 
Other bias Low risk Baseline comparisons: within-participant study was not applicable
Diagnostic certainty: yes
The study was completed
 
Fairris 1985
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Methods Within-participant, randomised controlled trial
The study was conducted at a single centre in the UK and was carried out in
secondary care setting
 
Participants 25 participants with chronic constitutional therapy-resistant hand eczema
Dropouts: 5
Inclusion criteria of the trial
Chronic symmetrical constitutional hand eczema resistant to topical therapy
Exclusion criteria of the trial
Not defined
Study population
Gender: not stated
Age: not stated
 
Interventions Intervention
• Superficial X-ray 300 Rad 10 kV 3 times with 21-day interval in 20/25 hands
• 100 Rad 50 kV 3 times with 21-day interval in 20/25 contralateral hands
Participants were followed for 18 weeks after initial treatment
Duration
21 weeks (3 weeks active treatment, 18 weeks follow-up)
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Participant-rated comparisons between both hands based on best improvement at
weeks 3, 6, 12, and 18
Participant -rated score of increasing severity 0 to 10 on VAS. All 3 ratings at weeks
3, 6, 12, and 18
Observer-rated score (0 = normal skin, 1 = mild scaling and erythema, 2 =
moderate scaling and erythema and shallow fissures, 3 = severe scaling, erythema,
and deep bleeding fissures, 4 = active pompholyx)
Adverse events
 
Notes The secondary outcomes - reduction in severity, participant-rated and investigator-
rated - were included but did not provide reproducible data. Only graphic presentation
of scores with statistical significance
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "one hand received 100 rad (1 Gy) of conventional superficial X-
ray (...), the other 300 rad (3 Gy) of Grenz ray (...) according to a
predetermined random code operated by the radiographer..."
Comment: reference to a predetermined random code operated by the
radiographer
 
Allocation concealment (selection
bias)
Unclear risk No details about how allocation was concealed from participants and
investigators
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "...operated by the radiographer and unknown to the observer"
Comment: no information about participant blinding; however the
difference between grenz ray and X-ray therapy is indistinguishable for a
participant. Although the radiographer (staff) was aware of the treatment,
this study could not have been done in another fashion; therefore we
judged low risk of bias
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "...operated by the radiographer and unknown to the observer"
Comment: the study claims to be double-blinded and thus observer-
blinded, which was probably adequate as in Fairris 1984, because the
study designs are similar
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (20 of 25 = 80%)
 
Selective reporting (reporting bias) Low risk No trial registration found; however, all outcomes described in the
Methods section are clearly described in the Results section
 
Other bias Low risk Baseline comparisons: within-participant study was not applicable
Diagnostic certainty: yes
The study was completed
 
Fowler 2005
Methods Within-participant, randomised controlled trial of 3 parallel groups
This was a multi-centre study conducted in the USA and carried out in a secondary
care setting
 
Participants 86 participants with chronic hand eczema
Dropouts: 4
Inclusion criteria of the trial
Between 18 and 65 years old
Symmetrical hand or atopic dermatitis of moderate severity for at least 2 weeks
Exclusion criteria of the trial
Use of systemic treatments in the last month or topical corticosteroids in the last
week before study entry
Study population
Gender: 52 female, 34 male
Age: mean 46 years
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Interventions Intervention
• Hydrocortisone butyrate 0.1% cream on the one hand vs fluticasone propionate
0.05% cream twice daily on the other hand for 2 weeks in 26 participants
• Hydrocortisone butyrate 0.1% cream on the one hand vs prednicarbate emollient
0.1% cream twice daily on the other hand for 2 weeks in 28 participants
• Hydrocortisone butyrate 0.1% cream on the one hand vs mometasone furoate 0.1%
cream twice daily on the other hand for 2 weeks in 31 participants
Duration
2 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Investigator-rated severity of hand eczema on a 4-point scale (0 = none, 1 = mild, 2
= moderate, 3 = severe) for 4 clinical signs (erythema, cracking/ fissuring, scaling,
papules/vesicles)
Investigator-rated severity total sum score
Participant-rated severity of hand eczema on a 4-point scale (0 = none, 1 = mild, 2
= moderate, 3 = severe) for 6 clinical signs (erythema, cracking/ fissuring, scaling,
papules/vesicles, pruritus, burning/pain)
Participant-rated severity total sum score
Investigator-rated mean reduction in percentage of hand involvement
Participants-rated preference and cosmetic acceptability
Adverse events
 
Notes Three participants with atopic dermatitis participated in the study. Percentage of hand
involvement was the only outcome whereby exclusively participants with hand eczema
were analysed. Each intervention group had a within-participant design. in addition,
the difference in efficacy between the 3 groups was evaluated
The study did include a participant- and investigator-rated severity score, but we were
unable to use the data. The study also included adverse events, but we were unable to
use this information because only numbers for both treatment groups combined were
stated
Study authors were contacted on 4 March 2014 and replied 6 March 2014
Declarations of interest: 2 study authors acted as consultants
Funding: the study was funded by Ferndale Laboratories, Inc., manufacturer of the
study drugs. Two study authors were investigator and consultant for Ferndale
Laboratories, Inc.
Sample size rationale: not stated; personal communication clarified this was not
conducted
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "patients were randomised in balanced cohorts to 3 parallel
treatment groups"
Comment: no further details given in the article; personal communication
with the study author clarified that a computer programme was used to
create the randomisation code
 
Allocation concealment (selection
bias)
Low risk No details in the article about how allocation was concealed from
participants and investigators. Personal communication revealed that
allocation was conducted by the sponsor, who was at a remote site.
Participants were enrolled without knowledge of the expected treatment
group
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "the medication[s] were dispensed to the subjects in blind-labelled
tubes that were clearly marked with the subject's identification number
and the word left or right"
Comment: study authors state double-blind design. The sponsor and the
study co-ordinator had access to the randomisation code list; treating
physicians and participants were unaware of this
 
Blinding of outcome assessment
(detection bias)
Low risk Double-blind study, which includes observer blinding. Observers had no
access to the randomisation code and were truly blinded (personal
communication)
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (82 of 86 = more than 80%)
 
Selective reporting (reporting bias) Low risk No trial registration found; however all outcomes described in the
Methods section are described in the Results
 
Other bias Low risk Baseline comparisons: no significant differences among the 3 groups in
terms of age, gender, race, and eczema severity
Diagnostic certainty: yes
The study was completed
 
Fowler 2014
Methods Randomised, parallel-group, placebo-controlled trial
This study was carried out in a secondary care setting
This was a multi-centre study conducted at 70 centres in the United States
The study consisted of 4 phases: screening, run-in, treatment, and follow-up
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Participants 596 participants with severe chronic hand eczema refractory to potent topical
corticosteroids
Dropouts during treatment phase: 307 participants
162 participants entered the follow-up period after achieving a PGA rating of clear or
almost clear
Dropouts during follow-up: 35
A total of 467 entered the safety follow-up phase
Dropouts during safety follow-up: 116
Inclusion criteria of the trial
All types of chronic hand eczema lasting for at least 6 months since initial diagnosis
Rated as severe by the physician after at least 2 weeks of treatment with potent
topical corticosteroids
Unresponsive to highly potent topical corticosteroids, such as clobetasol
History of unsatisfactory treatment outcomes
18 to 75 years of age
Exclusion criteria of the trial
Patients with known allergens and irritants who have not made a reasonable effort
to avoid these substances
Patients with psoriasis lesions
Active fungal, bacterial, or viral infections of the hands
Female patients who are pregnant or breastfeeding
Female patients of child-bearing potential who cannot use or will not commit to
using 2 effective methods of contraception
Atopic dermatitis lesions requiring medication
Acute episodes of pompholyx/dyshidrosis or contact dermatitis
Metabolic bone disease, disease affecting the bone, or patients receiving bone
active drugs
Active psychiatric disorder and/or > 1 in question 9 or overall score > 15 on the
Patient Health Questionnaire
History of hearing loss or otological or balance disorders deemed medically relevant
Study population
Gender: alitretinoin 30 mg female 133, male 165; placebo female 149, male 149
Age: alitretinoin 30 mg mean 47.1 years, SD 12.6 years, median 48.0 years;
placebo mean 47.5 years, SD 13.0 years, median 50.0 years
 
Interventions Intervention
• Oral alitretinoin 30 mg once daily for 24 weeks in 298 participants
Control intervention
• Placebo capsules once daily for 24 weeks in 298 participants
Duration
72 weeks (24 weeks of active treatment and follow-up up to 48 weeks after the end of
treatment)
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Outcomes Primary outcomes of the trial
The proportion of responding participants with a PGA of "clear" or "almost clear"
after 24 weeks or at the latest assessment for patients withdrawing maturely
Secondary outcomes of the trial
Change from baseline in mTLSS (modified Total Lesion Symptom Score)
PaGA (Patient Global Assessment)
Time to response
Duration of response
Time to relapse
Other outcomes
Extent of disease at baseline and at end of treatment
Quality of life assessment (Skindex-29)
Adverse events
Other safety monitors (PHQ-9 and Brief Symptom Inventory (BSI-53), depression
screening questionnaires, bone markers, skeletal X-rays, dual-energy X-ray
absorptiometry, ophthalmological and audiological evaluations)
 
Notes The treatment phase was included in this review
Study authors were contacted for additional information
Declarations of interest: the first study author was a sponsored investigator and served
as consultant to GSK
The other study authors were employed by Stiefel, a GSK Company
Funding: the study was supported and funded by Stiefel, a GlaxoSmithKline Company
(GSK), manufacturer of the study drug. No information was provided about external
monitoring or quality control
Sample size rationale: adequate
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "participants were randomized 1:1 to receive once-daily
alitretinoin 30 mg or placebo through a central randomization system that
used an interactive voice response system"
Comment: randomisation method adequate
 
Allocation concealment (selection
bias)
Low risk Quote: "investigators, study personnel, patients and statisticians were
unaware of assigned study treatment"
Comment: the central randomisation point was used at a distance
location
 
Blinding of participants and
personnel (performance bias)
Low risk Quote from the clinical trial register: "patients receive matching placebo
for up to 24 weeks"
Comment: placebo was used to achieve blinding
 
Blinding of outcome assessment
(detection bias)
Unclear risk It is not clear who assessed the outcome - probably the 70 providers of
the treatment
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "the intent-to-treat (ITT) population (randomised patients who
were dispensed medication) was used for efficacy analyses"
Comment: intention-to-treat analysis
 
Selective reporting (reporting bias) Low risk The study was registered at clinicaltrials.gov NCT00817063. Except for
some small differences in the exclusion criteria, no substantial
differences between protocol and study report were found
 
Other bias Low risk Baseline comparison: no significant differences were reported
Diagnostic certainty: yes
The study was completed
 
Fredriksson 1975
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Methods Within-participant, randomised controlled trial
The study was probably conducted at a single centre in Sweden
 
Participants 30 participants with bilateral eczematous dermatitis of the hands were selected from a
clinical pool
No dropouts
Inclusion criteria of the trial
Patients with bilateral eczematous dermatitis of the hands were selected from a
clinical pool for treatment
Exclusion criteria of the trial
Not stated
Study population
Gender: not stated
Age: not stated
 
Interventions Intervention
• Aquacare HP cream, a moisturising emulsion containing multi-sterols, phospholipids,
and fatty diols (pH 6) twice a day (morning and evening) for 4 weeks in 30 hands
Control intervention
• Calmurid cream containing betaine and lactic acid (pH 3) twice a day for 4 weeks in
30 contralateral hands
Duration
4 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Participant preference rating based on efficacy
Investigator preference rating on basis of efficacy
Participant preference rating on basis of cosmetic acceptability
Adverse events
An unclear scale for effectiveness ranging from 0 to 5: 0 = no objective symptoms;
5 = severest possible condition. Unclear whether this was observer or participant
rated
 
Notes The last outcome is unclear, and results are not depicted in the article. Study authors
state only that Aquacare was statistically significantly more effective over Calmurid; no
exact results or data are given
Declarations of interest: not stated.
Funding: not stated.
Sample size rationale: not stated
 
Risk of bias table
#29 Interventions for hand eczema
86 / 280
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "tubes containing 90 gpm of Aqaucare HP cream and Calmurid
cream were packed into identical cartons after being randomly marked
left and right"
Comment: no clarification on how random marking of left and right was
done; therefore risk was judged as unclear
 
Allocation concealment (selection
bias)
Low risk Quote: "tubes containing 90 gpm of Aqaucare HP cream and Calmurid
cream were packed into identical cartons after being randomly marked
left and right. These were dispensed in a double-blind fashion"
Comment: the drugs were dispensed in identical looking cartons that at
random were marked with left or right, without any organisation; therefore
physicians and participants were unaware of treatment allocation
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "...double-blind fashion..."
Comment: study authors stated double-blinded design. Randomly
marked tubes were dispensed in a "double-blind fashion", which is
considered an adequate way to blind participants
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "...double-blind fashion..."
Comment: double-blind study
 
Incomplete outcome data (attrition
bias)
Low risk All included participants were analysed
 
Selective reporting (reporting bias) High risk No trial registration found. The article describes an unclear severity scale
ranging from 0 to 5; however the results for this outcome are not
registered in the article
 
Other bias Low risk No baseline comparisons; however within-participant study was not
applicable
Diagnostic certainty: yes
The study was completed
 
Granlund 1996
Methods Randomised, parallel-group design, with a partial cross-over design in the second
phase
Randomisation procedure unclear
The study was carried out in a secondary care setting
This was a single-centre study conducted in Finland
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Participants 41 participants with hand eczema, continuously for 6 months, significant disability,
inadequate response to conventional treatment, confirmation by histopathology
Dropouts: 6 in the first phase, 1 in the second phase
Inclusion criteria of the trial
18 to 70 years old
Continuous hand eczema for at least 6 months
Causing significant disability
Inadequate response to conventional treatment
Exclusion criteria of the trial
Other skin disorders
Treatment with systemic corticosteroids within 4 weeks or topical steroids or UV
radiation within 2 weeks before the study
Standard exclusion criteria for participants undergoing cyclosporin treatment
Study population
Gender: cyclosporin group 13 female, 7 male; betamethasone group 10 female, 11
male
Age: cyclosporin group mean 36 years, SD 9 years, 95% CI 32 to 40;
betamethasone group mean 40 years, SD 11 years, 95% CI 35 to 45
 
Interventions Intervention
• Oral cyclosporin 3 mg/kg/d and placebo cream for 6 weeks in 17/20 participants
• Topical betamethasone dipropionate 0.05% cream and placebo capsules identical to
cyclosporin in 19/21 participants
At week 6, cross-over of those who had treatment failure in the first 6 week phase: 8
participants switched to betamethasone, and 6 to cyclosporin
In the third phase, a 24-week follow-up period without intervention
Use of own emollients was allowed in both groups
Duration
Maximum 36 weeks with 6 to 12 weeks of active treatment
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Outcomes Grandlund 1996:
Primary outcomes of the trial
Not defined
Other outcomes
Participant-rated overall assessment of efficacy (1 = very good, 2 = good, 3 =
moderate, 4 = slight, 5 = none)
Observer-rated overall assessment of efficacy (1 = very good, 2 = good, 3 =
moderate, 4 = slight, 5 = none)
Observer-rated disease activity score: grading 0 to 3 (0 = none, 1 = mild, 2 =
moderate, 3 = severe) on erythema, scaling, infiltration, excoriation, crusting,
vesicles
Observer-rated extent of disease
Use of emollients
Participant-rated itch and sleep disturbances for the final 2 weeks on a VAS
Treatment success, defined as decrease in disease activity score (see first outcome
above) to < 5.0% of baseline score
Adverse events
Grandlund 1997:
Primary outcome of the trial
Quality of life assessed by the Eczema Disability Index (EDI) at week 6 and week
12
Other outcomes
Observer-rated disease activity score: grading 0 to 3 (0 = none, 1 = mild, 2 =
moderate, 3 = severe) on erythema, scaling, infiltration, excoriation, crusting,
vesicles for both hands
Observer-rated extent of disease
Use of emollients
Participant-rated itch and sleep disturbances for the final 2 weeks on a VAS
 
Notes Grandlund 1996: study had 3 phases, which were partially overlapping. The second
phase dealt with participants who had treatment failure in phase 1. In this second
phase, participants were switched over to the alternative intervention. The third phase
includes only participants who had treatment success in phase 1. Outcome
assessment based on intention-to-treat analysis. This review deals with only phase 1
and phase 3
Granlund 1997: paper is based on the same trial (same participants) as Granlund
1996, but deals only with phases 1 and 2. The study had 3 phases, which were
partially overlapping. The second phase dealt with participants who had treatment
failure in phase 1. In this second phase, participants were switched over to the
alternative intervention. The third phase includes only participants who had treatment
success in phase 1. In this review, only results of the first phase will be discussed.
Outcome assessment was based on intention-to-treat analysis
The secondary outcomes - reduction in severity, participant-rated scoring, time until
relapse, and dose reduction - were included in the study but did not provide
reproducible data
Declarations of interest: not stated
Funding: the study was supported by Sandoz Pharmaceuticals, Switzerland
(manufacturer of the study drug) and Finland, and by a grant from Finska
Läkaresällskapet, Finland
Sample size rationale: not stated
 
Risk of bias table
#29 Interventions for hand eczema
89 / 280
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "patients were given numbers 1-41 in consecutive order, which
had been reassigned to treatment with..."
Comment: however, neither article clarifies how this reassignment was
done
 
Allocation concealment (selection
bias)
Low risk Quote: "the codes were not opened until all participants had finished all
parts of the study"
Comment: the study used identical placebos for topical and oral
treatment, and participants were given consecutive numbers
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "soft gelatine capsules containing 25, 50 or 100 mg and identical
placebo capsules were supplied by ..." "Identical 100 tubes were used for
the creams"
Comment: study authors stated double-blinded design. Sufficient
information provided about how participant blinding was achieved and
identical tubes and placebos were used
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "the codes were not opened until all patients had finished all parts
of the study"
Comment: double-blind design; because identical placebos were used
and the randomisation code was not broken before the end of the study,
it is unlikely that assessors were aware of the treatment group
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "results were analyzed on an intention to treat basis"
Comment: intention-to-treat analysis
 
Selective reporting (reporting bias) Low risk No trial registration found; however all relevant outcomes are addressed
in the Materials and Methods sections of the 2 articles and are depicted
in graphs in the Results section
 
Other bias Unclear risk Baseline comparisons revealed a significant difference between groups
in terms of pre-study antibiotics treatment Diagnostic certainty: yes
The study was completed
 
Grattan 1991
Methods Within-participant, randomised controlled trial
The study was probably conducted in a secondary care setting at a single centre in the
UK
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Participants 15 participants with vesicular hand eczema for at least 6 months
Dropouts: 3
Inclusion criteria of the trial
16 years of age or older
Recurrent disabling symmetrical vesicular hand eczema for at least 6 months with
periods of remission (complete clearance) not exceeding 1 month in the previous 6
Exclusion criteria of the trial
Pustular psoriasis
Chronic hyperkeratotic dermatitis
Chronic fungal infection
Relevant allergy
Predominantly irritant dermatitis
Pregnancy
Phototoxicity
Use of immunosuppressive drugs
Study population
Gender: 3 female, 9 male
Age: mean 49.7 years, SEM 4.1 years, range 24 to 69 years
 
Interventions Intervention
• Topical PUVA 3 times a week for 8 weeks on 12/15 hands
Control intervention
• UVA (with placebo psoralen paint) on 12/15 contralateral hands
Moisturisers were allowed on both hands, and both hands received a small fraction of
UVB from UVA lamps
During an unclear follow-up period, participants received a questionnaire
Duration
8 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Observer-rated global rating on a 5-point scale (0 = clear, 1 = minimal, 2 = mild, 3 =
moderate, 4 = severe) at a weekly interval
Participant-rated VAS to indicate improvement at weeks 0, 4, 8, 12, and 16
Observer-rated severity score: T-120 scores: multiplying surface area involved with
severity scores (0 to 4) for vesiculation, erythema and scaling in weeks 0, 4, 8, 12,
and 16
Questionnaire after completion of the study
Adverse events
 
Notes Small number of participants. The secondary outcomes - reduction in severity,
investigator-rated and participant-rated, and time until relapse - were included but did
not provide reproducible data. Exact figures for main outcomes are not given; instead
there are graphic presentations. Questionnaire assessment was performed after
completion of the study, but duration of follow-up in this questionnaire assessment
remains unclear
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear
risk
Quote: "psoralen and placebo were randomised and coded by one
independent investigator (GJS) and supplied in bottles labelled left and
right"
Comment: no further details
 
Allocation concealment (selection
bias)
Low risk Quote: "psoralen and placebo were randomised and coded by one
independent investigator (GJS) and supplied in bottles labelled left and
right"
Comment: randomisation and coding were accomplished by an
independent investigator, and bottles were supplied labelled 'left' and
'right'; therefore the physician was unaware of allocation
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "psoralen and placebo were randomised and coded by one
independent investigator (GJS) and supplied in bottles labelled left and
right"
Quote: "the placebo was...."
Comment: double-blind study with a similar looking placebo; it was not
possible for the participant to distinguish these
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "the code was not broken until completion of the study"
Comment: double-blind design in which an independent investigator
supplied the treatments. It was not possible for observers to know the
treatment groups
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (12 of 15 = 80%)
 
Selective reporting (reporting bias) Unclear
risk
No trial register found. No major differences between outcomes described
in the Methods section and outcomes described in the Results section;
however although the article text claims that separate scores for the
T-120 are described, we were unable to find a score for separate items
 
Other bias Low risk Baseline comparisons: as within-participant study not applicable
Diagnostic certainty: yes
The study was completed
 
Gupta 1993
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Methods Parallel-group, randomised controlled trial
The study was conducted at a single dermatology centre in Canada
 
Participants 58 participants with steroid-responsive dermatitis limited to the hands
Evaluable: 54
Dropouts: 6, of whom 4 permitted a protocol violation and 2 ended prematurely
because of an exacerbation of hand eczema
Inclusion criteria of the trial
Corticosteroid-responsive dermatitis limited to the hands
Exclusion criteria of the trial
Medically significant cutaneous conditions other than hand eczema
Clinically infected hand dermatitis
Known sensitivity to study medication
Use of topical corticosteroids in the last 14 days, other topical treatments in last
week, systemic corticosteroids during last 12 weeks. Systemic antimicrobials, all
other investigational drugs and radiation therapy last 30 days, systemic or topical
antihistamines in last 14 days, and topical anaesthetics or topical and systemic
analgesics in last 48 hours
Study population
Gender: not stated
Age: 18 to 70 years
 
Interventions Intervention
• Betamethasone dipropionate film-forming lotion in 28/29 participants daily for 7 days
• Betamethasone dipropionate thickened lotion in 26/29 participants for 7 days
Duration
1 week
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Investigator-rated overall severity of hand eczema:(0 = absent, 1 = mild, 2 =
moderate, 3 = severe) at days 2, 4, and 7
Investigator-rated scores (0 = absent, 1 = mild, 2 = moderate, 3 = severe) of
pruritus, scaling, erythema, induration at days 2, 4, and 7
Physician global assessment of eczema relief (+3 = cleared to -2 = much worse) at
days 2, 4, and 7
Adverse events
 
Notes Very short study of only 7 days. Unclear about withdrawals in lotion group. Exact
number allocated to each treatment not specified. Among the different outcomes,
unclear how change in overall severity was calculated
Declarations of interest: not stated.
Funding: the study was supported in part by a grant from GenDerm Corporation,
Montreal, Canada, manufacturer of the study drugs
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "participants were randomly assigned to 2 groups..."
Comment: no further details
 
Allocation concealment (selection
bias)
Low risk Quote: "bottles were dispensed in their marketed containers with identical
overlabels and the contents were not known to the patients or the
investigator who assessed the results. Only the study coordinator was
aware of the contents of the bottles"
Comment: sequentially numbered drug containers of identical
appearance are considered as adequate allocation concealment
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "bottles were dispensed in their marketed containers with
identically appearing overlabels and the contents were not known to the
patients or the investigator who assessed the results. Only the study
coordinator was aware of the contents of the bottles"
Comment: double-blind study; identical looking containers were used
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "bottles were dispensed in their marketed containers with
identically appearing overlabels and the contents were not known to the
patients or the investigator who assessed the results. Only the study
coordinator was aware of the contents of the bottles"
Comment: observers were unaware of the study drug, which was
identical in appearance
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (54 or 52 of 58 = more than
80%)
 
Selective reporting (reporting bias) Unclear risk No trial registration found. No major differences between the Methods
and Results sections found; however for erythema and pruritus, study
authors state only that no significant differences were found
 
Other bias Low risk Baseline comparisons: at baseline, significant differences in scaling
between groups, but controlled for by statistical procedure. No significant
differences at baseline with regard to age, gender, race, erythema,
induration, pruritus, or area of eczematous involvement
Diagnostic certainty: yes
The study was completed
 
Hanifin 2004
Methods A phase I-II, open-label, randomised controlled, parallel-group (3 groups) study
The study was conducted at various dermatology departments in the USA
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Participants 55 participants with chronic severe hand dermatitis (32 atopic, 18 irritant, 5 dyshidrotic
or other): duration at least 6 months and severity score 3 or 4
Dropouts: 13
Inclusion criteria of the trial
Hand eczema for at least 6 months with a score of 3 or 4 on 3 out of 6 severity
scales
Exclusion criteria of the trial
Psoriasis on the hands
Urticaria
Active fungal or bacterial infection on the hands
Identified allergic contact dermatitis
Use of oral retinoids was contraindicated with a washout period of 12 weeks
Use of other oral therapies (washout 4 weeks), topical retinoids, or
immunomodulating therapies in the last 4 weeks
Use of topical steroids in the last 2 weeks
Pregnancy
Lactating women
Study population
Gender: 37 female, 18 male
Age: median 42 years, range 20 to 74 years
 
Interventions Intervention
• Bexarotene 1% gel escalated stepwise from 1× every other day to 3× daily in 28
participants for 22 weeks
• Bexarotene gel stepwise plus mometasone furoate 0.1% ointment 2× daily in 13
participants for 22 weeks
• Bexarotene gel stepwise plus hydrocortisone 1% ointment 2× daily in 14 participants
for 22 weeks
In all 3 groups, daily use of emollients was allowed
Duration
22 weeks
 
Outcomes Primary outcome of the trial
Observer-rated treatment success defined by 90% or better clearance using a
physician assessment score (not exactly defined)
Secondary outcomes of the trial
Observer-rated percentage improvement in HEASI (adaptation of EASI for the
hands) score. The HEASI equals (sum of severity scores for signs) × (involved
hand area integer), whereby for the area 1 = < 10% involvement, 2 = 10% to 29%, 3
= 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, and 6 = 90% to 100%. Severity
score of signs is 0 = none, 1 = mild, 2 = moderate, 3 = moderately severe, and 4 =
severe for, respectively, erythema, scaling, oedema, lichenification, vesiculation,
and fissuring at weeks 2, 4, 6, 8, 10, 14, 18, and 22
Other outcomes
Observer-rated clinically significant response, defined by 50% improvement using a
physician assessment score (not exactly defined)
Participant-rated pruritus on a scale from 0 = none to 4 = severe
Adverse events
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Notes Phase I to II open-label study. Intention-to-treat principle not stated, but the proportion
of participants with treatment success is based on the number of all participants
enrolled in each treatment group. Of the 12 dropouts/withdrawals, it is unknown to
which treatment group they belong
The secondary outcome - reduction in severity, participant-rated scoring - was
included but no reproducible data were provided
Study authors were contacted by email and LinkedIn; however they were unable to
answer all of our questions
Declarations of interest: one of the study authors was an employee of Ligand
Pharmaceuticals, San Diego, USA
Funding: not stated
Sample size rationale: not stated
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "patients were randomized at 2:1:1 into three treatment arms..."
Comment: no further details given in the article; personal communication
clarified that a computer-generated scheme was used
 
Allocation concealment (selection
bias)
Unclear risk No details about how allocation was concealed from participants and
clinicians
 
Blinding of participants and
personnel (performance bias)
High risk Quote: "a phase I-II open label randomized clinical study...."
Comment: no blinding of participants or observers as open-label study
 
Blinding of outcome assessment
(detection bias)
High risk Quote: "a phase I-II open label randomized clinical study...."
Comment: observers were not blinded
 
Incomplete outcome data (attrition
bias)
Unclear risk No intention-to-treat analysis according to the text; however in the tables,
55 participants seems to be included, where the text clearly states that
13 participants withdrew before completing the 22 weeks of the study
42 of 55 = less than 80%
 
Selective reporting (reporting bias) Low risk No trial registration found; however, relevant outcomes were described,
such as HEASI score, and we found no major discrepancies between
participants in the Methods section and the Results section
 
Other bias Low risk Baseline comparisons: no significant difference among groups in
demographic or disease characteristics
Diagnostic certainty: yes
The study was completed
 
Hill 1998
Methods Randomised, parallel-group design.
The study was conducted in a secondary care setting at different dermatology
departments in the UK
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Participants 120 participants with diagnosis of eczema on one or both hands, and with suspected
or confirmed infection
Dropouts: 10
Inclusion criteria of the trial
Clinical diagnosis of hand eczema with secondary bacterial infection
Presence of erythema induration or itching (2 out of 3)
18 years of age or older
Exclusion criteria of the trial
Psoriasis of the hands
Primary cutaneous infections on the hands
Non-eczematous lesions with secondary infection on the hands
Topical or systemic antibiotics in previous week
Use of other drugs in the past 4 weeks that could affect eczema
Known hypersensitivity to study medication
Women with inadequate contraception, pregnancy, and breastfeeding
Patients unable to comply with the study protocol
Study population
Gender: 40 female, 18 male
Age: mean 35.6 years, range 18 to 79 years
 
Interventions Intervention
• Betamethasone-valerate 0.1% + clioquinol 3% cream twice daily for 4 weeks in 57/61
participants
• Betamethasone-v 0.1% + fusidic acid 2% cream twice daily in 53/55 participants for 4
weeks
Duration
4 weeks
 
Outcomes Primary outcome of the trial
Observer-rated proportion of participants with satisfactory (i.e. good or excellent)
response at the last on-treatment visit based on global rating: excellent, good, fair,
or poor
Other outcomes
Participant-rated response to treatment: excellent, good, fair, or poor at weeks 1, 2,
and 4
Observer-rated changes in scores for erythema, pruritus, induration,
dryness/scaling, cracking/fissuring, clinical signs of infection (for each: 0 = absent, 1
= mild, 2 = moderate, 3 = severe) at weeks 1, 2, and 4
Participant-rated severity of itching: 0 = absent, 1 = mild, 2 = moderate, 3 = severe
at weeks 1, 2, and 4
Participants' assessment of treatment acceptability with regards to stickiness,
staining of skin and/or clothing, ease of application, and overall acceptability
Bacterial culture at entry and at end of treatment: successful if pretreatment
pathogen, if present, was eradicated
Adverse events
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Notes Primary outcome assessed at last on-treatment visit: probably for most participants at
week 4, but unclear how much earlier for dropouts (graph suggests after week 4). Not
clear if data for secondary outcome number 2 (participant-rated response) are
presented
The primary outcome percentage of participants with self-rated good/excellent control
and the secondary outcomes - reduction in severity, investigator- and participant-rated
scoring - were included but provided no reproducible data
Declarations of interest: one study author was an employee of Leo Pharmaceuticals,
Princes Risborourg, UK
Funding: the study was designed and sponsored by Leo Pharmaceuticals, Princes
Risborough, UK, manufacturer of the study drug
Sample size rationale: not stated
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "treatment was allocated at random"
Comment: the article states only that treatment was allocated at random,
without further details
 
Allocation concealment (selection
bias)
Unclear risk No details about how allocation was concealed from participants and
clinicians
 
Blinding of participants and
personnel (performance bias)
High risk Quote: "this was a multicentre, prospective, randomized, open-parallel-
group comparison"
Comment: not blinded
 
Blinding of outcome assessment
(detection bias)
High risk Quote: "this was a multicentre, prospective, randomized, open-parallel-
group comparison"
Comment: not blinded, which might have affected observer-rated
outcomes
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "... and were included in an intention-to-treat analysis in respect of
the primary efficacy criterion only"
Comment: intention-to-treat analysis
 
Selective reporting (reporting bias) Unclear risk No trial registration found. We did not find major differences between what
was stated in the Methods section and in the Results section; however the
subscores for clinical signs and symptoms were not given, and it was
stated only whether they were statistically significantly different
 
Other bias Unclear risk Baseline comparisons: more 'severe' classification of signs in the
betamethasone/fusidic acid group; unclear whether this constitutes a
significant difference and was controlled for
Diagnostic certainty: yes
The study was completed
 
Hordinsky 2010
Methods Randomised controlled, parallel-group design
This was a multi-centre study conducted at 57 centres in 7 countries (Austria, Canada,
Denmark, Hungary, Italy, Norway, USA)
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Participants 652 (246 male, 406 female) with diagnosis of mild to moderate hand dermatitis as
defined by IGA
555 participants completed the double-blind phase, 544 (269 in the pimecrolimus
group and 275 in vehicle group) entered the open extension phase, and 512 (248 and
264, respectively) completed the study
Inclusion criteria of the trial
History of hand eczema (according to IGA: mild to moderate) of at least 90 days'
duration
Minimum age of 18 years
Exclusion criteria of the trial
Medication or concomitant conditions that could interfere with conduct of the study
or results
Immunocompromised participants
History of malignant disease
Endogenous dermatoses: dyshidrotic dermatitis, psoriasis of the hands, flares of
atopic dermatitis
Study population
Gender: pimecrolimus group 185 female, 130 male; vehicle group 211 female, 116
male
Age: pimecrolimus group mean 43.9 years, SD 14.4 years, range 18 to 84 years;
vehicle group mean 44.1 years, SD 15.1 years, range 18 to 85 years
 
Interventions Intervention
• Pimecrolimus 1% ointment twice daily with daily occlusion by use of vinyl gloves of at
least 6 hours after second (evening) application for up to 43 weeks in 325 participants
Control intervention
• Vehicle ointment twice daily with daily occlusion by use of vinyl gloves of at least 6
hours after second (evening) application for up to 43 weeks in 327 participants
Duration
Up to 43 weeks
 
Outcomes Primary outcome of the trial
Investigators Global Assessment (IGA) of the target hand at day 43 or at time of
early (according to trial registration, not clear from article) (0 = clear, 1 = almost
clear, 2 = mild, 3 = moderate, 4 = severe)
Other outcomes
Observer rated: clear or almost clear of hand dermatitis at end of trial as defined by
IGA (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe) at weekly
intervals
Participant-rated: pruritus severity 0 to 3 (0 = absent, 3 = severe) at weekly intervals
Participant-rated: burning sensation/severity of burning 0 to 3 (0 = absent, 3 =
severe)
Safety and tolerability (adverse events)
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Notes Participants could enter open-label phase before 42nd day if hand dermatitis had
remained cleared on 2 consecutive weekly assessments. However, efficacy
comparisons were made at day 42 in intention-to-treat analysis. Not clear how many
participants were blind to treatment during assessments at days 29, 36, and 43, as
open-label phase could already have started
We were unable to obtain additional information from study authors
Declarations of interest: one study author was an employee of Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA
Funding: the study was supported by Novartis Pharma AG, manufacturer of the study
drug
Sample size rationale: provided
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "eligible patients were randomized in a 1:1 ratio to receive..."
Quote: "randomization was performed using a validated automated
system and was stratified by baseline IGA score at each centre"
Comment: randomisation method was considered adequate
 
Allocation concealment (selection
bias)
Unclear risk No details about how allocation was concealed from participants and
clinicians
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quote: "...double-blind and vehicle-controlled..."
Comment: study authors state double-blinded design, although unclear
whether pimecrolimus and vehicle were identical in appearance
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "...double-blind and vehicle-controlled..."
Comment: double-blind study; however, insufficient details are given
about investigator blinding
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "all the efficacy assessments were done in the intent-to-treat
population using a last observation carried forward approach"
Comment: intention-to-treat analysis
 
Selective reporting (reporting bias) Unclear risk Trial registration was found on clinicaltrials.gov (NCT00226707)
Work productivity and activity impairment questionnaires are included in
the trial registration but are not mentioned in the article
The trial register stated that the primary outcome was IGA on day 43,
although this is not clearly stated in the article
 
Other bias Low risk Baseline comparisons conducted: "there were no clinically relevant
differences in baseline demographic characteristics or disease history
between the pimecrolimus cream 1% and vehicle groups"
Diagnostic certainty: yes
The study was completed
 
Jowkar 2011
#29 Interventions for hand eczema
100 / 280
Methods Randomised controlled, parallel-group design
This study was conducted at a single dermatology centre in Iran
 
Participants 44 "healthy patients with hand eczema that did not use topical medication in 2 weeks
ago or systemic medication in 1 month ago were enrolled" (participants aged 12 to 60
years with hand eczema)
No dropouts
Inclusion criteria of the trial
Healthy participants with hand eczema
Exclusion criteria of the trial
Use of topical medication in the 2 weeks before the study
Systemic treatments 1 month before the study
Pregnancy
Lactation
Hypersensitivity to study drugs
Study population
Gender: 30 female, 14 male
Age: mean 33.3 years, range 13 to 58 years
 
Interventions Intervention
• 4% topical cream of Fumaria parviflora L. alcoholic extract for 4 weeks twice daily, 10
grams on hand surface skin in probably 22 participants, although this is not clearly
described in the article
Control intervention
• Placebo twice daily in probably 22 participants for 4 weeks
Participants were followed up until 2 weeks after the end of treatment
Duration
6 weeks (4 weeks active treatment, 2 weeks follow-up)
 
Outcomes Primary outcome of the trial
Investigator-rated reduction in severity of hand eczema at week 0 and week 6 (2
weeks after termination of therapy) by means of the Eczema Area and Severity
Index (EASI), which is validated for atopic dermatitis and scores erythema, papules,
excoriation, and lichenification on a scale of 0 = none, 1 = mild, 2 = moderate, and 3
= severe and multiplies this by an area score
Other outcomes of the trial
Adverse events
 
Notes The number of participants in each group is not described, and the ratio intervention vs
placebo is unclear
Because the data are presented in a graphical manner, they are difficult to reproduce.
The secondary outcome - reduction in severity investigator-rated - was included but
did not provide reproducible data
Study authors were contacted on 28 February 2014 and replied the same day
Declarations of interest: none declared
Funding: the study was supported by Shiraz University of Medical Science
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "randomization was conducted based on block randomization
design"
Comment: randomisation block design suggests the use of a
randomisation code list; however study authors denied the existence of a
randomisation list in personal communication
 
Allocation concealment (selection
bias)
Low risk No details about allocation concealment in the article; however personal
communication clarified that treatment allocation was done by a third
person
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "double-blind (patient-physician) placebo-controlled study"
Comment: no additional information is provided in the article. Personal
communication clarified that placebo and actual treatment were the same
in appearance, and the secretary (third party, not involved in actual
treatment) dispensed the study drugs
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "both dermatologist and patients were blind to study groups. Data
were recorded by an assessor"
Comment: physicians were blinded and unaware of treatment allocation,
which was done by a third person
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "a total of 44 patients completed the study"
Comment: one patient was excluded from the study due to side effects;
however more than 80% completed the study
 
Selective reporting (reporting bias) Low risk No discrepancy between the registered trial (IRCT 1388103030741N1)
and the original article with regard to outcomes
 
Other bias Unclear risk Baseline characteristics depicted in graphs; not stated whether there was
a significant difference between groups Diagnostic certainty: yes
The study was completed
 
Jowkar 2014
#29 Interventions for hand eczema
102 / 280
Methods Randomised controlled, parallel-group study
This study was conducted at teaching dermatology clinics of the Shiraz University of
Medical Sciences
 
Participants 92 consecutive patients with a clinical diagnosis of hand eczema
Dropouts: 58 participants were analysed, of whom 4 were excluded due to adverse
events; unclear what happened to the remaining 34 participants
Inclusion criteria of the trial
Clinical diagnosis of hand eczema
Exclusion criteria of the trial
Pregnancy
Lactation
Use of any topical or systemic immunosuppressants during the last month
Patients under 12 years of age
Psoriasis proven by a biopsy in clinically probable cases
Patients who used topical therapy during the last 2 weeks
Patients who used systemic therapy during the last month
Development of adverse events during the study
Study population
Gender: fumaric acid group 21 female, 9 male; triamcinolone group 19 female, 11
male
Age: fumaric acid group mean 28.7 years; triamcinolone group mean 31 years
 
Interventions Interventions
• Topical fumaric acid 5% cream twice a day for 1 month in 30 participants
• Triamcinolone 0.1% cream twice a day for 1 month in 28 participants
Duration
4 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes of the trial
Signs of the disease including erythema, excoriation, population, and lichenification
at week 0 and week 4
Disease score based on the EASI (Eczema Area and Severity Index) at week 0 and
week 4
Degree of pruritus ranging from 0 to 3 (0 = no pruritus, 3 = severe) at week 0 and
week 4
 
Notes 92 consecutive patients were recruited; a substantial portion of these patients were
lost to follow-up
Study authors were contacted for additional information by email and provided
additional information regarding design and risk of bias
Declarations of interest: none declared
Funding: the study was sponsored by Shiraz University of Medical Sciences.
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "a list of randomized coded groups was given to the study
investigator, and as patients consecutively were enrolled in the study,
they were assigned to the next available randomized group on the list"
Comment: consecutive patients were enrolled, and the investigator was
given a list of randomised coded groups Study authors clarified they
used a random number table generated by a statistical computer
programme
 
Allocation concealment (selection
bias)
Low risk No details about how allocation was concealed from participants and
clinicians besides the above stated. Study authors clarified that
assignment of study medication was done by a third party - the hospital
pharmacy
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "double-blind study"
Comment: no additional information is provided in the article, but study
authors stated that study drugs were prescribed in similar looking bottles
of 40 grams
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "double-blind study"
Comment: no additional information is provided in the article, but study
authors explained that observers were unaware of the allocation and
were not involved in application or distrubution of study drugs
 
Incomplete outcome data (attrition
bias)
High risk No intention-to-treat analysis but per protocol (58 of 92 = less than 80%).
A substantial number of the 92 participants were lost to follow-up, and 4
left the study due to adverse events (explanation of the study author)
 
Selective reporting (reporting bias) Low risk No trial registration found; however all outcomes listed in the Materials
and Methods section are also listed in the Results section
 
Other bias Low risk Baseline comparisons were conducted, and no differences were found
regarding age, gender, and duration of disease
Diagnostic certainty: yes
The study was completed
 
Kaaber 1983
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Methods Randomised controlled, parallel-group design
This study was probably conducted in a secondary care setting at 2 Danish
departments of dermatology
 
Participants 30 female participants with pompholyx more than 6 months, and positive patch test to
nickel
Dropouts: 6
Inclusion criteria of the trial
Pompholyx of the hands of more than 6 months' duration
At least 1 flare every 2 weeks
A positive patch test to nickel
Exclusion criteria of the trial 
Not defined
Study population
Gender: 30 female, no male
Age: median 25 years, range 19 to 67 years
 
Interventions Intervention
• Oral tetraethylthiuram disulphide (TETDS) 50 mg/d first week, increasing to 200 mg/d
for at least 6 weeks in 11/15 participants for at least 6 weeks
Control intervention
• Placebo tablets in 13/15
The total duration of the study was probably 8 weeks (?); however run-in time and total
duration of treatment are not completely clear
Both groups were allowed to use desoximetasone ointment and emollients
Duration
Probably 8 weeksIS
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Participant-rated (?) number of flares at each 2- to 3-week visit
Observer-rated score of severity: area involved 0 to 4, erythema 0 to 3, number of
vesicles 0 to 3, scaling 0 to 3
Number of participants healed (not specified in Methods)
Amount of corticosteroid ointment used since last visit
Adverse events
 
Notes Study duration unclear. Timing of outcome assessments not clear. Comparison based
on slopes of linear regression of scores.
The secondary outcomes - reduction in severity, investigator-rated, and dose reduction
- were included but did not provide reproducible data
Declarations of interest: not stated
Funding: Hoechst Danmark and Dumex Ltd. Danmark supplied the study drugs
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "referring to a system of random numbers, the patients
received..."
Comment: reference to a system of random numbers
 
Allocation concealment (selection
bias)
Unclear risk Unclear if this concerned an open list and unclear how allocation was
concealed
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "the tablets were identical in appearance"
Comment: study authors stated double-blinded design; this is considered
an adequate way to blind participants
 
Blinding of outcome assessment
(detection bias)
Unclear risk Double-blind design. No information is given about how observer blinding
was achieved
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (24 of 30 = 80%)
 
Selective reporting (reporting bias) Unclear risk No trial registration found. For observer-rated severity score, the Results
section states only that this was not statistically significant, only with
regards to scaling and the frequency of flares. The Results section is
very concise
 
Other bias Unclear risk Baseline comparisons: not stated
Diagnostic certainty: yes
The study was completed
 
Katsarou 2012
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Methods Randomised controlled, parallel-group study
This study was conducted in a specialised unit for contact dermatitis at a single centre
in Greece
 
Participants 30 participants with chronic hand eczema and a relevant allergic contact dermatitis
No dropouts
Inclusion criteria of the trial
Adult participants with chronic hand eczema (present at least 6 months before
referral to clinic)
Positive relevant patch test reaction
Absence of atopy
No use of systemic corticosteroids and/or immunosuppressants 2 weeks before
inclusion
Exclusion criteria of the trial
Not stated
Study population
Gender: tacrolimus group 8 female, 7 male; mometasone group 9 female, 6 male
Age: tacrolimus group mean for females 39 years, mean for males 34 years;
mometasone group mean for females 40 years, mean for males 32 years
 
Interventions Intervention
• Tacrolimus 0.1% twice daily for 30 days and once daily for 31 to 90 days in 15
participants
• Mometasone furoate ointment twice daily for 1 week, once daily during week 2 and
week 3, once daily 3 times a week for weeks 4 and 5, and once daily 2 times a week
during the rest of the study until 90 days in 15 participants
Duration
90 days
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Investigator-rated severity of erythema judged on a 5-point VAS scale at days 0, 30,
60, and 90
Investigator-rated severity of infiltration judged on a 5-point VAS scale
Investigator-rated severity of vesiculation judged on a 5-point VAS scale
Investigator-rated severity of desquamation judged on a 5-point VAS scale
Investigator-rated severity by presence of cracks judged on a 5-point VAS scale
Investigator-rated severity of itching judged on a 5-point VAS scale
Adverse events
 
Notes The secondary outcome - reduction in severity, participant-rated - was included but not
provide reproducible data. The conducted analyses are inappropriate and insufficient,
and in consequence, the conclusions are invalid
Study authors were contacted on 28 February 2014 but were not responsive
Declarations of interest: none declared
Funding: no financial support received
Sample size rationale: not stated
 
Risk of bias table
#29 Interventions for hand eczema
107 / 280
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "according to the study design, patients were randomized
according to random numbers in a computerized way"
Comment: the study used randomisation according to random numbers
generated in a computerised way
 
Allocation concealment (selection
bias)
Unclear risk Quote: "an investigator’s assistant enrolled and assigned the treatment of
the participants while the clinical evaluation was performed by a group of
three investigators..."
Comment: an investigator's assistant enrolled and assigned treatment;
unclear whether this person was aware of treatment allocations
 
Blinding of participants and
personnel (performance bias)
High risk Participants were not blinded
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "an investigator’s assistant enrolled and assigned the treatment of
the participants while the clinical evaluation was performed by a group of
three investigators, in order to make the assessments more objective as
the investigators were unaware of the patient’s group"
Comment: assessors were blinded
 
Incomplete outcome data (attrition
bias)
Low risk All included participants completed the study
 
Selective reporting (reporting bias) Low risk No trial registration found; however all outcomes listed in the Materials
and Methods section are also listed in the Results section
 
Other bias Low risk Baseline comparison: there were no statistical differences in baseline
variables according to study authors Diagnostic certainty: yes
The study was completed
 
Kemper 1998
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Methods Within-participant, randomised controlled study
This study was conducted in a secondary care setting at 2 Dutch departments of
dermatology
 
Participants 19 participants with hand eczema (all types)
Dropouts: 7
Inclusion criteria of the trial
Bilateral hand eczema of all types
Exclusion criteria of the trial
Not stated
Study population
Gender: 8 female, 4 male
Age: not stated
 
Interventions Intervention
• Coal tar 5% paste (pix lithanthracis) once weekly on the one hand in 12 participants
for 4 weeks
• Betamethasone valerate 0.1% ointment once weekly in 6 contralateral hands for 4
weeks
• Zinc oxide paste once weekly during 4 weeks in the remaining 6 contralateral hands
All participants had to wear gloves for an entire week after application of the ointment
Use of oral antihistamines was allowed in all groups
Duration
4 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes of the trial
Investigator-rated improvement in total score based on erythema, vesicles, papules,
scaling/hyperkeratosis, and lichenification multiplied by the affected area at week 0
and week 4
Participant's assessment of subjective complaints (itch, pain, and insomnia)
Adverse events
 
Notes The only trial included studying the effect of coal tar paste. Small number of
participants with relatively high dropout rate. The secondary outcomes - reduction in
severity, investigator-rated and participant-rated - were included but did not provide
reproducible data. The results are listed as overall mean scores. No exact data are
given
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "door middel van loting werd bepaald welke hand..." (free
translation: "by means of a draw was decided which hand...")
Comment: the paper refers to a lottery system
 
Allocation concealment (selection
bias)
Unclear
risk
No details about how allocation was concealed from participants and
clinicians
 
Blinding of participants and
personnel (performance bias)
High risk Not blinded, which is also difficult given the colour and smell of coal tar
treatment
 
Blinding of outcome assessment
(detection bias)
High risk Not blinded, which might have affected the investigator-rated outcome
 
Incomplete outcome data (attrition
bias)
High risk No intention-to-treat analysis but per protocol (12 of 19 = less than 80%)
 
Selective reporting (reporting bias) High risk No trial registration found. In the Methods section, study authors list a
scoring system based on erythema, vesicles, papules,
scaling/hyperkeratosis, and lichenification multiplied by the affected area,
and refer to 2 different references with scoring systems; however in the
Results section, a total sum score is given, along with scores for
inflammation, hyperproliferation, and lichenification; these are not
explained in the article, nor in the references
 
Other bias Low risk Baseline comparisons: as within-participant study not applicable
Diagnostic certainty: yes
The study was completed
 
King 1984
#29 Interventions for hand eczema
110 / 280
Methods Within-participant, randomised controlled study
This study was conducted at a single centre in a secondary care setting in the UK
 
Participants 20 participants with chronic palmar eczema
Evaluable: 15 (8 hyperkeratotic, 7 pompholyx).
Dropouts: 5
Inclusion criteria of the trial
Chronic symmetrical palmar eczema unresponsive to topical steroids or tar
Stable for at least 3 months before the beginning of the study
Exclusion criteria of the trial
Pregnancy
Under 25 years of age
Treatment with oral steroids or cytotoxic agents
History of skin neoplasia or previous radiotherapy
Study population
Gender: not stated
Age: not stated
 
Interventions Intervention
• Superficial ionising radiation fractionated 100 rad at 45 kV once weekly for 3 weeks;
total dose 300 rad in 15/20 hands
Control intervention
• Placebo radiation once weekly for 3 weeks in 15/20 contralateral hands
In both groups, the topical medication was continued unchanged
Duration
3 weeks' active treatment with follow-up until 6 months
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Observer-rated assessment of extent of lesions: good response (clear and nearly
clear) vs poor response (partly clear, no change, relapse). Response was assessed
at 1, 3, and 6 months
Photographs
 
Notes Outcome 2 (photographs) was not used in the presentation of results
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "the radiographer randomly selected one palm..."
Comment: no further details are given
 
Allocation concealment (selection
bias)
Low risk Quote: "neither patient nor doctor was aware which hand had received
treatment, but a record was kept by a radiographer in a sealed envelope"
Comment: the study used sealed envelopes. This is a clear description of
an adequate allocation concealment procedure
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "neither patient nor doctor was aware which hand had received
treatment, but a record was kept by a radiographer in a sealed envelope"
Comment: double-blinded. One hand received actual radiotherapy; the
other received "simulated radiotherapy" in the same regimen. This was
considered as an adequate way to blind participants. The radiographer
(staff) was aware of the treatment arm, but we consider this the best
possible way to blind participants
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "neither patient nor doctor was aware which hand had received
treatment, but a record was kept by a radiographer in a sealed envelope"
Comment: double-blind design. At the end of the study, the records of the
radiographer were studied. Observers had no direct access to the
randomisation code due to the sealed envelope and were not involved in
administration of treatment. This is considered an adequate method to
blind outcome assessors
 
Incomplete outcome data (attrition
bias)
High risk No intention-to-treat analysis but per protocol (15 of 20 = less than 80%)
 
Selective reporting (reporting bias) Low risk No trial registration found. We did not find discrepancies between
Methods and Results sections
 
Other bias Low risk Baseline comparisons: as within-participant study not applicable
Diagnostic certainty: yes
The study was completed
 
Kircik 2013
Methods Parallel-group, randomised controlled study
This study was probably conducted in North America
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Participants 125 participants with moderate to severe hand eczema
Inclusion criteria of the trial
Capable of understanding and willing to provide signed informed consent
Male or female at least 12 years of age at time of consent and at time of first dose
Able to complete the study and to comply with study instructions
Moderate to severe hand dermatitis
Chronic hand dermatitis for at least 6 months
Exclusion criteria of the trial
Females who are pregnant, trying to become pregnant, or breastfeeding
Current diagnosis of allergic contact dermatitis
Participated in a previous study of the same study product
Any major illness within 30 days before the screening/baseline visit
Considered immunocompromised
Clinically relevant history of or current evidence of abuse of alcohol or other drugs
Considered unable or unlikely to attend the necessary visits
Study population
Gender: 70 female, 55 male
Age: mean 49.4 years, SD 15.5 years, median 51 years, range 15 to 84 years
 
Interventions Intervention
• Clobetasol propionate 0.05% foam twice a day for 14 days in 62 participants
Control intervention
• Vehicle/Placebo foam twice a day for 14 days in 63 participants
Duration
2 weeks
 
Outcomes Primary outcome of the trial
Number of participants with improvement of at least 2 grades in the Investigator's
Static Global Assessment (ISGA) score from baseline to day 15. The ISGA is an
investigator-rated 5-point scale for severity (0 = clear, 4 = severe)
Other outcomes of the trial
Number of participants with improvement of at least 1 grade in ISGA score from
baseline to day 15
Number of participants with improvement of at least 2 grades in ISGA score from
baseline to day 3 and to day 8
Number of participants with improvement of at least 1 grade in ISGA score from
baseline to day 3 and to day 8
Number of participants with ISGA score of 0 or 1 at days 3, 8, and 15
Number of participants with improvement of at least 1 grade in Subject Global
Assessment (SGA) score from baseline to days 3, 8, and 15
Number of participants with SGA score of 0 or 1 at days 3, 8, and 15
Percentage change from baseline in pruritus, stinging, burning, and pain scores at
days 3, 8, and 15
Adverse events
Concomitant medication
Participant-rated quality of life: for participants between 12 and 16 years of age, the
Children's Dermatology Life Quality Index (CDLQI) was used; for participants 16
years of age and older, the Dermatology Quality of Life index (DLQI) was used at
baseline, day 8, and day 15
Participant-rated work productivity and activity impairment questionnaire
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Notes Sponsor: Stiefel, a GSK company
We contacted study authors for additional information; however they remained
unresponsive
Declarations of interest: the primary study author has worked as consultant,
researcher, or speaker for GSK Stiefel; 2 other study authors are employees of Stiefel,
a GSK company
Funding: the study was supported by Stiefel, a GSK company
Sample size rationale: adequate
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "subjects were randomized 1:1 at baseline using a computerized-
generated schedule..."
Comment: subjects were randomised 1:1 at baseline according to a
computer-generated schedule, which is considered as low risk
 
Allocation concealment (selection
bias)
Low risk Quote: "study product assignments were unavailable to study
personnel..."
Comment: allocation was likely concealed
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "both products were identical in packaging, labelling and
ingredients except for the presence or absence of clobetasol propionate"
Comment: the study claims to be double-blind. Identical looking placebos
were used, which we consider an adequate method of blinding of
participants
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "study product assignments were unavailable to study personnel
until after all data had been collected and validated following applicable
standard operating procedures"
Comment: observers were unaware of treatment allocation and had no
direct access to the randomisation code
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "the intent-to-treat (ITT) population included all randomized
subjects who were dispensed the study product. The per-protocol (PP)
analysis set was used for the primary and key secondary analyses (which
were also performed for the ITT analysis set)"
Comment: an intention-to-treat analysis was carried out next to a per-
protocol analysis
 
Selective reporting (reporting bias) Unclear risk The study design and results were registered on clinicaltrials.gov
(NCT01323673). In the article, substantially more outcomes are listed
that were not registered in the trial register, for example, quality of life and
work impairment
 
Other bias Low risk Baseline comparisons: an extensive baseline comparison was given
Diagnostic certainty: yes
The study was completed
 
Krejci-Manwaring 2008
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Methods Parallel-group, randomised controlled study
This study was conducted in a secondary care setting at a single centre in the USA
 
Participants 32 participants with moderate to severe hand dermatitis who did not use topical
tacrolimus during the previous 28 days and did not use topical corticosteroids, non-
steroidal immunosuppressants, or light treatment during the last 7 days
Dropouts: 13 (including 1 participant who dropped out before the intervention was
started)
Inclusion criteria of the trial
Adults 18 years of age or older
Hand eczema with a combined severity score of 5 to 16
Exclusion criteria of the trial
Pregnancy
Use of topical tacrolimus 28 days before the study
Use of topical corticosteroids, immunosuppressants, or light treatments to the hand
1 week before the study
Use of systemic corticosteroids
Study population
Gender: 24 female, 8 male
Age: mean 46 years, range 20 to 70 years
 
Interventions Intervention
• Topical tacrolimus twice daily for 12 weeks in addition to a daily dose of prednisone
during 3 weeks; 30 mg in week 1, 20 mg in week 2, 10 mg in week 3 in 14/21
participants
Control intervention
• Vehicle ointment applied twice daily for 12 weeks; in addition, a daily dose of
prednisone during 3 weeks: 30 mg in week 1, 20 mg in week 2, 10 mg in week 3 in
6/11 participants
Participants were followed up at 5-week intervals until week 14 after initial treatment
Duration
14 weeks (3 weeks active treatment, 11 weeks follow-up)
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Observer-rated reduction in severity based on symptom grading scale for erythema,
scaling, induration, and fissuring (5-point scale; 0 = none to 4 = marked/intense) at
weeks 1, 4, 8, 12 (end of treatment), and 14 (end of study)
Investigator's global assessment at weeks 1, 4, 8, 12, and 14
Participant-rated visual analogue scale (VAS) of pruritus
Participant-rated improvement
Adverse events
 
Notes Pilot study on maintenance therapy. Exact numbers of results for main outcomes not
given - only whether there was a statistically significant difference between the 2
interventions
The study did include the secondary outcomes reduction in severity, investigator and
participant-rated and time until relapse, but we were unable to reproduce these data
Declarations of interest: study authors received research, speaking, and/or consulting
support from various pharmaceutical companies
Funding: the study was supported by a grant from Astellas Pharma Inc.
Sample size rationale: not stated
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Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "the randomization code list, correlating the kit number with the
content of each kit, was kept on file at Fuijsawa Healthcare Medical
Information Department until the time of analysis"
Comment: reference to a randomisation code list
 
Allocation concealment (selection
bias)
Low risk Quote: "the vehicle and tacrolimus ointments were packaged in identical
containers labelled with the subject number, so neither the subject,
coordinator, nor the investigator knew which treatment the patient
received"
Comment: randomisation was remote from the participant-recruitment
centre. Vehicle and tacrolimus were packaged in pre-labelled identical
containers corresponding to a participant number
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "the vehicle and tacrolimus ointments were packaged in identical
containers labelled with the subject number, so neither the subject,
coordinator, nor the investigator knew which treatment the patient
received"
Comment: double-blinded; this is considered an adequate blinding
method
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "the vehicle and tacrolimus ointments were packaged in identical
containers labelled with the subject number, so neither the subject,
coordinator, nor the investigator knew which treatment the patient
received"
Comment: by the use of pre-labelled and identical containers, observers
were blinded
 
Incomplete outcome data (attrition
bias)
High risk No intention-to-treat analysis but per protocol (20 of 33 = less than 80%)
 
Selective reporting (reporting bias) Low risk No trial registration found. All relevant outcomes described in the
Materials section are described in the Results section
 
Other bias Unclear risk Baseline comparisons: at baseline, significant difference between groups
for demographic characteristics was given. All participants had a
combined symptom severity score of 5 to 16
Diagnostic certainty: yes
The study was completed
 
Kucharekova 2003
Methods Parallel-group, randomised controlled trial
This study was carried out in a secondary care setting; it was a single-centre study.
This study was conducted in the Netherlands
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Participants 32 participants with bilateral chronic hand dermatitis for more than 6 months, with mild
to moderate severity and good response to topical steroids
Dropouts: 6
Inclusion criteria of the trial
Mild to moderate bilateral hand dermatitis since > 6 months
Good response to class I or II topical corticosteroids
Exclusion criteria of the trial
Clinically relevant allergic or irritant contact dermatitis with inability to avoid
exposure
Severe and very severe hand eczema
Severe vesiculation or bullae
History of contact urticaria and pustular disease
Recent therapy with class III or IV topical corticosteroids
Recent systemic therapy or phototherapy
Study population
Gender: 22 female, 10 male
Age: mean 39.15 years, range 19 to 65 years
 
Interventions Intervention
• Emollient with ceramides twice daily for 2 months in 14/17 participants
• Traditional pet-based emollient in 12/15 participants
Both groups were allowed to use triamcinolone ointment in case of active dermatitis
Duration
2 months
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Participant-rated efficacy of response (1 = worse, 2 = no change, 3 = minimal
improvement, 4 = moderate improvement, 5 = marked improvement, 6 = clearing or
almost clearing)
Participant-rated cosmetic acceptability (very poor, poor, acceptable, good,
excellent)
Participant-rated use of corticosteroids and emollients
Participant-rated severity of itch
Observer-rated global assessment of severity with the Investigator Global
Assessment (IGA) (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe,
5 = very severe) at baseline, after 1 and 2 months
Observer-rated Hand Eczema Area and Severity (HEAS) score, which divides the
hands into 7 areas; involvement was assessed for each area on a scale of 0 to 4. In
each area, intensity of erythema, vesicles, papules, scaling, fissures, excoriations,
and hyperkeratosis was scored on a of 0 to 3 scale (0 = none, 1 = slight, 2 =
moderate, 3 = severe). The affected area was multiplied by a correction factor and
by the sum of intensities of symptoms. Finally, all areas were added up, resulting in
a total symptom score
Adverse events
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Notes Unclear about 2 dropouts. Study authors state that this is a pilot study. Analysis may
have been intention-to-treat, but procedure unclear. Results presented graphically,
without exact numbers. Accuracy of the statistics is unclear because all between-
group comparisons were conducted at each time individually rather than comparing
difference scores between groups.
The primary outcomes percentage of participants with self-rated and observer-rated
improvement and the secondary outcomes reduction in severity, investigator-rated and
participant-rated, were included in the study, although no useable data were provided.
Data were given in a graphic presentation; no exact figures were given
Study authors were contacted for additional information on 4 March 2014 and
responded 10 March 2014
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "patients were randomised into 2 groups"
Comment: no further details given in the article. Personal communication
with the study author revealed that sealed, numbered envelopes were
used
 
Allocation concealment (selection
bias)
Low risk No details in the article about how allocation was concealed from
participants and clinicians; personal communication clarified that the study
author used sealed envelopes that were distributed after informed consent
was obtained. Participants did not know the randomisation before signing
informed consent but became aware of the allocation afterwards
 
Blinding of participants and
personnel (performance bias)
High risk Observer-blinded, but not participant-blinded. Participants were aware of
their treatment, and the study nurse who distributed study drugs was
aware of the treatment arms
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "the same study investigator blindly assessed the dermatitis at
various time-points"
Comment: observer-blinded. Personal communication clarified that the
study nurse was responsible for distribution of study drugs; outcomes
were observed by a third person
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (26 of 32 = more than 80%)
 
Selective reporting (reporting bias) Low risk No trial registration found; no major differences between Methods and
Results sections
 
Other bias Unclear risk Baseline comparisons: no baseline comparisons regarding group
differences (randomisation check)
Diagnostic certainty: yes
The study was completed
 
Lauriola 2011
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Methods Parallel-group, randomised controlled trial
This study was carried out in a secondary care setting at a single centre in Italy
 
Participants 40 participants with mild to moderate atopic dermatitis of hands
No dropouts
Inclusion criteria of the trial
Participants aged 18 years or older
Mild to moderate atopic dermatitis of hands, grading 3.0 to 5.0
Exclusion criteria of the trial
Topical treatment in the last 10 days
Systemic treatment in the last 2 weeks
Study population
Gender: not stated
Age: not stated
 
Interventions Intervention
• Furpalmate-containing creams (0.3%) twice a day for 14 days in 20 participants
• Corticosteroid (hydrocortisone acetate 0.5%) twice a day for 14 days in 20
participants
Duration
2 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Observer-rated: physician's global evaluation of clinical response and of individual
signs (erythema, xerosis)
Participant-rated assessment of itch (VAS)
Global response (unclear whether observer or participant rated)
Tolerability (adverse events)
Cosmetic compliance (unclear whether observer or participant rated)
 
Notes Conference abstract, from which only limited information can be extracted
The secondary outcomes - reduction in severity, participant- and investigator-rated -
were included but did not provide reproducible data
Study authors were contacted on 28 February 2014 but were not responsive
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "a single-center, randomized, prospective, investigator blinded,
controlled trial..."
Quote: "...patients were randomly allocated..."
Comment: study authors stated randomised but gave no clear
description of how this was attained
 
Allocation concealment (selection
bias)
Unclear risk No details of how allocation was concealed from participants and
investigators
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quote: "a single-center, randomized, perspective, investigator blinded,
controlled trial..."
Comment: study authors stated investigator-blinded; participants were
not blinded (open-label?), although this is not clear
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "a single-center, randomized, prospective, investigator blinded,
controlled trial..."
Comment: the article states only that the study was done in an
investigator-blinded way. We considered this as insufficient information
to judge this risk of bias
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "all patients completed the study period"
Comment: all participants completed the study
 
Selective reporting (reporting bias) High risk No trial registration found. The abstract is very concise, and not all
outcomes listed in the Methods section are described in the Results
section, for example, cosmetic aspects or adverse events
 
Other bias Unclear risk Baseline comparisons: no baseline comparisons regarding group
differences (randomisation check)
Diagnostic certainty: yes
The study was completed
 
Lindelöf 1987
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Methods Within-participant, randomised controlled study
This study was carried out in a secondary care setting at a single centre. The study
was conducted in Sweden
 
Participants 24 participants with chronic hand eczema (13 allergic, 5 atopic, 3 irritant, 2 tylotic, 1
pompholyx)
Dropouts: 1
Inclusion criteria of the trial
Chronic symmetrical hand eczema unresponsive to topical steroids
Stable for at least 3 months
Exclusion criteria of the trial
Not defined
Study population
Gender: not stated
Age: not stated
 
Interventions Intervention
• Ionising radiation (Grenz rays, 300 rad) 1× weekly for 6 weeks in 23/24 hands
Control intervention
• Placebo radiation once a week for 6 weeks in 23/24 contralateral hands
Participants were followed up to 10 weeks after initial treatment
Duration
10 weeks (6 weeks active treatment, 4 weeks follow-up)
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Observer-rated severity score (0 = no symptoms, 4 = very severe symptoms for
erythema, scaling, itching, vesicles, fissures, and distribution (size of area
involved)) at week 5 and week 10
Comparison of number of participants who are better on the treated hand versus
number of participants who are better on the placebo hand
Adverse events
 
Notes The secondary outcome - reduction in severity, investigator-rated - was included but
provided no reproducible data. Total scores are only graphically presented, without
statistical analysis
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "the treatments were administered by a nurse according to a
predetermined randomized code unknown to both patients and doctors"
Comment: reference to a predetermined randomisation code
 
Allocation concealment (selection
bias)
Low risk Quote: "the treatments were administered by a nurse according to a
predetermined randomized code unknown to both patients and doctors"
Comment: by including a third person, neither the physician/observer, nor
the participants can be aware of the treatment allocation. Therefore we
considered this as low risk of bias
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "the treatments were administered by a nurse according to a
predetermined randomised code unknown to both patients and doctors"
Comment: double-blinded. Placebo therapy was achieved by "allowing the
apparatus to hum without emitting radiation", which could be considered
as adequate; however the treatments were administered by a nurse who
was aware of the predetermined randomised code. Although one might
argue that part of the staff was aware of the treatment allocation, we
decided this is the best way to blind participants
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "the treatments were administered by a nurse according to a
predetermined randomized code unknown to both patients and doctors"
Comment: the observer was blinded, and treatment was administered by
someone else
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (23 of 24 = more than 80%)
 
Selective reporting (reporting bias) Low risk No trial registration found. No major differences between the Methods and
Results sections
 
Other bias Low risk Baseline comparisons: as within-participant study not applicable
Diagnostic certainty: yes
The study was completed
 
Lodén 2012a
Methods Parallel-group, randomised controlled trial
This study was carried out in a secondary setting at 4 outpatient clinics in Norway
This study consists of 2 parts (Lodén 2010); only the second part is included in this
review
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Participants 44 participants with a clinically proven history of hand eczema and a recent relapse
participated in part 1 of this trial
No dropouts
Inclusion criteria of the trial
Clinically proven history of hand eczema with a recent relapse
Daily use of moisturising treatment
Either gender
Age 18 or older
Written informed consent
Exclusion criteria of the trial
Possible allergy to ingredients in the study medications
At study start, active psoriatic lesions or active atopic eczema lesions on the hands
Active bacterial, fungal, or viral infection of the hands
Participants who are pregnant or breastfeeding, or who plan to become pregnant
during the course of the study
Use of any concomitant medication that may interfere with study-related activities or
assessment of efficacy
Any participant-related factor suggesting potentially poor compliance with study
procedures (e.g. psychiatric disorders, history of alcohol or substance abuse)
Any serious medical condition that, in the opinion of the investigator, may interfere
with evaluation of results
Inclusion in a study of an investigational drug within 60 days before the start of
treatment
Study population
Gender: 27 female, 17 male
Age: mean 46 years, range 22 to 76 years
 
Interventions Intervention
• Betamethasone 0.1% cream twice daily in 22 participants during 2 weeks
• Betamethasone 0.1% cream once daily + urea 5% cream once daily in 22
participants during 2 weeks
Duration
2 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Participant-rated severity on a 100-mm visual analogue scale (VAS), where 0 was
no eczema and 100 extreme severe eczema. This was done daily
Investigator-rated severity of Hand Eczema Extent score (HEES); clearance was
defined as a score ≤ 3
Participant-rated quality of life using the validated Dermatology Life Quality Index
(DLQI) at baseline and after 2 weeks
 
Notes Short duration of 2 weeks
Declarations of interest: study authors were paid consultants or employees of ACO
Hud Nordic AB
Funding: the study was funded by ACO Hud Nordic AB (manufacturer of the study
drug) and by Knowledge Foundation, Stockholm, Sweden
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "the coded tubes were sequentially numbered according to a
randomization list which was prepared and retained by the contract
research organization"
Comment: reference to a prepared randomisation list
 
Allocation concealment (selection
bias)
Low risk Quote: "the coded tubes were sequentially numbered according to a
randomization list which was prepared and retained by the contract
research organization"
Comment: the randomisation list was prepared and retained by the
contract research organisation. The tubes were coded and sequentially
numbered, and the clinicians who dispensed the tubes to participants
were blinded. This is considered as low risk of selection bias because
randomisation was done at a remote site
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "the patients, the clinicians, those assessing the outcomes and
those making the data analyses were blinded"
Quote: "the treatment was double-blinded and combined with a
moisturizer cream (M) (5% urea, Canoderm, ACO Hud AB, Sweden). All
patients received two coded tubes; one for evening applications, labelled
‘evening’ and containing BV and one for morning applications, labelled
‘morning’ and containing either BV or M. The creams had a similar texture,
were white and did not contain perfume"
Comment: double-blind design. The different creams were identical in
appearance and were labelled by a contract research organisation
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "the patients, the clinicians, those assessing the outcomes and
those making the data analyses were blinded"
Comment: the observations and the data analysis were conducted by
blinded assessors
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "all included participants received treatment and were analysed"
Comment: no dropouts
 
Selective reporting (reporting bias) Unclear riskThe trial was registered on clinicaltrials.gov (NCT00576550) as part
2. The primary outcomes registered in the trial register are for part 1
of the study (Lodén 2010), not for part 2. Therefore it is difficult to judge
the risk of reporting bias
In the article, there are no major discrepancies between the Methods and
Results sections
 
Other bias Unclear riskBaseline comparisons: no baseline comparisons regarding group
differences (randomisation check)
Diagnostic certainty: yes
The study was completed
 
Möller 1983
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Methods Within-participant, randomised controlled trial
This study was carried out in a secondary care setting; it was a multi-centre study
involving 14 dermatological centres in Sweden
 
Participants 55 participants with chronic symmetrical hand eczema > 6 months, who had been
treated with clobetasol twice daily in a preceding 3-week healing phase; 46
participants completed the trial
Dropouts: unclear on status of 9 withdrawals
Inclusion criteria of the trial
Symmetrical hand eczema of at least 6 months' duration
Exclusion criteria of the trial
Not defined
Study population
Gender: not stated
Age: not stated
 
Interventions Intervention
• Clobetasol propionate cream twice weekly for unclear duration (55 to 193 days) in
46/55 hands
• Fluprednidene acetate cream twice weekly in 46/55 contralateral hands
Emollients were allowed on both hands
When relapse occurred during the maintenance phase, the cream allocated to that
hand could be applied more frequently; if this failed, the cream of the other (best) hand
could be used temporarily
Duration
Unclear
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Number of hands that relapsed, and time of relapse
Efficacy judgement (not specified) by a dermatologist, at unknown point in time
Adverse events
 
Notes Study on maintenance therapy. Handling of dropouts unclear: 9 participants were
withdrawn because of unsatisfactory results (this could be an outcome). Study
duration unclear. Difficult to interpret results for participants with relapses. Unclear
which of the 2 treatments was the intervention or the comparator
The secondary outcomes - reduction in severity investigator-rated and time until
relapse - were included in the study but did not provide reproducible data
Declarations of interest: 2 authors were employees of Glaxo Läkemedel AB, Mölndal,
Sweden
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "the side distribution was randomly allocated..."
Comment: no further details given
 
Allocation concealment (selection
bias)
Low risk Quote: "the side distribution was randomly allocated and the creams
were provided in coded samples of identical appearance except for the
pairing in ‘left’ and ‘right’"
Comment: allocation was likely concealed
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "...identical appearance...."
Comment: double-blind study in which an identical looking placebo was
used
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "...double-blind study..."
Comment: although the study claims to be double-blind, no information
was given about how observers were blinded
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (46 of 55 = more than
80%)
 
Selective reporting (reporting bias) High risk No trial registration found. It is not clear from the Methods section which
are outcomes from the study, and the Results section contains various
parameters that are not described in the Methods section
 
Other bias Low risk Baseline comparisons: within-participant study not applicable
Diagnostic certainty: yes
The study was completed
 
NCT01231854
Methods Parallel-group, randomised controlled trial
This study was conducted at a single centre in Germany
 
Participants The study planned on 78 participants with severe atopic hand dermatitis but ended
prematurely
Included: 15
Dropouts: 6
Inclusion criteria of the trial
Male and female
Age > 18 years and ≤ 75 years
Body weight 50 to 100 kg
Chronic hand dermatitis (duration > 6 months)
Atopic constitution according to Erlanger Atopiescore 1 and/or positive personal
history for atopic eczema, allergic rhinitis, allergic asthma, and/or elevated serum
IgE
Severe hand dermatitis not responding to treatment with potent topical steroids for
at least 4 weeks within the past 6 months due to IGA
Written informed consent
Exclusion criteria of the trial
Participation in another clinical trial within past 4 weeks
Pregnancy/breastfeeding
Women of reproductive age except those who fulfil at least 1 of the following criteria
throughout the total study and until at least 5 weeks after active study treatment in
case of early study termination: post-menopausal women (12 months physiological
amenorrhoea or 6 months amenorrhoea with serum FSH level > 40 mlU/mL),
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postoperative (6 weeks after bilateral ovariectomy with or without hysterectomy),
regular and proper use of at least 2 methods of contraception, including at least 1
method of contraception with a failure rate < 1% per year (e.g. implants, depot
preparations, oral contraceptives, IUD), or vasectomy of the partner. Women of
reproductive age who do not meet all of the following criteria throughout the whole
study or - in case of early study termination - up to 5 weeks after active therapy:
The participant understands the teratogenic risk associated with taking the study
medication
The participant understands the need for strict monthly monitoring, the need for
reliable, continuous contraception, and the need for regular pregnancy tests
throughout the study and - in case of early study termination - up to 5 weeks of
active therapy
The participant is able to adequately and reliably apply methods of contraception
The participant is informed about the possible consequences of pregnancy and
knows that she must immediately contact her physician in case of suspected
pregnancy
The participant gives informed consent about knowing the potential risks and
necessary measures to avoid pregnancy
Blood and/or plasma donation during the whole study period. In case of early study
termination, blood and plasma donation is not allowed until 1 month after the end of
active study treatment
UV therapy within the past 3 months
Concurrent photo- and/or photochemotherapy
Known hypersensitivity/intolerance against cyclosporin, alitretinoin, or any other
ingredients of Immunosporin or Toctino
Known allergy against peanuts or soya
Known hereditary fructose intolerance
Acute and/or uncontrolled chronic infectious disease
Known congenital or acquired immune deficiency
Malignant tumour (past or present)
Uncontrolled arterial hypertension (RR systolic ≥ 160 mmHg and/or RR diastolic ≥
90 mmHg despite anti-hypertensive treatment)
Renal insufficiency (serum creatinine above normal range)
Liver insufficiency (CHILD ≥ Stadium B)
Not sufficiently controlled hyperlipidaemia (LDL/HDL ratio > 4 despite medical
treatment)
Clinically significant thyroid hypofunction
Known hypervitaminosis A
Concurrent supplementation of vitamin A or treatment with other retinoids
Concurrent tetracycline therapy
Concurrent therapy with St. John's wort ("Johanniskraut")
Known genetic diseases causing increased UV light sensitivity such as xeroderma
pigmentosum, Cockayne syndrome, Bloom syndrome
Known drug and/or alcohol abuse
Known significant psychiatric morbidity
Study population
Gender: cyclosporin group 1 female, 6 male; alitretinoin group 4 female, 3 male
Age: cyclosporin group mean 42.1 years, SD 13.9 years; alitretinoin group mean
33.1 years, SD 12.7 years
 
Interventions Intervention
• Oral cyclosporin depending on body weight: 50 to 74.9 kg: daily dosage 200 mg; 75
to 100 kg: daily dosage 300 mg (7 participants)
• Oral alitretinoin 30 mg once daily in 8 participants
Duration
24 weeks
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Outcomes Primary outcome of the trial
Proportion of participants with complete or almost complete clearance according to
the Investigator Global Assessment (IGA) within 24 weeks of active therapy in both
groups
Secondary outcomes of the trial
Time to complete or almost complete clearance according to IGA in both groups
Proportion of participants with complete or almost complete clearance according to
the Patient's Global Assessment (PGA) within 12 weeks and 24 weeks of active
therapy
Mean relative change in objective disease severity by means of the Hand Eczema
Severity Index (HECSI) between baseline and weeks 4, 8, 12, 16, 20, and 24 in
both groups
Mean relative change in quality of life (Skindex 17) between baseline and week 24
in both groups
Cost-effectiveness of studied treatment options (cost/QALY gained; assessed by
the EQ-5D)
Mean relative change in work productivity (assessed by the work limitations
questionnaire (WLQ)) in both groups
Mean utilisation of topical steroids within the follow-up period in both groups
Participant satisfaction with treatment in both groups (assessed using a 100-mm
VAS)
Proportion of participants with relapse (≥ 75% of baseline HECSI) within 24-week
follow-up after previous complete/almost complete clearance
For participants with atopic dermatitis on the body: measured percentage of
participants with at least 50% improvement in disease severity with active therapy
using SCORAD
Tolerability and safety in both study groups
 
Notes The study was ended prematurely. According to the sample size calculation, 78
participants should have been included; however only 15 participants were included,
and 14 were analysed. Results are not yet published. The study author released the
preliminary study results in personal communication and is aware of the fact that the
data are used in this review. The secondary outcome - reduction in severity,
investigator-rated - was included, but we were unable to reproduce the data
Declarations of interest: not stated
Funding: TU Dresden, Germany
Sample size rationale: adequate, although the needed number of participants was not
included
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "during the baseline visit patients underwent central randomization
with the use of a randomization table with constant length of blocks and
stratification according to the patients’ body weights (50-74.9 kg vs.
75-100 kg) with equal allocation to ciclosporin and alitretinoin. The
allocation sequence was generated by the KKS Dresden utilizing the trial
software MACRO 3.0, and stored by the clinical trials pharmacist at the
Technical University Dresden"
Comment: random sequence generation method was considered
adequate
 
Allocation concealment (selection
bias)
Low risk Quote: "treatment packs were prepared and labelled at the pharmacy. The
research assistants used consecutively numbered packs to allocate new
participants to treatment groups"
Comment: study authors declared that they were blinded during allocation
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "participants and assessors were blinded to group assignment
during collection of the data"
Comment: drug dispensation was done by a third party (the pharmacist).
Unclear whether drugs were identical in appearance
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "participants and assessors were blinded to group assignment
during collection of the data. Database lock was on January 28, 2013.
Unblinding occurred on March 07, 2013 before data analyses"
Comment: the article claims that the observer had no access to the
randomisation list, and a third party was used for drug dispensation.
Unblinding occurred before data analyses
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "all analyses were performed on the Intention-to-Treat (ITT)
population. This population includes all patients that completed the
baseline visit and used the trial medication at least once during the study"
The study aimed to include 78 participants but was terminated early due to
inability to include this number of participants. Finally, 15 participants were
randomised and 1 withdrew before the study drug was used. The
intention-to-treat analysis included all participants who received the study
drug (14 of 15 participants)
Comment: intention-to-treat analysis
 
Selective reporting (reporting bias) Low risk The trial was registered under NCT01231854 before it was begun. We
found no major discrepancies between the trial register and the final study
report
 
Other bias High risk Baseline comparison: groups were comparable at baseline with regards to
disease severity
Diagnostic certainty: yes
The study was ended prematurely
 
Odia 1996
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Methods Within-participant, randomised controlled trial
This study was most likely conducted at a single centre in Germany, although this is
not clear from the article
 
Participants 20 participants with bilateral dyshidrotic hand eczema (13 male, 7 female). Atopic 7
and 9 with nickel allergy (4/9 also atopic)
No dropouts
Inclusion criteria of the trial
Mild to moderate dyshidrotic hand eczema in a stable phase
Poor response to steroid-free topical therapy
Exclusion criteria of the trial
Not defined
Study population
Gender: 7 female, 13 male
Age: range 18 to 30 years
 
Interventions Intervention
• One hand pulsed direct current iontophoresis, 20 times of 15 minutes each during 3
weeks in 20 hands
Control intervention
• No iontophoresis on 20 contralateral hands for 3 weeks
Both hands received steroid-free tar solution and zinc paste
Duration
3 weeks
 
Outcomes Primary outcomes of the trial
Observer rated: decrease in authors' special investigator-rated score: sum of score
points on vesicles, erythema, desquamation, itching, multiplied by size of affected
area, which will become known as the Dyshidrotic eczema Area and Severity Index
score (DASI)
Participant-rated severity of pruritus
 
Notes Unclear at which point in time outcome was assessed. Same scoring system (DASI)
was used in Adams 2007, Polderman 2003, and Schnopp 2002
The report did not provide any useful data for analyses, although the secondary
outcomes - reduction in severity, participant-rated and investigator-rated - were
included
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "...were subjected to tap water iontophoresis in a randomised one-
side comparison..."
Comment: no further details given
 
Allocation concealment (selection
bias)
Unclear risk No details about how allocation was concealed from participants and
clinicians
 
Blinding of participants and
personnel (performance bias)
High risk Participants received unilateral iontophoresis, so one side was left
untreated. Participants were allowed to use additional tar solutions and
zinc paste. This might have influenced the amount of additional topical
therapy used and thus the performance of the study
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "scoring was performed by a second investigator, who did not
know which side had been treated with iontophoresis"
Comment: observer-blinded: scorings were performed by a third person
who was not involved in the treatment
 
Incomplete outcome data (attrition
bias)
Low risk All included participants were analysed. (20 of 20 = 100%)
 
Selective reporting (reporting bias) Low risk No trial registration found. No major discrepancies between Methods and
Results sections
 
Other bias Low risk Baseline comparisons: within-participant study not applicable
Diagnostic certainty: yes
The study was completed
 
Pacor 2006
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Methods Parallel-group, randomised controlled trial
This study was carried out in a secondary care setting. It was a single-centre study
conducted in Italy
 
Participants 28 participants with moderate to severe nickel sulphate-induced allergic contact
dermatitis based on clinical history (hand eczema) and proven by patch testing,
resistant to topical corticosteroids
No dropouts
Inclusion criteria of the trial
Moderate to severe nickel sulphate-induced allergic contact dermatitis based on
clinical history (hand eczema) and prior patch testing
Resistant to topical corticosteroids
Exclusion criteria of the trial
Treatment with systemic corticosteroids, cytotoxic agents, or phototherapy within 6
weeks before participation
Previous treatment with tacrolimus
Pregnancy and lactation
Study population
Gender: 24 female, 4 male
Age: range 17 to 58 years
 
Interventions Intervention
• 0.1% tacrolimus ointment twice daily for 2 weeks in 14 participants
Control intervention
• Vehicle twice daily for 2 weeks in 14 participants
2 weeks of treatment was followed by 1 week of follow-up
Duration
3 weeks (2 weeks active treatment, 1 week follow-up)
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Participant's assessment of the following symptoms: erythema, oozing, scaling,
itching, on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe on a daily
diary card
Investigator's Global Assessment reduction in severity: 0 = no improvement, 1 =
mild improvement, 2 = marked improvement, 3 = complete remission
Adverse events
Frequency of rescue medication usage
 
Notes Unclear from the abstract whether all participants had hand eczema, but contact with
study authors confirmed that all participants had active hand eczema at the beginning
of the trial. Treatment started after a run-in period of 7 days
The primary outcome percentage of participants with participant-rated good/excellent
control and the secondary outcome - reduction in severity, investigator-rated - were
included in the study, but no reproducible data were provided
Study authors were contacted on 28 February 2014 and replied 2 March 2014
Declarations of interest: none declared
Funding: the study was supported by grants from the Ministero Italiano Universita e
Ricerca (MIUR)
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "a randomized, double-blind, placebo-controlled, parallel-group
study design..."
Comment: study authors state this is a randomised study but gave no
details in the article
Personal communication clarified that StatsDirect Statistical software was
used, which is considered to provide adequate random sequence
generation
 
Allocation concealment (selection
bias)
Low risk No details in the article about how allocation was concealed from
participants and clinicians. Personal communication revealed that the
personnel recruiting participants were unaware of treatment allocation
because this was done by a third party (the hospital pharmacist)
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "the test compounds were contained in opaque syringes and the
treatment was not distinguishable from placebo and was blinded for both
investigator and patients"
Comment: the authors state that the study uses a double-blind design.
The placebo ointment of tacrolimus was made of the same components
as the study drug, only without the active component. All personnel
involved in direct contact with participants were unaware of treatment
allocation. Only the pharmacist was aware of the allocation
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "the test compounds were contained in opaque syringes and the
treatment was not distinguishable from placebo and was blinded for both
investigator and patients"
Comment: the article claims to be double-blind. Personal communication
with the study author clarified that the outcomes were observed by a blind
observer and were analysed in blind
 
Incomplete outcome data (attrition
bias)
Low risk All participants completed the study (28 of 28 = 100%)
 
Selective reporting (reporting bias) Low risk No trial registration found. No major discrepancies between Methods and
Results sections
 
Other bias Low risk Baseline comparisons: no significant difference between groups in terms
of age, gender, and severity of hand eczema
Diagnostic certainty: yes
The study was completed
 
Pigatto 1990
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Methods Parallel-group, randomised controlled trial (3 groups)
This study was carried out in a secondary care setting at 1 centre in Italy
 
Participants 16+8 participants with dyshidrotic eczema (pompholyx) and positive patch test to
nickel, confirmed by reaction on oral challenge with nickel
No dropouts
Inclusion criteria of the trial
Hand eczema with palmar vesicles
Type IV allergy to nickel at 5% pet
Exclusion criteria of the trial
Not defined
Study population
Gender: unclear; in the entire study 21 female, 3 male, although 8 participants in
the control group should be excluded from the review
Age: unclear; female from 23 to 45.3 years of age, male from 28 to 50 years of age
 
Interventions Intervention
• Low-nickel diet for 3 months in 8 participants
• Oral disodium cromoglycate (DSCG) 1500 to 2000 mg 3× daily for 3 months in 8
participants
Control intervention
• No treatment for 3 months in 8 participants - not included in the review
Duration
3 months
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Observer-rated reduction in severity of itching: improvement/slight improvement/no
improvement in degree of itching every 2 weeks
Observer-rated number of vesicles in an area (exact location not stated) of 2 × 2 cm
every 2 weeks
Nickel urinary levels at beginning and at week 4
Differences in intestinal permeability in a subgroup of 10 participants at day 0 and
at day 15
Adverse events
 
Notes Unclear which of the 2 is intervention and which is comparator. The third group
consisted of participants who did not give consent for the interventions and was
observed without undergoing any treatment. This group was not randomised and
therefore was not included in the analysis
Unclear how the outcome 'Degree of itching' was assessed. In addition, an intestinal
permeability study was performed in 5 DSCG and 5 diet participants
The secondary outcome - reduction in severity, investigator-rated - was included but
no reproducible data were provided
The article states different numbers of participants included in intervention and control
groups (8;8;8 vs 8;9;7)
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "the patients were then randomly divided into 3 groups"
Comment: groups 1 and 2 were probably randomised; however, the third
group consisted of patients who did not give informed consent for the
study and therefore were not randomised. Group 3 is not included in the
analysis
 
Allocation concealment (selection
bias)
Unclear risk No details about how allocation was concealed from participants and
clinicians
 
Blinding of participants and
personnel (performance bias)
High risk Quote: "the patients avoided eating the foods indicated on a list, reduced
the quantity of vegetables and of dairy products, and avoided using
stainless steel utensils and ornaments"
Comment: because the intervention group in group A had to follow a low-
nickel diet with strict dietary restrictions for 3 months, blinding was not
possible
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "the patients were evaluated blind by an observer...."
Comment: observer blinded but no further details
 
Incomplete outcome data (attrition
bias)
Low risk None of the participants dropped out, and all included participants were
analysed (16 of 16 = 100%)
 
Selective reporting (reporting bias) Low risk No trial registration found. No major differences between Methods and
Results sections
 
Other bias Unclear risk Baseline comparisons: no baseline analyses regarding group differences
(randomisation check)
Diagnostic certainty: yes
The study was completed
 
Polderman 2003
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Methods Parallel-group, randomised controlled trial
This study was carried out in a secondary care setting at a single dermatology clinic in
the Netherlands
 
Participants 28 participants with dyshidrotic hand eczema, with duration of 4 months to 34 years
Dropouts: 3
Inclusion criteria of the trial
Dyshidrotic hand eczema
Exclusion criteria of the trial
Younger than 18 years old
Use of systemic immunosuppressive or immunomodulating medication in the last 2
months
Pregnancy
History of UV sensitivity or skin malignancy
Study population
Gender: not stated
Age: not stated
 
Interventions Intervention
• UVA-1 irradiation 40 J/cm² on the hands in 15/15 participants 5 times weekly for 3
weeks
Control intervention
• Placebo (simulated blue light) in 10/13 participants
Emollients probably were allowed in both groups
Participants were followed until 6 weeks after the end of treatment
Duration
9 weeks (3 weeks active treatment, 6 weeks follow-up)
 
Outcomes Primary outcomes of the trial
Observer-rated severity by the dyshidrotic eczema area and severity index (DASI;
based on sum score for severity 1 = mild, 2 = moderate, 3 = severe for,
respectively, vesicles, erythema, desquamation, itch, multiplied by score for
affected area); time point unclear
Other outcomes
VAS for itch (probably participant-rated) at the end of each week and 3 and 6
weeks after treatment
Observer-rated reduction in severity for separate items of DASI at the end of each
week and 3 and 6 weeks after treatment
Adverse events
 
Notes Primary outcome probably at week 3 (i.e. at end of treatment). Analysis based on
intention-to-treat principle. There was a follow-up 6 weeks after treatment, but only
summary data were given for the treatment group
Study authors were contacted on 28 February 2014 but remained not responsive
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "they were randomly assigned to either UVA-1 (n=15) or placebo
treatment (n=13) by an independent investigator using a lottery system"
Comment: reference to a lottery system, which is an adequate way to
prevent selection bias
 
Allocation concealment (selection
bias)
Low risk Quote: "they were randomly assigned to either UVA-1 (n=15) or placebo
treatment (n=13) by an independent investigator using a lottery system"
Comment: participants were assigned to different study arms by an
independent investigator using a lottery system
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "placebo treatment comprised of TL tubes, emitting visible light,
covered with a blue plastic plate to mimic the blue UVA-1 light"
Comment: participants: placebo design to mimic the intervention;
participants wore protective eyewear and protection on their forearms
during both interventions. For participants, the placebo is probably
indistinguishable from the actual treatment; however personnel who
delivered the treatment were not blinded. Given that the staff had to
administer the treatment, and we could not think of a better way to blind
participants and staff, this was considered as low risk
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "a blinded investigator was responsible for the evaluation of the
parameters"
Comment: observer-blinded; this was another person, then the one who
assigned participants to treatment arms
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "analysis was performed according to the intention-to-treat
principle"
Comment: intention-to-treat analyses
 
Selective reporting (reporting bias) Unclear
risk
No trial registration found. No major differences between Methods and
Results sections for results during the treatment phase, except that results
6 weeks after treatment are very scarce. Study authors remarked that for
ethical reasons, a lot of participants were prescribed topical
corticosteroids; therefore these results are less reliable and probably are
poorly reported
 
Other bias Unclear
risk
Baseline comparisons: no baseline comparisons regarding group
differences (randomisation check)
Diagnostic certainty: yes
The study was completed
 
Ruzicka 2004
Methods Randomised controlled, parallel-group design study of 1 placebo group and 3
treatment groups given different doses of the same (oral) medicament
This study was carried out in a secondary care setting
This was a multi-centre study involving 43 clinics in Belgium, Denmark, Finland,
France, Germany, Holland, Hungary, Poland, Switzerland, and the United Kingdom
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Participants 319 participants (235 male, 84 female) with moderate or severe chronic hand
dermatitis of at least 3 months' duration and refractory to standard therapy. All types of
hand dermatitis
Dropouts: 75
Inclusion criteria of the trial
Moderate or severe hand eczema for at least 3 months
Refractory to standard therapy
18 to 70 years of age
Exclusion criteria of the trial
Well defined
Study population
Gender: placebo group 22 female, 56 male; alitretinoin 10 mg group 24 female, 56
male; alitretinoin 20 mg group 21 female, 59 male; alitretinoin 40 mg group 17
female, 64 male
Age: placebo group mean 48.7 years; alitretinoin 10 mg group mean 48.7 years;
alitretinoin 20 mg group mean 46.7 years; alitretinoin 40 mg group mean 48.7 years
 
Interventions Intervention
• Oral alitretinoin 10 mg daily for 12 weeks in 62/80 participants
• Oral alitretinoin 20 mg/d in 67/80 participants for 12 weeks
• Oral alitretinoin 40 mg/d in 63/81 participants for 12 weeks
Control intervention
• Placebo capsules in 62/78 participants for 12 weeks
Standard emollients were allowed in all treatment groups
Responders were followed up for 3 months
Duration
6 months (12 weeks active treatment, 3 months follow-up)
 
Outcomes Primary outcomes of the trial
Responders according to physician global assessment of overall severity, whereby
physician global assessment is categorised as clear, almost clear, mild, moderate,
or severe. Responders are defined as clear or almost clear at week 12 or at last
evaluation
Secondary outcomes of the trial
Observer-rated total lesion symptom score: sum of scores (0 = absent, 1 = mild, 2 =
moderate, 3 = severe) for erythema, oedema, vesicles, desquamation,
hyperkeratosis, fissures, and pruritus/pain
Participant-rated global assessment: clearing or almost clearing (> 90% clearing of
signs and symptoms compared with baseline), marked improvement (> 75%),
moderate improvement (> 50%), mild improvement (> 25%), no change, worsening
Observer-rated extent of disease: total percentage involvement of palm and dorsum
of both hands
Dermatological life quality index (DLQI)
Adverse events
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Notes No other active treatment as comparator. More males enrolled because of exclusion of
women of child-bearing potential. Study included a safety assessment by careful
medical and laboratory monitoring. Analysis of efficacy based on intention-to-treat
principle
Of the 127 responders, 117 were followed up for another 12 weeks after end of
treatment; only summary data about this extra follow-up are presented
Declarations of interest: some study authors were employees, received grants, or had
received consultancy fees from Basilea Pharmaceutica
Funding: the study was supported and funded by Basilea Pharmaceutica Ltd., Basel,
Switzerland, manufacturer of the study drug
Sample size rationale: provided
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "eligible patients were randomized to treatment by center, in blocks
of 4 without stratification, by use of computer-generated randomization
codes...."
Comment: computer-generated randomisation codes
 
Allocation concealment (selection
bias)
Low risk Quote: "eligible patients were randomized to treatment by center, in blocks
of 4 without stratification, by use of computer-generated randomization
codes provided by the study sponsor (Basilea Pharmaceutica Ltd, Basel,
Switzerland) and incorporated into double-blind coded drug packaging"
Comment: the site staff had no direct access to randomisation codes
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "placebo and active drug (as soft gelatine capsules) and packaging
were indistinguishable"
Comment: participant blinding. The double-blind coded packages were
provided by the sponsor, which blinded site personnel and participants
sufficiently
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "design: multicenter, randomized, double-blind, placebo-control,
prospective trial"
Comment: observers were blinded during the study because the identical
looking package of study drugs was provided by a third party. One might
argue that the observer could have guessed the treatment group due to
headache and dry mucosa; however this was also seen in the control
group and therefore was not conclusive. The trial was designed in such a
way to minimise risk of bias; we agree that this could not have been done
in a better way
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "all statistical tests were 2 sided and based on a level of .05 and
were carried out using SAS (version 8.1; SAS Institute Inc, Cary, NC) with
the intention-to-treat population"
Comment: intention-to-treat analysis
 
Selective reporting (reporting bias) Low risk No trial register found. No major discrepancies between Methods and
Results sections
 
Other bias Low risk Baseline comparisons: no significant differences between groups in
demographic or disease characteristics Diagnostic certainty: yes
The study was completed
 
Ruzicka 2008
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Methods Parallel-group, randomised controlled trial including 1 placebo group and 2 treatment
groups given different doses of the same (oral) retinoid
This study was carried out in a secondary care setting
This was a multi-centre study at 111 clinics in Europe and Canada
 
Participants 1032 participants (582 male, 450 female) with severe chronic hand dermatitis of at
least 6 months' duration and refractory to standard therapy. All types of hand
dermatitis
Dropouts: 273
Inclusion criteria of the trial
Severe chronic hand eczema refractory to standard therapy
18 to 75 years of age
Exclusion criteria of the trial
Well defined
Study population
Gender: placebo group 84 female, 121 male; alitretinoin 10 mg group 180 female,
238 male; alitretinoin 30 mg group 186 female, 223 male
Age: placebo group mean 48 years, SD 12 years; alitretinoin 10 mg group mean 47
years, SD 13 years; alitretinoin 30 mg group mean 48 years, SD 13 years
 
Interventions Intervention
• Oral alitretinoin 10 mg once daily for 12 or 24 weeks (depending on moment of
response according to the PGA) in 319/418 participants
• Oral alitretinoin 30 mg/d in 303/409 participants for 12 or 24 weeks
Control intervention
• Placebo capsules in 137/205 participants for 12 or 24 weeks
Standard emollient in all treatment groups
All participants were followed up for 4 weeks, and responders were observed for
relapses for 24 weeks after end of treatment
Duration
Up to 48 weeks (12 to 24 weeks of active treatment, up to 24 weeks of follow-up)
 
Outcomes Primary outcome of the trial
Responders according to physician global assessment of overall severity, whereby
physician global assessment is categorised as clear, almost clear, mild, moderate,
or severe. Responders are defined as clear or almost clear at week 12 or at last
evaluation
Other outcomes
Time to response
Partial response (PGA assessment of clear, almost clear, or mild)
Observer-rated modified total lesion symptom score: sum of scores (0 = absent, 1 =
mild, 2 = moderate, 3 = severe) for erythema, oedema, vesicles, desquamation,
hyperkeratosis, fissures, pruritus/pain
Participant-rated global assessment: clearing or almost clearing (> 90% clearing of
signs and symptoms compared with baseline), marked improvement (> 75%),
moderate improvement (> 50%), mild improvement (> 25%), no change, worsening
Time to relapse
Observer-rated extent of disease: total percentage involvement of palm and dorsum
of both hands
Adverse events
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Notes No other active treatment as comparator. Analysis of efficacy based on intention-to-
treat principle. Study included a safety assessment by careful medical and laboratory
monitoring. More males were enrolled because of exclusion of women of child-bearing
potential
Declarations of interest: some study authors were employees, received grants, or had
received consultancy fees from Basilea Pharmaceutica
Funding: see above item
Sample size rationale: provided
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "eligible patients were randomized to treatment by centre, in blocks
of 5 without stratification, by the use of computer-generated randomization
codes provided by the study sponsor (Basilea Pharmaceutica)..."
Comment: computer-generated randomisation codes
 
Allocation concealment (selection
bias)
Low risk Quote: "eligible patients were randomized to treatment by centre, in blocks
of 5 without stratification, by the use of computer-generated randomization
codes provided by the study sponsor (Basilea Pharmaceutica) and
incorporated into double-blind coded drug packaging. Placebo, active drug
and packaging were indistinguishable. Investigators allocated
consecutively numbered packages of medication to patients in their order
of enrolment"
Comment: codes provided by study sponsor. Sequentially numbered
packages of different treatment modalities of identical appearance were
used
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "... incorporated into double-blind coded drug packaging. Placebo,
active drug and packaging were indistinguishable"
Comment: double-blinded; the identical looking packages were provided
by the sponsor and by site staff, and participants were unaware of the
treatment
 
Blinding of outcome assessment
(detection bias)
Low risk Observers were blinded during the study because the identical looking
package of study drugs was provided by a third party. One might argue
that the observer could have guessed the treatment group due to
headache and dry mucosa; however these were also seen in the control
group and therefore were not conclusive. The trial was designed in such a
way as to minimise risk of bias; we agree that this could not have been
done in a better way
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "all efficacy evaluations were based on the intent-to-treat
population. All randomized patients were included in this population, and
were analysed according to their randomization with last observation
carried forward (LOCF) in cases of missing data"
Comment: intention-to-treat analysis
 
Selective reporting (reporting bias) Unclear
risk
Trial registration on clinicaltrials.gov (NCT00124475). No differences in
primary outcomes; however small discrepancies in other outcomes
between trial registration and article
 
Other bias Low risk Baseline comparisons: no significant differences between groups in
demographic or disease characteristics Diagnostic certainty: yes
The study was completed
 
Said 2010
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Methods Parallel-group, randomised controlled trial
This study was carried out in a secondary care setting in a single dermatology
department in Singapore
 
Participants 47 participants with chronic vesicular hand eczema
Dropouts: 7
Inclusion criteria of the trial
Chronic vesicular hand eczema
Exclusion criteria of the trial
Not defined
Study population
Gender: not stated
Age: not stated
 
Interventions Interventions
• UVA-1 phototherapy 3 times a week for 6 weeks in 24 participants
• Betamethasone-valerate 0.1% cream twice a day for 6 weeks in 23 participants
Duration
6 weeks active treatment, 6 weeks follow-up. Total duration: 12 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Degree of improvement based on the Dyshidrotic Area and Severity Index (DASI) at
week 3, week 6, and week 12
Adverse events
 
Notes Conference abstract, from which only limited information can be extracted
We were unable to contact the study authors
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "twenty-four patients were randomly assigned to..."
Comment: insufficient data
 
Allocation concealment (selection
bias)
Unclear risk Insufficient data
 
Blinding of participants and
personnel (performance bias)
High risk Quote: "open-label study"
Comment: no blinding
 
Blinding of outcome assessment
(detection bias)
High risk Quote: "open-label study"
Comment: no blinding
 
Incomplete outcome data (attrition
bias)
Low risk More than 80% of participants were analysed (40/47)
 
Selective reporting (reporting bias) Unclear risk No trial register was found
 
Other bias Unclear risk Baseline comparisons: no baseline comparisons regarding group
differences (randomisation check)
Diagnostic certainty: no
The study was completed
 
Schnopp 2002
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Methods Within-participant, randomised controlled study
This study was carried out in a secondary care setting at a single dermatology
department in Germany
 
Participants 16 participants with moderate to severe chronic relapsing dyshidrotic eczema on
hands
No dropouts
Inclusion criteria of the trial
Moderate to severe chronic relapsing dyshidrotic hand eczema
Exclusion criteria of the trial
Use of topical glucocorticoids or any systemic treatment with possible influence on
the course of hand eczema
Study population
Gender: 15 female, 1 male
Age: mean 43 years, range 23 to 54 years
 
Interventions Intervention
• Tacrolimus 0.1% ointment twice daily on 12/12 hands for 4 weeks
• Mometasone furoate 0.1% ointment twice daily on 12/12 contralateral hands for 4
weeks
Follow-up period was up to 8 weeks after the end of treatment
Duration
12 weeks (4 weeks of active treatment, up to 8 weeks of follow-up)
 
Outcomes Primary outcome of the trial
Observer-rated dyshidrotic eczema area and severity index (DASI) at baseline,
week 2, and week 4 (based on sum-score for severity 1 = mild, 2 = moderate, 3 =
severe for, respectively, vesicles, erythema, desquamation, and itch multiplied by
score for affected area)
Other outcomes
Adverse events
 
Notes Originally, 20 participants with hand and/or foot involvement, 4 of whom were excluded
due to poor disease control during the trial-preceding washout phase. Study in 16
participants, of whom 12 had their hands involved. The limited data on the 4-week
post-treatment follow-up period are difficult to interpret. Outcome scores at week 4
presented graphically, without exact numbers Scoring of outcome (DASI) same as the
study by Odia
The secondary outcomes - reduction in severity, participant-rated, and time until
relapse - were included but did not provide reproducible data
Study authors were contacted 3 March 2014 and replied 4 March 2014
Declarations of interest: none declared
Funding: no funding
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "patients were randomly assigned....."
Comment: no further details were given in the article; however personal
communication with study authors clarified that they threw dice to create a
randomisation list
 
Allocation concealment (selection
bias)
Low risk No details in the article about how allocation was concealed from
participants and clinicians. Contact with study authors clarified that the
randomisation list was composed by a third person. This person was
involved in the distribution of study drugs, but not in the recruiting. The
third person held office in a different building of the hospital that was not
accessible for physicians
 
Blinding of participants and
personnel (performance bias)
High risk Quote: "this study was a randomized, observer-blinded, intraindividual
comparison study..."
Comment: participants were not blinded during the study
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "all assessments were performed by an independent observer on
separate sheets on different premises. Patients were instructed not to talk
about treatment modalities"
Comment: study authors clearly described how they tried to prevent
detection bias. Observers were blinded adequately
 
Incomplete outcome data (attrition
bias)
Low risk None of the participants dropped out during the study; all participants
were included in the analyses (16 of 16 = 100%)
 
Selective reporting (reporting bias) Low risk No trial registration found; however the DASI is a valid score for hand
eczema and was described in the Methods and Results sections without
major discrepancies
 
Other bias Low risk Baseline comparisons: within-participant study not applicable
Diagnostic certainty: yes
The study was completed
 
Sezer 2007
#29 Interventions for hand eczema
145 / 280
Methods Within-participant, randomised controlled study
This study was conducted in a secondary care setting at a single centre in Turkey
 
Participants 15 participants with chronic hand eczema of the dry or dyshidrotic type were
randomised
Dropouts: 3
Inclusion criteria of the trial
Diagnosis of biopsy-proven chronic hand eczema of dry and dyshidrotic types
Duration > 4 months
Resistant to conventional therapies
Exclusion criteria of the trial
Hyperkeratotic hand eczema
Treatment with topical corticosteroids in the prefacing 2 weeks
Treatment with systemic corticosteroids or other immunosuppressive agents within
the last 4 weeks
Unilateral disease
Pregnancy
Inability to meet for follow-up consultations
Study population
Gender: 6 female, 9 male
Age: range 18 to 73 years
 
Interventions Intervention
• Local narrow-band UVB 3 times a week for 9 weeks in 12/15 hands. The initial dose
was 150 mJ/cm² for each participant. A 20% increasing dose schedule was used until
a final dose of 2000 mJ/cm² was reached
• Local PUVA 3 times a week during 9 weeks in 12/15 contralateral hands. The initial
dose of psoralen plus UVA irradiation was 1.0 J/cm² with an increase of 0.5 J/cm² at
every second session until a final dose of 7.5 J/cm² was achieved
Participants who completed the treatment sessions were followed up for 10 weeks
after the last therapy
Duration
19 weeks (9 weeks of active treatment, 10 weeks of follow-up)
 
Outcomes Primary outcomes of the trial
Investigator-rated reduction in severity of a total sum score defined by degree of
erythema, desquamation, induration, fissuring, and itching, as scored on a 4-point
scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) in weeks 0, 3, 6, and 9
Investigator-rated number of participants with clearance defined as a total sum
score of 0; participants with marked improvement had a reduction of more than
70% at week 9
Number of relapses during follow-up phase
Adverse events
 
Notes Unblinded study with a small number of participants
Study author was contacted on 4 March 2014 by email, but we were unable to obtain
additional information
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "the NB-UVB and PUVA treatments were randomly assigned to
the left or right hand. The hand treated was selected using a computer-
based program..."
Comment: treatment was randomly assigned to the left or right hand
using a computer-based programme
 
Allocation concealment (selection
bias)
Unclear risk No details about how allocation was concealed from participants and
clinicians
 
Blinding of participants and
personnel (performance bias)
Unclear risk No information on whether participant- and/or observer-blinded study
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "clinical assessments were performed by the same investigator
(E.S.) every 3 weeks during the 9-week treatment period"
Comment: unclear. All observations were made by the same
investigator, although it is unknown whether this observer was aware of
the treatment modalities
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (12 of 15 = 80%)
 
Selective reporting (reporting bias) Low risk No trial registration found. No major differences between Methods and
Results sections
 
Other bias Low risk Baseline comparisons: at baseline, no significant differences between
groups in total clinical scores; however within-participant study not
applicable
Diagnostic certainty: yes
The study was completed
 
Sharma 2006
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Methods Parallel-group, randomised controlled trial
This study was carried out in a secondary care setting at a single centre in India
 
Participants 21 participants with proven nickel allergy by patch testing
No dropouts
Inclusion criteria of the trial
Chronic recurring vesicular hand eczema
Solely allergic to nickel as proven by patch testing
Exclusion criteria of the trial
Usage of prosthesis
Pregnancy
Lactation
History of alcoholism
Abnormal biochemistry (glucose and liver function tests) or blood counts
Study population
Gender: 15 female, 6 male
Age: mean 34.1 years, range 18 to 50 years
 
Interventions Intervention
• Low-nickel diet and disulphiram 125 mg daily in the first 2 weeks and 250 mg daily in
weeks 3 and 4 in 11 participants
Control intervention
• Normal diet and placebo tablet (lactose) for 4 weeks in 10 participants
Participants were followed up for 2 to 12 weeks after end of treatment
Duration
Up to 16 weeks (4 weeks of active treatment, 2 to 12 weeks of follow-up)
 
Outcomes Primary outcome of the trial
Investigator-rated (?) severity of hand eczema (total severity scores for the
parameters itching, vesicles, crusting, scaling, and fissuring) at baseline, week 2,
and week 4
Other outcomes
Adverse events
 
Notes Two weeks after the start of a low-nickel diet in the experimental group, disulphiram
was started for a duration of 4 weeks. Participants in the control group were treated
only with a placebo tablet during those 4 weeks. In addition, the low-nickel diet was
continued during follow-up (i.e. 12 weeks after disulphiram was stopped)
The secondary outcome - reduction in severity, investigator-rated - was included, but
the article did not provide reproducible data
Study authors were contacted for additional information with regards to the risk of bias
table
Declarations of interest: none declared
Funding: no funding
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "all the 21 patients were randomly divided in 2 groups"
Comment: no further details in the article. Personal communication with
study authors clarified that they had used a lottery system
 
Allocation concealment (selection
bias)
Low risk No details about how allocation was concealed from participants and
clinicians. Personal communication clarified that this was done by a third
person
 
Blinding of participants and
personnel (performance bias)
High risk Quote: "it was a comparative study and participants were not aware if
they belonged to study group or control group (single blind trial)"
Comment: participant blinding attempted with the use of placebo tablets
(lactose tablets), although participants in the control group were allowed
to continue with their normal diet, while the intervention group remained
on the low-nickel diet. Site personnel probably were not blinded
 
Blinding of outcome assessment
(detection bias)
High risk Quote: "it was a comparative study and participants were not aware if
they belonged to study group or control group (single blind trial)"
Comment: observers were not blinded
 
Incomplete outcome data (attrition
bias)
Low risk None of the participants dropped out, and all participants were included in
the analyses (21 of 21 = 100%)
 
Selective reporting (reporting bias) Unclear
risk
No trial registration found. In the Methods section, no clear description is
given of the outcome parameters; in the Results section, outcomes are
listed that are not described in the Materials section
 
Other bias Unclear
risk
Baseline comparisons: no baseline comparisons
Diagnostic certainty: yes
The study was completed
 
Sheehan-Dare 1989
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Methods Within-participant, randomised controlled trial. Hands were unit of randomisation and
analysis
This study was conducted at a single department of dermatology in the UK
 
Participants 25 participants with chronic constitutional hand eczema; participants with irritant or
allergic contact dermatitis were excluded
Dropouts: 4
Inclusion criteria of the trial
Bilateral and symmetrical chronic, constitutional vesicular palmar eczema for at
least 6 months with continued or episodic vesiculation
Resistant to topical emollients, steroid and tar preparations
Exclusion criteria of the trial
Irritant and allergic dermatitis
Study population
Gender: 14 female, 7 male
Age: mean 52.3 years, range 19 to 79 years
 
Interventions Intervention
• Topical PUVA thrice weekly for 6 weeks in 21/24 hands
• Radiotherapy 90 Rad 50 KV 3 times with 21-day interval in 21/24 contralateral hands
for 6 weeks
Participants were followed up until 18 weeks after initial treatment
Duration
18 weeks (6 weeks of active treatment, 12 weeks of follow-up)
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Participant-rated severity on linear analogue scale of 10 cm
Observer-rated severity score 0 to 4 (0 = normal skin; 1 = eczema, mild scaling,
and erythema; 2 = moderate scaling, erythema, and shallow fissures; 3 = severe
scaling, erythema, and deep bleeding fissures; 4 = active pompholyx) at baseline
and at weeks 6, 9, and 18
Adverse events
 
Notes The primary outcome adverse events and the secondary outcomes reduction in
severity, participant-rated and investigator-rated, were included but did not provide
reproducible data. Means of outcome scores were not given as exact figures but in a
graphical presentation
Declarations of interest: not stated
Funding: not stated
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "patients were randomly allocated topical PUVA to one hand and
superficial radiotherapy to the other using a pre-determined code"
Comment: participants were randomly allocated using a predetermined
code
 
Allocation concealment (selection
bias)
Unclear risk No details about how allocation was concealed from participants and
clinicians
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "the procedure was carried out in such a way that patients were
unable to tell which hand had received active treatment"
Quote: "the topical PUVA treated hand received sham radiotherapy
during which the X-ray machine appeared to function normally but the
power supply to the tube was interrupted such that no X-rays were
received by the patient"
Quote: "the superficial radiotherapy treated hand was treated with a
sham PUVA procedure. This consisted of an application of the organic
solvent base without psoralen 5 min prior to exposure to the light source"
Comment: participant blinding. We consider this an adequate way to
blind participants, although personnel probably were not blinded to
perform the procedures
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "patients were assessed by 2 observers (R.S-D and M.G) who
were unaware of the treatment status of each hand until the codes were
broken at the end of the study"
Comment: observer blinding; independent observers are considered an
adequate method for detection bias
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (21 of 25 = more than 80%)
 
Selective reporting (reporting bias) Low risk No trial registration found. No discrepancies between the Materials and
Results sections
 
Other bias Low risk Baseline comparisons: within-participant design not applicable
Diagnostic certainty: yes
The study was completed
 
Sjövall 1987
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Methods Parallel-group, randomised controlled trial (3 groups)
This study was carried out in a secondary care setting and was probably a single-
centre study in Sweden
 
Participants 18 participants (3 male, 15 female) with chronic hand eczema of different types
resistant to conventional therapy (11 patch test-proven relevant allergy, 4 atopic, 3
endogenous)
Dropouts: 3
Inclusion criteria of the trial
Chronic hand eczema
Resistant to conventional topical treatment with potent corticosteroids and
moisturisers
Exclusion criteria of the trial
Not defined
Study population
Gender: 15 female, 3 male
Age: mean 45 years, range 26 to 67 years
 
Interventions Intervention
• UVB irradiation only on hands 4 times a week for 8 weeks in 6 participants
• Filtered light (placebo UVB, no UVB) on the hands 4 times a week for 8 weeks in 6
participants
• Hand UVB followed by whole-body UVB + UVA 4 times a week during 8 weeks in 6
participants
Their 'ordinary topical treatment' was permitted in all groups
Three months after end of treatment, participants were mailed a questionnaire
regarding the course of their hand eczema and their opinions on treatment
Duration
8 weeks with an email follow-up after 3 months
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Observer-rated severity scoring system (0 = unchanged/worse, 1 = improved, 2 =
cleared) after 4 weeks (16 exposures), if a participant cleared before the end of the
study, or at 8 weeks (end of treatment after 32 exposures)
Participant-rated follow-up questionnaire 3 months after end of treatment, regarding
the course of hand dermatitis and the burden of treatment (time consuming)
Adverse events
 
Notes Small number of participants. Main table unclear: results at 8 weeks or at 20 weeks?
Follow-up at 3 months presented in a descriptive way, without exact details
Declarations of interest: not stated
Funding: the study was supported by grants from Alfred Österlund and Finsen
Foundations
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "the patients were randomly divided..."
Comment: no further details
 
Allocation concealment (selection
bias)
Unclear risk No details about how allocation was concealed from participants and
clinicians
 
Blinding of participants and
personnel (performance bias)
High risk Quote: "the whole device was covered by green clothes, thus making it
possible to perform a double blind trial between the patients in group 1
and 2"
Comment: the investigators covered the machine with green clothes; by
this method, 2 groups (A and B) were blinded; however the third group of
participants was not blinded because they received whole-body
irradiation. Staff probably was not blinded
 
Blinding of outcome assessment
(detection bias)
Unclear risk The investigators state a partly double-blind design; however it is unclear
how observers were blinded, and if they were independent observers
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (15 of 18 = more than 80%)
 
Selective reporting (reporting bias) Low risk No trial registration found. No major differences between Materials and
Methods sections
 
Other bias Unclear risk Baseline comparisons: no baseline comparisons
Diagnostic certainty: yes
The study was completed
 
Thestrup-Pedersen 2001
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Methods Parallel-group, randomised controlled trial
This study was conducted in a secondary care setting at 4 dermatology departments
or clinics in Denmark
 
Participants 29 participants (21 male, 8 female) with hyperkeratotic eczema on palms, patch-test
negative or irrelevant
No dropouts
Inclusion criteria of the trial
Hand eczema based on clinical diagnosis
Exclusion criteria of the trial
Allergic contact dermatitis
Study population
Gender: 8 female, 21 male
Age: median 54 years, range 30 to 76 years
 
Interventions Intervention
• Acitretin orally 30 mg daily for 8 weeks in 14/14 participants
Control intervention
• Placebo capsules for 8 weeks in 15/15 participants
Both groups were allowed to use topical emollients
Duration
8 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Mean observer-rated severity scores (0 = absent, 1 = slight, 2 = moderate, 3 =
severe) combined of these signs: hyperkeratosis, fissures, scaling, itch, redness,
and vesicles at week 4 and at week 8
Change in biochemical parameters (Hb, hepatic function, cholesterol, triglyceride)
Adverse events
 
Notes We contacted the study author for additional information by letter; however he was
unable to respond to all of our questions
No overall scores were presented as outcomes. Details of biochemical parameters
were not given
A proper between-group comparison was not conducted; only within-group
comparisons with Wilcoxon-rank sum test were conducted
The study did include the secondary outcomes - reduction in severity, participant- and
investigator-rated - although we were unable to include these data because of missing
data
Declarations of interest: none declared
Funding: Roche A/S, Copenhagen, supplied the study drug free of charge, but the
investigators did not receive financial support nor consultant fees from Roche
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "they were asked to take three 10-mg capsules of acitretin once
daily for 8 weeks or identically looking placebo capsules"
Comment: from the article, it is unclear whether the study was randomised
at all. Personal communication with study authors clarified that
randomisation was done by a third party according to a pre-defined
randomisation list
 
Allocation concealment (selection
bias)
Low risk No details about how allocation was concealed from participants and
clinicians. Personal communication clarified that the sponsor shipped 4
identical boxes to all participating centres, which could at random be
dispensed to participants. The investigators were unaware of the content
of the boxes; therefore we judged this as low risk
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "they were asked to take three 10-mg capsules of acitretin once
daily for 8 weeks or identically looking placebo capsules"
Comment: the study contained an identical looking placebo in an attempt
to blind participants, and randomisation and dispensation of drugs were
done at a remote site by a third party. Therefore we judged this as
adequate blinding of participants
 
Blinding of outcome assessment
(detection bias)
High risk Quote: "as several patients in the active treatment group experienced
dryness of the lips, we have called our study single-blind"
Comment: study authors declared this a single-blind study because the
observers could have guessed the acitretin group due to adverse events
of acitretin
 
Incomplete outcome data (attrition
bias)
Low risk None of the participants dropped out, and all participants were included in
the analyses
 
Selective reporting (reporting bias) Low risk No trial registration found. However we found no major discrepancies
between Methods and Results sections
 
Other bias Unclear risk Baseline comparisons: not stated whether there was a significant
difference in disease severity between groups Diagnostic certainty: yes
The study was completed
 
Tzaneva 2009
Methods Parallel-group, randomised controlled trial
This study was carried out in a secondary care setting at a dermatology department in
Austria
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Participants 29 participants with moderate to severe dyshidrotic or hyperkeratotic palmar and/or
plantar eczema, with symmetrical distribution
Dropouts: 2
Inclusion criteria of the trial 
Moderate to severe dyshidrotic or hyperkeratotic palmar and/or plantar eczema for
at least 1 year
Symmetrical distribution
Unsatisfactory response to conventional topical treatment
Exclusion criteria of the trial
Pregnant or lactating women
Age < 18 years
History of abnormal UVA sensitivity
Intake of photo-sensitising drugs
Local therapy within 2 weeks or systemic therapy within 4 weeks before study entry
Study population
Gender: oral PUVA group 10 female, 4 male; bath PUVA group 8 female, 5 male
Age: oral PUVA group mean 49.7 years, SD 16.4 years; bath PUVA group mean
44.2 years, SD 13.5 years
 
Interventions Intervention
• Oral PUVA: 8-MOP at a dose of 0.6 mg/kg 1 hour before irradiation with UVA in 14
participants. Irradiation dose: 1.5 J/cm² for the palms and soles and 1.0 J/cm² for the
backs of the hands and feet in participants with skin type III/IV. Respective doses for
skin type I/II were 1.2 and 0.8 J/cm²
• Bath PUVA: 2 mL of a 0.5% 8-MOP concentration of 5 mg/L in 13/15 participants.
Immediately after immersion for 15 minutes, the hands and feet were exposed to UVA
irradiation. Skin type III/IV: initial dose of 0.7 J/cm² for the backs of the hands and feet.
Skin type I/II: 0.8 and 0.55 J/cm², respectively
Irradiation doses in both groups were increased depending on the degree of an
erythematous response. Treatment was given 3 to 4 times a week until complete
clearance or over a maximum period of 20 weeks. After clearing, participants were
maintained on PUVA twice weekly for 2 weeks, then once weekly for another 4 weeks
At the end of treatment, participants were followed up until relapse, or for a maximum
of 40 months
Duration
Up to 40 months (up to 20 weeks of active treatment, up to 40 months of follow-up)
 
Outcomes Primary outcome of the trial
Investigator-rated reduction in severity of eczema score at end of treatment: score
based on extent of involvement (0 = 0%, 1 = 1% to 25%, 3 = 51% to 75%, 4 = 76%
to 100%), intensity (0 = absent, 1 = slight, 2 = moderate, 3 = severe, 4 = very
severe) of erythema, and infiltration of vesicles and scaling
Other outcomes
Investigator-rated reduction in severity of eczema: score based on extent of
involvement (0 = 0%, 1 = 1% to 25%, 3 = 51% to 75%, 4 = 76% to 100%), intensity
(0 = absent, 1 = slight, 2 = moderate, 3 = severe, 4 = very severe) of erythema, and
infiltration of vesicles and scaling at baseline and at weeks 4, 8, 12, 16, and 20
during treatment, and at 1, 3, 6, 12, 18, 30, and 40 months after end of treatment
Time until relapse defined as an eczema score > 50% of baseline score during a
follow-up period of maximal 40 months
Cumulative UVA exposure dose and number of exposures required for achieving a
good or excellent response (> 75% reduction of eczema score)
Tolerability of the 2 regimens (adverse events)
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Notes From the article, it is unclear whether all participants had hand eczema. After writing to
study authors, it became clear that all participants had hand eczema, and some also
had plantar eczema
Study authors were contacted with an additional request for allocation on 4 March
2014, but we were unable to obtain further data
The secondary outcome - reduction in severity, investigator-rated - was used, and
study authors did not find a statistically significant difference in dyshidrotic hand
eczema (stated P = 0.67; multi-factorial ANOVA) and a significant difference in the
hyperkeratotic group (stated P = 0.03; multi-variate ANOVA), although we were unable
to reproduce these data because the standard deviation was not available
The secondary outcome - time until relapse - was included, but we were unable to
reproduce these data
Declarations of interest: none declared
Funding: no clear indication of funding that might lead to conflict of interest
Sample size rationale: not stated
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "patients were randomly allocated to receive either oral or bath
PUVA therapy by means of a computer-generated sequentially
numbered randomization list"
Comment: randomisation method was adequate
 
Allocation concealment (selection
bias)
Unclear risk Insufficient details provided
 
Blinding of participants and
personnel (performance bias)
High risk Quote: "...observer-blinded study..."
Comment: participants and personnel were not blinded, and no placebo
was used
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "eczema severity was determined by a blinded investigator (A.
T.) at baseline and every 4 weeks..."
Comment: a single, blinded observer assessed all outcomes
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (27 of 29 = more than
80%)
 
Selective reporting (reporting bias) Low risk No trial registration found. No major discrepancies between Methods
and Results sections. The Methods section gives a clear description of
the definitions of relapse and clearance
 
Other bias Unclear risk Baseline comparisons: not stated
Diagnostic certainty: yes
The study was completed
 
Uggeldahl 1986
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Methods Within-participant, randomised controlled trial
This study was conducted in a secondary care setting, probably at 2 centres in Finland
 
Participants 50 (46) participants (1.5 to 70 years) with bilateral moderate hand/wrist/lower arm
eczema, with left-right comparable severity, were included; 4 were excluded because
of asymmetrical hand eczema
Dropouts: 2
Inclusion criteria of the trial
Bilateral and symmetrical moderate eczema of the hand, wrist, and lower arm
Exclusion criteria of the trial
Not stated
Study population
Gender: not stated
Age: mean 27 years, range 1.5 to 70 years
 
Interventions Intervention
• Desonide cream 0.1% twice daily for 2 weeks in 44/46 hands
• Desonide cream 0.05% twice daily in 44/46 contralateral hands for 2 weeks
Duration
2 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Observer-rated score 0 to 4 (0 = absent and 4 = maximum severity) for
inflammation, infiltration, desquamation, lichenification, itching, tenderness, and
chapping, after 4 to 7 days and after 11 to 14 days
Participant-rated therapeutic effect: both hands equal or one hand better than the
other at days 11 to 14
Adverse events
 
Notes In fact, 50 participants were randomised, but 4 participants were excluded at the start.
Not clear whether inclusion criteria of the trial (hand/wrist/lower arm) stipulated that the
hands had to be involved in all participants. The youngest participant was 1.5 years
old
Aim was to study equivalency, but this was not reflected in the analysis
The secondary outcomes - reduction in severity, investigator-rated and participant-
rated - were included but did not provide reproducible data
Declarations of interest: 2 study authors were employees of the research department
at Apothekernes Laboratorium A.S., Oslo, Norway, the manufacturer of the study
drugs
Funding: see above item
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "the study consisted of a double-blind, randomized, left-right
comparative study..."
Comment: stated only that this was a randomised study. No further
details provided
 
Allocation concealment (selection
bias)
Low risk Quote: "each patient was given 2 tubes identical in appearance...."
Quote: "according to the double-blind nature of the study, the creams
were randomly allocated to the left and right side..."
Comment: no details about how allocation was concealed from
participants and clinicians. The identical tubes were randomly allocated
to left and right sides
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "each patient was given 2 tubes identical in appearance...."
Comment: the only difference between the 2 tubes was the
concentration, wherefore this is considered as low risk
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "...double-blind nature..."
Comment: unclear whether observers were aware of the treatment
modalities, although study authors claim double-blind design
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (44 or 46 of 50 = more
than 80%)
 
Selective reporting (reporting bias) Low risk No trial registration found. No major discrepancies between Methods
and Results sections
 
Other bias Low risk Baseline comparisons: within-participant study not applicable
Diagnostic certainty: yes
The study was completed
 
van Coevorden 2004a
Methods Parallel group, open-label randomised controlled trial
This study was conducted at 2 university hospital outpatient clinics in the Netherlands
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Participants 158 participants (88 male, 70 female) with chronic hand eczema of at least 1 year's
duration, with at least 2 relapses of at least 3 weeks' duration, moderate to severe,
grade 6 on a hand eczema score at start of treatment
Dropouts: 33 during treatment, 8 during follow-up
Inclusion criteria of the trial
Bilateral or unilateral hand eczema since at least 1 year
At least 2 relapses or more than 3 consecutive weeks with visible signs in the last 3
months
Moderate to severe hand eczema with a score of at least 6
Exclusion criteria of the trial
Active eczematous lesions elsewhere on the body
Use of photosensitive drugs or anticoagulants
Treatment with cytostatics or ionising radiation or PUVA of the hands in the last 6
months
Other forms of photosensitivity
Alcohol abuse
Liver or renal dysfunction
Congestive heart failure
Hypertension
Epilepsy
(Pre)malignant skin tumours
Pregnancy (wish)
Study population
Gender: 70 female, 88 male
Age: mean 42 years, range 18 to 70 years; SD 14 years; SE 1.1 years
 
Interventions Intervention
• Oral PUVA (methoxypsoralen) phototherapy at home on both hands thrice weekly for
10 weeks in 63/78 participants
• Topical bath PUVA (trioxsalen) twice weekly in hospital for 10 weeks in 62/80
participants
Emollients were allowed in both groups
Participants were followed up for an additional 8 weeks after the end of treatment
Duration
18 weeks (10 weeks of active treatment, 8 weeks of follow-up)
 
Outcomes Primary outcome of the trial
Observer-rated severity score based on sum of scores 0 to 3 (0 = none, 1 = slight, 2
= moderate, 3 = severe) for erythema, desquamation, vesiculation, infiltration,
fissures, itch, and pain at week 10 (end of treatment)
Other outcomes
Observer-rated severity score (as described above) at weeks 3 and 6 of treatment
and at weeks 4 and 8 after end of treatment
Participant-registered travel costs and time off work
Number of participants improved at week 10
Adverse events
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Notes Blinding of participants impossible. Observers of outcomes not blinded. Analysis
based on intention-to-treat principle. Scoring of eczema was similar to the scoring
used by Rosén 1987a
Secondary outcome number 3 (number of participants improved at week 10) not
specified in the Methods. Study authors mention adherence to CONSORT statement.
Missing standard deviations were calculated according to formula provided in Chapter
7.7.3.2 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011a)
Declarations of interest: none declared
Funding: the study was supported in part by the Netherlands Healthcare Insurance
Board, Amstelveen, the Netherlands
Sample size rationale: provided
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "computer-generated randomization lists with blocks of 4 were
created by a secretary"
Comment: randomisation method was considered adequate
 
Allocation concealment (selection
bias)
Low risk Quote: "consecutive patients were given consecutive numbers on the list
and randomized accordingly by the trial’s dermatologists. The
randomization sequence was kept concealed by the secretary until the
end of the trial"
Comment: allocation was concealed
 
Blinding of participants and
personnel (performance bias)
High risk Quote: "blinding of the patient and the outcome assessor was not
practically feasible: patients are aware of their treatment modality and
assessors can easily identify a hand treated with bath PUVA because of
its rim of pigmentation"
Comment: no blinding was attempted. Study authors state that blinding
was not practically feasible. In addition, outcomes of this study were time
off work and travel time. When participants would have received placebo
in hospital or at home radiation, this outcome would not be applicable
 
Blinding of outcome assessment
(detection bias)
High risk Quote: "hand eczema severity was assessed by one of the unblinded
trial’s dermatologists (trained in assessment of hand eczema)"
Quote: "blinding of the patient and the outcome assessor was not
practically feasible: patients are aware of their treatment modality and
assessors can easily identify a hand treated with bath PUVA because of
its rim of pigmentation"
Comment: no blinding; study authors state in a comment that blinding of
observers was practically not feasible because observers would be able to
guess the difference based on the rim of pigmentation in the bath PUVA-
treated group
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "the statistical analysis was based on the intention-to-treat
principle, using the “last value carried forward” method"
Comment: intention-to-treat analysis
 
Selective reporting (reporting bias) Low risk No trial registration found. The article provides a clear participant flow
chart based on CONSORT guidelines. With regards to one of the
important outcomes - travel costs and time of work - study authors stated
only that "patients treating themselves at home had substantially lower
travel costs and substantially less time of work"; however additional
information is provided in a separate report
 
Other bias Low risk Baseline comparisons did not reveal significant differences in hand
eczema between groups
Diagnostic certainty: yes
The study was completed
 
Veien 1995
Methods Parallel-group, randomised controlled trial
This study was conducted at 4 dermatological departments and clinics in Denmark
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Participants 47 participants (11 male and 36 female) with hand eczema of at least 6 months'
duration. All had or previously had atopic dermatitis. All without positive reaction to
standard patch test series
Dropouts: 9
Inclusion criteria of the trial
Eczema of the hands and/or fingers for at least 6 months
A minimum score of 5 according to the adopted scoring system
At least 18 years of age
Current or past atopic dermatitis according to criteria of Hanifin and Rajka
Exclusion criteria of the trial
Type IV allergy
Study population
Gender: 36 female, 11 male
Age: not stated
 
Interventions Intervention
• Oral ranitidine 300 mg twice daily (21/23 participants) for 16 weeks
Control intervention
• Placebo tablets (17/24 participants) for 16 weeks
Both groups received betamethasone cream/ointment and emollient
Duration
16 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Observer-rated severity scoring based on scoring (0 = absent, 1 = mild, 2 =
moderate, 3 = severe) for erythema, vesicles, scaling, pruritus, and fissures, and 1
to 3 score for area involved
Participant-rated treatment result: 0 = unchanged/aggravated, 1 = slight
improvement, 2 = marked improvement, 3 = clear at baseline and at weeks 4, 8, 12,
and 16
Observer-rated treatment result: 0 = unchanged/aggravated, 1 = slight
improvement, 2 = marked improvement, 3 = clear at baseline and at weeks 4, 8, 12,
and 16
Participant- and physician-rated (combined?) overall result: successful (marked
alleviation or clear) or failed (unchanged/aggravated)
Scores of separate items for outcome 1
Adverse events
 
Notes Published as brief communication. Analysis according to intention-to-treat principle,
but no details given
The secondary outcome - reduction in severity, investigator-rated - was included,
although because standard deviations were missing, we were unable to reproduce the
data
Study authors were contacted by email but were unable to answer all of our questions
because the study was conducted such a long time ago
Declarations of interest: not stated
Funding: the study drugs were provided by Glaxo Denmark A/S, and Glaxo provided
an employee to assist with the study. The emollients were provided by Rhône-
Poulene, and statistical analyses were performed by Biomedica, Copenhagen,
Denmark
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "the patients were randomly selected"
Comment: no further details given in the article; personal communication
with study authors clarified that a computer-generated code was used
 
Allocation concealment (selection
bias)
Low risk No details in the article about how allocation was concealed from
participants and clinicians. Personal communication with study authors
clarified the following: "The allocation was concealed from patients and
investigators by numbers on identical boxes of tablets containing either
ranitidine or placebo". Because randomisation was done by a third party,
boxes were identical, and investigators received the randomisation code
only in a sealed envelope, this was considered an adequate method to
prevent selection bias
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "the patients were randomly selected to receive oral ranitidine, 300
mg twice daily, or placebo tablets of identical appearance"
Comment: double-blind design. Because randomisation was done by a
third party and staff received identical looking boxes for ranitidine and
placebo, it was not possible for participants and staff to know the treatment
arm
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "the code was broken when all the patients had completed the
study and all results were recorded"
Comment: randomisation was carried out by a third party; therefore
observers could not have known the treatment allocation
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "statistical evaluations were based on the intention-to-treat
principle"
Comment: intention-to-treat analysis
 
Selective reporting (reporting bias) High risk No trial registration found. The Results section is very concise. In the
Results section, it is unclear whether the outcome was based on
participants' or investigators' scores or on a combination of these, and only
total scores or significance levels are given
 
Other bias Low risk Baseline comparisons: the 2 groups were comparable with regard to age,
duration of dermatitis, eczema at other sites, and presence of other atopic
symptoms
Diagnostic certainty: yes
The study was completed
 
Veien 1999
Methods Parallel-group (3 groups), randomised controlled trial
This study was conducted in a secondary care setting at 3 centres in Denmark (study
was carried out at a university department as well as at 2 private dermatology clinics)
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Participants 106 participants were randomised (all patch tested) with hand eczema > 6 months that
had cleared upon daily treatment for a maximum of 9 weeks with mometasone furoate
cream
120 participants were recruited, and 14 dropped out during the initial phase
No dropouts after randomisation (see notes)
Inclusion criteria of the trial
Eczematous hand dermatitis for longer than 6 months with a minimum score of 6
according to the adopted scoring system
Exclusion criteria of the trial
Infection to the hands
Hyperkeratotic hand eczema
Other hand dermatoses
Contact allergy to the topical remedies used in the study
Fungal infection of hands/feet
Pregnant and lactating women
Use of systemic immunosuppressants
Study population
Gender: 100 female, 20 male in the recruited group
Age: median 31 years, range 17 to 70 years, in the recruited group
 
Interventions Intervention
• Mometasone furoate cream thrice weekly (Sunday/Tuesday/Thursday) for up to 36
weeks or 30 (?) in 35/35 participants
• Mometasone cream twice weekly (Saturday/Sunday) for up to 36 weeks in 37/37
participants
Control intervention
• No corticosteroids in 34/34 participants
Emollients (Essex cream and ointment) used in all groups
In case of recurrence, all groups were permitted to use mometasone daily for a
maximum of 3 weeks at separate period
Additional treatment was permitted in all groups in case of a bacterial infection
Duration
Up to 36 weeks
 
Outcomes Primary outcome of the trial
Number of recurrences of hand eczema and times at which recurrence occurred
(recurrence defined as eczema score equal to or higher than initial score)
Other outcomes
Length of time it took to control the dermatitis during the initial treatment period
Numbers and times of recurrence in subgroups. Data analysis by survival analysis
Adverse events
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Notes All randomised participants were supposed to be free of eczema due to preceding
treatment (induction of remission) with mometasone, yet recurrence was defined as a
score equal to or higher than before this remission induction phase. In each group, a
few participants received additional treatment. Dropout was defined as participant who
had more than 2 recurrences
The secondary outcome - time until relapse - was included in the study, but data were
not reproducible
Study authors were contacted on 7 March 2014 but responded on 13 March 2014 that
they were unable to provide additional information
Declarations of interest: not stated
Funding: Schering-Plough A/S Farum, Denmark, supplied the study drugs and
covered the expenses of processing the data
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "patients.... were randomised into 1 of 3 groups"
Comment: no further details in the article. Personal contact with the study
author clarified that the randomisation table was computer generated with
blocks of 5, and this was carried out by Schering-Plough A/S, Farum,
Denmark
 
Allocation concealment (selection
bias)
Low risk No details in the article about how allocation was concealed from
participants and clinicians; however personal contact with study authors
clarified that randomisation was created by a third party. The investigators
received sealed and numbered envelopes for allocation to a treatment arm
 
Blinding of participants and
personnel (performance bias)
High risk Quote: "ideally, the maintenance phase should have been double-blind.
This would, however, have required a very complicated distribution of the
medicaments, with many different tubes for various days of the week. We
felt the risks of mistakes by the patients and of poor compliance to be too
great"
Comment: no blinding; blinding was difficult because participants had to
follow different treatment schedules
 
Blinding of outcome assessment
(detection bias)
High risk Quote: "the investigation was carried out as an open, prospective,
randomized trial"
Comment: no blinding
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "the intention-to-treat principle was used to calculate the effect of
the treatments"
Comment: intention-to-treat analysis
 
Selective reporting (reporting bias) Low risk No trial registration found. Severity of pruritus, erythema and vesicles,
scaling, and fissures is described in the Materials and Methods section,
but separate results for these are not given in the Results section;
however, because these are not listed as outcome, we judged this as low
risk. All (clearly described) outcomes listed in the Materials and Methods
section are included in the Results section
 
Other bias Low risk Baseline comparisons: "there were no statistically significant differences in
the demographic features represented in the 3 centres or in the 3
randomisation groups"
Diagnostic certainty: yes
The study was completed
 
Whitaker 1996
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Methods Parallel-group, randomised controlled trial
This study was carried out in a secondary setting for outpatients at a single centre in
South Africa
 
Participants 39 participants with chronic stable hand eczema of > 12 months' duration
Dropouts: 5
Inclusion criteria of the trial
Stable hand eczema for at least 12 months
Exclusion criteria of the trial
Inflammatory skin disorders other than eczema
Allergic contact dermatitis that resolves after avoidance of the relevant contact
allergens
Severe intercurrent illness
Currently treated with oral steroids, PUVA, immune suppressants, phenothiazines,
or antidepressants
Study population
Gender: not stated
Age: range 19 to 75 years
 
Interventions Intervention
• GLA (gamma linolenic acid) 50 mg (in 500 mg evening primrose oil capsules) daily
for 16 weeks in 19/20 participants
Control intervention
• Gelatine capsules with 500 mg sunflower oil daily for 16 weeks in 15/19 participants
Both groups were allowed to use unlimited quantities of standard emollient and a
limited quantity of group III corticosteroids
Participants were followed up for 8 weeks after the end of treatment
Duration
24 weeks (16 weeks of active treatment, 8 weeks of follow-up)
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Observer-rated clinical evaluations (using a 100-mm visual analogue scale to
evaluate dryness, redness, itch, cracking, vesiculation, oedema, and overall
impression) at 4-week intervals, up to 24 weeks, from which score decreases
(improvements) from baseline to week 16 and week 24 are analysed
Change in epidermal GLA content
Decrease in steroid usage
 
Notes Part of the study was a laboratory investigation in 10 matched healthy controls. At the
beginning of the study, all participants had blood taken for laboratory parameters, as
well as biopsies for histology and electron microscopy. No participant-rated outcomes
Study authors were contacted for additional information but remained unresponsive
Declarations of interest: not stated
Funding: the study was planned and funded by Scotia Pharmaceuticals
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "a blind random method was used..."
Comment: no further details
 
Allocation concealment (selection
bias)
Unclear risk No details about how allocation was concealed from participants and
clinicians, although study authors stated that they used a "blind random
method"
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "placebo was given to 19 patients as identical-appearing
gelatine capsules..."
Comment: study authors stated double-blinded design and included a
placebo of identical appearance, which is an adequate way to blind
participants
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "a parallel, double-blind, placebo-controlled trial..."
Comment: study authors stated a double-blind design but provided no
information regarding observer blinding
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (34 of 39 = more than
80%)
 
Selective reporting (reporting bias) Low risk No trial registration found. All results described in the Materials and
Methods section are depicted in the Results section
 
Other bias Unclear risk Baseline comparisons: redness was significantly more severe in the
placebo group than in the intervention group Diagnostic certainty: yes
The study was completed
 
Yousefi 2012
#29 Interventions for hand eczema
169 / 280
Methods Parallel-group, randomised controlled trial
This study was conducted in a secondary care setting at a single centre in Iran
 
Participants 60 participants with chronic hand eczema
Dropouts: 8
Inclusion criteria of the trial
Participants with chronic hand eczema that is confirmed by 2 dermatologists
18 to 60 years of age
Hand eczema could be due to occupational dermatitis, atopic dermatitis, or irritant
dermatitis of the hands (bilateral or unilateral)
Exclusion criteria of the trial
History of allergic reactions to the study medication
Use of systemic corticosteroids or immunosuppressive drugs during the last 4
weeks
Synchronous local infection at the site of eczema
Women during pregnancy or lactation
Obsessive-compulsive disorder concerning over-washing
Any other medical or mental conditions that interfered with participation in this study
Study population
Gender: Eucerin group 14 female, 4 male; Nigella group 15 female, 4 male;
betamethasone group 10 female, 5 male
Age: Eucerin group mean 31.89 years, 11.61 SD years; Nigella group mean 35.79
years, 15.03 SD years; betamethasone group mean 32.60 years, 13.74 SD years
 
Interventions Intervention
• Nigella sativa oil extract 2% with Eucerin base applied twice a day for a period of 4
weeks in 19 participants
• 0.1% betamethasone ointment applied twice a day for a period of 4 weeks in 15
participants
Control intervention
• Only Eucerin ointment applied twice a day for a period of 4 weeks in 18 participants
Duration
4 weeks
 
Outcomes Primary outcomes of the trial
Resolution of severity and intensity of lesions after 2 weeks measured by Hand
Eczema Severity Index (HECSI)
Quality of life after 2 weeks measured by Dermatology Life Quality Index (DLQI)
Other outcomes
Irritant or allergic contact dermatitis after 4 weeks measured by physician
assessment
Adverse events
 
Notes The secondary outcomes - reduction in severity, participant-rated and investigator-
rated - were included but did not provide reproducible data
Declarations of interest: none declared
Funding: the study was planned and funded by Shahid Beheshti University of Medical
Science, Tehran, Iran
Sample size rationale: not stated
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "assigning patients to the treatment groups was performed based
on randomly permuted blocks of size 6. The project biostatistician
prepared the randomization list"
Comment: this was considered an adequate method to generate a
randomisation sequence
 
Allocation concealment (selection
bias)
Low risk Quote: "they were pre-packed in tubes and consecutively numbered for
each participant according to the randomization list. This was done by the
project pharmacologist. Each participant was assigned an order number
and the dermatology resident used the corresponding numbered packs to
allocate participants to treatment groups. Both patients and dermatologists
were blind to the assigned drugs due to randomization procedure"
Comment: this is considered an adequate and well-described procedure
 
Blinding of participants and
personnel (performance bias)
Low risk Quotes (Iranian Clinical Trial Register IRCT201111266959N3): "blinding:
single blind"
"For blinding the participants but not investigators, all 3 creams( Nigella,
Betamethasone, Eucerin as placebo) will be prepared in the identical
tubes which only labelled A, B, and C with no other information"
Comment: the trial registrations stated a single-blind study, although the
original article claims that the study is double-blind
Quotes (from article): "in this randomised, controlled, double-blind clinical
trial..."
"The therapeutic medications were manufactured identical in appearance,
odour and other characteristics by adding ineffective ingredients. We
added the essence of 0.1% mint oil to create the same smell in all
ointments"
"Each participant was assigned an order number and the dermatology
resident used the corresponding numbered packs to allocate participants
to treatment groups. Both patients and dermatologists were blind to the
assigned drugs due to randomization procedure"
Comment: we assume that participants were unaware of their treatment
modality by this method
 
Blinding of outcome assessment
(detection bias)
Unclear
risk
Quote (from Iranian Clinical Trial Register IRCT201111266959N3): "for
blinding the participants but not investigators, all 3 creams (Nigella,
Betamethasone, Eucerin as placebo) will be prepared in the identical
tubes which only labelled A, B, and C with no other information"
Quote (from article): "in this randomised, controlled, double-blind clinical
trial..."
Comment: unclear if outcome assessors were blinded
 
Incomplete outcome data (attrition
bias)
Low risk No intention-to-treat analysis but per protocol (52 of 60 = more than 80%)
 
Selective reporting (reporting bias) Low risk Trial registration found (IRCT201111266959N3), registered before
publication; no major differences between trial registration and the study
were found
 
Other bias Low risk Baseline comparison: no significant difference was observed between
treatment groups with respect to disease severity at baseline as measured
by HECSI and DLQI scores (P = 0.43; Welch’s ANOVA; and P = 0.99;
ANOVA, respectively)
Diagnostic certainty: yes
The study was completed
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Footnotes
ALT: alanine aminotransferase.
ANOVA: analysis of variance.
AST: asparate aminotransferase.
BSI: brief symptom inventory.
CDLQI: Children's Dermatology Life Quality Index.
CI: confidence interval.
CPK: creatine phosphokinase.
DASI: Dyshidrotic eczema Area and Severity Index.
DLQI: Dermatology Life Quality Index.
DSCG: disodium cromoglycate.
EASI: Eczema Area and Severity Index.
EDI: Eczema Disability Index.
EQ-5D: standardised index for measuring quality of life.
FSH: follicle-stimulating hormone.
GLA: gamma linolenic acid.
HDL: high-density lipoprotein.
HEAS: Hand Eczema Area and Severity Score.
HEASI: adaptation of EASI for the hands.
HECSI: hand eczema severity scoring index.
HEES: hand eczema extent score.
IGA: investigators' global assessment.
ISGA: investigators' static global assessment.
LDH: lactate dehydrogenase.
LDL: low-density lipoprotein.
MOP-8: XXX.
mTLSS: modified total lesion symptom score.
NB-UVB: XXX.
PaGA: participants' global assessment.
PGA: physicians' global assessment.
PHQ: patient health questionnaire.
PSA: patient self-assessment.
PUVA: topical and oral psoralen combined with UVA.
QALY: quality-adjusted life-year.
RR: risk ratio.
SCORAD: Scoring Atopic Dermatitis tool.
SD: standard deviation.
SGA: subjects' global assessment.
TETDS: tetraethylthiuram disulfide.
TEWL: transepidermal water loss.
TLSS: total lesion symptom score.
UVA: ultraviolet A.
UVA-1: newer form of UV therapy that contains only long-wavelength UVA-1 radiation (340 to 400 nm) and thus reduces the
risk of burning.
UVB: ultraviolet B.
VAS: visual analogue scale.
Characteristics of excluded studies 
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Aertgeerts 1985
Reason for exclusion The study included participants with different dermatoses on arms, hands, and legs. It
was not clear for which participants the hands were involved and how the outcome
was in the participants with hand eczema. This within-participant study was not
randomised and therefore was excluded
 
Berndt 2001
Reason for exclusion Participants did not have hand eczema. The study examined slightly irritated hands in
nurses. The study may be included in the Skin Group Review titled "Interventions for
preventing occupational irritant hand dermatitis"
 
Chen 2015
Reason for exclusion Hand and foot eczema combined; no separate data available
 
Gergovska 2017
Reason for exclusion Study focusses on prevention instead of treatment for active disease
 
Grivcheva-Panovska 2013
Reason for exclusion Study on Staphylococcus aureus colonisation instead of hand eczema
 
Güler Özden 2004
Reason for exclusion Not clear whether participants were randomised to different treatment arms
 
HogenEsch 1998
Reason for exclusion Pilot study, in which it is unclear how many were allocated to each intervention. Not
clear if the study was randomised
 
Petering 2004
Reason for exclusion Non-randomised study with a within-participant (left-right) design. It could be argued
whether randomisation is important in this left-right study with bilateral hand eczema of
similar severity. Observer of outcomes was blinded
 
Rosén 1987
Reason for exclusion Quasi-randomised
 
Zeichner 2018
Reason for exclusion Single-arm study without a comparator
 
Zimmerman 1967
Reason for exclusion It is unclear whether this within-participant study was randomised
Study on 54 participants with "bilateral, symmetrical areas of dermatitis" and stating
only the preference for betamethasone 17-valerate or fluocinolone acetonide ointment
for 8 participants with hand eczema. No other outcomes for hand eczema specified.
No information on frequency, dosage, and duration of treatment
 
Footnotes
Characteristics of studies awaiting classification 
Beitner 1996
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Methods Randomised controlled trial
This study was conducted at a single centre in Sweden
The study probably was not blinded
 
Participants 30 consecutive participants with different dermatological hand dermatoses including
pustulosis palmoplantaris (n = 5), psoriasis (n = 1), tylotic eczema (n = 4), atopic
eczema (n = 3), dyshidrotic eczema (n = 1), allergic eczema (n = 7), and non-allergic
eczema (n = 1), both allergic eczema and dyshidrotic (n = 2)
Dropouts: 6
Inclusion and exclusion criteria were not stated
 
Interventions Intervention
• Clobetsaol propionate (Dermovate Glaxo) solution under occlusion with a
hydrocolloid dressing twice a week for the first 2 weeks and once a week for the next 2
weeks
• Clobetasol propionate ointment under occlusion with a hydrocolloid dressing twice a
week for the first 2 weeks and once a week for the next 2 weeks
Follow-up included a visit 12 weeks after the start of treatment
 
Outcomes Primary outcomes of the trial
Not stated
Other outcomes
Symptom severity for itching, erythema, infiltration, and scaling, each graded on a
4-point scale (0 = no symptoms, 1 = mild, 2 = moderate, 3 = severe)
Participant-rated severity of itch on a visual analogue scale (VAS)
Vesicles/pustules: absent or present
Relapse within 12 weeks
Adverse events
 
Notes Study results for hand eczema participants were not presented separately, and we
were unable to obtain additional data from the study author
This study was published as a very concise letter to the editor, and a lot was uncertain,
for example, visits and outcome parameters
 
CTRI/2009/091/000212
#29 Interventions for hand eczema
174 / 280
Methods Randomised parallel-group open-label study
 
Participants 60 participants with hand eczema
Inclusion criteria
18 years of age or older
Mild to moderate hand dermatitis, according to the Investigator Global Assessment
(score 2 to 3)
Generally healthy, as determined by brief medical history
Capable of understanding and signing the consent form
Exclusion criteria
Clinically relevant allergic or irritant contact dermatitis and inability to avoid
exposure
Severe dermatitis according to the Investigator Global Assessment (score 4)
Severe vesiculation or bullae
History of psoriasis, contact urticaria, and/or pustular disease
Therapy with potent topical corticosteroids within 1 month before enrolment
Systemic treatment with oral retinoids, corticosteroids, or PUVA within the 8-week
period before the beginning of the study
History or current evidence of a chronic or infectious skin disease
Pregnant or lactating, or women not using highly effective contraception
Current participation in any other interventional clinical trial
Received treatment with any non-marketed drug substance (i.e. an agent that has
not yet been made available for clinical use) within 4 weeks before randomisation
Participant known or, in the opinion of the investigator, unlikely to comply with the
Clinical Study Protocol (e.g. alcoholism, drug dependency, psychotic state)
 
Interventions Interventions
• Herbavate applied on affected area 3 times a day for 4 weeks
• Betamethasone + Gentamycin applied on affected area 3 times a day for 4 weeks
 
Outcomes Primary outcome of the trial
Investigators' Global Assessment (IGA) at baseline, week 2, and week 4
Secondary outcomes of the trial
Global assessment by patients (PaGA): at baseline and at the end of 2 and 4
weeks of treatment
Number of adverse events during 4 weeks of treatment
Number of participants with adverse events during 4 weeks of treatment
Adverse events reported during the study at baseline and at the end of 2 and 4
weeks of treatment
Total lesion symptom score (TLSS) at week 0, week 2, and week 4
 
Notes Sponsor: Troikaa Pharmaceuticals Limited
Study author was contacted on 20 February; however email was not-working:
medicalservices@troikaapharma.com. Contact through LinkedIn revealed that study
results have not been published and provided no further details
 
Draelos 2000
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Methods Randomised controlled trial with a within-participant design
This study was conducted at a single centre in North Carolina, USA
The study was double-blind; an intention-to-treat analysis was not carried out
 
Participants 80 participants between the ages of newborn and 80 years with the following
dermatological conditions: household hand dermatitis (n = 21), occupational hand
dermatitis (n = 18), latex glove irritant contact dermatitis (n = 9), diaper dermatitis (n =
5), cutaneous wounds (n = 17), and allergic contact dermatitis (n = 10)
Dropouts: 7
Exclusion criteria of the trial
Use of any prescription skin medications or other treatments at the study site for a
2-week washout period before initiation of the study
Use of topical corticosteroid creams or oral corticosteroids
 
Interventions Intervention
• The study hydrogel barrier/repair cream (Hydron) for 4 weeks in 80 participants
Control
• Control moisturising cream (Eucerin, Beiersdorf, Germany) for 4 weeks in 80
participants
 
Outcomes Primary outcomes of the trial
Not stated
Other outcomes
Participant-rated: overall skin appearance and feel based on a questionnaire in
week 2 and week 4
Investigator-rated improvement in erythema, roughness, desquamation, serum
crusting (where appropriate), and inflammation on an ordinal rating system (–2,
noticeably worse; –1, worse; 0, no change; 1, better; 2, noticeably better)
Photographs
 
Notes RCT on different diseases, mostly on hand eczema. Number of participants with hand
eczema and results for participants with this condition are impossible to reconstruct.
We were unable to obtain separate data from the study investigator
 
English 1989
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Methods Randomised controlled parallel-group study
This study was conducted at 2 dermatology departments in the United Kingdom
 
Participants 97 outpatients with steroid-responsive dermatoses including 63 with endogenous
eczema (38 with atopic dermatitis, 19 with hand eczema, and 6 with discoid eczema)
and 34 with chronic plaque psoriasis
Dropouts: 12
Inclusion and exclusion criteria were not stated
 
Interventions Intervention
• Betamethasone dipropionate cream 005% twice daily during 3 weeks
• Betamethasone dipropionate cream 0.05% in the morning and base cream in the
evening during 3 weeks
 
Outcomes Primary outcomes of the trial
Not stated
Other outcomes
Physician-rated severity (absent, mild, moderate, severe): erythema, induration,
scaling, crusting, pruritus, excoriation, and pain
Physician-rated overall evaluation of participants' responses: excellent (95% clear),
good (50% to 95% clear), improvement (50% clear), poor (no response or
exacerbation)
Participant-rated response on a 10-cm VAS line (visual analogue scale)
Participant-rated improvement: yes/no
Participant-rated acceptability of treatment
Adverse events
 
Notes This study was part of a larger study on eczema and psoriasis. Analyses/outcomes
among the 19 hand eczema participants were not given. We contacted the study
author on 11 March 2014. This author responded 13 March 2014 that he was unable
to provide additional data
 
EUCTR2004-002398-22-DE
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Methods Randomised placebo-controlled double-blind study
 
Participants 240 participants with different dermatoses, of which dyshidrotic hand eczema was one
Inclusion criteria
One of the following dermal indications (mild to moderate):
Atopic eczema in the crook of the arm or the hollow of the knee
Dishidrotic hand eczema
Plaque-type psoriasis (hyperkeratoses removed before treatment by urea or
salicylic acid)
Seborrhaeic eczema
Acne vulgaris
Aged 18 to 80 years
Reliable method of contraception for women of child-bearing potentia
Exclusion criteria
Systemic therapy for skin disease within 2 weeks before the start of treatment,
except if maintained stable during the whole course of the study and approved by
the safety officer
UV therapy for dermal indications within 4 weeks before the start of treatment
Chronic or acute illness requiring systemic anti-inflammatory treatment except if
maintained stable during the whole course of the study and approved by the safety
officer
Skin cancer and precancerous skin lesions, except basal cell carcinoma (BCC),
squamous cell carcinoma (SCC), and actinic keratosis, if located outside the target
area
History of peptic ulcers or gastric intolerance with NSAIDs
History of asthma bronchiale
History of chronic airway infection
History of renal insufficiency
Thrombocytopathia
Immunosuppressants (e.g. corticosteroids) within 2 weeks before the start of
treatment
Known sensitisation to NSAIDs
Pregnancy or lactation
Mental disorder
 
Interventions Intervention
• IDEA-070 (ketoprofen in Transfersome)
Control intervention
• Placebo
 
Outcomes Primary outcomes of the trial
Investigator Global Assessment score (IGA)
Secondary outcomes of the trial
Clinical evaluation of the efficacy of IDEA-070 (ketoprofen in Transfersome) in
participants with different dermatological diseases using the following scores:
Patient Global Assessment score (PGA)
Indication-specific scores which include the DASI for dyshidrotic hand eczema
Safety of IDEA-070 evaluated by
Description of AE profile
Changes in laboratory values
Physical examination
Vital signs including body weight and body temperature
Ketoprofen plasma levels
 
Notes Study conducted in Germany
Sponsor: IDEA AG
Current status: not recruiting
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EUCTR2005-005793-75-DE
Methods Double-blind randomised parallel-group design
 
Participants 40 patients with chronic hand dermatitis rated mild to moderate according to
Investigator’s global assessment (score, see page 20) that has persisted for longer
than 6 month in spite of attempts to identify and remove the cause
Inclusion criteria
Men and women 18 to 70 years of age
Chronic hand dermatitis rated mild to moderate according to investigator’s global
assessment (score, see page 20) that has persisted for longer than 6 months in
spite of attempts to identify and remove the cause
Physical examination must be without disease findings unless the investigator
considers an abnormality to be irrelevant to the outcome of the study
Danish sites: sexually active females of child-bearing potential should be surgically
sterile (hysterectomy or tubal ligation), or should use a medically accepted
contraceptive regimen: systemic contraceptive (oral, implant, vaginal or
transdermal, injection) or intrauterine device (IUD) during the trial and at least 15
days after the end of the study
German sites: sexually active females of child-bearing potential should be surgically
sterile (hysterectomy or tubal ligation), or should use a medically accepted
contraceptive regimen: systemic contraceptive (oral, implant, injection), diaphragm
or cervical cap with intravaginal spermicide, intrauterine device (IUD), condom with
intravaginal spermicide
Danish sites: an epicutaneous test was performed within the previous 36 months
before the first treatment and was documented in the participant record
German sites: an epicutaneous test was performed within the previous 12 months
before the first treatment and was documented in the participant record
Written informed consent obtained
Exclusion criteria
Primary hyperkeratotic forms of dermatitis, hand dermatosis other than eczematous
dermatoses, or acute infection
Allergic contact dermatitis if the allergen is identified and patient remained in
contact with the allergen
Metal-workers who are in permanent contact with cutting fluids
Sun-tanned or hyperpigmentation or tattoos in the test fields
Dark-skinned persons whose skin colour prevents ready assessment of skin
reactions
Treatment within 3 months before study day 1 with systemic medications (i.e.
glucocorticoids or immune modulators), treatment within 2 weeks with topical
glucocorticosteroids, or treatment with other systemic or locally acting medications
that might counter or influence the trial aim within 2 weeks before study day 1 and
during the study
UV therapy within 4 weeks before study day 1 and during the study
Medical history of skin cancer in the area of the hands or generalised skin cancer
Known to be drug-resistant for this indication
Evidence of drug or alcohol abuse
Pregnancy or nursing
Symptoms of a clinically significant illness that may influence the outcome of the
study in the 4 weeks before study day 1 and during the study
Participation in another clinical trial involving pharmaceutical products in the 4
weeks before study day 1
Known allergic reactions to components of the study preparations
German sites: known allergic reactions with symptoms such as asthma, allergic
rhinitis, or urticaria to 2-acetoxy-benzoic acid (acetylsalicylic acid) or other non-
steroidal antirheumatics (because of possible cross-allergic reactions)
If in the opinion of the investigator or physician performing the initial examination,
the patient should not participate in the study (e.g. due to probable non-compliance
or inability to understand the study and give adequately informed consent)
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Interventions Intervention
• ASF-1075 cream
Control intervention
• Placebo cream
 
Outcomes Primary outcomes of the trial
Clinical assessment of skin condition using the hand eczema severity index
(HECSI)
 
Notes Current status: not recruiting
 
EUCTR2008-006148-20-DE
Methods Double-blind randomised parallel or within-participant design
 
Participants Individuals with mild to moderate plaque-type psoriasis (PASI < 10) or hand and foot
eczema with at least 2 symmetrical lesions
 
Interventions Intervention
• Mometasone furoate 0.1% ointment
Control intervention
• Placebo ointment
 
Outcomes Primary outcomes of the trial
Tolerability and safety of Momegalen by assessment of AEs
Frequency, severity, and relationship to study medication are presented in
frequencies, and percentages broken down by treatment group and visit
Secondary outcomes of the trial
Evaluated safety assessed by vital signs and clinician’s and participant’s
assessment of local skin reaction and irritability, as well as on a 4-point Likert scale,
during a 3-week treatment. Efficacy assessed by PGA on a 5-point scale.
Secondary objectives analysed descriptively
 
Notes Not available
 
Goh 1999
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Methods Within-participant randomised controlled trial
This study was conducted at a single centre in Singapore in a secondary setting
This was an open-label, observer-blinded study; an intention-to-treat analysis was not
done
 
Participants 60 consecutive patients with moderate to severe bilateral chronic eczema on the limbs
for at least 6 months. Patients had different dermatological diseases such as hand and
foot eczema, lichen simplex chronicus, discoid eczema, prurigo nodularis, and
unclassifiable eczema. In 8 patients, the hands were treated
Dropouts: 2
Exclusion criteria of the trial
Pregnancy
Known hypersensitivity to corticosteroids
Presence of skin atrophy
Use of systemic steroids within 28 days before the start of the study
Use of antihistamines 1 day before and during the study
 
Interventions Intervention
• Mometasone furoate cream 0.1% once daily during 3 weeks
• Clobetasol propionate cream 0.05% applied twice daily during 3 weeks
No other medication was allowed during the study
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Physician-rated overall evaluation of severity of eczema
Physician-rated symptom scores for erythema, induration, crusting, scaling,
excoriation, and pruritus using a severity scale from 0 (none) to 3 (severe) and the
combination of these signs/symptoms
Percentages of improvement in the signs and symptoms score
Cosmetic acceptability
Adverse events
 
Notes Study on different types of eczema in different body regions. Specific data on
outcomes among the 8 hand eczema participants were not given. We contacted study
authors on 11 March 2014; they responded 13 March 2014 that they were unable to
obtain these data
 
Grundmann 1999
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Methods Randomised within-participant study
This study probably was conducted at a single centre in Germany
The study was not blinded, and all participants were included in the analyses
 
Participants 12 patients with severe plaque psoriasis (n = 4), severe atopic dermatitis (n = 4), or
severe hyperkeratotic eczema (n = 4)
Dropouts: none
Inclusion criteria
Resistance to topical therapy
Severity score of at least 16 points in self-created scoring system (see outcomes)
 
Interventions Intervention
• PUVA cream therapy with 8-methoxypsoralen (8-MOP) 4 times a week
• PUVA bath therapy 4 times a week
Participants were followed up for an additional 8 weeks after the end of treatment.
Exact duration of treatment and number of treatments were not clear
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes 
Investigator-rated severity score for each item on each hand and/or foot for
erythema, scaling, infiltration, pustulation, and hyperkeratosis from 0 to 4 (0 = no
symptoms, 4 = maximum), resulting in a total score of 20 every week
Investigator-rated improvement in total score (0 to 4 excellent, 5 to 8 good) every
week
 
Notes RCT on different dermatoses among hand eczema. We were unable to reconstruct the
results from the paper among participants with hand eczema, and we were
unsuccessful in locating the study authors
 
Haddican 2014
#29 Interventions for hand eczema
182 / 280
Methods Randomised double-blind vehicle-controlled parallel-group study
 
Participants 60 patients with hand and/or foot eczema
Inclusion criteria
> 18 years of age
Written and informed consent
Clinical diagnosis of HFD affecting at least 1 hand or foot
Physician Global Assessment (PGA) of at least 3 (moderate) for HFD
Negative urine pregnancy test for females of child-bearing potential
Approved method of birth control for females of child-bearing potential
Exclusion criteria
Pregnant or breastfeeding females
Known or suspected intolerance to retapamulin 1% ointment or clobetasol
propionate 0.05% foam
Any overt signs of skin atrophy, telangiectasias, and/or striae in the treatment area
Any known history of active skin malignancy
Use of any topical corticosteroids, topical antibiotics, topical immunosuppressants,
other topical therapies (tar, calcineurin inhibitors), or phototherapy within 8 weeks of
the baseline visit
Use of any systemic corticosteroid, systemic antibiotic, or systemic
immunosuppressant therapies within 8 weeks of baseline visit
 
Interventions Intervention
• Clobetasol propionate 0.05% foam twice-daily application to the hands or feet for 2
weeks and retapamulin 1% ointment twice-daily application to anterior nares and the
hands or feet for 5 consecutive days
• Clobetasol propionate 0.05% foam twice-daily application to the hands or feet for 2
weeks and vehicle (placebo) ointment application twice daily to anterior nares and the
hands or feet for 5 consecutive days
 
Outcomes Primary outcomes of the trial
Proportion of participants with a PGA of clear or almost clear at day 6, day 15, and day
28 compared to baseline
Other outcomes
Portion of participants with intranasal and hand/foot S aureus carriage rates
Portion of participants with methicillin resistance in S aureus isolates
Comparison of mean PGA score for participants with and without S aureus present
in the target lesion, the proportion of participants in each treatment group who were
culture-positive for S aureus on the skin, nares, or both at baseline, who were also
culture-negative on both the skin and nares and clear/almost clear based on PGA
at follow-up visits
 
Notes RCT on hand and foot dermatitis combined. It was not possible to extract from the
paper results of hand eczema participants
 
Handa 1988
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Methods Randomised parallel-group study
 
Participants 100 patients with moderate to severe eczema or other steroid-responsive dermatoses
including eczema (n = 45), lichen simplex chronicus (n = 27), atopic dermatitis (n =
14), psoriasis (n = 4), contact dermatitis (n = 2), stasis dermatitis (n = 2), seborrhoeic
dermatitis (n = 1), actinic dermatoses (n = 1), unclear (n = 4)
Dropouts: 4
Inclusion criteria
Moderate to severe eczema or another steroid-responsive disorder
Over 12 years of age
Exclusion criteria
Lesions associated with tuberculosis or viral infection
Requirement of another systemic or topical intervention for the primary diagnosis
 
Interventions Intervention
• Alclometasone dipropionate 0.05% ointment twice a day without occlusion for 3
weeks
• Hydrocortisone 1.0% ointment twice a day without occlusion for 3 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes
Investigator-rated severity score for each item: erythema, induration, and pruritus
from 0 to 3 (0 = none; 1 = mild; 2 = moderate; 3 = severe) at baseline and at weeks
1, 2, and 3
Investigator-rated overall severity score: clearing = 100% improvement; marked
improvement = 75% to 99% improvement; moderate improvement = 50% to 74%;
slight improvement = 25% to 49%; no change < 25% improvement
Adverse events
 
Notes RCT on different dermatoses. It was impossible to extract from the paper the results of
hand eczema participants, and we were unable to locate the study authors
 
IRCT201112018263N1
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Methods Double-blind randomised parallel-group design, placebo-controlled
 
Participants 70 patients with moderate to severe hand eczema, aged 12 to 70 years
Exclusion criteria
Treatment with systemic steroid less than 1 month before the trial
Treatment with topical steroid and antihistamines at the time of presentation
Pregnancy
Lactation
Younger than 12 years
 
Interventions Intervention
• Doxepine 5% cream applied twice daily for 8 days and clobetasol 0.05% applied
twice daily for 8 days
Control intervention
• Placebo and clobetasol 0.05% applied twice daily for 8 days
 
Outcomes Primary outcome of the trial
Reduction or improvement in hand eczema before and 8 days after treatment
measured with the hand eczema severity index (HECSI)
Secondary outcomes of the trial
Adverse events 8 days after initiation of treatment
 
Notes Recruitment completed
Study authors contacted for additional information on 20 February 2014, but they
remained unresponsive
Sponsor: Shahid Sadoughi University of Medical Sciences, Yazd
 
IRCT201212303734N2
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Methods Randomised double-blind parallel-group study
 
Participants 108 patients with hand eczema confirmed by a dermatologist
Inclusion criteria
18 to 75 years of age
Eager to participate in the trial
With hand eczema confirmed by a dermatologist
Exclusion criteria
Pregnancy and lactation
Application of topical drugs during previous 2 weeks
Systemic therapies such as corticosteroids
Immunosuppressive drugs and antibiotics during the past 4 weeks
Localised hand infection
History of allergic reaction to study medication
 
Interventions Intervention
• Anti Dry cream (contains Aloe Vera essence, Geranium essence, Lavander essence,
respectively, with ratio of 50:1:15 in vanishing cream), 1 fingertip unit (0.5 grams) for
10 × 10 cm², twice daily for 2 weeks
• Fluocinolone acetonide cream 0.025%, twice daily, for 2 weeks
 
Outcomes Primary outcome of the trial
Change in signs and symptoms of hand eczema on day 14 compared to day 0,
measured by a questionnaire containing clinical signs and symptoms: erythema,
scaling, lichenification/hyperkeratosis, oedema, vesicle, fissure, pruritus, and pain
Secondary outcomes of the trial
Adverse events
Change in pruritus, erythema and scaling, bullae
 
Notes Sponsor: Barij Essence Herbal Medicine Research Center
Current status: recruiting
 
Lassus 1981
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Methods Randomised within-participant study
Probably conducted at a single centre in Finland
This study claims to be double-blind
 
Participants 80 patients with various symmetrical eczemas: allergic eczema (n = 27), atopic
dermatitis (n = 21), toxic hand eczema (n = 10), chronic eczema (n = 7), stasis
eczema (n = 5), nummular eczema (n = 4), neurodermatitis (n = 3), dyshidrotic
eczema (n = 2), seborrhoeic eczema (n = 1)
Dropouts:probably none
Inclusion and exclusion criteria were not stated
 
Interventions All participants were first treated with placebo for 1 week. Afterwards, they were
randomised
Dropouts
Intervention
• Budesonide 0.025% ointment twice daily probably with occlusive dressing
• Betamethasone-17-valerate 0.1% ointment twice daily probably with occlusive
dressing
Duration is not really clear from the article, but probably 2 weeks
 
Outcomes Primary outcomes of the trial
Not defined
Other outcomes 
Investigator-rated severity for itching, scaling, erythema, and induration from 0 to 4
(0 = absent, 4 = very severe) at baseline, week 1, and week 2
Investigator-rated overall expression of response at baseline, week 1, and week 2
Participant-rated overall expression of response at baseline, week 1, and week 2
Adverse events
 
Notes RCT on different forms of symmetrical eczema; this study is published alongside a
study on psoriasis. We were unable to reconstruct the results in participants with hand
eczema, and we were unsuccessful in locating study authors
 
NCT00404196
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Methods Double-blind randomised parallel-group design
 
Participants 75 patients with clinical diagnosis of hand eczema with or without atopic
aetiology/background
Inclusion criteria
Clinical diagnosis of hand eczema with or without atopic aetiology/background
Investigators Global Assessment of disease severity graded as at least mild at visit
1
Caucasian males 18 years of age or older
Attending a hospital outpatient clinic or the private practice of a dermatologist
Following receipt of verbal and written information about the trial, the patient must
provide signed and dated informed consent before any trial-related activity is
carried out, including activities related to washout periods
Exclusion criteria
Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporin,
azathioprine) or corticosteroids within 4 weeks before randomisation (inhaled or
intranasal steroids for asthma or rhinitis may be used)
PUVA or UVB therapy on the hands within 4 weeks before randomisation
Topical treatment with immunomodulators (pimecrolimus, tacrolimus) or
corticosteroids from WHO groups III and IV on the hands within 2 weeks before
randomisation
Other topical therapy on the hands (except for use of emollients) within 1 week
before randomisation
Use of other treatment (drug, non-drug) on the hands during the study except for
use of investigational product and emollient
Concurrent skin disease on the hands
Current diagnosis of exfoliative dermatitis
Significant clinical infection (impetiginised hand eczema) on the hands that requires
antibiotic treatment
Known or suspected hypersensitivity to component(s) of the investigational product
Positive patch test as defined in Section 11.7.4.2 of the protocol
Known or suspected severe renal insufficiency or severe hepatic disorders
History/signs/symptoms suggestive of an abnormality of calcium homeostasis
associated with clinically significant hypercalcaemia
History of cancer except for basal cell carcinoma
Current participation in any other interventional clinical trial
Received treatment with any non-marketed drug substance (i.e. an agent that has
not yet been made available for clinical use following registration) within 4 weeks
before randomisation
Previously randomised in this study
Patients known or, in the opinion of the investigator, unlikely to comply with the
Clinical Study Protocol (e.g. alcoholism, drug dependency, psychotic state)
 
Interventions Intervention
• LEO19123 cream (calcipotriol 50 mcg/g and LEO80122 0.6 mg/g) for 3 weeks
• LEO19123 cream (calcipotriol 15 mcg/g and LEO80122 0.2 mg/g) for 3 weeks
• LEO19123 cream vehicle alone for 3 weeks
 
Outcomes Primary outcome of the trial
Proof of concept
Secondary outcomes of the trial
Safety
 
Notes Sponsor: LEO Pharma
Study has been completed; john.english@nuh.nhs.uk was contacted on 20 February
2014. However, he was not at liberty to disclose information regarding the study. We
therefore contacted LEO Pharma, which was unresponsive
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NCT00614289
Methods Double-blind randomised within-participant design
 
Participants 30 patients with hand eczema
Inclusion criteria
18 years of age or older
Mild to moderate hand dermatitis, according to Investigator Global Assessment
Generally healthy, as determined by brief medical history
Negative urine test for pregnancy if female, and use of highly effective method of
birth control, such as condoms and spermicide, implants, injectables, combined oral
contraceptives, intrauterine device (IUD), sexual abstinence, or a vasectomised
partner. For those using a hormonal contraceptive method, the dose and type of
contraception should stay constant 1 month before enrolment and throughout the
study
Capable of understanding and signing the consent form
Exclusion criteria
Clinically relevant allergic or irritant contact dermatitis and inability to avoid
exposure
Severe and very severe hand dermatitis according to the Investigator Global
Assessment
Severe vesiculation or bullae
History of psoriasis, contact urticaria, and/or pustular disease of the hands
Therapy for the hands with potent topical corticosteroids within 1 month of
enrolment
Use of systemic treatment with oral retinoids, corticosteroids, or PUVA within 8
weeks before the beginning of the study
History of alcoholism or drug abuse
History or current evidence of a chronic or infectious skin disease
Pregnant or lactating females, or using method of birth control that does not comply
with highly effective methods of birth control listed under inclusion criteria; pregnant
or lactating females, or using method of birth control that does not comply with
highly effective methods of birth control listed under inclusion criteria
 
Interventions This study is designed as a prospective, randomised, double-blind right/left
comparison of Epikeia coatings to improve hand dermatitis
 
Outcomes Primary outcomes of the trial
Investigator Global Assessment after 85 days within participant (test vs control
hands)
Hand Eczema Area and Severity Scores after 85 days (within-participant
comparison)
Secondary outcomes of the trial
Ordinal scales measuring subjective efficacy, pain, and itching during 85 days
 
Notes Sponsor: Biomedical Development Corporation
Study has been completed; however we were unable to obtain data from the study
authors, who were unresponsive
 
NCT00843466
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Methods Randomised open-label parallel-group study
 
Participants 46 patients who experience mild to moderate hand dermatitis induced by frequent
cleansing
Inclusion criteria
18 to 65 years of age
General good health
Hands free of cuts and abrasions
Agrees to adhere to the requirements listed in the informed consent
Willing and able to use a mild, moisturising, non-antibacterial cleanser for all
handwashing purposes for the duration of the test period
Willing to refrain from participating in any other clinical research trial for the duration
of the study
Exclusion criteria
Documented allergies to study product components, soaps, latex, or fragrances
History of the following conditions, which may affect response of the skin or
interpretation of results: insulin-dependent diabetes, peripheral vascular disease
Participating in a concurrent clinical study involving treatment of the hands
Currently using a prescription medication for hand dermatitis
 
Interventions Intervention
• A test product (mild, moisturising hand cleanser) for all hand cleansing needs during
the duration of the study.
Control intervention
• No Intervention: the control group will continue to use their current cleanser for
handwashing
 
Outcomes Primary outcome of the trial
Efficacy of mild, moisturising hand cleanser for improvement in hand dermatitis
from frequent handwashing after 4 weeks
 
Notes Sponsor: Wake Forest School of Medicine
Study authors were contacted for additional information; they informed us that trial
results were marginal and this exploratory study was the terminus of this line of
investigation, but we were unable to obtain additional information
 
NCT00867607
Methods Double-blind randomised cross-over design
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Participants 80 patients 18 to 65 years of age with bilateral allergic contact dermatitis of the hands
and forearms
Inclusion criteria
Healthy adult men and women between 18 and 65 years old
Male or non-pregnant female patients who agree to comply with applicable
contraceptive requirements
Satisfactory medical assessment with no clinically significant and relevant
abnormalities (of medical history, physical examination, clinical or laboratory
evaluation (haematology, biochemistry, urinalysis)) as determined by the Principal
Investigator that might interfere with assessment of dermatitis or assessment of the
safety or efficacy of the Study Drug
Must understand and must be able, willing, and likely to fully comply with study
procedures and restrictions
Can understand and provide written informed consent to participate in the study, in
accordance with the International Conference on Harmonisation (ICH) Good
Clinical Practice (GCP) Guideline E6 and applicable regulations
Mild to moderate bilateral allergic contact dermatitis on each hand, possibly
extending to the forearm, according to Physicians Visual Assessment (PVA). Mild to
moderate disease is considered a PVA score of 10 or greater, and there should be
no more than a 1-point difference between hands
Positive reaction to the Standard European Series patch testing kit
(Chemotechnique Diagnostics Products, Malmo, Sweden) after application for 2
days
Exclusion criteria
Current or recurrent disease that could affect the action, absorption, or disposition
of the Study Drug, or clinical or laboratory assessments
Used topical antihistamines in the past 2 weeks, topical corticosteroids, or received
psoralen plus ultraviolet light therapy (PUVA) in the past 4 weeks, or have taken
oral retinoids, corticosteroids in the past 8 weeks (inhaled or intranasal
corticosteroids are allowed, if stable dose)
Used any prescription or OTC medication (excluding hormonal contraceptive,
hormonal replacement therapy, inhaled or intranasal corticosteroids, or oral
NSAIDs) that, in the opinion of the Principal Investigator, could affect (improve or
worsen) the condition being studied, or could affect the action, absorption, or
disposition of the Study Drug, or clinical or laboratory assessments
Must not have used another investigational product or taken part in a clinical trial
within the last 30 days before enrolment
Female patients who are pregnant or lactating, including those with a positive
pregnancy test at screening
Patient known to have a positive hepatitis virus test (hepatitis B virus surface
antigen or hepatitis C virus antibody) or a positive human immunodeficiency virus
(HIV) antibody test
History of hypersensitivity to any of the Study Drugs or their excipients
Any other significant dermatological condition that affects > 10% of the body
surface area, or general medical condition that could interfere with the study
evaluation
Any significant medical condition that could compromise immune responsiveness
History of alcoholism or drug abuse
 
Interventions Intervention
• MRX-6 (2%) twice daily for 21 days
• MRX-6 (1%) twice daily for 21 days
• MRX-6 (0.2%) twice daily for 21 days
• Steroid twice daily for 21 days
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Outcomes Primary outcome of the trial
Safety and tolerability of 3 dose levels of topical MRX-6 (0.2%, 1.0%, and 2%
HyPE) when administered twice daily for 21 consecutive days
Secondary outcomes of the trial
Difference in percentage change in each participant's total Physicians Visual
Assessment (PVA) score from baseline to day 21 between vehicle- and MRX-6-
treated hands/forearms
 
Notes Sponsor: Hadassah Medical Organization
 
NCT00890968
Methods Double-blind randomised parallel-group design
 
Participants 56 adults with chronic hand dermatitis
Inclusion criteria
Clinical diagnosis of stable chronic hand dermatitis (greater than 6 weeks in
duration) that is KOH-negative
Dermatitis of mild to moderate severity, as defined by an Investigator's Global
Assessment (a score of 2 or 3 on the Target Hand)
Individual signs of hand dermatitis disease of at least mild scaling and mild
erythema (a score of 2 or more on the Target Hand)
Written informed consent
Exclusion criteria
Female and pregnant, lactating, or planning to become pregnant during the study
Spontaneously improving or rapidly deteriorating hand dermatitis at the time of
enrolment; possible history of waxing and waning disease in the past
History of hand dermatitis that has been shown to be unresponsive to super-potent
(Group 1) topical steroids
Concurrent flaring of inflammatory skin disease (e.g. atopic dermatitis, psoriasis)
anywhere on the body outside the study areas
Bullous disorders or hand, foot, and mouth disease (HFMD); however, patients with
dyshidrotic hand dermatitis or pompholyx are allowed to participate provided they
meet all other Inclusion/Exclusion criteria
Known allergic mediated hand dermatitis (e.g. allergic to latex)
Concurrent skin disease in the study area that requires concomitant topical
treatment (e.g. tinea manuum, scabies, infected eczema, paronychia) that could
interfere with evaluation of his/her dermatitis
Pustular diseases of the hands (e.g. acrodermatitis perstans continua)
Used phototherapy, photochemotherapy, systemic immunomodulatory therapy
(such as systemic corticosteroids, methotrexate, retinoids, or cyclosporin), or other
therapy within 30 days before the first application of study medication that is known
or suspected, in the opinion of the investigator, to have an effect on hand dermatitis
Prolonged exposure to natural or artificial sources (e.g. UVB, UVA) of ultraviolet
radiation within 30 days before the first application of study medication or intending
to have such exposure during the study
Received intralesional therapy to the hands (e.g. corticosteroids) within 30 days
before first application of study medication
Treated with Grenz ray or soft X-ray therapy to the hands within 6 months of first
application of study medication
Treated with topical hand therapy (e.g. tar, topical corticosteroids, topical retinoids,
topical antimicrobials, topical calcineurin inhibitors, Burrow's solution soaks) within 7
days before first application of study medication that is known or suspected to have
an effect on hand dermatitis
Received systemic antibiotic for infection of the hands within 7 days before the first
application of study medication
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Interventions Intervention
• Triamcinolone acetonide (TAC) DuraPeel topical gel once daily (nightly) for total
duration of 4 weeks
Control intervention
• Placebo: placebo DuraPeel topical gel once daily (nightly) for a total duration of 4
weeks
 
Outcomes Primary outcome of the trial
Response as assessed by Investigator Global Assessment (IGA) at baseline, week
1, week 2, and week 4
Secondary outcomes of the trial
Subjects' Global Impression of Change (SGIC) at week 4 (end-of-treatment) 
Individual primary parameters of hand dermatitis at baseline, week 1, week 2, and
week 4 
Signs or symptoms of hand dermatitis at baseline, week 1, week 2, and week 4
Participant's self-assessment of overall hand disease at baseline and week 4 
Study medication assessment at week 1, week 2, and week 4 
 
Notes Study has been completed; additional information was requested on 20 February
2014; however study authors were unresponsive
Sponsor: ZARS Pharma Inc.
 
NCT01950494
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Methods A randomised double-blind placebo-controlled parallel-group study
 
Participants 20 patients with moderate to severe hand eczema
Inclusion criteria
Informed consent must be signed and understood by patient
Symptoms and history consistent with hand dermatitis based on symptoms and
clinical history
Male or female, 18 to 70 years of age, in generally good health, with no significant
underlying systemic disease requiring ongoing medications
Hand eczema severity index (HECSI) with a score greater than 50
Physician global assessment (PGA) of moderate to severe (PGA: severe,
moderate, mild, almost clear, clear)
Exclusion criteria
Topical corticosteroid or calcineurin inhibitor treatment of the hands and forearms
during the last 7 days before enrolment
Systemic treatment with corticosteroids or other immunosuppressives during the
last 14 days
Currently receiving (or received during the previous 4 weeks) other investigational
drugs, treatments, or devices, or participating in another clinical study
Treatment with ultraviolet (UV) light (including tanning) during the previous 4 weeks
Acute dermatitis outbreak on the arms or hands
Unable to comply with protocol restrictions
Known to be unreliable or non-compliant with medical treatment, or unwilling to
comply with multiple return visits
Any condition or prior/present treatment that in the opinion of investigators should
render the participant ineligible for the study
Known allergy to benzalkonium chloride or other ingredients in the fiteBac vehicle
 
Interventions Intervention
• FiteBac Hand Sanitizer
Control intervention
• Placebor: blinded emollient therapy
 
Outcomes Primary outcome of the trial
Efficacy of fiteBac compared to emollient therapy after 1 month via standardised
questionnaires, physical findings, and photography over a 1-month treatment period
in adults with hand dermatitis
Other outcomes of the trial
Bacterial counts after 1 month
Physician Global Assessment after 1 month, with excellent response defined as
clear or almost clear hands
Number of adverse events
Number of flares during 1 month
Number of study discontinuations during 1 month
Patients Global Assessment score after 1 month
 
Notes Both contact persons were emailed for additional information on 19 February 2014 but
did not respond to our request for additional information
Sponsor: National Jewish Health
 
Footnotes
8-MOP: XXX.
AEs: adverse events.
BCC: basal cell carcinoma.
DASI: Dyshidrotic eczema Area and Severity Index.
GCP: Good Clinical Practice.
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HECSI: hand eczema severity scoring index.
HFMD: hand foot and mouth disease.
ICH: International Conference on Harmonisation.
IGA: investigators' global assessment.
IUD: intrauterine device.
mTLSS: modified total lesion symptom score.
NSAIDs: non-steroidal anti-inflammatory drugs.
OTC: over-the-counter.
PaGA: participants' global assessment.
PASI: XXX.
PGA: physicians' global assessment.
PUVA: topical and oral psoralen combined with UVA.
PVA: physicians visual assessment.
RCT: randomised controlled trial.
SCC: squamous cell carcinoma.
SGIC: subjects' global impression of change.
TAC: triamcinolone acetonide.
TLSS: total lesion symptom score.
UV: ultraviolet.
UVA: ultraviolet A.
UVB: ultraviolet B.
VAS: visual analogue scale.
WHO: World Health Organization.
Characteristics of ongoing studies 
IRCT2014012916412N1
Study name Effects of pumpkin (Moschata cucurbita) ointment on chronic hand eczema
Official title: Effect of topical pumpkin, traditional medicine products, on the chronic
hand eczema
 
Methods Randomised double-blind parallel-group placebo-controlled study
 
Participants 60 patients with moderate chronic hand eczema
Inclusion criteria
Interested in participating in the study
18 to 60 years of age
Mild to moderate chronic hand eczema according to criteria HECSI (occupational
dermatitis, atopic dermatitis, contact dermatitis irritant)
Non-use of oral corticosteroids during the last 2 months
Lack of local immunosuppressors within 4 weeks before treatment
Lack of pregnancy and lactation
No history of contact dermatitis to prescription drugs
Lack of local infection
No obsessive and excessive washing with water and detergent
Absence of immunosuppressive disease
Exclusion criteria
History of allergy to drugs
Use of oral or topical corticosteroids during the 4 weeks before the study
Local infection at the site of the lesion eczema
Women during pregnancy or lactation
Severe obsessive washing
Physical or mental disorders that interfere with participation in the study
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Interventions Intervention
• Betamethasone ointment twice a day for 1 month
• Almond ointment twice a day for 1 month
• Eucerin ointment twice a day for 1 month
• Pumpkin ointment twice a day for 1 month
 
Outcomes Primary outcome of the trial
Hand Eczema Severity Index
Dermatology Life Quality Index
Secondary outcomes of the trial
Skin reactions
Recovery rates
 
Starting date September 2014
 
Contact information Alemeh Khademi
Imam Khomeini Hospital
Islamic Republic of Iran
Skin Clinic, Imam Khomeini Hospital, Keshavarz bulv 
Tehran 
00982166595911 
00989171132340 00 
alemehkhadi@gmail.com
 
Notes Sponsor: Vice Chancellor for Research at Tehran University School of Traditional
Medicine
 
IRCT2017070922965N10
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Study name Effect of topical atorvastatin on hand eczema
Official title: Evaluating the effect of topical atorvastatin as adjuvant therapy in
treatment of hand eczema
 
Methods Randomised double-blind placebo-controlled parallel-group study
 
Participants 70 patients with moderate to severe eczema
Inclusion criteria
18 to 65 years old
Moderate to severe eczema
Less than 25% of the skin involved
Discontinuation of glucocorticoid agents 4 weeks before the investigation
Discontinuation of antipruritus agents 1 week before the investigation 
Exclusion criteria
Younger than 18 years of age
Inflammatory skin disease
Pregnant woman
 
Interventions Intervention
• Betamethasone ointment plus atorvastatin 5% cream 2 times per day for 10 days
• Control group: betamethasone ointment plus placebo atorvastatin 5% cream 2 times
per day for 10 days
 
Outcomes Primary outcome of the trial
Hand eczema index for severity of eczema on day 5 and day 10
 
Starting date 2017-08-19
 
Contact information Maryam Mehrpooya
Hamedan University of Medical Sciences
Shahid Fahmide Avenue
Hamedan
Iran (Islamic Republic of)
+98 81 3838 1594
m_mehrpooya2003@yahoo.com
 
Notes Sponsor: Vice Chancellor for Research, Hamadan University of Medical Sciences
 
ISRCTN80206075
Study name Comparison of alitretinoin with PUVA as the first line treatment in patients with severe
chronic hand eczema: a randomised controlled trial
 
Methods Randomised open-label parallel-group design
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Participants 500 to 780 participants with severe chronic hand eczema
Inclusion criteria
Aged ≥ 18 years at the time of signing the informed consent form
Uncontrolled, severe chronic hand eczema defined as the presence of both of the
following criteria: 
PGA score of severe
Resistance to treatment with potent topical corticosteroids for ≥ 4 weeks before
the point of eligibility screening
Avoidance strategies for known contact allergens in place for at least a 2-week
period before randomisation
Has provided written informed consent 
Expected to comply with treatment and protocol schedule
Exclusion criteria
An extensive list including skin-related, treatment-related, and general exclusion
criteria
 
Interventions Intervention
• Alitretinoin 30 mg a day for 12 to 24 weeks
• Immersion PUVA (twice weekly) for 12 to 24 weeks
 
Outcomes Primary outcome of the trial
Disease activity of the index hand, quantified by the HECSI tool, at 12 weeks post
planned start of treatment
Secondary outcomes of the trial
Disease activity of the index hand, quantified by the HECSI tool, at 24 and 52
weeks post planned start of treatment
Disease activity of the index hand, quantified by the mTLSS tool, at 24 and 52
weeks post planned start of treatment
Disease activity of the index hand, quantified by the PGA tool at 24 and 52 weeks
post planned start of treatment
Time to relapse of the index hand (HECSI score > 75% baseline HECSI score of
the index hand) 
Time in remission of the index hand (defined by the period when the participant is
classed as clear/almost clear until the disease is scored as ‘mild’ or higher on the
PGA scale, and participants have been using topical corticosteroids daily for the
previous 7 or more days)
Patient-reported outcome using the DLQI tool, over the 52 weeks post planned start
of treatment
Patient-reported outcome using the PBI-HE over the 52 weeks post planned start of
treatment
PeDeSi over the 52 weeks post planned start of treatment
Cost-effectiveness over the 52 weeks post planned start of treatment 
 
Starting date 01/01/2015
 
Contact information Dr. Victoria Goss (Senior Trial Coordinator)
ctru-alpha@leeds.ac.uk
 
Notes The study protocol is published at
http://www.nihr.ac.uk/__data/assets/pdf_file/0005/136994/PRO-12-186-01.pdf
Sponsor: Unversity of Leeds (UK)
 
JPRN-UMIN000003326
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Study name A clinical trial to determine the effect of olopatadine on itching in hand eczema
 
Methods Randomised single-blind (participants are blinded) parallel-group placebo-controlled
study
 
Participants 50 patients with hand eczema and itch
Inclusion criteria
Outpatients
Hand eczema patients with itch
Able to provide their own written informed consent for taking part in the study
Male and female
Over 20 years of age
Exclusion criteria
Treated with oral or injectable steroids
Under specific or aspecific modulation therapy
With severe hepatic or renal disorders
Pregnant or lactating women and women who may be pregnant
 
Interventions Intervention
• Olopatadine-treated group
Control intervention
• Placebo olopatadine non-treated group
 
Outcomes Primary outcome of the trial
Visual analogue scale
Secondary outcomes of the trial
Skin index
 
Starting date 1 March 2010
 
Contact information Kaoru Takayama
Tokyo Medical and Dental University Dermatology
Department Dermatology
Bukyou-ku 1-5-45
Japan
tkaoru.derm@tmd.ac.jp
Telephone: +81-358035286
 
Notes Sponsor: Department of Dermatology, Tokyo Medical and Dental University
Current status: recruiting
 
NCT02664805
Study name Proof of concept, twice daily applications of LEO 124249 ointment in the treatment of
chronic hand eczema
Official title: A phase 2a, proof of concept trial, testing twice daily applications of LEO
124249 ointment in the treatment of chronic hand eczema
 
Methods Randomised double-blind vehicle-controlled parallel-group study
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Participants 91 patients with chronic hand eczema
Inclusion criteria
Clinical diagnosis of chronic hand eczema with or without atopic
aetiology/background with a history of not adequately controlled disease activity
with cutaneously applied steroid
Physician's Global Assessment of disease severity graded as at least mild at visit 1
In overall good health, including well-controlled disease
Exclusion criteria
Systemic treatment with immunosuppressive drugs (e.g. methotrexate,
cyclosporine, azathioprine), retinoids (e.g. alitretinoin), or corticosteroids within 6
weeks before randomisation (inhaled or intranasal steroids corresponding to up to 1
mg prednisone for asthma or rhinitis may be used)
PUVA (psoralen ultraviolet A) or UVB (ultraviolet B) therapy on the hands within 4
weeks before randomisation
Cutaneously applied treatment with immunomodulators (pimecrolimus, tacrolimus)
or corticosteroids on the hands within 2 weeks before randomisation
Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 2
weeks before randomisation
Concurrent skin disease on the hands
Current diagnosis of exfoliative dermatitis
Significant clinical infection (impetiginised hand eczema) on the hands that requires
antibiotic treatment
Markedly abnormal ECG at baseline
Known hepatic dysfunction or hepatic dysfunction tested at screening
Current participation in any other interventional clinical trial
 
Interventions Intervention
• LEO 124249 ointment twice-daily cutaneous application for 8 weeks
Control intervention
• LEO 124249 ointment vehicle twice-daily cutaneous application for 8 weeks
 
Outcomes Primary outcome of the trial
Treatment success according to Physician's Global Assessment (PGA) at end of
treatment (8 weeks). Treatment success according to the PGA is defined as
follows: subjects having mild disease at baseline must achieve clear. Subjects
having moderate or severe disease at baseline must achieve clear or almost clear
Secondary outcomes of the trial
Hand Eczema Severity Index (HECSI) at end of treatment (8 weeks)
Participants with treatment success according to the Patient's Global Assessment
of disease severity (PaGA) at end of treatment (8 weeks). Treatment success
according to the PaGA is defined as follows: Subjects having very mild or mild
disease at baseline must achieve clear. Subjects having moderate or severe
disease at baseline must achieve clear or very mild
 
Starting date February 2016
 
Contact information Prof. Dr. Margitta Worm,
Allergie-Centrum-Charité Klinik für Dermatologie, Venerologie und Allergologie
Berlin, Germany 10117
 
Notes Sponsor: LEO Pharma
 
NCT03026907
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Study name Efficacy of oral alitretinoin versus oral azathioprine in patients with severe chronic non-
hyperkeratotic hand eczema. A randomized prospective open-label trial with blinded
outcome assessment
 
Methods Randomised observer-blind vehicle-controlled parallel-group study
 
Participants 116 patients with severe chronic non-hyperkeratotic hand eczema
Inclusion criteria
≥ 18 years and ≤ 75 years of age
Severe or very severe chronic non-hyperkeratotic hand eczema for a minimum
duration of 3 months as defined by a Physician Global Assessment (PGA) using a
validated Photoguide
Refractory to standard therapy, defined as follows: patients received treatment with
topical corticosteroids of class II or higher for at least 8 weeks within 3 months
before enrolment, with no response or a transient response. Patients had also
received standard skin care, including emollients and barrier protection as
appropriate, without significant improvement. Patients had avoided irritants and
allergens, if identified, without significant improvement
Women of child-bearing potential are required to use at least 2 forms of
contraception for at least 1 month before starting treatment, during treatment, and
for at least 1 month after finishing treatment; these women are required to take
monthly pregnancy tests
Able to provide written informed consent
Able to speak and read the Dutch language
Exclusion criteria
Extensive list
 
Interventions Intervention
• Oral alitretinoin capsule of 30 mg once daily for a total of 24 weeks
• Oral azathioprine tablets twice daily at a dose of 1.5 or 2.5 mg/kg/d, depending on
thiopurine methyltransferase (TPMT) activity
 
Outcomes Primary outcome of the trial
Response to treatment/hand eczema severity (Photoguide) after 24 weeks (end of
treatment)
Secondary outcomes of the trial
Response to treatment/hand eczema severity (Photoguide) after 12 weeks
Response to treatment/hand eczema severity based on th Hand Eczema Severity
Index (HECSI) at weeks 4, 8, 12, and 24
Time to response at weeks 4, 8, 12, and 24
Patient-reported improvement based on the Patient Global Assessment (PaGA) at
weeks 12 and 24
Adverse events up to 24 weeks
Cost utility. QALYs: registered direct/indirect costs, combined with EQ-5D outcome
at weeks 12 and 24
Cost-effectiveness: registered direct/indirect costs combined with primary and
secondary effectiveness outcomes (Photoguide/HECSI) at weeks 12 and 24
Quality of life: questionnaire at weeks 12 and 24
 
Starting date May 2016
 
Contact information Marie-Louise A. Schuttelaar, MD, PhD
University Medical Center Groningen
The Netherlands
+31503612520
m.l.a.schuttelaar@umcg.nl
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Notes Sponsor: University Medical Center Groningen
 
NCT03026946
Study name Efficacy of oral alitretinoin versus oral cyclosporine in patients with severe recurrent
vesicular hand eczema. A randomised prospective open-label trial with blinded
outcome assessment
 
Methods Randomised observer-blind vehicle-controlled parallel-group study
 
Participants 116 patients with severe or very severe recurrent vesicular hand eczema
Inclusion criteria
Severe or very severe recurrent vesicular hand eczema for a minimum duration of 3
months as defined by a Physician Global Assessment (PGA) using a validated
Photoguide
≥ 18 years and ≤ 75 years of age
Severe or very severe chronic non-hyperkeratotic hand eczema for a minimum
duration of 3 months as defined by a Physician Global Assessment (PGA) using a
validated Photoguide
Refractory to standard therapy, defined as follows: patients received treatment with
topical corticosteroids of class II or higher for at least 8 weeks within 3 months
before enrolment, with no response or a transient response. Patients had also
received standard skin care, including emollients and barrier protection as
appropriate, without significant improvement. Patients had avoided irritants and
allergens, if identified, without significant improvement
Women of child-bearing potential are required to use at least 2 forms of
contraception for at least 1 month before starting treatment, during treatment, and
for at least 1 month after finishing treatment; these women are required to take
monthly pregnancy tests
Able to provide written informed consent
Able to speak and read the Dutch language
Exclusion criteria
Extensive list
 
Interventions Intervention
• Oral alitretinoin capsule of 30 mg once daily for a total of 24 weeks
• Oral cyclosporine A starting dose 5 mg/kg/d (split into 2 doses), with decreasing dose
after 8 weeks to 3 to 3.5 mg/kg/d (split into 2 doses). The treatment period is 24 weeks
 
Outcomes Primary outcome of the trial
Response to treatment/hand eczema severity (Photoguide) after 24 weeks (end of
treatment)
Secondary outcomes of the trial
Response to treatment/hand eczema severity (Photoguide) after 12 weeks
Response to treatment/hand eczema severity based on the Hand Eczema Severity
Index (HECSI) at weeks 4, 8, 12, and 24
Time to response at weeks 4, 8, 12, and 24
Patient-reported improvement based on the Patient Global Assessment (PaGA) at
weeks 12 and 24
Adverse events up to 24 weeks
Cost-utility. QALYs: registered direct/indirect costs, combined with EQ-5D outcome
at weeks 12 and 24
Cost-effectiveness: registered direct/indirect costs combined with primary and
secondary effectiveness outcomes (Photoguide/HECSI) at weeks 12 and 24
Quality of Life: questionnaire at weeks 12 and 24
 
Starting date 1 March 2017
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Contact information Marie-Louise A Schuttelaar, MD, PhD
University Medical Center Groningen
The Netherlands
+31503612520
m.l.a.schuttelaar@umcg.nl
 
Notes Sponsor: University Medical Center Groningen
ZonMw: The Netherlands Organisation for Health Research and Development
 
PACTR201704002194318
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Study name Assessment of botulinum toxin type A in the treatment of hand eczema
 
Methods Randomised double-blind placebo-controlled parallel-group study
 
Participants 60 patients with hand eczema
Inclusion criteria
Active symptomatic palmar hand eczema 
Bilateral involvement
18 to 70 years of age
Exclusion criteria
Skin infection at the site of injection 
History of use of botulinum toxin in the last 4 months
Pregnancy, lactation in females
Any contraindication to botulinum toxin injection including associated disorder that
may affect neuromuscular function, like myasthenia gravis and Lambert-Eaton
disease
History of previous allergy to BTXA
 
Interventions Intervention:
• Intradermal palmar injection of a minimum of 50 units of botulinum toxin type A
combined with topical corticosteroids
• Topical betamethasone twice daily
 
Outcomes Primary outcome of the trial
Visual linear analogue scale of pruritus at baseline at the third day, end of first
week, fourth week, then monthly for a whole period of 6 months
Secondary outcomes of the trial
Hand eczema severity index at baseline at third day, end of first week, fourth week,
then monthly for a whole period of 6 months
 
Starting date 2017-04-15
 
Contact information Carmen Amin
El Areesh Street, No. 2, Smouha, 3rd floor
#302 21646
Alexandria
Egypt
002-01222966670
carmen271173@yahoo.com
 
Notes Sponsor: Dermatology Department, Faculty of Medicine, University of Alexandria
 
Footnotes
BTXA: botulinum toxin A.
DLQI: Dermatology Life Quality Index.
ECG: electrocardiogram.
EQ-5D: standardised index for measuring quality of life.
HECSI: hand eczema severity scoring index.
mTLSS: modified total lesion symptom score.
PaGA: participants' global assessment.
PBI-HE: patient benefit index for chronic hand eczema.
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PeDeSi: XXX.
PGA: physicians' global assessment.
PUVA: topical and oral psoralen combined with UVA.
QALY: quality-adjusted life-year.
TLSS: total lesion symptom score.
UVB: ultraviolet B.
Summary of findings tables
1 Corticosteroid creams/ointments: clobetasol propionate foam compared to vehicle foam for hand eczema
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Corticosteroid creams/ointments: clobetasol propionate foam compared to vehicle foam for hand eczema
Patient or population: participants with moderate to severe hand eczema
Setting: secondary care with outpatients in Northern America
Intervention: clobetasol propionate 0.05% foam twice a day for 14 days
Comparison: vehicle/placebo foam twice a day for 14 days
Outcomes Anticipated absolute effects*
(95% CI)
Relative
effect
(95% CI)
No. of
participants
(studies)
Certainty of
the evidence
(GRADE)
Comments
Assumed
riska Corresponding risk
Risk with
vehicle foam
Risk with clobetasol
propionate foam
Primary: investigator-rated
good/excellent control of symptoms
Follow-up: day 15
Study population RR 1.43
(0.86 to
2.40)
125
(1 RCT)
⊕⊕⊕⊝
Moderateb
-
270 per
1000
386 per 1000
(232 to 648)
Primary: participants with self-rated
good/excellent control of symptoms
Follow-up: day 15
Study population RR 2.32
(1.38 to
3.91)
125
(1 RCT)
⊕⊕⊕⊝
Moderatec
NNTB 3 (95%
CI 2 to 8)222 per
1000
516 per 1000
(307 to 869)
Primary: adverse events - at least 1
adverse event
Follow-up: day 15
Study population RR 2.24
(0.82 to
6.06)
125
(1 RCT)
⊕⊕⊕⊝
Moderatec
-
79 per 1000 178 per 1000
(65 to 481)
Primary: adverse events - any
adverse event treatment-related
(application site pruritus)
Follow-up: day 15
Study population RR 1.02
(0.06 to
15.89)
125
(1 RCT)
⊕⊕⊕⊝
Moderated
-
16 per 1000 16 per 1000
(1 to 252)
Secondary: reduction in severity,
participant-rated scoring
Follow-up: day 15
Study population RR 1.57
(1.21 to
2.04)
125
(1 RCT)
⊕⊕⊕⊝
Moderateb
NNTB 3 (95%
CI 2 to 7)524 per
1000
822 per 1000
(634 to 1000)
Secondary: reduction in severity,
investigator-rated scoring -
improvement at least 2 grades
Follow-up: day 15
Study population RR 1.47
(0.90 to
2.39)
125
(1 RCT)
⊕⊕⊕⊝
Moderateb
 
286 per
1000
420 per 1000
(257 to 683)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; RCT: randomised controlled
trial; RR: risk ratio.
Kircik 2013
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate
of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different
from the estimate of effect.
Footnotes
aThe assumed risk is the mean control group risk.
bDowngraded by one level to moderate-certainty evidence for imprecision. Small sample size and small number of events.
cDowngraded by one level to moderate-certainty evidence for imprecision. Wide confidence interval with small sample size
and small number of events.
dDowngraded by one level to moderate-certainty evidence for imprecision. Summary effect contains both appreciable benefit
and harm; wide confidence interval with small sample size and small number of events.
2 Corticosteroid creams/ointments: mometasone furoate cream 3 times/week versus 2 times/week for hand
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eczema
Corticosteroid creams/ointments: mometasone furoate cream thrice a week versus twice a week
Patient or population: people (all patch-tested) with hand eczema > 6 months that had cleared upon daily treatment for a
maximum of 9 weeks with mometasone furoate cream
Settings: secondary care with outpatients from hospitals in Denmark
Intervention: mometasone furoate cream 3 times/week up to 36 weeks
Comparision: mometasone furoate cream 2 times/week up to 36 weeks
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
No. of
participants
(studies)
Certainty of
the evidence
(GRADE)
Comments
Assumed riska Corresponding risk
Risk with
mometasone furoate
twice a week
Risk with
mometasone furoate
thrice a week
Primary: investigator-rated
good/excellent control of
symptoms
Follow-up: 36 weeks
Study population RR 1.23 
(0.94 to
1.61)
72
(1 RCT)
⊕⊕⊝⊝
Lowb
-
676 per 1000 831 per 1000
(635 to 1000)
Primary: participant-rated
good/excellent control of
symptoms
Not measured
See comment See comment Not
estimable
- See
comment
No data
available
Primary: adverse events
Follow-up: 36 weeks
Study population RR 1.76 
(0.45 to
6.83)
72
(1 RCT)
⊕⊕⊝⊝
Lowc
-
81 per 1000 143 per 1000
(36 to 554)
Secondary: investigator-
rated reduction in severity 
Not measured
See comment See comment Notestimable -
See
comment
No data
available
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The
corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative
effect of the intervention (and its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio.
Veien 1999
GRADE Working Group grades of evidence.
High certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and
may change the estimate.
Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
Very low certainty: we are very uncertain about the estimate.
Footnotes
aThe assumed risk is the mean control group risk.
bDowngraded by two levels to low-certainty evidence. Imprecision downgraded by one level: the event number was small as
was the sample size. Downgraded one level for risk of bias, given the high risk of detection and performance bias.
cDowngraded by two levels to low-certainty evidence. Imprecision downgraded by one level: the summary effect contains
both appreciable benefit and harm; sample size was small as was the event rate. Downgraded one level for risk of bias,
given the high risk of detection and performance bias.
3 Irradiation with UV light: local narrow-band UVB compared to local PUVA for hand eczema
#29 Interventions for hand eczema
207 / 280
Irradiation with UV light: local narrow-band UVB compared to local PUVA for hand eczema
Patient or population: people with hand eczema unresponsive to clobetasol propionate
Setting: secondary care with outpatients in the United Kingdom.
Intervention: local narrow-band UVB twice weekly for 12 weeks
Comparison: immersion PUVA twice weekly for 12 weeks
Outcomes Anticipated absolute effects*
(95% CI)
Relative
effect
(95% CI)
No. of
participants
(studies)
Certainty of
the
evidence
(GRADE)
Comments
Assumed
riska
Corresponding
risk
Risk with
local PUVA
Risk with local
narrow-band
UVB
Primary: investigator-
rated good/excellent
control of symptoms
Follow-up: 12 weeks
Study population RR 0.50
(0.22 to 1.16)
60
(1 RCT)
⊕⊕⊕⊝
Moderateb
-
400 per 1000 200 per 1000
(88 to 464)
Primary: participant-
rated good/excellent
control of symptoms 
Not measured
See
comment See comment
Not
estimable -
See
comment No data reported
Primary: adverse
events - reported
adverse events,
mainly erythema
Follow-up: 12 weeks
See
comment
See comment RR 19.00
(1.16 to
312.42)
60
(1 RCT)
⊕⊕⊕⊝
Moderatec
PUVA:
No adverse events reported
(0/30)
Narrow-band UVB:
9 out of 30 participants
reported an adverse event,
mainly erythema
Fisher's exact test  P = 0.0019
 
Secondary:
investigator-rated
reduction in severity
in mTLSSd
Follow-up: 12 weeks
Data not
reproducible
Data not
reproducible
Data not
reproducible
43 (1 RCT) ⊕⊕⊕⊝
Moderatee
Reduction in mTLSS PUVA:
Median mTLSS of 8.5 (range 0
to 16) and 8 (range 3 to 15) for
the left and right hand, to a
median mTLSS 3 (range 0 to
13) and 3 (range 0 to 14) (n =
23)
Reduction mTLSS local
narrow-band UVB group:
Median mTLSS of 7 (range 0
to 16) and 8.5 (range 1 to 15)
to a median mTLSS5 (range 0
to 11) and 4.5 (range 0 to 11)
(n = 20)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; mTLSS: modified total lesion symptom score; PUVA: oral psoralen combined with UVA; RCT:
randomised controlled trial; RR: risk ratio; UV: ultraviolet.
2015
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate
of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different
from the estimate of effect.
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Footnotes
aThe assumed risk is the mean control group risk.
bDowngraded by one level to moderate-certainty evidence for imprecision. Small sample size, small number of events, and
high dropout rate.
cDowngraded by one level to moderate-certainty evidence for imprecision. Wide confidence interval with small sample size,
small number of events, and high dropout rate.
dThe Modified Total Lesion Symptom Score (mTLSS) is the sum of seven items (erythema, oedema, vesiculation, scaling,
lichenification/hyperkeratosis, fissures, and pruritus/pain) scored on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 =
severe). A high mTLSS represents severe hand eczema.
eDowngraded by one level to moderate-certainty evidence for imprecision. Small sample size based on single study.
4 Topical calcineurin inhibitors: tacrolimus 0.1% ointment compared to mometasone furoate ointment for
vesicular hand eczema
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Topical calcineurin inhibitors: tacrolimus 0.1% ointment compared to mometasone furoate ointment for vesicular hand
eczema
Patient or population: people with moderate to severe chronic relapsing dyshidrotic eczema on hands
Setting: secondary care setting at a single dermatology department in Germany
Intervention: topical calcineurin inhibitors tacrolimus 0.1% ointment twice daily during 4 weeks
Comparison: topical corticosteroid mometasone furoate ointment twice daily during 4 weeks
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
No. of
participants
(studies)
Certainty of
the
evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Risk with
mometasone
furoate ointment
Risk with topical
calcineurin inhibitor
tacrolimus 0.1%
ointment
Primary: investigator-
rated good/excellent
control of symptoms -
Not measured
See comment See comment Notestimable -
See
comment Not measured
Primary: participant-
rated good/excellent
control of symptoms -
Not measured
See comment See comment Notestimable -
See
comment Not measured
 
Primary: adverse
events 
Follow-up: 2 weeks
See comment See comment Notestimable
16 pairs of
hands (1
RCT)
⊕⊕⊕⊝
Moderatea
Within-participant
design
None of the
participants dropped
out because of
adverse events
Secondary:
investigator-rated
reduction in severity -
DASIb
Follow-up: 2 weeks
See comment See comment Not
estimable
16 pairs of
hands (1
RCT)
⊕⊕⊕⊝
Moderatea
Within-participant
design
Tacrolimus group:
Mean DASI from 18
(SD 12.68) to 6.6 (SD
6.18)
Mometasone furoate
group:
Mean DASI from 18.5
(SD 14.09) to 6.9 (SD
7.7)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The
corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative
effect of the intervention (and its 95% CI).
CI: confidence interval; DASI: Dyshydrotic Eczema Area and Severity Index; RCT: randomised controlled trial; RR: risk
ratio; SD: standard deviation.
Schnopp 2002
GRADE Working Group grades of evidence.
High certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and
may change the estimate.
Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
Very low certainty: we are very uncertain about the estimate.
Footnotes
aDowngraded by one level to moderate-certainty evidence for imprecision: small sample size in a single study and small
number of events.
bDASI: Dyshydrotic Eczema Area and Severity Index is an assessment of severity combining objective (vesicles, erythema,
and desquamation) and subjective (itch) evaluations on a scale from 0 (no eczema) to 60 (severe hand eczema).
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5 Topical calcineurin inhibitors: tacrolimus 0.1% ointment versus vehicle for hand eczema
Topical calcineurin inhibitor tacrolimus 0.1% ointment compared to vehicle for hand eczema 
Patient or population: people with moderate to severe nickel sulphate-induced allergic contact dermatitis based on clinical
history (hand eczema) and proven by patch testing, resistant to topical corticosteroids
Settings: secondary care setting in a single-centre study in Italy
Intervention: topical calcineurin inhibitor tacrolimus 0.1% ointment twice daily for 2 weeks
Comparison: vehicle twice daily for 2 weeks
Outcomes Anticipated absolute effects*
(95% CI)
Relative
effect
(95% CI)
No. of
participants
(studies)
Certainty of
the
evidence
(GRADE)
Comments
Assumed
risk
Corresponding
risk
Risk with
vehicle
Risk with
tacrolimus 0.1%
ointment
Primary: investigator-
rated good/excellent
control of symptoms
Follow-up: 3 weeks
See
comment
See comment RR 29.00
(1.90 to
443.25)
28
(1 RCT)
⊕⊕⊕⊝
Moderatea 
Unable to calculate assumed risk as
no events in the control group -
14/14 participants in the tacrolimus
group had good/excellent control of
symptoms.
Fisher's exact test P = 0.0001,
NNTB 1, 95% CI 1 to 1
Primary: participant-
rated good/excellent
control of symptoms 
Not measured
See
comment
See comment Not
estimable
- See
comment
No data reported
Primary: adverse
events -
burning/itching at
application site
Follow-up: 3 weeks
See
comment
See comment RR 9.00
(0.53 to
152.93)
28
(1 RCT)
⊕⊕⊕⊝
Moderatea
Unable to calculate assumed risk as
no events in the control group - 4/14
participants in the tacrolimus group
had burning/itching at the
application site.
Fisher's exact test P = 0.1129, RR
9.00, 95% CI 0.53 to 152.93
No data on "all adverse events"
Secondary:
investigator-rated
reduction in severity -
Not measured
See
comment See comment
Not
estimable -
See
comment No data reported
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The
corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative
effect of the intervention (and its 95% CI).
CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; RCT: randomised controlled
trial; RR: risk ratio.
Pacor 2006
GRADE Working Group grades of evidence.
High certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and
may change the estimate.
Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
Very low certainty: we are very uncertain about the estimate.
Footnotes
aDowngraded by one level to moderate-certainty evidence for imprecision: very small sample size, low event rate, and very
large confidence intervals.
6 Oral immunosuppressants: oral cyclosporin versus topical betamethasone dipropionate
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Oral cyclosporin compared to topical betamethasone for patient with hand eczema
Patient or population: people with hand eczema, continuously for 6 months, significant disability, inadequate response to
conventional treatment, confirmation by histopathology
Setting: secondary care setting at a single centre in Finland
Intervention: oral cyclosporin 3 mg/kg/d and placebo cream for 6 weeks
Comparison: topical betamethasone dipropionate 0.05% cream and placebo capsules for 6 weeks
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
No. of
participants
(studies)
Certainty of
the
evidence
(GRADE)
Comments
Assumed riska Correspondingrisk
Risk with topical
betamethasone
Risk with oral
cyclosporin
 
Primary:
investigator- rated
good/excellent
control of symptomsb
Follow-up: 6 weeks
Study population RR 1.88
(0.88 to
3.99)
34
(1 RCT)
⊕⊕⊕⊝
Moderatec
-
333 per 1000 627 per 1000
(293 to 1000)
Primary: participant-
rated good/excellent
control of symptomsb
Follow-up: 6 weeks
Study population RR 1.25
(0.69 to
2.27)
34
(1 RCT)
⊕⊕⊕⊝
Moderatec
-
500 per 1000 625 per 1000
(345 to 1000)
Primary: adverse
events - at least 1
adverse event
Follow-up: 36 weeks
Study population RR 1.22
(0.80 to
1.86)
55d
(1 RCT)
⊕⊕⊕⊝
Moderatec
Because of partial
cross-over design, a
different number of
participants is given for
this outcome
556 per 1000 678 per 1000
(444 to 1000)
Secondary:
investigator-rated
reduction in severityb
Follow-up: 6 weeks
Mean investigator-rated
reduction in severity in total
disease activity score after
6 weeks of treatment
was 5.7
MD 0.30 higher
(2.50 lower to
3.10 higher)
- 34(1 RCT)
⊕⊕⊕⊝
Moderatec -
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The
corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative
effect of the intervention (and its 95% CI).
CI: confidence interval; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio.
Granlund 1996
GRADE Working Group grades of evidence.
High certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and
may change the estimate.
Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
Very low certainty: we are very uncertain about the estimate.
Footnotes
aThe assumed risk is the mean control group risk.
bObserver-rated disease activity score: grading 0 to 3 (0 = none, 1 = mild, 2 = moderate, 3 = severe) on erythema, scaling,
infiltration, excoriation, crusting, and vesicles for both hands. A high score represents severe hand eczema.
cDowngraded by one level to moderate-certainty evidence. Imprecision downgraded by one level: small sample size.
dThe number of participants varies between different outcomes because this is a cross-over study, and adverse events were
included from all different phases of the trial.
7 Oral retinoids: alitretinoin 30 mg versus placebo for hand eczema
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Oral retinoids: alitretinoin 30 mg versus placebo for hand eczema
Patient or population: people with moderate to severe chronic hand eczema
Settings: secondary care with outpatients in an international multi-centre setting
Intervention: oral retinoid alitretinoin 30 mg for 12 to 24 weeks
Comparison: oral placebo for 12 to 24 weeks
Outcomes Anticipated absolute effects*
(95% CI)
Relative
effect
(95% CI)
No. of
participants
(studies)
Certainty of
the evidence
(GRADE)
Comments
Assumed
riska
Corresponding
risk
Risk with
placebo
Risk with
alitretinoin 30 mg
Primary: investigator-rated
good/excellent control of
symptoms
Follow-up: 48 weeks to 72
weeks
Study population RR 2.75
(2.20 to
3.43)
1210
(2 RCTs)
⊕⊕⊕⊕
Highb
NNTB 4, 95% CI 3 to 5
157 per
1000
432 per 1000
(346 to 539)
Primary: participant-rated
good/excellent control of
symptoms
Folluw-up: 48 weeks to 72
weeks
Study population RR 2.75
(2.18 to
3.48)
1210
(2 RCTs)
⊕⊕⊕⊕
Highb
NNTB 4, 95% CI 3 to 5
143 per
1000
394 per 1000
(312 to 498)
Primary: adverse events -
headache
Folluw-up: 48 weeks to 72
weeks
Study population RR 3.43
(2.45 to
4.81)
1210
(2 RCTs)
⊕⊕⊕⊕
Highb
All adverse events not
stated in Ruzicka 2008
NNTH 6, 95% CI 4 to 11
74 per
1000
251 per 1000
(179 to 352)
Secondary: investigator-
rated reduction in severity
in TLSSc and mTLSSd
See
comment See comment
Not
estimable -
See
comment
Only incomplete data
reported; therefore we
were unable to extract
these data
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The
corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative
effect of the intervention (and its 95% CI).
CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to treat
for an additional harmful outcome; RCT: randomised controlled trial; RR: risk ratio.
Ruzicka 2008; Fowler 2014
GRADE Working Group grades of evidence.
High certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and
may change the estimate.
Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
Very low certainty: we are very uncertain about the estimate.
Footnotes
aThe assumed risk is the mean control group risk.
bRelatively high number of dropouts, although analysed via intention-to-treat analysis. Risk of bias was low, the two included
studies were consistent, and the evidence is applicable to patients with (moderate to) severe hand eczema. Risk of
publication bias was considered low, although the studies were sponsored by a pharmaceutical company.
cThe total lesion symptom score (TLSS) is the sum of seven items (erythema, oedema, vesicles, desquamation,
hyperkeratosis, fissures, and pruritus/pain) scored on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe). A high
TLSS represents severe hand eczema.
dThe modified total lesion symptom score (mTLSS) is the sum of seven items (erythema, oedema, vesiculation, scaling,
lichenification/hyperkeratosis, fissures, and pruritus/pain) scored on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 =
severe). A high mTLSS represents severe hand eczema.
8 Oral retinoids: alitretinoin 10 mg versus placebo for hand eczema
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Oral retinoids: alitretinoin 10 mg versus placebo for hand eczema
Patient or population: people with moderate to severe chronic hand eczema
Settings: secondary care with outpatients in an international multi-centre setting
Intervention: oral retinoid alitretinoin 10 mg for 12 to 24 weeks
Comparison: oral placebo for 12 to 24 weeks
Outcomes Anticipated absolute effects*
(95% CI)
Relative
effect
(95% CI)
No. of
participants
(studies)
Certainty of
the evidence
(GRADE)
Comments
Assumed
riska
Corresponding
risk
Risk with
placebo
Risk with
alitretinoin
Primary: investigator-rated
good/excellent control of
symptoms 
Follow-up: up to 48 weeks
Study population RR 1.58
(1.20 to
2.07)
781
(2 RCTs)
⊕⊕⊕⊕
Highb
NNTB 11, 95% CI 6.3
to 26.5194 per
1000
307 per 1000
(233 to 402)
Primary: participant-rated
good/excellent control of
symptoms
Follow-up: up to 48 weeks
Study population RR 1.73
(1.25 to
2.40)
765
(2 RCTs)
⊕⊕⊕⊕
Highb
NNTB 9, 95% CI 6 to
20144 per
1000
249 per 1000
(180 to 345)
Primary: all adverse events
Follow-up: up to 48 weeks
Study population RR 1.01
(0.66 to
1.55)
158
(1 RCT)
⊕⊕⊕⊝
Moderatec
NNTH 260, 95% CI
-14.47 to 15.24346 per
1000
350 per 1000
(228 to 537)
Secondary: investigator-
rated reduction in severity
of TLSSd
Follow-up: up to 48 weeks
See
comment See comment -
158
(1 RCT) ⊕⊕⊕⊝Moderatec
 
Median % change in
score from baseline
(95% CI)
Placebo group:
-25% (95% CI -42 to
-14)
Aitretinoin 10 mg:
–59 (95% CI –73 to
–33)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The
corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative
effect of the intervention (and its 95% CI).
CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to treat
for an additional harmful outcome; RCT: randomised controlled trial; RR: risk ratio; TLSS: total lesion symptom score.
Ruzicka 2004; Ruzicka 2008
GRADE Working Group grades of evidence.
High certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and
may change the estimate.
Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
Very low certainty: we are very uncertain about the estimate.
Footnotes
aThe assumed risk is the mean control group risk.
b Both studies were at low risk of bias and results were precise.
cDowngraded by one level to moderate-certainty evidence: imprecision downgraded by one level: small sample size.
dThe total lesion symptom score (TLSS) is the sum of seven items (erythema, oedema, vesicles, desquamation,
hyperkeratosis, fissures, and pruritus/pain) scored on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe). A high
TLSS represents severe hand eczema.
Additional tables 
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1 Overview of studies on bland emollients: investigator-rated good/excellent control
Study Comparison Investigator-rated good/excellent control in RR (95%CI) Comment
Kucharekova
2003
Ceramide-containing emollient vs
regular petrolatum-based emollient
No data regarding the primary outcome investigator-
rated good/excellent control -
Chu 2009 E-DO lotion vs vehicle lotion
E-DO: 37 responders, 12 of whom responded to E-
DO only (19%), and 25 to both (39.7%)
Vehicle: 36 responders, 11 of whom responded to
vehicle only (17.5%), and 25 to both (39.7%)
Investigator-rated RR 1.06 (95% CI 0.54 to 2.10)
Within-patient
study
Footnotes
E-DO is a trade/product name.
2 Overview of studies on topical corticosteroids: investigator-rated good/excellent control
Study Comparison of topical corticosteroids Investigator-rated good/excellent control in RR(95% CI) Comment
Möller
1983 Intermittent clobetasol vs fluprednidene
Clobetasol better since 32/46 vs 14/46 hands
remained in remission; investigator-rated Within-patient study
Uggeldahl
1986 Desonide 0.1% vs desonide 0.05%
No data regarding the primary outcome
investigator-rated good/excellent control Within-patient study
Bleeker
1989 Fluprednidene vs betamethasone
RR 0.59 (95% CI 0.28 to 1.23); investigator-
rated -
Gupta
1993
Betamethasone film vs betamethasone
lotion
RR 10.24 (95% CI 0.59 to 176.56);
investigator-rated -
Veien
1999
Mometasone 3 times/week vs
mometasone 2 times/week
RR 1.23 (95% CI 0.94 to 1.61); investigator-
rated -
Fowler
2005
Hydrocortisone butyrate vs fluticasone
propionate twice daily
Hydrocortisone butyrate vs prednicarbate
emollient twice daily
Hydrocortisone butyrate 0.1% cream vs
mometasone furoate twice daily
No data regarding the primary outcome
investigator-rated good/excellent control
Three parallel
treatment groups Each
group separately
within-patient
Faghihi
2008
0.05% clobetasol cream vs 0.05%
clobetasol + zinc sulphate cream
Clobetasol + zinc sulphate better in terms of
respectively scaling (25/47 vs 3/47), redness
(41/47 vs 1/41), and lichenification (24/47 vs
7/47); investigator-rated
Within-patient study
Lodén
2012a
Betamethasone-valerate 0.1% cream
twice daily vs betamethasone-valerate
0.1% cream once daily + urea 5% cream
once daily
RR 0.75 (0.55 to 1.03); investigator-rated -
Kircik 2013 Clobetasol propionate 0.05% foam twicedaily vs vehicle foam twice daily RR 1.43 (0.86 to 2.40); investigator-rated -
Footnotes
CI: confidence interval.
RR: risk ratio.
3 Overview of studies on coal tar and derivatives: investigator-rated good/excellent control
Study Comparison Investigator-rated good/excellent control in RR(95% CI) Comment
Kemper
1998
Coal tar paste vs betamethasone-valerate or
zinc oxide once a week
No data regarding the primary outcome
investigator-rated good/excellent control
Within-patient
study
Footnotes
4 Overview of studies on irradiation with UV light: investigator-rated good/excellent control
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Study Comparison Investigator-rated good/excellent control in RR (95%CI) Comment
Bayerl 1999 UVB vs no UVB No data regarding the primary outcome investigator-rated good/excellent control -
Sjövall 1987 Local UVB vs placebo RR 2.0 (95% CI 0.26 to 15.6) -
Sjövall 1987 Local UVB hand vs whole body +hand UVB RR 2.2 (95% CI 0.83 to 5.8) -
Sjövall 1987 Local UVB hand vs whole body vsplacebo RR 3.67 (95% CI 0.90 to 14.97) -
van Coevorden
2004a Oral PUVA vs topical bath PUVA
No data regarding the primary outcome investigator-
rated good/excellent control -
Grattan 1991 Topical PUVA vs UVA No data regarding the primary outcome investigator-rated good/excellent control
Within-patient
study
Polderman 2003 UVA-1 vs placebo No data regarding the primary outcome investigator-rated good/excellent control -
Brass 2015 Local NB-UVB vs topical PUVA RR 0.50 (95% CI 0.22 to 1.16) -
Sezer 2007 Local NB-UVB vs topical PUVA NB-UVB was effective in 2/12 hands and topicalPUVA was effective in 1/12 hands
 
Within-patient
study
Tzaneva 2009 Oral PUVA vs bath PUVA No data regarding the primary outcome investigator-rated good/excellent control -
Adams 2007 UVA-1 vs topical cream PUVA No data regarding the primary outcome investigator-rated good/excellent control
Within-patient
study
Said 2010 Local UVA-1 vs topicalbetamethasone-valerate cream
No data regarding the primary outcome investigator-
rated good/excellent control -
Footnotes
CI: confidence interval.
RR: risk ratio.
NB-UVB: narrow-band ultraviolet B.
PUVA: psoralen + ultraviolet A.
UVB: ultraviolet B.
UVA-1: a subtype of ultraviolet A.
5 Overview of studies on X-rays (ionising radiation): investigator-rated good/excellent control
Study Comparison Investigator-rated good/excellent control in RR (95% CI) Comments
King 1984 X-rays 300 rad vsplacebo
No difference after 6 months. Grenz ray effective in 11/15 hands
vs 8/15 hands with placebo.
Within-patient
study
Fairris 1984 X-rays 300 rad vsplacebo
No data regarding the primary outcome investigator-rated
good/excellent control
Within-patient
study
Lindelöf 1987 Grenz rays 1800 rad vsplacebo
No data regarding the primary outcome investigator-rated
good/excellent control
Within-patient
study
Cartwright 1987 Grenz rays 300 rad vsplacebo
No data regarding the primary outcome investigator-rated
good/excellent control
Within-patient
study
Fairris 1985 X-rays 1 Gy vs Grenzrays 3 Gy
No data regarding the primary outcome investigator-rated
good/excellent control
Within-patient
study
Sheehan-Dare
1989 X-rays vs PUVA
No data regarding the primary outcome investigator-rated
good/excellent control
Within-patient
study
Footnotes
CI: confidence interval.
Grenz rays: a type of X-rays (ionising radiation).
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Gy: Gray, a unit of radiation dose.
RR: risk ratio.
6 Overview of studies on topical calcineurin inhibitors: investigator-rated good/excellent control
Study Comparison Investigator-rated good/excellent controlin RR (95% CI) Comments
Schnopp 2002 Tacrolimus ointment vsmometasone furoate
No data regarding the primary outcome
investigator-rated good/excellent control Within-patient study
Katsarou 2012 Tacrolimus ointment vsmometasone furoate
No data regarding the primary outcome
investigator-rated good/excellent control
Improvement was reported separately
for subcategories of clinical signs
Krejci-
Manwaring
2008
Tacrolimus ointment vs
vehicle
No data regarding the primary outcome
investigator-rated good/excellent control -
Pacor 2006 Tacrolimus ointment vsvehicle RR 29.0 (95% CI 1.9 to 443.25) -
Belsito 2004 Pimecrolimus cream vsvehicle RR 1.53 (95% CI 0.99 to 2.36) -
Hordinsky 2010 Pimecrolimus cream vsvehicle RR 1.28 (95% CI 0.99 to 1.66) -
Bauer 2012 Pimecrolimus cream vsvehicle
No data regarding the primary outcome
investigator-rated good/excellent control -
Baskan 2005 Pimecrolimus cream vsvehicle
No data regarding the primary outcome
investigator-rated good/excellent control -
Cherill 2000 Pimecrolimus cream vsvehicle
No data regarding the primary outcome
investigator-rated good/excellent control -
Footnotes
CI: confidence interval.
RR: risk ratio.
7 Overview of studies on other topical interventions: investigator-rated good/excellent control
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Study Comparison Investigator-rated good/excellent control in RR(95% CI) Comments
Hill 1998 Betamethasone-valerate + clioquinol vsbetamethasone-valerate + fusidic acid RR 1.03 (95% CI 0.74 to 1.43) -
Fredriksson
1975
Aquacare HP cream vs calmurid cream
containing betaine and lactic acid
No data regarding the primary outcome
investigator-rated good/excellent control
Within-
patient study
Odia 1996 Iontophoresis vs no iontophoresis No data regarding the primary outcomeinvestigator-rated good/excellent control
Within-
patient study
Boroujeni
2017
Herbal cream containing fenugreek seeds 5%,
marshmallow 5%, chamomile 5%, and walnut
leaves 5% vs fluocinolone acetonide cream
2% twice daily
No data regarding the primary outcome
investigator-rated good/excellent control -
Hanifin 2004 Bexarotene 1% gel vs bexarotene with eithermometasone furoate or hydrocortisone
RR 0.85 (95% CI 0.40 to 1.80) for bexarotene only
vs B + MF; 1.83 (95% CI 0.61 to 5.53) for
bexarotene only vs B + HC; and 2.15 (95% CI
0.67 to 6.89) for B + MF vs B + HC
-
Jowkar 2014 Fumaric acid 5% cream vs triamcinolone 0.1%cream
No data regarding the primary outcome
investigator-rated good/excellent control -
Lauriola
2011 Furpalmate vs hydrocortisone acetate cream RR 0.90 (95% CI 0.76 to 1.07) -
Jowkar 2011 4% Fumaria Parviflora Lam cream vs vehiclecream twice daily
No data regarding the primary outcome
investigator-rated good/excellent control -
Yousefi
2012
Nigella sativa L. vs betamethasone ointment
vs Eucerin
No data regarding the primary outcome
investigator-rated good/excellent control -
Footnotes
B: bexarotene 1% gel.
CI: confidence interval.
Fumaria Parviflora Lam: Fumaria Parviflora Lamarck.
HC: hydrocortisone.
MF: mometasone furoate.
Nigella sativa L: Nigella sativa Linne.
RR: risk ratio.
8 Overview of studies on immunosuppressants: investigator-rated good/excellent control
Study Comparison
Investigator-
rated good/excellent
control in RR (95% CI)
Comments
Granlund
1996 Oral cyclosporin vs topical betamethasone
RR 1.88 (95% CI 0.88 to
3.99) -
Agarwal 2013
Oral azathioprine and clobetasol propionate 0.05%
cream twice daily vs topical clobetasol propionate
0.05% cream twice daily
RR 2.33 (95% CI 1.61 to
3.38) -
NCT01231854Oral cyclosporin vs alitretinoin RR 1.50 (95% CI 0.35 to6.40)
Study terminated
prematurely and included 15
participants only
Footnotes
CI: confidence interval.
RR: risk ratio. 
9 Overview of studies on oral retinoids: investigator-rated good/excellent control
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Study Comparison Investigator- or participant-rated good/excellentcontrol in RR (95% CI) Comments
Thestrup-Pedersen
2001 Oral acitretin vs placebo
No data regarding the primary outcome
investigator-rated good/excellent control -
Ruzicka 2004 Oral alitretinoin (20 mg and 40 mg) vsplacebo
40 mg
Participant-rated
RR 3.51 (95% CI 1.80 to 6.82)
Investigator-rated
RR 1.97 (95% CI 1.3 to 3.0)
20 mg
Participant rated
RR 2.74 (95% CI 1.37 to 5.46)
Investigator-rated
RR 1.49 (95% CI 0.94 to 2.34)
-
 
Ruzicka 2008; 
Fowler 2014
Oral alitretinoin 30 mg vs placebo
 
30 mg
Participant-rated
RR 2.75 (95% CI 2.18 to 3.48)
Investigator-rated
RR 2.75 (95% CI 2.20 to 3.43)
-
Ruzicka 2004; 
Ruzicka 2008 Oral alitretinoin 10 mg vs placebo
10 mg
Participant-rated
RR 1.73 (95% CI 1.25 to 2.40)
Investigator-rated
RR 1.58 (95% CI 1.20 to 2.07)
-
Bissonnette 2010
 
Re-treatment with oral alitretinoin (30
mg and 10 mg) vs placebo
30 mg
Investigator-rated
RR 9.55 (95% CI 2.51 to 36.27)
10 mg
Investigator-rated
RR 4.76 (95% CI 0.70 to 32.25)
-
Footnotes
CI: confidence interval.
RR: risk ratio.
10 Overview of other oral interventions: investigator-rated good/excellent control
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Study Comparison Investigator-rated good/excellent controlin RR (95% CI) Comments
Burrows
1986 Oral triethylenetetramine vs placebo
Trientine was effective in 6/20 participants
vs 10/20 in the placebo group
 
Unclear whether
participant- or investigator-
rated
Kaaber
1983
Oral tetraethylthiuram disulphide vs
placebo
Investigator-rated
RR 2.95 (95% CI 0.71 to 12.34)
-
Pigatto
1990
Oral disodium cromoglycate without
dietary restriction vs a low-nickel diet
No data regarding the primary outcome
investigator-rated good/excellent control -
Sharma
2006
Low-nickel diet and disulphiram vs a
normal diet and placebo
Investigator-rated
RR 9.09 (95% CI 1.40 to 58.91)
-
Veien
1995 Ranitidine vs placebo RR 2.22 (95% CI 1.20 to 4.10)
Unclear whether
participant- or investigator-
rated
Whitaker
1996
Oral gamma-linoleic acid (GLA; evening
primrose oil) vs placebo
No data regarding the primary outcome
investigator-rated good/excellent control
 
Footnotes
CI: confidence interval.
RR: risk ratio.
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Data and analyses 
1 Bland emollients: ceramide-containing emollient versus regular petrolatum-based emollient
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
1.1 Primary: adverse events:
exacerbation resulting in dropout 1   Risk Ratio(M-H, Random, 95% CI) No totals
2 Bland emollients: emollient E-DO versus vehicle
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
2.1 Primary: percentage of
participants with self-rated
good/excellent control at week 4
1   Other data No numeric data
2.2 Primary: percentage of
participants with investigator-rated
good/excellent control at week 4
1   Other data No numeric data
2.3 Adverse events 1   Other data No numeric data
   2.3.1 At least 1 adverse event 1   Other data No numeric data
   2.3.2 Pruritus 1   Other data No numeric data
3 Corticosteroid creams/ointments: fluprednidene versus betamethasone
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Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
3.1 Primary: investigator-rated
good/excellent control of symptoms
after 3 weeks of treatment
1   Risk Ratio(M-H, Random, 95% CI) No totals
3.2 Primary: number of participants
with at least 1 adverse event 1   Risk Ratio(M-H, Random, 95% CI) No totals
3.3 Secondary: investigator-rated
improvement > 50% after 3 weeks 1   Risk Ratio(M-H, Random, 95% CI) No totals
4 Corticosteroid creams/ointments: betamethasone-dipropionate film-forming lotion versus betamethasone-
dipropionate thick lotion
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
4.1 Primary: investigator-rated
good/excellent control of symptoms
at day 7
1   Other data No numeric data
4.2 Primary: adverse events 1   Risk Ratio(M-H, Random, 95% CI) No totals
   4.2.1 At least 1 adverse event 1   Risk Ratio(M-H, Random, 95% CI) No totals
   4.2.2 Application site reaction 1   Risk Ratio(M-H, Random, 95% CI) No totals
   4.2.3 Headache 1   Risk Ratio(M-H, Random, 95% CI) No totals
   4.2.4 Exacerbation eczema
leading to withdrawal 1   Risk Ratio(M-H, Random, 95% CI) No totals
4.3 Secondary: investigator-rated
reduction (not specified) in severity
at day 7
1   Risk Ratio(M-H, Random, 95% CI) No totals
4.4 Secondary: investigator-rated
global improvement in eczema 1   Risk Ratio(M-H, Random, 95% CI) No totals
5 Corticosteroids creams/ointments: clobetasol propionate versus flupredniden acetate
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
5.1 Primary: percentage of
participants with investigator-rated
good/excellent control
1   Other data No numeric data
5.2 Adverse events 1   Other data No numeric data
   5.2.1 At least 1 adverse event 1   Other data No numeric data
   5.2.2 Burning sensation 1   Other data No numeric data
   5.2.3 Reversible atrophy 1   Other data No numeric data
   5.2.4 Brittle skin 1   Other data No numeric data
6 Corticosteroids creams/ointments: clobetasol propionate foam 0.05% versus vehicle
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
6.1 Primary: percentage of
participants with investigator-rated
good/excellent control at day 15
1   Risk Ratio(M-H, Random, 95% CI) No totals
6.2 Primary: percentage of
participants with self-rated
good/excellent control at day 15
1   Risk Ratio(M-H, Random, 95% CI) No totals
6.3 Primary: adverse events 1   Risk Ratio(M-H, Random, 95% CI) No totals
   6.3.1 Discontinuation due to
adverse events (fissures) 1   Risk Ratio(M-H, Random, 95% CI) No totals
   6.3.2 At least 1 adverse event 1   Risk Ratio(M-H, Random, 95% CI) No totals
   6.3.3 Any adverse event
treatment-related (application site
pruritus)
1   Risk Ratio(M-H, Random, 95% CI) No totals
   6.3.4 Nasopharyngitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
6.4 Secondary: reduction in severity,
participant-rated scoring at day 15 1   Risk Ratio(M-H, Random, 95% CI) No totals
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6.5 Secondary: reduction in severity,
investigator-rated scoring at day 15 1   Risk Ratio(M-H, Random, 95% CI) No totals
   6.5.1 Improvement at least 2
grades 1   Risk Ratio(M-H, Random, 95% CI) No totals
   6.5.2 Improvement at least 1 grade1   Risk Ratio(M-H, Random, 95% CI) No totals
7 Corticosteriods creams/ointments: desonide cream 0.1% versus desonide cream 0.05%
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
7.1 Adverse events 1   Other data No numeric data
8 Corticosteroid creams/ointments: mometasone furoate cream 3 times/week versus 2 times/week versus no
steroids
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
8.1 Primary: investigator-rated
good/excellent control 1   Risk Ratio(M-H, Random, 95% CI) No totals
   8.1.1 Mometasone furoate 3
times/week vs mometasone furoate
2 times/week
1   Risk Ratio(M-H, Random, 95% CI) No totals
8.2 Primary: investigator-rated
good/excellent control 1   Risk Ratio(M-H, Random, 95% CI) No totals
   8.2.1 Mometasone furoate 3
times/week vs emollient and
ointment only
1   Risk Ratio(M-H, Random, 95% CI) No totals
   8.2.2 Mometasone furoate 2
times/week vs emollient and
ointment only
1   Risk Ratio(M-H, Random, 95% CI) No totals
8.3 Primary: adverse events 1   Risk Ratio(M-H, Random, 95% CI) No totals
   8.3.1 Mild atrophy 1   Risk Ratio(M-H, Random, 95% CI) No totals
9 Corticosteroid creams/ointments: clobetasol and zinc sulphate cream versus clobetasol cream
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
9.1 Primary outcome: percentage of
participants with investigator-rated
good/excellent control
1   Other data No numeric data
   9.1.1 Scaling 1   Other data No numeric data
   9.1.2 Redness 1   Other data No numeric data
   9.1.3 Lichenification 1   Other data No numeric data
10 Corticosteroid creams/ointments: betamethasone-valerate 0.1% cream versus urea 5% cream
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
10.1 Primary: investigator-rated
good/excellent control of symptoms 1   Risk Ratio(M-H, Random, 95% CI) No totals
10.2 Secondary: participant-rated
reduction in severity (bigger
reduction in severity = better
outcome)
1   Mean Difference(IV, Random, 95%CI) No totals
10.3 Secondary: investigator-rated
reduction in severity (bigger
reduction in severity = better
outcome)
1   Mean Difference(IV, Random, 95%CI) No totals
11 Topical others: coal tar versus betamethasone-valerate
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
11.1 Primary outcome: adverse
events 1   Other data No numeric data
12 Irradiation with UV light versus no UVB
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
12.1 Primary: adverse events -
exacerbation 1   Risk Ratio(M-H, Random, 95% CI) No totals
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13 Irradiation with UV light: whole-body UVB versus placebo or local UVB hands
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
13.1 Primary: investigator-rated
good/excellent control of symptoms
by UVB hand vs whole-body UVB vs
placebo
1   Risk Ratio(M-H, Random, 95% CI) No totals
   13.1.1 Local UVB hands alone vs
placebo 1   Risk Ratio(M-H, Random, 95% CI) No totals
   13.1.2 Whole-body UVB + local
UVB hands vs placebo 1   Risk Ratio(M-H, Random, 95% CI) No totals
   13.1.3 Whole body UVB + local
UVB hands versus local UVB hands
alone
1   Risk Ratio(M-H, Random, 95% CI) No totals
13.2 Secondary: time until relapse
depicted in weeks of remission 1  
Mean Difference(IV, Random, 95%
CI) No totals
   13.2.1 Local UVB hands alone vs
placebo (high score = better
outcome)
1   Mean Difference(IV, Random, 95%CI) No totals
   13.2.2 Whole-body UVB + local
UVB hands vs placebo (high score =
better outcome)
1   Mean Difference(IV, Random, 95%CI) No totals
   13.2.3 Whole-body UVB + local
UVB hands vs local UVB hands
alone (high score = better outcome)
1   Mean Difference(IV, Random, 95%CI) No totals
14 Irradiation with UV light: local narrow-band UVB versus local PUVA
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
14.1 Primary: investigator-rated
good/excellent control of symptoms
in UVB vs PUVA
1   Risk Ratio(M-H, Fixed, 95% CI) No totals
14.2 Primary: adverse events -
reported adverse event, mainly
erythema
1   Risk Ratio(M-H, Fixed, 95% CI) No totals
15 Irradiation with UV light: local narrow-band UVB versus local PUVA
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
15.1 Primary: investigator-rated
good/excellent control of symptoms
in UVB vs PUVA
1   Other data No numeric data
15.2 Primary: adverse events 1   Other data No numeric data
   15.2.1 Palmar hyperpigmentation 1   Other data No numeric data
15.3 Secondary: investigator-rated
improvement by local narrow-band
UVB vs local PUVA
1   Other data No numeric data
16 Irradiation with UV light: oral PUVA versus topical bath PUVA
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
16.1 Primary: adverse events 2   Risk Ratio(M-H, Random, 95% CI) No totals
   16.1.1 Nausea leading to dropout 1   Risk Ratio(M-H, Random, 95% CI) No totals
   16.1.2 Burn leading to dropout 1   Risk Ratio(M-H, Random, 95% CI) No totals
   16.1.3 Erythema 1   Risk Ratio(M-H, Random, 95% CI) No totals
   16.1.4 Dizziness 1   Risk Ratio(M-H, Random, 95% CI) No totals
   16.1.5 Nausea 1   Risk Ratio(M-H, Random, 95% CI) No totals
   16.1.6 Headache 1   Risk Ratio(M-H, Random, 95% CI) No totals
16.2 Secondary: investigator-rated
reduction in severity at week 10
(bigger reduction in severity = better
outcome)
1   Mean Difference(IV, Random, 95%CI) No totals
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16.3 Secondary: investigator-rated
reduction in severity at week 18
(bigger reduction in severity = better
outcome)
1   Mean Difference(IV, Random, 95%CI) No totals
17 Irradiation with UV light: topical PUVA versus UVA
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
17.1 Primary: adverse events 1   Other data No numeric data
   17.1.1 Discontinuation due to
adverse events 1   Other data No numeric data
   17.1.2 Burning 1   Other data No numeric data
   17.1.3 Exacerbation of eczema 1   Other data No numeric data
18 Irradiation with UV light: UVA-1 versus topical betamethasone valerate 0.1% cream
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
18.1 Primary: adverse events -
hyperpigmentation 1   Risk Ratio(M-H, Random, 95% CI) No totals
19 Irradiation with UV light: UVA-1 versus placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
19.1 Primary: adverse events -
discontinuation because of
exacerbation
1   Risk Ratio(M-H, Random, 95% CI) No totals
19.2 Secondary: participant-rated
reduction in severity on VAS for itch
(week 3, bigger reduction in severity
= better outcome)
1   Mean Difference(IV, Random, 95%CI) No totals
19.3 Secondary: investigator-rated
reduction in severity on dyshidrotic
eczema area and severity index
(DASI) (week 3, bigger reduction in
severity = better outcome)
1   Mean Difference(IV, Random, 95%CI) No totals
20 Irradiation with UV light: PUVA versus UVA-1
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
20.1 Primary: adverse events 1   Other data No numeric data
   20.1.1 Burning 1   Other data No numeric data
   20.1.2 Itching 1   Other data No numeric data
21 Irradiation with Grenz ray
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
21.1 Primary: investigator-rated
improvement good/excellent control 1   Other data No numeric data
   21.1.1 after 1 month 1   Other data No numeric data
   21.1.2 after 3 months 1   Other data No numeric data
   21.1.3 after 6 months 1   Other data No numeric data
   21.1.4 Hyperkeratotic eczema
after 6 months 1   Other data No numeric data
   21.1.5 Pompholyx after 6 months 1   Other data No numeric data
   21.1.6 Chronic palmar eczema
after 6 months 1   Other data No numeric data
21.2 Primary: adverse events -
hyperpigmentation 2   Other data No numeric data
22 Topical calcineurin inhibitors: tacrolimus 0.1% ointment versus mometasone furoate
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
22.1 Secondary: reduction in
investigator-rated severity - DASI 1   Other data No numeric data
23 Topical calcineurin inhibitors: tacrolimus 0.1% ointment versus vehicle
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Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
23.1 Primary: investigator-rated
good/excellent control of symptoms 1   Risk Ratio(M-H, Random, 95% CI) No totals
23.2 Primary: adverse events
burning/itching at application site 1   Risk Ratio(M-H, Random, 95% CI) No totals
   23.2.1 Burning/itching at
application site 1   Risk Ratio(M-H, Random, 95% CI) No totals
24 Topical calcineurin inhibitors: pimecrolimus 1% cream versus vehicle
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
24.1 Primary: investigator-rated
good/excellent control of symptoms
pimecrolimus cream vs vehicle
2   Risk Ratio(M-H, Random, 95% CI) Subtotals only
   24.1.1 Primary: investigator-rated
clear or almost clear pimecrolimus
cream vs vehicle 3 weeks
1 294 Risk Ratio(M-H, Random, 95% CI) 1.53 [0.99, 2.36]
   24.1.2 Primary: investigator-rated
clear or almost clear pimecrolimus
cream vs vehicle 6 weeks
1 652 Risk Ratio(M-H, Random, 95% CI) 1.28 [0.99, 1.66]
   24.1.3 Primary: investigator-rated
clear or almost clear pimecrolimus
cream vs vehicle 3 weeks irritant
hand eczema
1 185 Risk Ratio(M-H, Random, 95% CI) 1.70 [0.93, 3.10]
   24.1.4 Primary: investigator-rated
clear or almost clear pimecrolimus
cream vs vehicle 3 weeks allergic
hand eczema
1 49 Risk Ratio(M-H, Random, 95% CI) 1.33 [0.30, 5.96]
   24.1.5 Primary: investigator-rated
clear or almost clear pimecrolimus
cream vs vehicle 3 weeks
endogenous hand eczema
1 134 Risk Ratio(M-H, Random, 95% CI) 1.32 [0.75, 2.33]
24.2 Primary: adverse events 3   Risk Ratio(M-H, Random, 95% CI) No totals
   24.2.1 Discontinuation because of
adverse event 2   Risk Ratio(M-H, Random, 95% CI) No totals
   24.2.2 Application site reaction 1   Risk Ratio(M-H, Random, 95% CI) No totals
   24.2.3 At least 1 adverse event 2   Risk Ratio(M-H, Random, 95% CI) No totals
   24.2.4 Serious adverse event (not
related to study) 1   Risk Ratio(M-H, Random, 95% CI) No totals
   24.2.5 Treatment-related adverse
event 1   Risk Ratio(M-H, Random, 95% CI) No totals
   24.2.6 Erythema or irritation 1   Risk Ratio(M-H, Random, 95% CI) No totals
   24.2.7 Itching 1   Risk Ratio(M-H, Random, 95% CI) No totals
   24.2.8 Warmth, stinging, burning 1   Risk Ratio(M-H, Random, 95% CI) No totals
   24.2.9 Herpes simplex virus
infection 1   Risk Ratio(M-H, Random, 95% CI) No totals
24.3 Secondary: participant-rated
reduction in severity pruritus relief
between pimecrolimus 1% and
vehicle
1   Risk Ratio(M-H, Random, 95% CI) No totals
25 Topical antibacterial agents: betamethasone-valerate/clioquinol cream versus betamethasone-
valerate/fusidic acid
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
25.1 Primary: investigator-rated
good/excellent control of symptoms
(intention-to-treat)
1   Risk Ratio(M-H, Random, 95% CI) No totals
#29 Interventions for hand eczema
238 / 280
25.2 Primary: adverse events 1   Risk Ratio(M-H, Random, 95% CI) No totals
   25.2.1 At least 1 adverse event 1   Risk Ratio(M-H, Random, 95% CI) No totals
   25.2.2 Chest infection 1   Risk Ratio(M-H, Random, 95% CI) No totals
   25.2.3 Irritation associated with
application 1   Risk Ratio(M-H, Random, 95% CI) No totals
   25.2.4 Deterioration of eczema 1   Risk Ratio(M-H, Random, 95% CI) No totals
   25.2.5 Eyes watering 1   Risk Ratio(M-H, Random, 95% CI) No totals
   25.2.6 Hands coloured yellow 1   Risk Ratio(M-H, Random, 95% CI) No totals
   25.2.7 Hands felt thick 1   Risk Ratio(M-H, Random, 95% CI) No totals
   25.2.8 Vesicle on hand 1   Risk Ratio(M-H, Random, 95% CI) No totals
26 Topical retinoids: bexarotene 1% gel versus bexarotene with corticosteroids
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
26.1 Primary: investigator-rated
good/excellent control of symptoms
(> 90% clearance)
1   Risk Ratio(M-H, Random, 95% CI) No totals
   26.1.1 Bexarotene only (A) vs
bexarotene + mometasone (B) 1   Risk Ratio(M-H, Random, 95% CI) No totals
   26.1.2 Bexarotene only (A) vs
bexarotene + hydrocortisone (B) 1   Risk Ratio(M-H, Random, 95% CI) No totals
   26.1.3 Bexarotene + mometasone
(A) vs bexarotene + hydrocortisone
(B)
1   Risk Ratio(M-H, Random, 95% CI) No totals
26.2 Primary: adverse events
bexarotene vs bexarotene +
mometasone
1   Risk Ratio(M-H, Random, 95% CI) No totals
   26.2.1 Irritation/rash 1   Risk Ratio(M-H, Random, 95% CI) No totals
   26.2.2 Stinging/burning 1   Risk Ratio(M-H, Random, 95% CI) No totals
   26.2.3 Exacerbation of dermatitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
26.3 Primary: adverse events
bexarotene vs bexarotene +
hydrocortisone
1   Risk Ratio(M-H, Random, 95% CI) No totals
   26.3.1 Irritation/rash 1   Risk Ratio(M-H, Random, 95% CI) No totals
   26.3.2 Stinging/burning 1   Risk Ratio(M-H, Random, 95% CI) No totals
   26.3.3 Exacerbation of dermatitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
26.4 Secondary: investigator-rated
reduction in severity (> 50%
reduction in hand eczema area and
severity index (HEASI))
1   Risk Ratio(M-H, Random, 95% CI) No totals
   26.4.1 Bexarotene (A) only vs
bexarotene + mometasone (B) 1   Risk Ratio(M-H, Random, 95% CI) No totals
   26.4.2 Bexarotene (A) only vs
bexarotene + hydrocortisone (B) 1   Risk Ratio(M-H, Random, 95% CI) No totals
   26.4.3 Bexarotene + mometasone
(A) vs bexarotene + hydrocortisone
(B)
1   Risk Ratio(M-H, Random, 95% CI) No totals
27 Other topical agents: calmurid versus aquacare
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
27.1 Primary: adverse events:
burning 1   Other data No numeric data
28 Other topical agents: fumaric acid 5% cream verus triamcinolone 0.1% cream
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
28.1 Primary: adverse events 1   Risk Ratio(M-H, Random, 95% CI) No totals
29 Other topical agents: furpalmate 0.3% cream versus hydrocortisone acetate 0.5% cream
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
29.1 Primary: investigator-rated
good/excellent control of symptoms 1   Risk Ratio(M-H, Random, 95% CI) No totals
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30 Other topical agents: Fumaria parviflora versus vehicle cream
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
30.1 Primary: adverse events:
discontinuation due to erythema and
papels
1   Risk Ratio(M-H, Random, 95% CI) No totals
31 Oral immunosuppressants: oral azathioprine with topical clobetasol propionate versus topical clobetasol
propionate
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
31.1 Primary: percentage of
participants with investigator-rated
good/excellent control
1   Risk Ratio(M-H, Random, 95% CI) No totals
   31.1.1 Week 8 1   Risk Ratio(M-H, Random, 95% CI) No totals
   31.1.2 Week 24 1   Risk Ratio(M-H, Random, 95% CI) No totals
31.2 Secondary: investigator-rated
reduction in severity (bigger
reduction in severity = better
outcome)
1   Mean Difference(IV, Random, 95%CI) No totals
   31.2.1 Week 4 1   Mean Difference(IV, Random, 95%CI) No totals
   31.2.2 Week 8 1   Mean Difference(IV, Random, 95%CI) No totals
   31.2.3 Week 12 1   Mean Difference(IV, Random, 95%CI) No totals
   31.2.4 Week 24 1   Mean Difference(IV, Random, 95%CI) No totals
31.3 Secondary: participant-rated
reduction in severity (bigger
reduction in severity = better
outcome)
1   Mean Difference(IV, Random, 95%CI) No totals
   31.3.1 Week 4 1   Mean Difference(IV, Random, 95%CI) No totals
   31.3.2 Week 8 1   Mean Difference(IV, Random, 95%CI) No totals
   31.3.3 Week 12 1   Mean Difference(IV, Random, 95%CI) No totals
   31.3.4 Week 24 1   Mean Difference(IV, Random, 95%CI) No totals
32 Oral immunosuppressants: oral cyclosporin versus topical betamethasone dipropionate
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
32.1 Primary: investigator-rated very
good or good efficacy 1   Risk Ratio(M-H, Random, 95% CI) No totals
32.2 Primary: participant-rated very
good or good efficacy 1   Risk Ratio(M-H, Random, 95% CI) No totals
32.3 Primary: adverse events 1   Risk Ratio(M-H, Random, 95% CI) No totals
   32.3.1 At least 1 adverse event 1   Risk Ratio(M-H, Random, 95% CI) No totals
   32.3.2 Discontinuation due to
dizziness, vomiting, and facial
oedema
1   Risk Ratio(M-H, Random, 95% CI) No totals
   32.3.3 Discontinuation due to
severe insomnia 1   Risk Ratio(M-H, Random, 95% CI) No totals
   32.3.4 Increase in serum
creatinine > 30% 1   Risk Ratio(M-H, Random, 95% CI) No totals
32.4 Secondary: investigator-rated
reduction in severity in total disease
activity score (6 weeks; bigger
reduction in severity = better
outcome)
1   Mean Difference(IV, Random, 95%CI) No totals
33 Oral immunosuppressants: oral cyclosporin versus alitretinoin
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Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
33.1 Primary: investigator-rated
good/excellent control (IGA) after 24
weeks
1   Risk Ratio(M-H, Random, 95% CI) No totals
33.2 Primary: participant-rated
good/excellent control (PGA) after
24 weeks
1   Risk Ratio(M-H, Random, 95% CI) No totals
33.3 Primary: adverse events 1   Risk Ratio(M-H, Random, 95% CI) No totals
34 Oral retinoids: alitretinoin versus placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
34.1 Primary: investigator-rated
good/excellent control of symptoms 3   Risk Ratio(M-H, Random, 95% CI) Subtotals only
   34.1.1 Alitretinoin 40 mg vs
placebo 1 159 Risk Ratio(M-H, Random, 95% CI) 1.97 [1.30, 3.00]
   34.1.2 Alitretinoin 30 mg vs
placebo 2 1210 Risk Ratio(M-H, Random, 95% CI) 2.75 [2.20, 3.43]
   34.1.3 Alitretinoin 20 mg vs
placebo 1 158 Risk Ratio(M-H, Random, 95% CI) 1.49 [0.94, 2.34]
   34.1.4 Alitretinoin 10 mg vs
placebo 2 781 Risk Ratio(M-H, Random, 95% CI) 1.58 [1.20, 2.07]
34.2 Primary: investigator-rated
good/excellent control of symptoms
hyperkeratotic eczema
2   Risk Ratio(M-H, Random, 95% CI) Subtotals only
   34.2.1 Alitretinoin 40 mg vs
placebo hyperkeratotic eczema 1 131 Risk Ratio(M-H, Random, 95% CI) 2.61 [1.61, 4.23]
   34.2.2 Alitretinoin 30 mg vs
placebo hyperkeratotic eczema 1 519 Risk Ratio(M-H, Random, 95% CI) 3.94 [2.60, 5.97]
   34.2.3 Alitretinoin 20 mg vs
placebo hyperkeratotic eczema 1 136 Risk Ratio(M-H, Random, 95% CI) 1.72 [1.02, 2.90]
   34.2.4 Alitretinoin 10 mg vs
placebo hyperkeratotic eczema 2 662 Risk Ratio(M-H, Random, 95% CI) 2.05 [1.47, 2.86]
34.3 Primary: investigator-rated
good/excellent control of symptoms
pompholyx
2   Risk Ratio(M-H, Random, 95% CI) Subtotals only
   34.3.1 Alitretinoin 40 mg vs
placebo pompholyx 1 37 Risk Ratio(M-H, Random, 95% CI) 1.66 [0.58, 4.72]
   34.3.2 Alitretinoin 30 mg vs
placebo pompholyx 1 166 Risk Ratio(M-H, Random, 95% CI) 2.04 [1.06, 3.91]
   34.3.3 Alitretinoin 20 mg vs
placebo pompholyx 1 38 Risk Ratio(M-H, Random, 95% CI) 0.90 [0.26, 3.08]
   34.3.4 Alitretinoin 10 mg vs
placebo pompholyx 2 197 Risk Ratio(M-H, Random, 95% CI) 1.30 [0.70, 2.39]
34.4 Primary: investigator-rated
good/excellent control of symptoms
fingertip
2   Risk Ratio(M-H, Random, 95% CI) Subtotals only
   34.4.1 Alitretinoin 40 mg vs
placebo fingertip 1 51 Risk Ratio(M-H, Random, 95% CI) 1.77 [0.81, 3.86]
   34.4.2 Alitretinoin 30 mg vs
placebo fingertip 1 297 Risk Ratio(M-H, Random, 95% CI) 2.49 [1.59, 3.89]
   34.4.3 Alitretinoin 20 mg vs
placebo fingertip 1 53 Risk Ratio(M-H, Random, 95% CI) 1.18 [0.50, 2.77]
   34.4.4 Alitretinoin 10 mg vs
placebo fingertip 2 330 Risk Ratio(M-H, Random, 95% CI) 1.51 [0.99, 2.29]
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34.5 Primary: participant-rated
investigator-rated good/excellent
control of symptoms
3   Risk Ratio(M-H, Random, 95% CI) Subtotals only
   34.5.1 Alitretinoin 40 mg vs
placebo 1 147 Risk Ratio(M-H, Random, 95% CI) 3.51 [1.80, 6.82]
   34.5.2 Alitretinoin 30 mg vs
placebo 2 1210 Risk Ratio(M-H, Random, 95% CI) 2.75 [2.18, 3.48]
   34.5.3 Alitretinoin 20 mg vs
placebo 1 147 Risk Ratio(M-H, Random, 95% CI) 2.74 [1.37, 5.46]
   34.5.4 Alitretinoin 10 mg vs
placebo 2 765 Risk Ratio(M-H, Random, 95% CI) 1.73 [1.25, 2.40]
34.6 Primary: adverse events
alitretinoin 10 mg vs placebo 2   Risk Ratio(M-H, Random, 95% CI) Subtotals only
   34.6.1 All adverse events 1 158 Risk Ratio(M-H, Random, 95% CI) 1.01 [0.66, 1.55]
   34.6.2 Headache 2 781 Risk Ratio(M-H, Random, 95% CI) 1.10 [0.38, 3.19]
   34.6.3 Dry lips 2 781 Risk Ratio(M-H, Random, 95% CI) 0.50 [0.05, 4.66]
   34.6.4 Flushing 2 781 Risk Ratio(M-H, Random, 95% CI) 1.16 [0.28, 4.70]
   34.6.5 Dry mouth 2 781 Risk Ratio(M-H, Random, 95% CI) 1.98 [0.53, 7.44]
   34.6.6 Erythema 2 781 Risk Ratio(M-H, Random, 95% CI) 1.11 [0.33, 3.71]
   34.6.7 Eczema 2 781 Risk Ratio(M-H, Random, 95% CI) 0.80 [0.38, 1.68]
   34.6.8 Conjunctivitis 1 158 Risk Ratio(M-H, Random, 95% CI) 0.49 [0.05, 5.27]
   34.6.9 Eye pruritus 1 158 Risk Ratio(M-H, Random, 95% CI) 0.97 [0.06, 15.32]
   34.6.10 Fatigue 1 158 Risk Ratio(M-H, Random, 95% CI) 2.93 [0.12, 70.75]
   34.6.11 Rigors 1 158 Risk Ratio(M-H, Random, 95% CI) 2.93 [0.12, 70.75]
   34.6.12 Tonsilitis 2 781 Risk Ratio(M-H, Random, 95% CI) 0.51 [0.15, 1.70]
   34.6.13 Pharyngitis 2 781 Risk Ratio(M-H, Random, 95% CI) 0.82 [0.44, 1.54]
   34.6.14 Influenza 1 623 Risk Ratio(M-H, Random, 95% CI) 1.23 [0.39, 3.86]
   34.6.15 Nausea 1 623 Risk Ratio(M-H, Random, 95% CI) 1.63 [0.45, 5.88]
   34.6.16 Elevated blood creatinine
kinase 2 781 Risk Ratio(M-H, Random, 95% CI) 1.43 [0.73, 2.80]
   34.6.17 Elevated blood
triglycerides 2 781 Risk Ratio(M-H, Random, 95% CI) 1.03 [0.56, 1.88]
34.7 Primary: adverse events
alitretinoin 20 mg vs placebo 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.7.1 All adverse events 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.7.2 Headache 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.7.3 Dry lips 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.7.4 Flushing 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.7.5 Dry mouth 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.7.6 Erythema 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.7.7 Eczema 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.7.8 Conjunctivitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.7.9 Eye pruritus 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.7.10 Fatigue 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.7.11 Rigors 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.7.12 Tonsilitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.7.13 Pharyngitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
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34.8 Primary: adverse events
alitretinoin 30 mg vs placebo 2   Risk Ratio(M-H, Random, 95% CI) Subtotals only
   34.8.1 Headache 2 1210 Risk Ratio(M-H, Random, 95% CI) 3.43 [2.45, 4.81]
   34.8.2 Dry lips 1 614 Risk Ratio(M-H, Random, 95% CI) 1.88 [0.63, 5.59]
   34.8.3 Flushing 2 1210 Risk Ratio(M-H, Random, 95% CI) 7.28 [2.05, 25.86]
   34.8.4 Dry mouth 1 614 Risk Ratio(M-H, Random, 95% CI) 2.51 [0.55, 11.33]
   34.8.5 Erythema 2 1210 Risk Ratio(M-H, Random, 95% CI) 5.79 [2.09, 16.06]
   34.8.6 Eczema 1 614 Risk Ratio(M-H, Random, 95% CI) 0.65 [0.29, 1.46]
   34.8.7 Pharyngitis 2 1210 Risk Ratio(M-H, Random, 95% CI) 0.82 [0.49, 1.36]
   34.8.8 Influenza 2 1210 Risk Ratio(M-H, Random, 95% CI) 1.17 [0.45, 3.06]
   34.8.9 Nausea 2 1210 Risk Ratio(M-H, Random, 95% CI) 3.82 [1.67, 8.76]
   34.8.10 Elevated blood creatinine
kinase 1 614 Risk Ratio(M-H, Random, 95% CI) 1.63 [0.54, 4.93]
   34.8.11 Elevated blood
triglycerides 2 1210 Risk Ratio(M-H, Random, 95% CI) 7.05 [1.89, 26.28]
   34.8.12 Dizziness 1 596 Risk Ratio(M-H, Random, 95% CI) 2.00 [0.61, 6.57]
   34.8.13 Upper respiratory tract
infection 1 596 Risk Ratio(M-H, Random, 95% CI) 1.54 [0.78, 3.04]
   34.8.14 Sinusitis 1 596 Risk Ratio(M-H, Random, 95% CI) 0.89 [0.35, 2.27]
   34.8.15 Rash 1 596 Risk Ratio(M-H, Random, 95% CI) 1.50 [0.54, 4.16]
   34.8.16 Vomiting 1 596 Risk Ratio(M-H, Random, 95% CI) 8.00 [1.01, 63.57]
   34.8.17 Arthralgia 1 596 Risk Ratio(M-H, Random, 95% CI) 1.20 [0.37, 3.89]
   34.8.18 Depression 1 596 Risk Ratio(M-H, Random, 95% CI) 2.33 [0.61, 8.94]
   34.8.19 Laceration 1 596 Risk Ratio(M-H, Random, 95% CI) 13.00 [0.74, 229.73]
   34.8.20 Tinnitus 1 596 Risk Ratio(M-H, Random, 95% CI) 4.33 [1.25, 15.05]
   34.8.21 Cough 1 596 Risk Ratio(M-H, Random, 95% CI) 2.25 [0.70, 7.23]
   34.8.22 Hypertriglceridaemia 1 596 Risk Ratio(M-H, Random, 95% CI) 6.00 [0.73, 49.53]
34.9 Primary: adverse events
alitretinoin 40 mg vs placebo 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.9.1 All adverse events 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.9.2 Headache 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.9.3 Dry lips 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.9.4 Flushing 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.9.5 Dry mouth 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.9.6 Erythema 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.9.7 Eczema 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.9.8 Conjunctivitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.9.9 Eye pruritus 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.9.10 Fatigue 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.9.11 Rigors 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.9.12 Tonsilitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
   34.9.13 Pharyngitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
34.10 Secondary: investigator-rated
reduction in severity in total lesion
symptom score
2   Other data No numeric data
   34.10.1 Alitretinoin 40 mg 1   Other data No numeric data
   34.10.2 Alitretinoin 30 mg 1   Other data No numeric data
   34.10.3 Alitretinoin 20 mg 1   Other data No numeric data
   34.10.4 Alitretinoin 10 mg 2   Other data No numeric data
34.11 Secondary: investigator-rated
reduction in severity in total lesion
symptom score
1   Other data No numeric data
   34.11.1 Alitretinoin 40 mg vs
placebo 1   Other data No numeric data
   34.11.2 Alitretinoin 20 mg vs
placebo 1   Other data No numeric data
   34.11.3 Alitretinoin 10 mg vs
placebo 1   Other data No numeric data
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34.12 Secondary: reduction in
severity, investigator-rated in
modified total lesion symptom score
(bigger reduction in severity scored
negative = better outcome)
1   Mean Difference(IV, Random, 95%CI) No totals
35 Oral retinoids: re-treatment alitretinoin versus placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
35.1 Primary: investigator-rated
good/excellent control of symptoms 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.1.1 Alitretinoin 30 mg vs
placebo 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.1.2 Alitretinoin 10 mg vs
placebo 1   Risk Ratio(M-H, Random, 95% CI) No totals
35.2 Primary: adverse events 10 mg
vs placebo 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.2.1 Any adverse event 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.2.2 Treatment-related adverse
event 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.2.3 Nasopharyngitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.2.4 Influenza 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.2.5 Erythema 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.2.6 Eczema 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.2.7 Dermatitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.2.8 Dry lips 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.2.9 Cheilitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.2.10 Dry mouth 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.2.11 Elevated triglycerides 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.2.12 High cholesterol 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.2.13 High triglycerides 1   Risk Ratio(M-H, Random, 95% CI) No totals
35.3 Primary: adverse events 30 mg
vs placebo 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.1 Any adverse event 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.2 Treatment-related adverse
event 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.3 Treatment-related serious
adverse event 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.4 Nasopharyngitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.5 Rhinitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.6 Bronchitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.7 Upper respiratory tract
infection 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.8 Influenza 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.9 Erythema 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.10 Eczema 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.11 Dermatitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.12 Dry skin 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.13 Headache 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.14 Dry lips 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.15 Nausea 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.16 Cheilitis 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.17 Dry mouth 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.18 Elevated creatinine 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.19 TSH high 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.20 TSH low 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.21 High cholesterol 1   Risk Ratio(M-H, Random, 95% CI) No totals
   35.3.22 High triglycerides 1   Risk Ratio(M-H, Random, 95% CI) No totals
36 Other oral interventions: oral triethylenetetramine versus placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
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36.1 Primary: investigator- and/or
participant-rated improvement 1   Other data No numeric data
37 Other oral interventions: oral tetraethylthiuram disulfide (TETDS) versus placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
37.1 Primary: investigator-rated
good/excellent control of symptoms
during treatment period
1   Risk Ratio(M-H, Random, 95% CI) No totals
37.2 Primary: adverse events 1   Risk Ratio(M-H, Random, 95% CI) No totals
   37.2.1 Discontinuation due to
depression 1   Risk Ratio(M-H, Random, 95% CI) No totals
   37.2.2 Discontinuation due to
dyspepsia 1   Risk Ratio(M-H, Random, 95% CI) No totals
   37.2.3 Hepatic toxicity 1   Risk Ratio(M-H, Random, 95% CI) No totals
   37.2.4 Headache requiring dose
reduction 1   Risk Ratio(M-H, Random, 95% CI) No totals
38 Other oral interventions: low-nickel diet (LND) + disulphiram versus normal diet + placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
38.1 Primary: investigator-rated
good/excellent control of symptoms
after 4 weeks
1   Risk Ratio(M-H, Random, 95% CI) No totals
38.2 Primary: adverse events 1   Risk Ratio(M-H, Random, 95% CI) No totals
   38.2.1 Metallic taste 1   Risk Ratio(M-H, Random, 95% CI) No totals
   38.2.2 Drowsiness 1   Risk Ratio(M-H, Random, 95% CI) No totals
   38.2.3 Elevation of liver enzymes 1   Risk Ratio(M-H, Random, 95% CI) No totals
39 Other oral interventions: oral evening primrose oil versus placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
39.1 Secondary: investigator-rated
reduction in severity score at week
24 (bigger reduction in severity =
better outcome)
1   Mean Difference(IV, Random, 95%CI) No totals
40 Other oral interventions: oral ranitidine versus placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
40.1 Primary: participant- and
investigator-rated good/excellent
control of symptoms
1   Risk Ratio(M-H, Random, 95% CI) No totals
41 Other oral interventions: disodium cromoglycate diet (DSCG) versus low-nickel diet
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
41.1 Primary: participant-rated
good/excellent control of symptoms
(itch) after 3 months of itch in DSCG
versus diet
1   Risk Ratio(M-H, Random, 95% CI) No totals
Other data tables
2 Bland emollients: emollient E-DO versus vehicle
2.1 Primary: percentage of participants with self-rated good/excellent control at week 4
Study ID
Group - within-participant
study
Total number of
events
Total number of pairs of hands analysedTotal number of hands
randomised
Chu
2009
Emollient E-DO 22 67
Vehicle 23 67
2.2 Primary: percentage of participants with investigator-rated good/excellent control at week 4
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Study ID Group- within-participant studyEvent number Total number of pairs of hands randomisedTotal N number
Chu 2009
Emollient E-DO 37 67
Vehicle 36 67
2.3 Adverse events
2.3.1 At least 1 adverse event
Study ID Group - within-participant studyEvent number Total number of hands pairs of analysedTotal N number
Chu 2009
Emollient E-DO 12 67
Vehicle 8 67
2.3.2 Pruritus
Study ID Group - within-participant studyEvent number Total number of hands pairs of analysedTotal N number
Chu 2009
Emollient E-DO 6 67
Vehicle 2 67
4 Corticosteroid creams/ointments: betamethasone-dipropionate film-forming lotion versus betamethasone-
dipropionate thick lotion
4.1 Primary: investigator-rated good/excellent control of symptoms at day 7
Study ID GroupHeading 1 Number of participants with good/excellent controlHeading 2Total number of participants 3
Gupta 1993
B-film forming lotion5 28
B-thick lotion 0 26
5 Corticosteroids creams/ointments: clobetasol propionate versus flupredniden acetate
5.1 Primary: percentage of participants with investigator-rated good/excellent control
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysed Total N number
Möller 1983
Clobetasol 32 46
Flupredniden 14 46
5.2 Adverse events
5.2.1 At least 1 adverse event
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
Möller 1983
Clobetasol 4 46
Flupredniden 3 46
5.2.2 Burning sensation
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
Möller 1983
Clobetasol 2 46
Flupredniden 2 46
5.2.3 Reversible atrophy
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
Möller 1983
Clobetasol 1 46
Flupredniden 0 46
5.2.4 Brittle skin
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
Möller 1983
Clobetasol 1 46
Flupredniden 1 46
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7 Corticosteriods creams/ointments: desonide cream 0.1% versus desonide cream 0.05%
7.1 Adverse events
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
Uggeldahl 1986
Desonide cream 0.1% 0 50
Desonide cream 0.05% 2 50
9 Corticosteroid creams/ointments: clobetasol and zinc sulphate cream versus clobetasol cream
9.1 Primary outcome: percentage of participants with investigator-rated good/excellent control
9.1.1 Scaling
Study ID Group - within-participant study
Event
number
Total number of pairs of hands analysedTotal N
number
Faghihi
2008
Clobetasol cream 3 47
Clobetasol cream Clobetasol & Zinc sulphate
cream 25 47
9.1.2 Redness
Study ID Group - within-participant study
Event
number
Total number of pairs of hands analysedTotal N
number
Faghihi
2008
Clobetasol cream 1 47
Clobetasol cream Clobetasol & Zinc sulphate
cream 41 47
9.1.3 Lichenification
Study ID Group - within-participant study
Event
number
Total number of pairs of hands analysedTotal N
number
Faghihi
2008
Clobetasol cream 7 47
Clobetasol cream Clobetasol & Zinc sulphate
cream 24 47
11 Topical others: coal tar versus betamethasone-valerate
11.1 Primary outcome: adverse events
Study ID Group - within-participant study Event number Total number of pairs of hands analysedTotal N number
Kemper 1998
Betamethasone valerate 0.1% cream0 19
Coal tar paste Urea 5% cream 1 19
15 Irradiation with UV light: local narrow-band UVB versus local PUVA
15.1 Primary: investigator-rated good/excellent control of symptoms in UVB vs PUVA
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
Sezer 2007
NB-UVB 2 12
Local PUVA 1 12
15.2 Primary: adverse events
15.2.1 Palmar hyperpigmentation
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
Sezer 2007
NB-UVB 0 1215
Local PUVA 3 1215
15.3 Secondary: investigator-rated improvement by local narrow-band UVB vs local PUVA
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Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
Sezer 2007
NB-UVB 9 12
Local PUVA 9 12
17 Irradiation with UV light: topical PUVA versus UVA
17.1 Primary: adverse events
17.1.1 Discontinuation due to adverse events
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
Grattan 1991
Topical PUVA 1 15
UVA 1 15
17.1.2 Burning
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
Grattan 1991
Topical PUVA 1 15
UVA 0 15
17.1.3 Exacerbation of eczema
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
Grattan 1991
Topical PUVA 1 15
UVA 0 15
20 Irradiation with UV light: PUVA versus UVA-1
20.1 Primary: adverse events
20.1.1 Burning
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysed
Adams 2007
PUVA 3 11
UVA-1 1 11
20.1.2 Itching
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysed
Adams 2007
PUVA 5 11
UVA-1 3 11
21 Irradiation with Grenz ray
21.1 Primary: investigator-rated improvement good/excellent control
21.1.1 after 1 month
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
King 1984
Grenz Ray 71 15
Placebo 0 15
21.1.2 after 3 months
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
King 1984
Grenz Ray 10 15
Placebo 6 15
21.1.3 after 6 months
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Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
King 1984
Grenz Ray 11 15
Placebo 8 15
21.1.4 Hyperkeratotic eczema after 6 months
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
King 1984
Grenz Ray 4 8
Placebo 2 6
21.1.5 Pompholyx after 6 months
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
King 1984
Grenz Ray 7 7
Placebo 6 7
21.1.6 Chronic palmar eczema after 6 months
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
King 1984
Grenz Ray 11 15
Placebo 0 15
21.2 Primary: adverse events - hyperpigmentation
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
Cartwright 1987
Grenz 1 30
Placebo 0 30
Lindelöf 1987
Grenz 5 24
Placebo 0 24
22 Topical calcineurin inhibitors: tacrolimus 0.1% ointment versus mometasone furoate
22.1 Secondary: reduction in investigator-rated severity - DASI
Study ID Group - within-participant studyMeanSD Total number of pairs of hands analysedN Number
Schnopp 2002
Tacrolimus  6.6 6.188
Mometasone 6.9 7.7 8
27 Other topical agents: calmurid versus aquacare
27.1 Primary: adverse events: burning
Study ID Group - within-participant studyEvent number Total number of pairs of hands analysedTotal N number
Fredriksson 1975
Aquacare 0 30
Calmurid 13 30
34 Oral retinoids: alitretinoin versus placebo
34.10 Secondary: investigator-rated reduction in severity in total lesion symptom score
34.10.1 Alitretinoin 40 mg
Study ID Heading 1
Ruzicka 2004
Median of % change from baseline: -70.5% (95% CI -44 to -80).
Significant more reduction than placebo (P < 0.001; Kruskal-Wallis test).
34.10.2 Alitretinoin 30 mg
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Study ID Heading 1
Ruzicka 2008
Median of % change from baseline: -75%
Significant more reduction than placebo (P < 0.001; Kruskal-Wallis test).
34.10.3 Alitretinoin 20 mg
Study ID Heading 1
Ruzicka 2004
Median of % change from baseline: -52 (95% CI -42 to -73)
Significant more reduction than placebo (P < 0.01; Kruskal-Wallis test).
34.10.4 Alitretinoin 10 mg
Study ID Heading 1
Ruzicka 2004
Median of % change from baseline: -25% (95% CI -14 to -42)
Significant more reduction than placebo (P < 0.01; Kruskal-Wallis test).
Ruzicka 2008
Median of % change from baseline: -56%
Significant more reduction than placebo (P < 0.01; Kruskal-Wallis test).
34.11 Secondary: investigator-rated reduction in severity in total lesion symptom score
34.11.1 Alitretinoin 40 mg vs placebo
Study ID Group MedianSD N
Ruzicka 2004
Alitretinoin 40 mg 70.5 81.40781
Placebo 25.0 62.13 78
34.11.2 Alitretinoin 20 mg vs placebo
Study ID Group MedianSD N
Ruzicka 2004
Alitretinoin 20 mg 52.0 80.9 80
Placebo 25.0 62.1378
34.11.3 Alitretinoin 10 mg vs placebo
Study ID Group MedianSD N
Ruzicka 2004
Alitretinoin 10 mg 59.0 89.89280
Placebo 25.0 62.13 78
36 Other oral interventions: oral triethylenetetramine versus placebo
36.1 Primary: investigator- and/or participant-rated improvement
Study ID Group - within-participant studyEventTotal number of participants analysedN
Burrows 1986
Trientine 6 20
Placebo 10 20
Figures
Figure 1
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Caption
Study flow diagram.
Figure 2
Caption
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included
studies.
Figure 3
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Caption
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Feedback 
Appendices 
1 Glossary of medical terms
Medical term Explanation
Acrovesicular eczema Form of vesicular hand eczema. (Large) vesicle eruptions on the palms that usually tend to recur.
Also called dyshidrotic eczema or pompholyx
Betamethasone Topical corticosteroid, high potency
Clobetasol propionate Topical corticosteroid, very high potency
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Medical term Explanation
Desonide Topical corticosteroid, low potency
Dyshidrotic hand
eczema
Form of vesicular hand eczema. (Large) vesicle eruptions on the palms that usually tend to recur.
Also called dyshidrotic eczema, pompholyx or acro vesicular eczema
Fluprednidene acetate Topical corticosteroid, medium potency
Heterogeneity Differences in which studies have been undertaken with regard to methods and/or materials
Hydrocortisone butyrate Topical corticosteroid, low potency
Hyperkeratotic hand
eczema
Form of hand eczema with areas of thick scaling on the palms, also called tylotic hand eczema
IGA Investigator global assessment: global assessment of disease severity usually on a 5-point scale
Immunomodulator Drug which changes the immune response such as tacrolimus
Immunosuppressor Drug which suppresses the immune response such ad topical corticosteroids
Iontophoresis Treatment by which the skin is soaked in (tap) water through which a weak electric current is
passed
Mometasone furoate
cream
Potent steroid cream
Nummular hand
eczema
Round (“coin sized”) eczematous patches on the back of the hands
Palmar Hand palms, the inside surface of the hands
Palmoplantar Hand palms and foot soles
Phase I clinical trial A clinical trial of a new drug or therapy. Phase I trials are conducted in small groups of participants
Phase II clinical trial A clinical trial of a new drug or therapy. Phase II trials are conducted in larger groups of participants
than phase I trials
Pimecrolimus Topical calcineurin inhibitor, also known as "elidel"
Placebo Simulated or otherwise medically ineffective treatment
Pompholyx Form of vesicular hand eczema. (Large) vesicle eruptions on the palms that usually tend to recur.
Also called dyshidrotic eczema, pompholyx or acro vesicular eczema
Potency Strength
Prevalence The proportion of a population having a particular condition or characteristic: e.g. the percentage of
people in a city with hand eczema, or the proportion of people who smoke
Primary care Health care provided at the principal point of consultation for patients within a healthcare system,
e.g. GP
Pruritus Itch
Psychosomatic disorder A disorder in which physical symptoms originate from mental or emotional causes
Pulpitis A dry, fissured, scaling dermatitis of the fingertips with occasional episodes of vesicles. Also known
as fingertip dermatitis
Randomised control
trials
A study in which a number of similar people are randomly assigned to two (or more) groups to test
a specific drug, treatment or other intervention. (National Institute for Health and Care Excellence)
RR Relative risk
Secondary care Health care provided by medical specialists and other health professionals, including
dermatologists, who generally do not have first contact with patients. This contains hospital and
out-patient care
Systemic treatment Treatment which does not pertain to a certain surface area but might affect the entire body, usually
taken by mouth or injection.
Tacrolimus Topical calcineurin inhibitor, also known as "protopic"
Teratogenicity Developmental abnormalities in the foetus
Therapy A treatment that helps someone feel better, grow stronger, etc., especially after an illness
(Cambridge dictionary)
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Medical term Explanation
Topical treatment Treatment pertaining to a certain surface area (usually the skin) and only affecting the area to
which it is applied
Transepidermal water
loss (TEWL)
The amount of water that moves from inside the body to the surrounding atmosphere through the
epidermal layer of the skin by means of diffusion and evaporation.
Tylotic hand eczema Form of hand eczema with areas of thick scaling on the palms, also called hyperkeratotic hand
eczema
UVA-1 Form of UV-phototherapy which only uses the longer UV wavelengths (340 to 400 nm) and
reduces the risk of burning, which is associated with the shorter-wavelength UVA2 (320 to 340 nm)
and UVB (290 to 320 nm).
VAS (Visual Analogue
Scale)
Continious scale to measure a (subjective) response
Vehicle Something used to transport people or goods (Cambridge dictionary), in this case something to
help the treatment get transport in/on the skin, but a vehicle alone (without the active substance)
can be used as placebo.
2 Cochrane Skin Specialised Register (CRSW)
pompholyx or cheiropompholyx or acrodermatitis or "hand eczema" or ((eczema or dermatitis) and (dyshidro* or dyshydro* or
dishidro* or dishydro* or tylotic or hyperkeratotic or microbial or discoid or nummular or pulpitis or pulpite) and (hand* or
finger* or palm*))
3 CENTRAL (Cochrane Library) search strategy
#1 tylotic or hyperkeratotic or nummular or microbial or discoid
#2 MeSH descriptor: [Eczema] explode all trees
#3 MeSH descriptor: [Dermatitis] explode all trees
#4 eczema or dermatitis
#5 #2 or #3 or #4
#6 MeSH descriptor: [Hand Dermatoses] explode all trees
#7 MeSH descriptor: [Eczema, Dyshidrotic] explode all trees
#8 hand eczema
#9 MeSH descriptor: [Acrodermatitis] explode all trees
#10 pompholyx
#11 cheiropompholyx
#12 {or #6-#11}
#13 MeSH descriptor: [Hand] explode all trees
#14 (hand* or finger* palm*)
#15 #13 or #14
#16 #1 and #5 and #15
#17 pulpitis or pulpite
#18 #15 and #17
#19 dyshidro* or dyshydro* or dishidro* or dishydro*
#20 #5 and #19
#21 #12 or #16 or #18 or #20
4 MEDLINE (Ovid) search strategy
1. exp *Hand Dermatoses/
2. exp Eczema, Dyshidrotic/
3. hand eczema.mp.
4. exp *Acrodermatitis/
5. pompholyx.mp.
6. cheiropompholyx.mp.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Eczema/ or eczema.mp.
9. exp Dermatitis/ or dermatitis.mp.
10. 8 or 9
11. (tylotic or hyperkeratotic).mp.
12. (nummular or microbial or discoid).mp.
13. (pulpitis or pulpite).mp.
14. (dyshidro$ or dyshydro$ or dishidro$ or dishydro$).mp.
15. 11 or 12
16. exp Hand/
17. (hand$ or finger$ or palm$).mp.
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18. 16 or 17
19. 13 and 18
20. 10 and 15 and 18
21. 10 and 14
22. 7 or 19 or 20 or 21
23. randomised controlled trial.pt.
24. controlled clinical trial.pt.
25. randomized.ab.
26. placebo.ab.
27. clinical trials as topic.sh.
28. randomly.ab.
29. trial.ti.
30. 23 or 24 or 25 or 26 or 27 or 28 or 29
31. exp animals/ not humans.sh.
32. 30 not 31
33. 22 and 32
[Lines 23-32: Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and
precision-maximizing version (2008 revision)]
5 Embase (Ovid) search strategy
1. exp *pompholyx/
2. hand eczema.mp.
3. exp *acrodermatitis/
4. cheiropompholyx.mp.
5. pompholyx.mp.
6. exp *hand eczema/
7. or/1-6
8. eczema.mp. or exp *eczema/
9. exp *dermatitis/ or dermatitis.mp.
10. 8 or 9
11. (tylotic or hyperkeratotic).mp.
12. (nummular or microbial or discoid).mp.
13. (pulpitis or pulpite).mp.
14. (dyshidro$ or dyshydro$ or dishidro$ or dishydro$).mp.
15. 11 or 12
16. exp hand/
17. (hand$ or finger$ or palm$).mp.
18. 16 or 17
19. 13 and 18
20. 10 and 15 and 18
21. 10 and 14
22. 7 or 19 or 20 or 21
23. crossover procedure.sh.
24. double-blind procedure.sh.
25. single-blind procedure.sh.
26. (crossover$ or cross over$).tw.
27. placebo$.tw.
28. (doubl$ adj blind$).tw.
29. allocat$.tw.
30. trial.ti.
31. randomized controlled trial.sh.
32. random$.tw.
33. or/23-32
34. exp animal/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
35. human/ or normal human/
36. 34 and 35
37. 34 not 36
38. 33 not 37
39. 22 and 38
6 AMED (Ovid) search strategy
1. random allocation/
2. double blind method/
3. single blind method.mp.
4. exp Clinical trials/
5. (clin$ adj25 trial$).mp.
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6. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$ or dummy)).mp.
7. (placebo$ or random$).mp.
8. research design/ or clinical trials/ or comparative study/ or double blind method/ or random allocation/
9. prospective studies.mp.
10. cross over studies.mp.
11. Follow up studies/
12. control$.mp.
13. (multicent$ or multi-cent$).mp.
14. ((stud or design$) adj25 (factorial or prospective or intervention or crossover or cross-over or quasi-experiment$)).mp.
15. Randomized controlled trials/
16. or/1-15
17. hand eczema.mp.
18. hand dermatoses.mp.
19. acrodermatitis.mp.
20. pompholyx.mp.
21. or/17-20
22. exp Eczema/ or eczema.mp.
23. dermatitis.mp. or exp Dermatitis/
24. 22 or 23
25. exp Hand/ or hand.mp.
26. (hand$ or finger$ or palm$).mp.
27. 25 or 26
28. 24 and 27
29. (dyshidro$ or dyshydro$ or dishidro$ or dishydro$).mp.
30. 24 and 29
31. (tylotic or hyperkeratotic).mp.
32. (nummular or microbial or discoid).mp.
33. (pulpitis or pulpite).mp.
34. 27 and 33
35. 31 or 32
36. 24 and 27 and 35
37. 21 or 28 or 30 or 34 or 36
38. 16 and 37
7 LILACS search strategy
(pompholyx or ponfolix or cheiropompholyx or acrodermatitis or ((eczema or eccema or dermatitis) and (hand$ or finger$ or
palm$ or mano$)))
In LILACS we searched using the above terms and the Controlled clinical trials topic-specific query filter.
8 Journals handsearched
1. Acta Dermato-Venereologica
2. Archives of Dermatological Research
3. Archives of Dermatology
4. British Journal of Dermatology
5. British Medical Journal
6. Clinical and Experimental Dermatology
7. Contact Dermatitis
8. Cutis
9. Dermatology (formerly Dermatologica)
10. Environmental Dermatology
11. Journal of Investigative Dermatology
12. Journal of the American Academy of Dermatology
13. Journal of the American Medical Association
14. Lancet
15. New England Journal of Medicine
16. Der Hautarzt
17. Giornale Italiano di Dermatologia e Venereologia
18. Nederlands Tijdschrift voor Dermatologie en Venereologie
19. H+G Zeitschrift für Hautkrankheiten
20. Annales de Dermatologie et Venerelogie
21 Journal of Dermatologic Treatment
Graphs
1 - Bland emollients: ceramide-containing emollient versus regular petrolatum-based emollient
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2 - Bland emollients: emollient E-DO versus vehicle
3 - Corticosteroid creams/ointments: fluprednidene versus betamethasone
4 - Corticosteroid creams/ointments: betamethasone-dipropionate film-forming lotion versus betamethasone-
dipropionate thick lotion
5 - Corticosteroids creams/ointments: clobetasol propionate versus flupredniden acetate
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6 - Corticosteroids creams/ointments: clobetasol propionate foam 0.05% versus vehicle
7 - Corticosteriods creams/ointments: desonide cream 0.1% versus desonide cream 0.05%
8 - Corticosteroid creams/ointments: mometasone furoate cream 3 times/week versus 2 times/week versus no
steroids
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9 - Corticosteroid creams/ointments: clobetasol and zinc sulphate cream versus clobetasol cream
10 - Corticosteroid creams/ointments: betamethasone-valerate 0.1% cream versus urea 5% cream
11 - Topical others: coal tar versus betamethasone-valerate
12 - Irradiation with UV light versus no UVB
13 - Irradiation with UV light: whole-body UVB versus placebo or local UVB hands
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14 - Irradiation with UV light: local narrow-band UVB versus local PUVA
15 - Irradiation with UV light: local narrow-band UVB versus local PUVA
16 - Irradiation with UV light: oral PUVA versus topical bath PUVA
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17 - Irradiation with UV light: topical PUVA versus UVA
18 - Irradiation with UV light: UVA-1 versus topical betamethasone valerate 0.1% cream
19 - Irradiation with UV light: UVA-1 versus placebo
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20 - Irradiation with UV light: PUVA versus UVA-1
21 - Irradiation with Grenz ray
22 - Topical calcineurin inhibitors: tacrolimus 0.1% ointment versus mometasone furoate
23 - Topical calcineurin inhibitors: tacrolimus 0.1% ointment versus vehicle
24 - Topical calcineurin inhibitors: pimecrolimus 1% cream versus vehicle
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25 - Topical antibacterial agents: betamethasone-valerate/clioquinol cream versus betamethasone-
valerate/fusidic acid
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26 - Topical retinoids: bexarotene 1% gel versus bexarotene with corticosteroids
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27 - Other topical agents: calmurid versus aquacare
28 - Other topical agents: fumaric acid 5% cream verus triamcinolone 0.1% cream
29 - Other topical agents: furpalmate 0.3% cream versus hydrocortisone acetate 0.5% cream
30 - Other topical agents: Fumaria parviflora versus vehicle cream
31 - Oral immunosuppressants: oral azathioprine with topical clobetasol propionate versus topical clobetasol
propionate
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32 - Oral immunosuppressants: oral cyclosporin versus topical betamethasone dipropionate
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33 - Oral immunosuppressants: oral cyclosporin versus alitretinoin
34 - Oral retinoids: alitretinoin versus placebo
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35 - Oral retinoids: re-treatment alitretinoin versus placebo
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36 - Other oral interventions: oral triethylenetetramine versus placebo
37 - Other oral interventions: oral tetraethylthiuram disulfide (TETDS) versus placebo
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38 - Other oral interventions: low-nickel diet (LND) + disulphiram versus normal diet + placebo
39 - Other oral interventions: oral evening primrose oil versus placebo
40 - Other oral interventions: oral ranitidine versus placebo
41 - Other oral interventions: disodium cromoglycate diet (DSCG) versus low-nickel diet
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